“CLINICAL PROFILE AND OUTCOME IN PATIENTS WITH HYPERCALCEMIA IN A TERTIARY CARE CENTRE”

A THESIS SUBMITTED TO THE BABA FARID UNIVERSITY OF HEALTH SCIENCES, FARIDKOT (PUNJAB)

For the Award of Degree of

DOCTOR OF MEDICINE

IN

MEDICINE

BY

Dr. TANIYA SUKHIJA

SUPERVISOR

Dr. VANDANA MIDHA

DEPARTMENT OF MEDICINE

DAYANAND MEDICAL COLLEGE AND HOSPITAL

LUDHIANA, PUNJAB

(MAY 2021)

DECLARATION

I declare that the thesis entitled **"CLINICAL PROFILE AND OUTCOME IN PATIENTS WITH HYPERCALCEMIA IN A TERTIARY CARE CENTRE"** has been prepared by me under the guidance of Dr. Vandana Midha, Professor, Department of Medicine, Dayanand Medical College and Hospital, Ludhiana. No part of this thesis has formed the basis for the award of any degree previously.

Dr. Taniya Sukhija
Department of Medicine
Dayanand Medical College & Hospital
Ludhiana

Date:

CERTIFICATE

I certify that **Dr. Taniya Sukhija** has prepared her thesis entitled **"CLINICAL PROFILE AND OUTCOME IN PATIENTS WITH HYPERCALCEMIA IN A TERTIARY CARE CENTRE"** for the award of degree of M.D. in Medicine of Baba Farid University of Health Sciences, under my guidance. She has carried out the work at the Department of Medicine, Dayanand Medical College & Hospital, Ludhiana.

The data collected in this thesis is genuine and the work has been carried out by the candidate herself.

Supervisor

Dr. Vandana Midha
Professor
Department of Medicine
DMC&H, Ludhiana

Co-Supervisor

Dr. Naveen Mittal
Professor
Department of Endocrinology
DMC&H, Ludhiana

Dr. Navjot Bajwa
Professor & Head
Department of Biochemistry
DMC&H, Ludhiana

Date:

ENDORSEMENT BY THE HEAD OF THE DEPARTMENT AND PRINCIPAL

This is to certify that the thesis entitled **"CLINICAL PROFILE AND OUTCOME IN PATIENTS WITH HYPERCALCEMIA IN A TERTIARY CARE CENTRE"** is a bonafide research work done by Dr. Taniya Sukhija under the guidance of **Dr. Vandana Midha**, Professor, Department of Medicine, Dayanand Medical College & Hospital, Ludhiana.

Head of Department

Dr. Dinesh Gupta
Professor & Head
Department of Medicine
DMCH, Ludhiana

Principal

Dr. Sandeep Puri
Principal & Professor
DMCH, Ludhiana

Date:

COPYRIGHT

Declaration by the Candidate

I hereby declare that the Baba Farid University of Health Sciences, Faridkot, shall have the rights to preserve, use and disseminate this thesis in print or electronic format for academic / research purpose.

Dr. Taniya Sukhija
Department of Medicine
Dayanand Medical College & Hospital
Ludhiana

Date:

© Baba Farid University of Health Sciences, Faridkot

ACKNOWLEDGEMENT

"As we express our gratitude, we must never forget that the highest appreciation is not to utter words, but to live by them."

As the word acknowledgement means, I truly agree and admit in the magnitude of the same, a special debt of gratitude to my worthy teacher and supervisor

Dr. Vandana Midha, Professor, Department of Medicine, Dayanand Medical College & Hospital, Ludhiana for her unfailing support and inexhaustible guidance. She has always been an epitome of excellence for me.

It is with great reverence and profound pleasure that I acknowledge the valuable suggestions, scholarly guidance and constant encouragement rendered by my co-supervisors **Dr. Naveen Mittal,** Professor, Department of Endocrinology and **Dr. Navjot Bajwa,** Professor and Head, Department of Biochemistry, Dayanand Medical College & Hospital, Ludhiana. An opportunity to learn from them has been one of special things that this work provided. I am really indebted to them for being so supportive throughout.

I take great pride in expressing my gratitude to them. I am thankful to **Dr. H.S. Dhooria,** Associate Professor, Department of Medicine and **Dr. Saurav Arora,** Assistant Professor, Department of Endocrinology for their

invaluable help and constant support during the course of study.

Above all I am greatly indebted to my family members for their innumerable sacrifices, especially my parents **Smt. Sudesh Sukhija** *and* **Shri Madan Gopal Sukhija**. *No words are enough to express my heartfelt gratitude towards my brother* **Dr Bharat Sukhija** *and his wife* **Dr. Nupur Sukhija** *who have always stood by me through thick and thin like pillars and have supported me in every decision of my life. Special thanks to my nephew* **Vivaan** *for always cheering me up.*

My sincere thanks to all colleagues & friends **Dr. Suruchi , Dr. Abhiraj, Dr. Devesh, Dr. Nishant, Dr. Sankalp, Dr. Ishan, Dr. Navjot** *and my seniors* **Dr. Onkar, Dr. Pawan , Dr. Monika , Dr. Amardeep** *and all my juniors for their brilliant company in this journey. They have been an invaluable support day in and out for the entire course of work.*

Thanks to all the patients who have been a part of this study and DMCH staff & residents who made this uphill task possible.

A Special Thanks to **Mrs. Namita, Miss. Ani, Miss Neha Bhatt** *&* **Mr. Naveen Bhatia,** *Research & Development centre for their efforts.*

Dr. Taniya Sukhija...

ABSTRACT

Introduction: Calcium is an essential mineral for life and is involved in many physiological and biochemical processes. Serum calcium levels are maintained in a narrow range by powerful homeostatic mechanisms. However, it is not uncommon to find calcium related metabolic abnormalities either hypercalcemia or hypocalcemia. As the clinical profile of hypercalcemia is evolving from that described in the past, we intended to improve our understanding of the disease in patients of north India.

Aim: To determine the clinical-etiological profile of patients with hypercalcemia and assess the outcome in these patients at an interval of one month and three months respectively.

Materials and Methods: This prospective study was conducted at Dayanand Medical College and Hospital, Ludhiana from 1st January 2019 to 31st December 2019. All the consecutive patients from emergency with verified hypercalcemia were considered and those fulfilling the inclusion criteria were enrolled in our study.

Results: The mean age of the cohort associated with hypercalcemia was found to be 58.3 years ± 13.6. Majority of the cases in our study had mild hypercalcemia (n=82, 41%) at admission. Malignancy was found to be the commonest cause of hypercalcemia (n= 85, 42.5%) followed by hyperparathyroidism (n=45, 22.5%) and Vitamin D intoxication (n=29, 14.5%). The most common malignancies observed were multiple myeloma (37.6%) followed by lymphoma (15.3%), breast cancer (11.8%) and ovarian cancer (8.2 %).Vitamin D intoxication is not uncommon these days. Median dose of 60,000.0 IU per day of vitamin D over median duration of 29.6 weeks (1.4 - 52.1) was found to be associated with vitamin D intoxication in our study. Symptomatic hyperparathyroidism (HPTH) still predominates in developing countries. HPTH associated pancreatitis was seen in 20 cases. A total of 22 (11%) patients died by the end of three months of follow up and maximum mortality was attributed to the malignancy (68.2%).

Conclusion: Serum calcium levels should be included in the routine health checkup which might help in picking up the etiology at an early stage and thus, improve outcome.

Keywords: Hypercalcemia, HPTH, Malignancy, vitamin D intoxication

ABBREVIATIONS

ACE	ANGIOTENSIN CONVERTING ENZYME
CBNAAT	CATRIDGE BASED NUCLEIC ACID AMPLIFICATION TEST
CLD	CHRONIC LIVER DISEASE
CAD	CORONARY ARTERY DISEASE
CKD	CHRONIC KIDNEY DISEASE
DOR	DISCHARGE ON REQUEST
DAMA	DISCHARGE AGAINST MEDICAL ADVICE
FHH	FAMILIAL HYPOCALCIURIC HYPERCALCEMIA
FNAC	FINE NEEDLE ASPIRATION CYTOLOGY
HPTH	HYPERPARATHYROIDISM
i.v	INTRAVENOUS
i.m	INTRAMUSCULARLY
LFT	LIVER FUNCTION TEST

PHPT	PRIMARY HYPERPARATHYROIDISM
PTH	PARATHYROID HORMONE
PTHrP	PARATHYROID HORMONE RELATED PEPTIDE
RFT	RENAL FUNCTION TEST
SPEP	SERUM PROTEIN ELECTROPHORESIS
s.c.	SUBCUTANEOUSLY
25(OH)D	VITAMIN D/ CALCIDIOL
1,25(OH)D	1,25 DIHYDROXY VITAMIN D/ACTIVE VITAMIN D/CALCITRIOL/1,25 HYDROXY VITAMIN D

KEY TO MASTER CHART

ALP	ALKALINE PHOSPHATASE
ABN	ABNORMAL
CAD	CORONARY ARTERY DISEASE
CA	CALCIUM, CARCINOMA
Cl	CHLORIDE
COPD	CHRONIC OBSTRUCTIVE AIRWAY DISEASE
CLD	CHRONIC LIVER DISEASE
CKD	CHRONIC KIDNEY DISEASE
DM	DIABETES MELLITUS
Hb	HEMOGLOBIN
HCC	HEPATOCELLULAR CARCINOMA
HTN	HYPERTENSION
GB	GALL BLADDER
K	POTTASIUM
N	NO
Na	SODIUM
NA	NOT APPLICABLE
n1	DIED BY 1MONTH OF FOLLOW UP
nor	NORMAL
TB	TUBERCULOSIS
TLC	TOTAL LEUKOCYTE COUNT
Y	YES
?	PROBABLY

TABLE OF CONTENTS

S. NO.	TOPIC	PAGES
I	INTRODUCTION	1-3
II	AIMS AND OBJECTIVES	4
III	REVIEW OF LITERATURE	5-23
IV	MATERIAL AND METHODS	24-25
V	OBSERVATIONS AND RESULTS	26-41
VI	DISCUSSION	42-56
VII	SUMMARY AND CONCLUSION	57-59
VIII	BIBLIOGRAPHY	60-68

APPENDICES – I

- PROFORMA
- MASTER CHART

APPENDICES – II

- APPROVAL LETTER OF THESIS PLAN
- THESIS PLAN

LIST OF TABLES

Table no.	Title	Page no
1	Showing common etiologies associated with hypercalcemia	9
2	Showing the changing epidemiology of HPTH in the developing countries	12
3	Showing comparison of various biochemical parameters associated with HPTH in various studies	13
4	Comparison of various Indian studies with vitamin d intoxication	16
5	Clinical manifestations of hypercalcemia	18
6	Baseline demographic characteristics of patients in our study	26
7	Clinical manifestations of patients with hypercalcemia symptoms	27
8	Correlation among age, gender and symptoms with hypercalcemia	29
9	Etiology of hypercalcemia in our study	30
10	Commonest malignancies associated with hypercalcemia in our study	32
11	Correlation among age, gender and symptoms with malignancy	33
12	Relationship among age, gender and symptoms with hyperparathyroidism	34

13	Radionuclear imaging in hyperparathyroidism	35
14	Relationship among age, gender and symptoms in patients with vitamin D intoxication	36
15	Outcome of patients with hypercalcemia in hospital	39
16	Outcome of patients with hypercalcemia at 3 months of follow up	40

LIST OF FIGURES

Figure no.	Title	Page no.
1	Showing schematic presentation of calcium homeostasis	6
2	Clinical manifestations of patients with hypercalcemia	28
3	Etiology of hypercalcemia in our study	31

INTRODUCTION

Calcium is a mineral that is essential for life. While most of the calcium in our body is sequestered in the skeleton as hydroxyapatite salt, it is the free ionized calcium which plays a key role in cellular functioning and signaling[1] .

Hypercalcemia is defined as total serum calcium levels more than 10.5 mg/dl or 2.5 mmol/l. The hypercalcemia is further classified as

1. Mild- 10.5 to 11.9 mg/dl (2.5-3mmol/l)
2. Moderate- 12-13.9 mg/dl (3-3.5mmol/l)
3. Severe- >14 mg/dl (>3.5mmol/l)

The hypercalcemic crisis is said when either severe neurological symptoms or cardiac arrhythmias are present in a patient with serum calcium levels more than 14 mg/dl or when serum calcium levels are more than 16 mg/dl. [2]

Calcium homeostasis in body is maintained through a series of feedback mechanisms involving parathyroid hormone (PTH), calcitonin and vitamin D via fluxes of calcium from gastrointestinal tract, kidney and bone.[3] Mild hypercalcemia is usually asymptomatic and identified incidentally on routine blood testing.[4]

Among the most common causes of hypercalcemia are malignancy and hyperparathyroidism.[4-6] Malignancy related hypercalcemia is seen with squamous cell carcinoma (lung, head and neck, urothelial cancer), multiple myeloma, breast cancer, RCC (renal cell carcinoma), lymphoma's etc.[5][7] Primary hyperparathyroidism (PHPT) is a common endocrine condition associated with hypercalcemia.[8-10] Parathyroid adenoma accounts for 80%–85% cases of hyperparathyroidism whereas parathyroid carcinoma is rare and accounts for < 1% of cases.[11] Other causes of hypercalcemia includes granulomatous diseases (sarcoidosis, tuberculosis) ; medications (lithium, thiazides, antiestrogens, vitamin D and calcium supplements); milk alkali syndrome; hyperthyroidism; immobilization; benign familial hypocalciuric hypercalcemia(FHH).[5][7][12]

Vitamin D intoxication has recently emerged as an important cause of hypercalcemia due to overcorrection of vitamin D deficiency.[13-17] This increase is due to growing awareness of vitamin D deficiency in today's lifestyle and various researches suggesting the beneficial effects of vitamin D in immune system, cardiovascular health, bone health and cancer prevention. Thus, leading to overdosing by either patients or prescribers.[18-20]

The clinical manifestations of hypercalcemia are well famous with the mnemonic "stones, bones, abdominal moans and psychic groans" since ages.[21] Indeed the major systems involved are gastrointestinal, musculoskeletal, neurological and renal. Gastrointestinal symptoms includes anorexia, constipation, nausea, vomiting and pain abdomen which can be due to peptic ulcer disease, cholelithiasis or pancreatitis etc.[22-24] Renal manifestations consists of nephrogenic diabetes insipidus and distal renal tubular acidosis. Chronic hypercalcemia can cause nephrolithiasis, nephrocalcinosis, tubular dysfunction and even renal failure.[25-26] Neurological symptoms includes behavioral disturbances like anxiety, mood fluctuations and a decrease in cognitive function [27]. In musculoskeletal symptoms patients may have bony pains, non healing fractures, fatigue, proximal myopathy etc. Patients with hypercalcemia have short QT interval in ecg and severe hypercalcemia can precipitate ventricular fibrillation.[28]

The first step in evaluation of hypercalcemia mandates a thorough history and examination. Next step is to verify the hypercalcemia with repeat measurement on atleast two occasions (corrected calcium for albumin is to be taken) followed by PTH and vitamin D estimation. Based on the PTH value, patients can be classified into PTH dependant (PTH >65pg/ml) and PTH independent (PTH either low i.e. < 15pg/ml or low normal) causes of hypercalcemia. PTH dependant hypercalcemia is seen in primary hyperparathyroidism and FHH whereas PTH independent hypercalcemia is seen in malignancies, granulomatous diseases and vitamin D

intoxication.[5][7] Vitamin D intoxication is associated with increased 25hydroxy vitamin D levels whereas lymphoma and granulomatous diseases are suspected when 1,25dihydroxy vitamin D levels are raised.[29] Serum protein electrophoresis, tissue biopsies, CBNAAT(cartridge- based nucleic acid amplification test), serum ACE levels and radio-nuclear imaging etc. can be done to further narrow down the diagnosis.

The basic approach for management of hypercalcemia is first aimed at providing symptomatic relief to the patient followed by specific management of the underlying etiology. The four goals of the therapy are to correct dehydration, increase renal excretion of calcium, inhibit bone resorption followed by targeted management of underlying disease.[29]

The pattern and clinical scenario of hypercalcemia is changing in developed countries. There is scarcity of data on clinical profile of hypercalcemia from Indian subcontinent. This study aims at studying the clinico-etiological profile of patients presenting to our tertiary care centre with hypercalcemia and assessing the short term outcome in these patients. This study also intends to make the clinicians aware of the usefulness of this basic test (serum calcium) in diagnosing the ailment and hence help avoid unnecessary investigations by streamlining the approach to hypercalcemia.

AIMS AND OBJECTIVES OF THE STUDY

To determine the clinical-etiological profile of patients with hypercalcemia and further assess the outcome in these patients.

REVIEW OF LITERATURE

Calcium is an essential element for life that participates in various biochemical reactions. Most of the calcium in our body is sequestered in the skeleton as hydroxyapatite salt and it is the free ionized calcium which plays a main role in the cellular functioning and signaling.[1] Ionized calcium constitutes approximately 45% of serum calcium and the remaining 65% of the calcium is bound to various proteins like albumin (40% of calcium), citric acid, sulfate, and phosphate.[3][30]. Calcium not only keeps our bones healthy but also plays a vital role in neuromuscular transmission, coagulation pathway, hormonal secretion etc.[1] Only 10-20% of ingested calcium is absorbed in the small intestine mainly and the rest is being excreted with the stool.

Calcium homeostasis

Calcium homeostasis in body is maintained through a series of tight feedback mechanisms involving PTH (parathyroid hormone), calcitonin and vitamin D via fluxes of calcium from gastrointestinal tract, kidney and bone.[3] Whenever the serum calcium levels falls in our body, PTH stimulates the proximal renal tubules to convert 25-hydroxy vitamin D into 1,25 dihydroxy vitamin D (active vitamin D/calcitriol) by the 1-alpha-hydroxylase activity. This active vitamin D in turn increases the calcium and phosphate absorption in the gastrointestinal tract.[3][7] PTH also increases calcium reabsorption via thick ascending limb of the loop of Henle and distal convoluted tubule along with renal phosphorus excretion by direct action on the kidney . In addition, it mobilizes calcium from the bone with the help of active vitamin D.[7] All these steps help to increase and normalize serum calcium levels.

A schematic presentation of calcium homeostasis is being shown in the Figure 1 below [31]-

Figure 1: Showing schematic presentation of calcium homeostasis



Severity of hypercalcemia

Hypercalcemia is defined as total serum calcium levels more than 10.5 mg/dl or 2.5 mmol/l. The hypercalcemia is further classified as

1. Mild- 10.5 to 11.9 mg/dl (2.5-3mmol/l)
2. Moderate- 12-13.9 mg/dl (3-3.5mmol/l)
3. Severe- >14 mg/dl (>3.5mmol/l)

The hypercalcemic crisis is said when either severe neurological symptoms or cardiac arrhythmias are present in a patient with serum calcium levels more than 14 mg/dl or when serum calcium levels are more than 16 mg/dl. [2]

Azzabi S et al [32] studied the etiology of hypercalcemia in 47 patients at France. Their results showed a positive correlation between the grade of hypercalcemia and the severity of clinical symptomatology. In their study,

multiple myeloma, hyperparathyroidism and the neoplasms accounted for 78% of the total cases.

Causes of hypercalcemia

The most common etiology for hypercalcemia in any hospital setting is malignancy followed by symptomatic primary hyperparathyroidism (PHPT).[5] In outpatient settings, PHPT is the the most common observed cause of hypercalcemia.[33-34]

Mohammad Kuchay S, et al[5] did a retrospective study to determine the profile of hypercalcemia in patients presenting to a tertiary care hospital in north India. In this study, a total of 552 patients were found to have hypercalcemia.The incidence of hypercalcemia was reported to be 2.09%.The most common cause was found to be malignancy (23.1%) followed by PHPT (21.9%). They also observed the emergence of two other causes of hypercalcemia i.e. vitamin D intoxication and hypercalcemia of advanced chronic liver disease.

Frolich A et al[33]reviewed the literature with respect to the prevalence of hypercalcemia in normal and in hospital populations. He observed malignancy was the most common cause of hypercalcemia followed by primary hyperparathyroidism in hospital settings whereas in normal population the most common cause was found to be primary hyperparathyroidism followed by transient hypercalcemia. He also observed that the prevalence of hypercalcemia in hospital populations varied from 0.17% to 2.92% whereas the prevalence in normal populations varied between 1.07% - 3.9% which was more than the levels in hospital populations.

A study was conducted by Gupta CM[35] at AFMC, PUNE in which they observed 89 cases with hypercalcemia during the period of 1975-87 and found that malignancy of nonparathyroid tissue was responsible for hypercalcemia in 72 cases followed by primary hyperparathyroidism (11 cases), hypervitaminosis D (5cases) and sarcoidosis (1case). They concluded that every patient with hypercalcemia requires a careful

evaluation to establish the diagnosis so that specific treatment might be given.

Diamond T et al[36] did a 1-year retrospective study of all the patients with hypercalcemia analysed at the Johannesburg Hospital . They wanted to find the causes of hypercalcemia and access physician awareness of primary hyperparathyroidism. Hypercalcemia was seen in 560 subjects (2.9% of 19200), and in 147 of these (26%) patients it was not confirmed by repeat estimations. Malignancy was found to be the commonest cause (38.4%) and was associated with most severe hypercalcemia (mean serum calcium 2.93 mmol/I). They observed that the renal disease was also associated with significant hypercalcemia and at times required parathyroidectomy. Drug-associated hypercalcemia was seen to be mild and reversible on drug withdrawl. Although primary hyperparathyroidism was found in 21.3% of cases, overall physician awareness of the disease was poor (39%).

In a prospective study conducted by Dent D, et al[37], the incidence of hypercalcemia was found to be 0.6%, being transient in 19.2% subjects and sustained in the remainder. The most common cause in the sustained group was found to be malignancy (45%) followed by PHPT (16.5%).

The following Table 1 shows the common etiologies associated with hypercalcemia.[5]

Table 1- Showing common etiologies associated with hypercalcemia

Common causes of hypercalcemia	
Conditions associated with increased PTH (PTH dependant)	Conditions associated with decreased PTH (PTH independent)
1. Primary hyperparathyroidism	1. Malignancy
2 Benign familial hypocalciuric hypercalcemia (FHH)	2.Calcium and vitamin D supplements, thiazide diuretics
3. Lithium induced hypercalcemia	3. Sarcoidosis, Tuberculosis
	4. Immobilisation, Thyrotoxicosis
	5. Milk alkali syndrome

Malignancy associated hypercalcemia:

The pathophysiology of hypercalcemia of malignancy can be explained by following three mechanisms[7],[29]:

- excessive secretion of parathyroid hormone-related peptide (PTHrP)
- skeletal metastasis with the release of osteoclast activating factors
- production of 1,25-dihydroxy vitamin D (calcitriol)

Increased secretion of PTHrP is the most common cause of malignancy associated hypercalcemia and it accounts for about 80% of the cases. It is usually seen in solid tumors like squamous cell carcinoma of the head, neck and lungs, breast cancer, ovarian cancers, renal carcinoma and few hematological malignancies like leukemia.

Skeletal metastasis causing the release of osteoclast activating factors attributes to 20% of the cases and is seen with multiple myeloma and solid organ tumors that metastasize to bones like breast cancer.

Lymphoma and granulomatous diseases like sarcoidosis and tuberculosis cause hypercalcemia by increasing calcitriol production.

Wijaya et al [38] studied 40 patients with hypercalcemia of malignancy and found 22 patients had hematological malignancies and 18 had solid tumors. Amongst hematological malignancies, 15 patients had malignant lymphoma and seven had myeloma multiple. Among solid tumors, most common tumor was found to be breast(7) followed by lung(5), head and neck cancer. Prostate cancer, pancreatic cancer and renal cell carcinomas were found in 1 patient for each cancer type.

Hyperparathyroidism associated hypercalcemia-

Worldwide, the presentation of PHPT is changing from a symptomatic to an asymptomatic disease [39] but in India symptomatic presentation is still predominant. Even the symptomatic cases are picked up late in India after a series of consultations for fractures and renal stones by the orthopedicians and the urologists.

Mithal A[8] did a retrospective study and included all the patients who underwent evaluation and surgery for primary hyperparathyroidism (PHPT) from January 2009 to December 2012 . In this study the asymptomatic form of PHPT was found in many north Indian patients. They also observed that asymptomatic PHPT patients were older in age and had lower parathyroid adenoma weights as well as PTH levels compared to symptomatic PHPT patients. Positive correlations were found between the adenoma weight, serum calcium, ALP and PTH levels.

Priya et al[40] did a retrospective study in 39 patients with primary hyperparathyroidism. The mean age of the group was found to be 38.4 $\pm$15.0 years ,range 12–72. The most common presenting features were bone pain (80%), fatigue (80%) and proximal muscle weakness (78%). Brown tumours were present in 58% of cases, renal calculi in 42% and

nephrocalcinosis in 12%. The mean (SD) corrected serum calcium concentration observed was 12.47 (1.58) mg/dl.

The following (Table 2 & 3) shows the changing epidemiology of hyperparathyroidism and comparison of various biochemical parameters associated with hyperparathyroidism in various studies -

Table 2- Showing the changing epidemiology of HPTH in the developing countries[42]

Study	Patient population	Findings
Shah VN et al[43]	202 patients, divided into 4 time groups 1990-1994 (n = 6) ,1995-1999 (n = 22), 2000-2004 (n = 43), 2005-2010 (n = 131)	Clinical presentation did not change over different time periods; non-significant decrease in serum calcium; significant decline in the serum alkaline phosphatase level in the last decade.
Jha S et al[44]	110 patients, divided into 2 time groups: 1994-2007 (n = 51) ,2007-2015 (n = 59)	Pathological fractures more common in earlier subgroup, bone pain was more common in later subgroup; median PTH values were similar in two time groups
Yadav SK et al[45]	333 patients divided into 3 time groups: 1990–1999 (n = 34) ,2000–2009 (n = 112), 2010–2016 (n = 187)	Progressive increase in age at presentation; decline in proportion of patients presenting with musculoskeletal disease; decline in mean serum PTH and serum alkaline phosphatase level
Ohe MN et al[46]	104 patients divided into 3 subgroups 1985-1989 (n = 9) ,1990-1994 (n = 30) ,1995-2002 (n = 65)	Patients from earlier subgroup were significantly younger and had significantly higher serum calcium values
Zhao L et al[47]	249 patients presenting between 2000-2010; Compared symtomatic and asymtomatic PHPT	The overall features of PHPT not changed but asymptomatic presentation increased to 50% of all cases after 2007; symptomatic patients had significantly higher serum calcium, PTH, alkaline phoshatase, and higher parathyroid gland weight

Table 3- Showing comparison of various biochemical parameters associated with HPTH in various studies [41]

		Parameters associated with HPTH				
Studies	Location	Age (mean ± s.d)	S.calcium(mmol/l)	S.PTH (pg/ml)	S. ALP (IU/ml)	S. vitamin D (ng/ml)
Yamashitha et al [48]	Japan	58±12	10.8±0.7	127±59	127±54	14.7±6.6
Carnivale et al[49]	Italy	59.6±1.6	11.4±0.2	185.5±29.2	137.6±22.5	19±1.2
Mishra et al[50]	SGPGI, Lucknow	38	12.4±3.1	82.7pmol/l	1544	13.6±33.8nmol/l
Jacob et al[51]	CMC Vellore	median age 37	2.97±0.25mmol/l	623±714	426±549	NA
Bhansali et al[52]	PGI, Chandigarh	38±13	12.2±1.1	809±696	361±360	NA
Priya et al[40]	Mumbai	38.4±15	12.4±1.6	662.68±446.92	1086.8±1515	10.2±5.8

Vitamin D associated hypercalcemia

Over the recent years, Vitamin D intoxication has emerged as an important cause of hypercalcemia due to overcorrection of vitamin D deficiency.[13-17]. This increase is likely because of the irrational prescription on the part of physicians for non specific complaints as well as for general well being of the patients because of its enumerous health benefits. Since it is an easily available over the counter drug, so it is being used excessively by the general public in lieu of multivitamin being a tonic with several health benefits.

Mechanism of hypercalcemia in patients with vitamin D intoxication-

Hypercalcemia in vitamin D toxicity results from increased levels of vitamin D metabolites reaching the nuclear Vitamin D receptor (VDR) and enhancing the gene expressions by the following mechanisms[53]-

1. Direct action of 25 hydroxy vitamin D and other vitamin D metabolities on the l,25-(OH) D receptor.
2. Displacement of l,25-(OH) D from D-binding protein by the high 25 hydroxy vitamin D levels which results in an increase in the concentration of free calcitriol levels which is the active form .

In the study done by Pandita K et al[17] on 15 patients with iatrogenic vitamin D intoxication , most common symptoms were found to be altered sensorium (82.4%), dehydration (88.2%), vomiting (35.3%), anorexia (70.6%), fatigue (82.4%), generalised body weakness (88.2%), constipation (52.9%), polyuria (76.5%) and polydipsia (70.6%). No mortality was observed during the hospital stay as well as after 3 months of follow-up. Two patients had readmissions, within 1 month of discharge, with the symptoms of altered sensorium and gait instability and were again found to have hypercalcemia along with high levels of serum vitamin D.

Galior K, et al[13]showed that inappropriate use of vitamin D supplements can lead to toxicity and life-threatening hypercalcemia. The vitamin D doses were observed to be ranging from 50,000 IU/day to 2,604,000 IU/day. The calcium levels were found to be in the range of 11.1 to 23.08

mg/dL and serum vitamin D levels were greater than 150 ng/mL. The clinical features observed were nausea, vomiting, weakness, polyuria, nephrocalcinosis and renal failure. This study concluded that vitamin D levels above 150 ng/mL are associated with toxicity and hence should be avoided.

The comparison of various Indian studies illustrating vitamin D intoxication is being shown in the Table 4.

Table 4: COMPARISON OF VARIOUS INDIAN STUDIES WITH VITAMIN D INTOXICATION

	Misgar RA[53] (Aug'15- Aug'18)	Kaur P[14] (Jan'11-Jan '13)	Koul PA[15] (2000-2010)	Pandita KK[17] (Dec'09-Sep'11)
Vitamin D intoxication cut off (ng/ml)	>100	>150	>150	>100
Median age in years(range)	65 (3–77)	64.5 (42–86)	61 (self calculated)	61 (48-75)
Median cumulative vitamin D dose in IU (range)	4,200,000 (1,800,000-30,000,000)	3,600,000 (2,220,000–6,360,000)	-	Range (3,000,000-60,000,000)
Mean duration of vitamin D intake in weeks (range)	-	7.4 (4 -12)	-	-
Median serum calcium in mg/dl (range)	13.95 (11.1-17.2)	13.0 (11.1–15.7)	Median 13.2 (self calculated)	13.2 (12-14.2)
Median vitamin D level in ng/ml(range)	306 (105–2800)	371 (175–1161)	188 (self calculated)	188(100-306)
Median serum PTH in pg/ml(range)	8.1 (0.1-25.0)	18.9 (5.0–198)	6.65 (2.5-15.1)	-
Median time for resolution of symptoms in months(range)	7 (4–18)	-	9 (6-12)	-

Clinical profile of hypercalcemia

The clinical manifestations of hypercalcemia are well famous with the mnemonic “stones, bones, abdominal moans and psychic groans” since ages.[21] Indeed the major systems involved are gastrointestinal, musculoskeletal, neurological and renal. Among gastrointestinal symptoms decreased appetite and constipation are associated with mild hypercalcemia[22]. Nausea, vomiting, pain abdomen due to peptic ulcer disease, cholelithiasis or pancreatitis are associated with moderate to severe hypercalcemia. Renal features consists of nephrogenic diabetes insipidus leading to polyuria and distal renal tubular acidosis. On the other hand, chronic hypercalcemia can cause nephrolithiasis, nephrocalcinosis, renal tubular dysfunction and kidney failure.[25-26]. Neurological symptoms of mild hypercalcemia includes behavioral disturbances like anxiety, mood swings and a decrease in cognitive function. However, with higher values of calcium changes in mental status like stupor, coma or even death may occur.[27] In musculoskeletal symptoms patients may present with bony pains, non healing fractures, lethargy, proximal myopathy etc. It has been seen that patients with severe hypercalcemia are usually dehydrated which can be explained by polyuria and decreased oral intake secondary to nausea and vomiting. This may precipitate pre-renal failure along with alteration in sensorium. The common clinical features associated with hypercalcemia are shown in the Table 5 below:

Table 5- Clinical manifestations of hypercalcemia:[21][22][25][26]

Renal	Gastrointestinal	Musculoskeletal	Neurological	Cardiovascular
Polyuria	Anorexia, nausea, vomiting	Muscle weakness	Decreased concentration	Short QT interval
Polydipsia	Constipation	Bone pain	Confusion, stupor, coma	Bradycardia
Nephrolithiasis, nephrocalcinosis	Pancreatitis	Osteopenia/ osteoporosis		Hypertension
Distal RTA	Peptic ulcer disease	Fractures		Arrhythmias
Nephrogenic diabetes insipidus		Fatigue		
Acute and chronic renal failure				

A study was done in Kashmir valley by Misgar RA, et al[54], in which a total of 78 patients were identified with PHPT during the two decades. In this study, 29 patients were studied retrospectively and 49 patients were studied prospectively. They found the most common manifestation being renal either nephrolithiasis and/or nephrocalcinosis (64.10%) followed by bone pain (44.1%), abdominal pain (39%), constipation (26%) and myopathy (14.10%). Fractures were found in 10.25% and brown tumors in 6.41% patients. The cure rate after parathyroidectomy was great (96.15%).

Another study done by Gopal RA et al[55] described the clinical manifestations of primary hyperparathyroidism from western India in a retrospective study conducted at a tertiary care center. The most common symptoms at presentation were skeletal manifestations (75.5%), renal calculi (40.5%) and proximal muscle weakness (45.5%). The mean

duration of symptoms was 33.70 (median: 24, range 1-120) months. The investigations revealed hypercalcemia (total corrected calcium 12.55+/-1.77 mg/dl), low phosphorus (1.81+/-0.682 mg/dl), increased alkaline phosphatase levels (mean: 762.2; range: 50-4930IU/L) and high PTH (mean+/-SD: 866.61+/-799.15;range: 52-3820 pg/ml). Before surgery localization was done in 74 patients and single adenoma was found in 72 patients during surgery. Hungry bone syndrome was seen in 30.3% cases.

Diagnostic approach to hypercalcemia

A careful history and examination is the basis of medicine which one must not forget. Investigations on the other hand help in concreting the diagnosis and improving the management of the patient. In diagnostic approach to hypercalcemia, the first step in evaluation of hypercalcemia is to verify the hypercalcemia with repeat measurement on atleast two occasions. One needs to take corrected calcium for albumin, which is calculated via this formula: Calcium (mg/dl) + 0.8 (4.0 − patient's albumin level). Basic work up for etiology requires serum PTH, vitamin D, corrected calcium, phosphorus, renal function tests, alkaline phosphatase, hemoglobin, urinary calcium: creatinine ratio.[56]Normal PTH levels are 15-65pg/ml. Based on the PTH value, patients can be classified into PTH dependant (PTH >65pg/ml) and PTH independent (PTH either low i.e. < 15pg/ml or low normal) causes of hypercalcemia. Hyperparathyroidism is characterized by high PTH levels and hypercalcemia. Imaging like USG neck and Sestamibi scan can help localize adenoma before surgical exploration. On the other hand, patients with FHH will not only have a positive family history but also low urinary calcium to creatinine ratio (i.e. <0.1).[57] In patients with malignancy associated hypercalcemia, the PTH-related peptide levels are elevated but PTH levels are either low or low normal. A complete malignancy screening (imaging, tumor markers, serum protein electrophoresis etc.) followed by confirmatory tests (FNAC/biopsy) should be done. Patients with vitamin D intoxication have high serum concentrations of calcidiol, whereas, patients with

a granulomatous disease and lymphoma have high levels of calcitriol. Vitamin D intoxication is said to be present if vitamin D levels are >100 ng/ml.[17][54]

A basic algorithm for approach to hypercalcemia is shown below-[22][58]

DIAGNOSTIC APPROACH TO HYPERCALCEMIA



Treatment of hypercalcemia

The approach to treat hypercalcemia varies with severity.[59] Aggressive management should be done in case of severe hypercalcemia using a combination of drugs. This would not only help to alleviate symptoms but also help in preventing hypercalcemic crisis.

The first step in the management of hypercalcemia is to restore the volume status of the patient by giving i.v.(intravenous) fluids which in turn will increase glomerular filteration rate and enhance renal excretion of calcium.[29] Utmost care should be taken in patients with renal and cardiac failure to avoid fluid overload.

After restoring the volume, simultaneous administration of furosemide will help to inhibit tubular reabsorption of calcium.

Calcitonin is a peptide hormone which inhibits osteoclastic resorption and has a rapid onset of action. It helps lower calcium within 2 to 6 hours of administration. It is given at a dose of 4 to 8 IU/kg either i.m. (intramuscularly) or s.c. (subcutaneously). It has a limitation that it gets ineffective after 24-48 hrs of administration because of the development of tachyphylaxis.[60-62]

Bisphosphonates (zoledronic acid and pamidronate) also inhibits osteoclastic bone resorption and in addition inhibits osteoclast development and osteoblast apoptosis.[63-64] They have a sustained duration of action and requires less frequent dosing. Their effect can be seen after 2-4 days of administration. Zoledronic acid and pamidronate are commonly used for malignancy related hypercalcemia. The dose of zoledronic acid is 4mg i.v.(intravenously) administered over 15-30minutes. The dose of pamidronate is 60mg to 90 mg i.v. given over 2 to 24 hours. Precautions should be taken while giving bisphosphonates in patients with renal failure. Side effects of these drugs are flu like symptoms, acute kidney injury, esophageal irritation and rarely can cause osteonecrosis of jaw.

Denosumab- It is a human monoclonal antibody to RANKL (receptor activator of nuclear factor kappa – B ligand). It inhibits osteoclast activity and hence, bone resorption.[65] The dose of denosumab is 120 mg given subcutaneously . It can be repeated after 1-week following the first administration but not before that. [66] The hypocalcemic effect is observed within 2-4 days after the administration. The use of denosumab is reserved for cases of severe hypercalcemia which are refractory to other conventional treatment including bisphosphonates.[67-70] It can also cause osteonecrosis of jaw but is observed rarely.

Dialysis (with calcium free dialysate fluid) is usually reserved for patients either refractory to other therapies or in patients with cardiac and renal failure.

Calcimimetic agents like Cinacalcet is used in the treatment of hypercalcemia secondary to parathyroid carcinoma. It acts by decreasing PTH production. [71-72]

Steroids have a role in management of vitamin D intoxication and some malignancies like lymphoma and myeloma.[7] Prednisolone is given in dose of 20-40mg orally. The side effects of long term use of steroids are hypertension, hyperglycemia, peptic ulcer, myopathy etc.

Apart from this, general education of the patient regarding sustainable use of the supplements, early mobilization of the patient and adequate hydration also play a major role in prevention of hypercalcemia.

MATERIALS AND METHODS

Source of Data

This prospective study was conducted at Dayanand Medical College and Hospital, Ludhiana from 1st January 2019 to 31st December 2019. All the consecutive patients from emergency with verified hypercalcemia (total calcium corrected for albumin >10.5 mg/dl) atleast on two occasions were considered and patients fulfilling the inclusion criteria were enrolled in our study.

INCLUSION CRITERIA

- Age >18years
- Serum calcium levels >10.5mg/dl
- Patient/legally authorized representative (LAR) giving consent to participate in the study

EXCLUSION CRITERIA

- Age < 18 years
- Patient/legally authorized representative (LAR) who were not willing to participate in the study

METHOD OF COLLECTION OF DATA

Consecutive patients from emergency with verified hypercalcemia on two occasions were enrolled in our study to evaluate for etiology, clinical profile, treatment and outcome. Further, they were followed up at an interval of one and three months respectively. A total of 200 patients met the selection criteria and were selected for the study. A detailed history considering the demographics, symptoms, past history, personal history including the drug history and family history was taken followed by detailed general and systemic examination. All the details were duly recorded in the proforma attached.

Apart from routine investigations, special investigations were carried out on the basis of provisional diagnosis like serum protein electrophoresis, tissue biopsies and aspiration cytologies, parathyroid assay, thyroid

profile, serum ACE levels etc. Relevant radio-nuclear imagings were done wherever they were necessary and feasible.

Fasting blood samples were collected in serum separator tubes containing gel and clot activator for estimation of serum total calcium, inorganic phosphorus, renal function tests, liver function tests, 25 hydroxy vitamin D or 25 (OH) D and parathyroid hormone (PTH). Serum calcium levels were analyzed using o-cresophthalein dye binding technique on an automated analyzer. Serum vitamin D and PTH levels were measured using electrochemiluminescence immunoassay (ECLIA) technique on an automated analyzer. All the patients with hypercalcemia were evaluated for etiology, clinical presentation, treatment and outcome.

The treatment was given as per the disease protocol.

The outcome was measured in terms of clinical course within the hospital followed by discharge, discharge on request (DOR), discharge against medical advice (DAMA) or death. Further, patients were followed up at an interval of 1 month and 3 months respectively.

STATISTICAL ANALYSIS-

Data was described in terms of range; mean ±standard deviation (± SD), median, frequencies (number of cases) and relative frequencies (percentages) as appropriate. Chi-square test was used for comparison between categorical variables and $P<0.05$ was considered statistically significant.

All statistical calculations were done using SPSS (Statistical Package for the Social Science) SPSS 21 version statistical program for Microsoft Windows.

OBSERVATIONS AND RESULTS

All the consecutive patients with verified hypercalcemia on two occasions presenting to Dayanand Medical College and Hospital, Ludhiana from 1 st January 2019 to 31 st December 2019 were enrolled in our study. Further, they were followed up at an interval of one and three months respectively.

- **Demographic characteristics of study population**

The baseline demographic characteristics of patients studied are shown in the following table (Table -6)

Table 6: BASELINE DEMOGRAPHIC CHARACTERISTICS OF PATIENTS IN OUR STUDY

Age group (in years)	No. of cases	Percentage
18-40	22	11.0%
41-60	87	43.5%
61-80	85	42.5%
>80	6	3.0%
Gender		
Female	97	48.5%
Male	103	51.5%
Serum calcium (in mg/dl) (at admission)		
Mild (10.5-11.9 mg/dl)	82	41.0%
Moderate (12-13.9mg/dl)	62	31.0%
Severe (>14 mg/dl)	56	28.0%

The mean age of the cohort associated with hypercalcemia was found to be 58.3 years ± 13.6 (range 18.0 – 95.0 years). There were 103 (51.5%) males (mean age 56.8 years ± 14.4 , range 18.0 – 83.0 years) and 97 (48.5%) females (mean age 59.8 years ± 12.6 , range 17.0 – 95.0 years) Majority of the cases in our study had mild hypercalcemia (n = 32, 41%)

at admission while those with moderate and severe hypercalcemia were (n= 62 , 31%) and (n = 56 , 28%) respectively.

- **Clinical manifestations of patients with hypercalcemia**

Table 7: CLINICAL MANIFESTATIONS OF PATIENTS WITH HYPERCALCEMIA

Symptoms		No. of cases	Percentage
Gastrointestinal	Nausea	123	61.5%
	Vomiting	89	44.5%
	Anorexia	147	73.5%
	Weight loss	78	39.0%
	Constipation	19	9.5%
	Abdominal pain	70	35.0%
	Dyspepsia	31	15.5%
Renal	Loin pain	6	3.0%
	Polyuria	18	9.0%
	Nocturia	16	8.0%
Musculoskeletal	Bony pain	58	29.0%
	Fracture	16	8.0%
Neurological	Altered sensorium	59	29.5%
	Depression	6	3.0%
Generalised	Fatigue	98	49.0%
	Weight loss	72	36.0%

Amongst symptoms, gastrointestinal symptoms were the most common group of symptoms in our study. Anorexia was found to be the most common individual symptom present in 147 (73.5%) patients followed by nausea 123 (61.5%) and fatigue 98 (49.0%).

Figure 2: CLINICAL MANIFESTATIONS OF PATIENTS WITH HYPERCALCEMIA



- **Correlation among age, gender and symptoms with hypercalcemia**

Table 8: CORRELATION AMONG AGE, GENDER AND SYMPTOMS WITH HYPERCALCEMIA

		Hypercalcemia (at admission)						Total	Chi-square value	p-value
		Mild (n=82)		Moderate (n=62)		Severe (n=56)				
Age group (in years)	18-40	15	18.3%	4	6.4%	3	5.4%	22	8.238	0.221
	41-60	33	40.2%	28	45.2%	26	46.4%	87		
	61-80	31	37.8%	28	45.2%	26	46.4%	85		
	>80	3	3.7%	2	3.2%	1	1.8%	6		
Gender	Female	44	53.7%	26	41.9%	27	48.2%	97	1.945	0.378
	Male	38	46.3%	36	58.1%	29	51.8%	103		
Symptoms	Gastrointestinal	79	96.3%	54	87.1%	53	94.6%	186	4.957	0.084
	Renal	7	8.5%	8	12.9%	9	16.1%	24	1.858	0.395
	Neurological	23	28.0%	29	46.8%	18	32.1%	70	5.721	0.057
	Generalised	38	46.3%	41	66.1%	34	60.7%	113	6.187	0.045
	Musculoskeletal	15	18.3%	16	25.8%	23	41.1%	54	8.825	0.012

It was observed that there was no statistical difference in the age and gender of patients with the severity of hypercalcemia. Amongst symptoms, the incidence of generalised symptoms was found to be more with moderate and severe hypercalcemia as compared to the mild hypercalcemia (p value < 0.05). However, the incidence of musculoskeletal symptoms was found to be more common in patients with severe hypercalcemia (p value < 0.05).

- **Etiology of hypercalcemia in our study population**

Table 9: ETIOLOGY OF HYPERCALCEMIA IN OUR STUDY

Etiology		No. of cases	Percentage
Malignancy		85	42.50%
Probable Malignancy		5	2.50%
Hyperparathyroidism		45	22.50%
Drug induced	Vitamin D intoxication	29	14.50%
	Thiazide	2	1.00%
	Lithium	1	0.50%
CLD (chronic liver disease)		12	6.00%
Thyrotoxicosis		7	3.50%
Granulomatous diseases	Tuberculosis	5	2.50%
	Sarcoidosis	1	0.50%
Other		8	4.00%

Malignancy was found to be the commonest cause of hypercalcemia in 85 (42.5%) cases followed by hyperparathyroidism in 45 (22.5%) cases. Five (2.5%) cases were classified in the category of probable malignancy. Amongst drug induced hypercalcemia, Vitamin D intoxication was found in 29 (14.5%) patients, thiazide induced hypercalcemia in 2 (1%) patients and lithium induced hypercalcemia in 1 (0.5%) patient. Advanced chronic liver disease (CTP grade B and C) was also seen to be associated with hypercalcemia in 12 (6%) cases with no other apparent cause of

hypercalcemia in these patients. Thyrotoxicosis was seen in 7 (3.5%) cases . Granulomatous etiology was found in six patients, out of which 5 (2.5%) patients had tuberculosis and 1 (0.5%) had sarcoidosis. There were eight patients in which either the cause could not be determined or had very rare cause of hypercalcemia like immobilization, chronic kidney disease etc.

Figure 3: ETIOLOGY OF HYPERCALCEMIA IN OUR STUDY



- **Malignancy associated hypercalcemia**

The mean age associated with malignancy was found to be 60.3 years ± 11.1 (range 18.0 – 82.0 years), 40 being females (mean age 60.6 years ± 8.0 , range 42.0 – 80.0 years) and 45 being males (mean age 60.0 years ± 13.4 , range 18.0 – 82.0 years).

Table 10: COMMONEST MALIGNANCIES ASSOCIATED WITH HYPERCALCEMIA IN OUR STUDY

Cancer	No. of cases	Percentage
Multiple myeloma	32	37.6%
Lymphoma	13	15.3%
Breast cancer	10	11.8%
Ovarian cancer	7	8.2%

Of all the malignancies associated with hypercalcemia, the most common malignancy associated with hypercalcemia in our study was found to be multiple myeloma (n = 32 ; 37.6%) followed by lymphoma (n=13 ; 15.3%), breast cancer (n=10 ; 11.8%) and ovarian cancer (n = 7 ; 8.2 %). Other malignancies associated with hypercalcemia were esophageal cancer (n=4 ; 4.7%), gall bladder and bile ducts cancer (n= 4 ; 4.7%), hepatocellular carcinoma (n=3 ; 3.5%), bladder cancer (n= 3 ; 3.5%), penile cancer (n= 1 ; 1.2%), cervical cancer (n = 1 ; 1.2%), renal cell carcinoma (n = 1 ; 1.2%), head and neck cancers (n =2 ; 2.4%), lung cancers (n= 2 ; 2.4%) and CML (n= 1 ; 1.2%).

Table 11: CORRELATION AMONG AGE, GENDER AND SYMPTOMS WITH MALIGNANCY

		Malignancy				Total	Chi-square value	p-value
		No (n= 115)		Yes (n = 85)				
Age group (in years)	18-40	17	14.8%	5	5.9%	22	7.478	0.058
	41-60	51	44.4%	36	42.3%	87		
	61-80	42	36.5%	43	50.6%	85		
	>80	5	4.3%	1	1.2%	6		
Gender	Female	57	49.6%	40	47.1%	97	0.123	0.726
	Male	58	50.4%	45	52.9%	103		
Symptoms	Gastrointestinal	105	91.3%	81	95.3%	186	1.195	0.274
	Renal	18	15.7%	6	7.1%	24	3.418	0.064
	Neurological	37	32.2%	33	38.8%	70	0.950	0.330
	Generalised	46	40.0%	67	78.8%	113	29.974	0.001
	Musculoskeletal	26	22.6%	28	32.9%	54	2.647	0.104

Most of the patients with malignancy were found to be in the age group of 61 – 80 years (n = 43 , 50.6%). No statistical correlation was observed in patients with malignancy and without malignancy with respect to the age (p value >0.05). Similarly, no statistical significance was observed between gender and malignancy (p value>0.05).

Most common group of symptoms associated with malignancy were gastrointestinal (n =81 , 95.3%) followed by generalised (n = 67 , 78.8 %), neurological (n= 33, 38.8%) , musculoskeletal (n= 28 , 32.9%) and renal symptoms (n= 6 , 7.1%). Also it was seen that the incidence of generalised symptoms was found to be more in patients with malignancy as compared to the patients without malignancy (p value < 0.05) .

- **Hyperparathyroidism associated hypercalcemia**

In our study, 45(22.5%) patients out of 200 were found to have hyperparathyroidism.

Table 12: RELATIONSHIP AMONG AGE, GENDER AND SYMPTOMS WITH HYPERPARATHYROIDISM

		Hyperparathyroidism				Total	Chi-square value	p-value
		No(n=155)		Yes(n=45)				
Age group (in years)	18-40	10	6.4%	12	26.7%	22	24.988	0.001
	41-60	62	40.0%	25	55.5%	87		
	61-80	77	49.7%	8	17.8%	85		
	>80	6	3.9%	0	0.0%	6		
Gender	Female	78	50.3%	19	42.2%	97	0.916	0.338
	Male	77	49.7%	26	57.8%	103		
Symptoms	Gastrointestinal	143	92.3%	43	95.6%	186	0.583	0.445
	Renal	14	9.0%	10	22.2%	24	5.746	0.017
	Neurological	64	41.3%	6	13.3%	70	11.982	0.001
	Generalised	103	66.5%	10	22.2%	113	27.759	0.001
	Musculoskeletal	45	29.0%	9	20.0%	54	1.444	0.230

The mean age associated with hyperparathyroidism was found to be 48.9 years ± 13.1 (range 18.0 – 72.0 years), 19 being females (mean age 50 years ± 13.6 , range 18.0 – 72.0 years) , 26 being males (mean age 48.1 years ± 13.0 , range 20.0 – 69.0 years). It was observed that the incidence of hyperparathyroidism was found to be the most common in the age group of 41 – 60 years (p value <0.05). However, no statistical significance was seen between gender and hyperparathyroidism.

Amongst symptoms, gastrointestinal group of symptoms were found to be the most common in patients with hyperparathyroidism (n=43,95.6%). Also it was observed that the incidence of renal symptoms was found to be

more in patients with hyperparathyroidism as compared to the patients without hyperparathyroidism (p value <0.05) whereas, the incidence of neurological, generalised and musculoskeletal symptoms was found to be more in the non hyperparathyroidism group.

It was observed that many patients were brought to the clinical attention because of the pain abdomen due to various etiologies like pancreatitis 20 (44.44%), cholelithiasis 16 (35.55%), gall bladder sludge 9 (20%), nephrolithiasis 10 (22.22%), nephrocalcinosis 1 (2.22%) and ureteric stones 1 (2.22%). Further on subsequent evaluation, these patients were found to have hyperparathyroidism.

Table 13: RADIONUCLEAR IMAGING IN HYPERPARATHYROIDISM

		USG neck		Sestamibi scan	
Cases diagnosed (number and %)		32	71.10%	45	100%
Location of parathyroid adenoma	Right superior	2	6.2%	4	8.9%
	Right inferior	12	37.5%	16	35.6%
	Left superior	2	6.3%	5	11.1%
	Left inferior	16	50.0%	20	44.4%

All the patients with hypercalcemia and increased levels of parathyroid hormone were subjected to radio-nuclear imaging to confirm hyperparathyroidism. The diagnosis of parathyroid adenoma had been made in 32 (71.11%) cases on the basis of USG neck whereas the additional 13 patients (total = 45) were diagnosed on the basis of

sestamibi scan. In our study, most of the parathyroid adenoma were found to be situated in left-inferior location on radio-nuclear imaging (n=16, 50% on USG neck and n=20, 44.4% on sestamibi scan).

Along with the medical treatment , it was observed that 24 (53%) cases got parathyroidectomy done during the hospital stay whereas the remaining 10 (22%) and 4 (9%) patients had undergone surgery by one month and three months of follow up respectively. Seven (15.5%) patients didn't get any surgical procedure done because of the underlying co-morbities and were managed with medical treatment only.

- **Drug induced hypercalcemia**

In this study, a total of 29 patients (14.5%) had vitamin D intoxication with levels more than equal to 100 ng/ml either due to iatrogenic or over the counter self-consumption of vitamin D supplements.

Table 14: RELATIONSHIP AMONG AGE, GENDER AND SYMPTOMS IN PATIENTS WITH VITAMIN D INTOXICATION

		Vitamin D intoxication				Total	Chi-square value	p-value'
		No (n=171)		Yes(n=29)				
Age group (in years)	18-40	19	11.1%	3	10.3%	22	6.790	0.079
	41-60	77	45.0%	10	34.5%	87		
	61-80	72	42.1%	13	44.8%	85		
	>80	3	1.8%	3	10.3%	6		
Gender	Female	82	48.0%	15	51.7%	97	0.141	0.707
	Male	89	52.0%	14	48.3%	103		
Symptoms	Gastrointestinal	162	94.7%	24	82.8%	186	5.465	0.019
	Renal	18	10.5%	6	20.7%	24	2.425	0.119
	Neurological	57	33.3%	5	17.2%	62	3.002	0.083
	Generalised	100	58.5%	17	58.6%	117	0.000	0.989
	Musculoskeletal	42	24.6%	18	62.1%	60	16.610	0.001

It was observed that the mean age associated with Vitamin D intoxication was found to be 62.6 years ± 14.4, (range 30.0 – 85.0 years), 15 being females (mean age 63.4 years ± 15.2, range 30.0 – 85.0 years) and 14 being males (mean age 61.9 years ± 14.2, range 36.0 – 83.0 years). It was observed that the maximum number of patients (n= 13; 44.8 %) with Vitamin D intoxication were found to be in the age group of 61 – 80 years. No statistical difference was found between the gender and Vitamin D intoxication.

It was observed in our study that the median dose of 60000 IU per day or median cumulative dose of 300,000 IU (60,000-600,000) of vitamin D over median duration of 225 days was associated with vitamin D intoxication. The mean calcium levels associated with Vitamin D intoxication were found to be 12.9 mg/dl ± 1.6.

Majority of the cases (n= 24, 82.8 %) had gastrointestinal group of symptoms followed by musculoskeletal (n= 18, 62.1%) and generalised (n = 17, 58.6 %). It was also noticed that the results were found to be statistically significant (p value <0.05) for musculoskeletal group of symptoms which were seen more in patients with Vitamin D intoxication (62.1%) as compared to the patients without Vitamin D intoxication(24.6%). Amongst renal symptoms all the five patients had polyuria and one had nocturia. None had renal stones.

In other causes of drug induced hypercalcemia, thiazide induced hypercalcemia was reported in 2 (1%) patients who were consuming 25mg of thiazides for more than a year. One (0.5%) patient was found to have lithium induced hypercalcemia who was consuming lithium for psychiatric illness since 1972 in the dose of 800mg per day.

- **Other causes of hypercalcemia**

Other causes were found to be thyrotoxicosis in 7 (3.5%) patients (n=6 females, n=1 male), granulomatous diseases like tuberculosis in 5 (2.5%) cases (n = 2 females , n =3 males) and sarcoidosis in 1 (0.5%) case who was male .We also found an unsual group as the cause of hypercalcemia i.e. chronic liver disease (CTP grade B and C) present in 12 (6%) cases out of which there were four females and eight males. In 8 (4%) cases the cause could either not be determined or was related to uncommon etiology like hypercalcemia of immobilization, chronic kidney disease etc.

- **Outcome of patients with hypercalcemia**

Table 15- OUTCOME OF PATIENTS WITH HYPERCALCEMIA IN HOSPITAL

	In hospital outcome								Total	Chi-square value	p-value
	Discharge (n=138)		DOR (n=31)		DAMA(n=22)		Death (n=9)				
Malignancy	50	36.20%	15	48.40%	16	72.70%	4	44.40%	85		
Hyperparathyroidism	34	24.60%	7	22.60%	2	9.10%	2	22.20%	45	2.631	0.452
Drug induced	26	18.80%	3	9.70%	2	9.10%	1	11.10%	32	2.692	0.442
CLD	10	7.20%	1	3.20%	0	0.00%	1	11.10%	12	2.262	0.453
Thyrotoxicosis	5	3.60%	0	0.00%	2	9.10%	0	0.00%	7	3.493	0.322
Granulomatous disease	5	3.60%	1	3.20%	0	0.00%	0	0.00%	6	0.952	0.813
Probable Malignancy	2	1.45%	3	9.68%	0	0.00%	0	0.00%	5	7.972	0.047
Other	6	4.30%	1	3.20%	0	0.00%	1	11.10%	8	5.831	0.757

It was observed that most of the patients were discharged (n=138, 69%), 31(15.5%) were discharged on request (DOR) and 22 (11%) were discharged against medical advice (DAMA). Most of the patients who were discharged against medical advice had underlying malignancy (n=16, 72.7%).

Table 16- OUTCOME OF PATIENTS WITH HYPERCALCEMIA AT 3 MONTHS OF FOLLOW UP

	Outcome at 3 months of follow up				Total	Chi-square value	p-value
	Died (n=22)		Alive (n=178)				
Malignancy	15	68.20%	70	39.30%	85	6.672	0.010
Hyperparathyroidism	2	9.10%	43	24.20%	45	2.549	0.173
Drug Induced	2	9.10%	30	16.90%	32	0.934	0.630
CLD	1	4.50%	11	6.20%	12	1.257	0.533
Thyrotoxicosis	1	4.50%	6	3.40%	7	1.012	0.603
Granulomatous disease	0	0.00%	6	3.40%	6	0.634	0.426
Probable Malignancy	0	0.00%	5	2.81%	5	0.634	0.426
Other	1	4.50%	7	3.90%	8	4.405	0.622

It was also observed that 9 patients had in hospital mortality whereas additional 13 patients died at the end of one month of follow up. No further mortality was observed by the end of three months of follow up. Out of these maximum patients died of malignancy (n= 15 , 68.2%) and four among these had in hospital mortality. Two (9.1%) patients with hyperparathyroidism died during hospital stay because of multiorgan dysfunction secondary to pancreatitis. One patient (4.5%) died of decompensated CLD in hospital. Among two patients (9.1%) in drug induced group, one died of sepsis due to pyelonephritis in hospital and in the other one cause could not be determined. One patient with thyrotoxicosis died of aspiration of the variceal bleed as she had underlying chronic liver disease.

- **Management of patients with hypercalcemia**

First line of treatment for all the patients was aimed at providing symptomatic relief by reducing calcium levels through medical management followed by definitive management of underlying etiology. In medical management patients were given iv fluids (n = 190, 95.0%), calcitonin (n = 191, 95.5%), furosemide (n = 182, 91.0%), bisphosphonates (n = 29 , 14.5%), steroids (n = 60 , 30%) and denosumab (n = 1 , 0.05%). Also dialysis was done in 33 (16.5%) cases. Steroids were given in patients with vitamin D intoxication, lymphoma and multiple myeloma. Chemotherapy and radiotherapy were given in 49 (24.5%) patients with malignancy whereas surgical procedures (debulking surgery or palliative procedures like PTBD) were done in 10 (5%) cases of malignancy. Parathyroidectomy was done in 24 (12%) patients with hyperparathyroidism during hospital stay whereas additional 14(31.1%) patients got it done by end of three months of follow up.

DISCUSSION

This prospective study was carried out at Dayanand Medical College and Hospital, Ludhiana, over a period of 1 year i.e. 1st January 2019 to 31st December 2019. Consecutive patients from emergency with verified hypercalcemia on two occasions were enrolled in our study to evaluate for etiology, clinical profile, treatment and outcome. Further, they were followed up at an interval of one and three months respectively.

A total of 200 patients fulfilling the inclusion criteria were enrolled in the study.

Age distribution

In the present study majority of the patients (n=87,43.5%) were between the age group of 41-60years . Eighty five patients (42.5%) were in the age group of 61-80 years whereas 22(11%) and 6 (3%) patients were in the age group of 18-40 and > 80 years respectively. The mean age of the cohort associated with hypercalcemia was found to be 58.3 years ± 13.6 (range 18.0 – 95.0 years) in our study and this figure was in close range to the study conducted by Mohammad Kuchay S et al[5] (55.2 years ±17.9)**.**

Gender distribution

There was no significant difference in the gender distribution of the cases included in our study (males-103, females-97). Our results were not in accordance with another study from north India done by Mohammad Kuchay S et al[5] who studied 552 patients with hypercalcemia and found male preponderance (males-322, females-230). However, our results were in accordance with the studies from the western literature done by Catalano et al[73] and Lindner G et al[74]. Catalano et al found hypercalcemia in 50.9% females and 49.1% males out of 585 patients studied with hypercalcemia. Similarly, the study by Lindner G et al[74] didn't show significant difference in the gender distribution (females-53%, males-47%).

Severity of hypercalcemia

The hypercalcemia was classified as mild (10.5-11.9mg/dl), moderate (12-13.9 mg/dl) and severe (>14mg/dl). Majority of the cases in our study had mild hypercalcemia (n=82,41%) at admission while those with moderate and severe hypercalcemia were (n=62, 31%) and (n=56, 28%) respectively.

Our results were comparable with the study from another Asian country (China) done by Lee CT et al[75] who also found majority of the cases with mild hypercalcemia (n=221 ,70.7%) followed by moderate (n=72 ,21.2%)and severe hypercalcemia (n= 28 ,8.1%).

Majority of the patients presenting with severe hypercalcemia in our study were found to have malignancy (n= 31, 55.3%) followed by hyperparathyroidism (n=12, 21.4%) and vitamin D intoxication (n=8, 14.2%). Hence in an admitted patient with severe hypercalcemia, malignancy should be kept as first differential followed by hyperparathyroidism and further work up should be planned on the basis of clinical history and examination.

In our study no significant difference was observed in the gender distribution with the severity of hypercalcemia whereas in the study conducted by Lee CT et al[75], more males(n=20) were found in the severe hypercalcemia group than females(n=8).

A significant association of musculoskeletal symptoms with the severity of hypercalcemia was observed in our study (p value-0.012). Twenty three (41.1%) patients with musculoskeletal symptoms had severe hypercalcemia whereas patients with moderate and mild hypercalcemia were 16 (25.8%) and 15 (18.3%) respectively. This correlates with the fact that majority of these patients had underlying malignancy or hyperparathyroidism, causing musculoskeletal pain as well as severe hypercalcemia secondary to metastasis and osteoclastic bone resorption.

Etiology of hypercalcemia

In our study malignancy was found to be the commonest cause of hypercalcemia in (n= 85, 42.5%) cases followed by hyperparathyroidism (n=45, 22.5%) and Vitamin D intoxication (n=29, 14.5%).

Other etiologies were: chronic liver disease (n=12, 6.0%), thyrotoxicosis (n =7, 3.5%), granulomatous diseases like tuberculosis (n=5, 2.5%) and sarcoidosis (n=1, 0.5%), drugs like thiazides (n=2, 1%) and lithium (n=1, 0.5%), chronic kidney disease (n=1, 0.5%) and hypercalcemia of immobilization (n=1, 0.5%). There were 11 patients in which exact etiology could not be ascertained. Out of these 11 patients, five patients probably had malignancy but were not much evaluated due to unwillingness on the part of patient and attendants.

Our findings were in accordance with the studies from Indian as well as western literature. In the study done by Mohammad Kuchay S et al[5] ,the most common cause of hypercalcemia was found to be malignancy (32.6%) followed by hyperparathyroidism (29.2%). Gupta CM et al[35] also reported malignancy as the most common cause seen in 80.9% patients followed by hyperparathyroidism (12.3% cases) in his study. The findings were also comparable with the studies by Azzabi et al[32], Frolich A et al[33] and Dent D et al[27] from other countries.

Hence over the last three decades, the literature reveals malignancy and hyperparathyroidism to be the most common cause for hypercalcemia in any hospital setting.

Clinical manifestations of hypercalcemia

The clinical manifestations of hypercalcemia are multisystemic, well known by the mnemonic “stones, bones, abdominal moans and psychic groans” since ages.[21] In our study, majority of the patients had gastrointestinal group of symptoms (n=186,93%) followed by generalised (n=117, 58.5%), neurological (n=62, 31%), musculoskeletal (n=60,30%) and renal (n=24,12%) symptoms. Of the individual manifestations, anorexia was found to be the most common (n=147, 73.5%) followed by

nausea (n= 123 ,61.5%) and fatigue (n=91 ,45.5%). On the contrary, in the study conducted by Lindner G et al[74] weakness was found to be the most common symptom (44%) followed by nausea (28%) and disorientation (19%).

Analysis of various causes of hypercalcemia

A. PTH independent hypercalcemia

1. Malignancy associated hypercalcemia

Of the malignancies, hematological malignancies were found to be more common (n=46, 54.1%) as compared to the solid tumors (n=39,45.9%). Amongst the hematological malignancies there were multiple myeloma (n=32,37.6%), lymphoma (n= 13, 15.3%) and CML (n=1, 1.2%).

Other malignancies associated with hypercalcemia in our study were breast cancer (11.8%), ovarian cancer (8.2 %), esophageal cancer (4.7%), gall bladder and bile ducts cancer (4.7%) , hepatocellular carcinoma (3.5%), bladder cancer (3.5%), penile cancer (1.2%), cervical cancer (1.2%), renal cell carcinoma (1.2%) , head and neck cancers (2.4%), lung cancers (2.4%) and metastasis with unknown primary (1.2%).

The results in our study were comparable with an Indian study done by Mohammad Kuchay S et al[5], a south asian study conducted by Wijaya et al[38] and a western study conducted by Mousseaux C et al[76] In the study conducted by Mohammad Kuchay S et al, hematological malignancies were the most common (25.8%) of all malignancies followed by gastrointestinal cancer (16.1%) and head neck cancers(16.1%). In the study conducted by Mousseaux C et al hematological malignancies were seen in 44.3% and solid tumors in 22.1% of cases. Similarly, Wijaya et al observed hematological malignancies (55%) more than solid tumors (44%).

Our results were not consistent with other study from an Asian country (Hong Kong) done by Shek et al[77] in which lung cancer was found to be the most common etiology and breast cancer the least. This difference might be attributed to the variation in geographical location, genetic

composition, demographics, oncology service availability and diagnostic facility.

The mean age of the patients associated with malignancy in our study was 60.3 years ± 11.1 (range 18.0 – 82.0 years) which was consistent with the Indian study conducted by Mohammad Kuchay S et al and another study done by Gastanaga VM et al[78] in the western country. In the study done by Mohammad Kuchay S et al[5], the mean age of the patients associated with malignancy was found to be 56.3 years whereas in the study done by Gastanaga VM et al[78], 65% of the cancer patients with hypercalcemia were aged ≥65 years.

Hence, malignancy should be kept as a differential in patients presenting with hypercalcemia with age around 60 years.

There was no significant difference in the gender distribution of cases with malignancy (males-45, females-40) in our study and results were comparable to the study by Wijaya et al[65], (males-21, females-19). Our results were not consistent with the study done by Mohammad Kuchay S et al[5] who observed male preponderance in his study with males being 89 and females being 35. This difference can be attributed to the low sample size in our study.

Mean calcium levels associated with malignancy in our study were 13.4mg/dl ± 1.9.

2. Vitamin D intoxication

Vitamin D intoxication is the most common cause of drug induced hypercalcemia (n=29,14.5% of total 200 cases). A recent surge of cases has been observed in this category not only due to the lack of knowledge of rational pharmacotherapy on the part of physicians but also because of self-consumption with over the counter formulations of vitamin D amongst general public in lieu of several benefits.

Cut off value for vitamin D intoxication was taken to be ≥100ng/ml in our study. There were 15(51.7%) females and 14 (48.3%) males in this study. No significant association was seen between the gender and vitamin D

intoxication. The data in our study was consistent with the study conducted by Kaur P et al[14] in north India in which there were 7 males and 9 females whereas Misgar RA et al[53] observed slightly female preponderance with 19 females and 13 males.

Most of the cases were found in the age group of 61-80 years (n=13,44.8%) in our study followed by 41-60 years (n=10, 34.5%). The median age associated with vitamin D intoxication was found to be 65 years (54.0-73.5). The results were found to be comparable with other Indian studies like Misgar RA et al[53] and Kaur p et al[14], who also found the median age to be 65 years (3.0-77.0) and 64.5 years (42.0-86.0) respectively.

Mean and median calcium levels were found to be 12.9 mg/dl ±1.6 and 12.4mg/dl(11.4-14.2) respectively. The results were not comparable with the other Indian studies by Misgar RA et al[51] and Kaur P et al[14] who observed the median calcium levels to be 13.9mg/dl (11.1-17.2) and 13mg/dl (11.1-15.7) .

Median vitamin D levels were found to be 163ng/ml (139.0-163.0).

It was observed in our study that either median cumulative dose of 300,000.0 IU (60,000.0 - 600,000.0) or median dose per day of 60,000.0 IU of vitamin D over median duration of 29.6 weeks (1.4-52.1) could lead to vitamin D intoxication.

In the study by Kaur P et al[14] it was observed that the median cumulative dose of 3,600,000.0 IU/ml (2,220,000.0 - 6,360,000.0) over 7.4 weeks (4.0-12.0) was associated with vitamin D intoxication. Thus it might be concluded that vitamin D intoxication is both dose and duration dependant.

The indications for prescription of vitamin D in our study were bony pains (n=17), fatigue (n=17), fracture (9) and chronic kidney disease (n=2). Similarly, indications for prescription of vitamin D were almost the same in the study done by Kaur P et al[14] and Misgar RA et al[53].

Hence, irrational prescription for non specific symptoms with huge doses of vitamin D for prolonged duration should be avoided. Prior documentation of vitamin D levels should be done before prescribing. Patient should also be educated about the possible side effects of prolonged or frequent medication on their own.

Most common group of symptoms associated with vitamin D intoxication were gastrointestinal 24(82.7%) followed by bony symptoms seen in 18 (62.0%), generalised symptoms seen in 17(58.6%) and renal symptoms seen in 6 (20.7%). None had nephrolithiasis, nephrocalcinosis or pancreatitis in our study. Similarly, Misgar RA et al[53] also found the incidence of gastrointestinal symptoms (constipation, nausea, vomiting) being the most common (n= 30, 93.7%) in their study followed by polyuria and polydipsia in 15 (46.8%) patients . But they also observed altered sensorium in 12 (37.5%) patients, pancreatitis in 4 (12.5%) and nephrocalcinosis in 6 (18.7%) patients.

In our study, one patient with vitamin D intoxication had in hospital mortality due to sepsis and multi organ dysfunction whereas the other patient expired by one month of follow up, cause could not be determined.

In another north Indian study conducted by Pandita KK et al[17], between December 2009 and September 2011, found that none of the patients out of 15 died either during the hospital stay or after 3 of months of follow up whereas in the study done by Kaur P et al[14], only one patient had in hospital mortality due to aspiration pneumonitis secondary to poor Glasgow coma scale.

Hence, it may be concluded that vitamin D intoxication is not a cause of mortality per se until unless it is complicated by hypercalcemic crisis leading to poor GCS and aspiration, and /or patients have underlying other comorbidities contributing to mortality.

3. Chronic liver disease (CLD)

We also documented 12 (6%) patients with decompensated chronic liver disease (CTP grade B and C) had hypercalcemia with no other apparent cause for hypercalcemia. It was probably because of the well developed gastroenterology unit in our tertiary care centre. The mean age of these patients was found to be 58.27 years ±13.6, out of which 4 were females and 8 were males. The results were in accordance with another study from north India done by Mohammad Kuchay S et al[5] who also found 34 (8.9%)patients had hypercalcemia with advanced chronic liver disease (CLD) in their study. Similarly, a study from the west by Gerhardt et al[79] found eleven patients with advanced CLD.

4. Thyrotoxicosis

Thyrotoxicosis is not an uncommon cause of hypercalcemia and was seen in 7 (3.5%) patients in our study (6 females and 1 male). They were diagnosed on the basis of clinical symptoms, thyroid profile, radionuclear imaging – USG neck and sestamibi scan along with other routine biochemical investigations. Three patients were found to have toxic nodular goiter and 2 had acute thyroiditis on radionuclear imaging in our study. Our results were comparable with the study done by Mohammad Kuchay S et al[5], who also reported 5 patients with thyrotoxicosis with four females and one male.

5. Granulomatous diseases

Granulomatous diseases like tuberculosis(TB) and sarcoidosis were responsible for 5 (2.5%) (3 males and 2 females) and 1 (0.5%) (male) case respectively in our study. Two patients had mild, two had moderate and one patient had severe hypercalcemia associated with TB in our study whereas the patient with sarcoidosis had moderate hypercalcemia in our study. Similarly Kaul A et al[80] reported hypercalcemia in 6 patients out of the studied 100 patients with pulmonary tuberculosis patients, but all the patients were asymptomatic in their study and had mild hypercalcemia.

6. Thiazide induced hypercalcemia

In our study thiazide induced hypercalcemia was observed in 2 (1%) patients who were consuming 25mg of thiazides for more than a year for hypertension. Both the patients were females aged 72 and 74 years, with moderate and mild hypercalcemia respectively. None of the patient had any other identifiable cause for hypercalcemia.

Our results were comparable to the western study by Griebeler et al[81] who observed 221 people with thiazide associated hypercalcemia during the 19-years study period (1992–2010). The mean age was found to be 67.0 years ± 11.3 and women comprised most of the cases (86.4%). Hypercalcemia was identified after thiazide intake for a mean duration of 5.2 years in their study. Most patient were being treated with thiazides for hypertension (94%).

7. Hypercalcemia of immobilization

In our study, a 95 year old female patient was diagnosed with hypercalcemia of immobilization. It is a rare etiology and requires an extensive evaluation to rule out other causes of hypercalcemia[82]. Increased awareness of immobilization as a possible etiology of hypercalcemia may help avoid unnecessary and invasive investigations along with life-threatening complications.[83]

B.) PTH dependant hypercalcemia

1. Hyperparathyroidism

The second most common cause of hypercalcemia in our study was found to be hyperparathyroidism present in 45 cases out of 200.

In our study most of the cases were between the age group of 41 to 60 years (n= 25, 55.6%) followed by 18-40 years (n=12,26.7%) and 61-80 years (n=8, 17.8%) . None had hyperparathyroidism with age >80 years. The mean age associated with hyperparathyroidism was found to be 48.9 years ± 13.1 (range 18.0 – 72.0 years) whereas Priya et al[40] observed the mean age to be 38.4years ±15 and Bhansali et al[52] found the mean age to be 38years ± 13. Similarly in the study by Mishra et al[50] the mean age

was found to be 38 years. The results were not comparable with most of the other studies from our country where the patients presented in younger age group. Our results were also not comparable with the studies from the western countries where the patients presented in older age group. Yamashitha et al[48] observed the mean age to be 58years ±12 in their studies. Similarly, Carnivale et al[49] found the mean age associated with hyperparathyroidism to be 59.6 years ±1.6.

There were 19 females and 26 males in our study.

No statistical correlation was seen between the gender and hyperparathyroidism (p value > 0.05) whereas in retrospective review of Indian studies by Pradeep PV et al[41], female preponderance was observed with female: male ratio of 1.7:1.

In our study mean calcium, PTH and ALP were 12.9±2.7mg/ml, 555±515pg/ml and 421 ±197IU/ml respectively. The results were consistent with other Indian studies in terms of biochemical features like moderate hypercalcemia, high PTH and high ALP levels. In the study done by Priya et al[40] mean calcium, PTH and ALP were 12.4mg/dl ± 1.6, 662.6pg/ml ± 446.9 and 1086.8 IU/ml ± 1515. Similarly in the study done by Bhansali et al[52] mean calcium, PTH and ALP were 12.2mg/dl ±1.1, 809pg/ml ± 696 and 361IU/ml ±360 and in study by Jacob et al[51] mean calcium was 11.9mg/dl ± 1.0, PTH was 623pg/ml ±714 and ALP was 426IU/ml ±549. Our results were not comparable with studies from the western countries where the biochemical severity was seen to be less severe than our country. In the study conducted by Yamashitha et al[48] and Carnivale et al[49] mean calcium was found to be 10.8mg/dl ± 0.7 and 11.4mg/dl ± 0.2, mean PTH was 127 pg/ml ± 59 and 185.5 pg/ml ± 29.2 and mean ALP was found to be 127 IU/ml ± 54 and 137.6 IU/ml ± 22.5 respectively.

In our study, mean serum vitamin D levels were found to be 20.3 ng/ml ± 10.8 which were comparable with the other studies from India as well as west. In the studies done by Bandeira F et al[42][88] and Pradeep PV et al[84]

mean vitamin D levels were found to be 20.8 ng/ml ± 8.9 and 11.6 ± 8.7 respectively. Thus, in India, patients with primary hyperparathyroidism not only presents at an advanced stage but have associated vitamin D deficiency also. Hence, care should be taken to replenish vitamin D stores before parathyroidectomy in order to decrease the incidence of hungry bone syndrome post operatively.

All the patients with hyperparathyroidism were found to be symptomatic in our study. Similarly, in other Indian studies done by Shah VN et al[43], Jha S et al[44] and Bhadada et al[85], most of the patients were found to be symptomatic (99%, 100% and 95 % respectively).

In the study by Ohe MN et al (Brazil)[46] and Zhao L et al (China)[47] 53% and 61.4 % patients were found to be symptomatic.

In our study the most common symptoms were gastrointestinal (n=43, 95.6%) followed by renal and generalised (n=10, 22.2% each), musculoskeletal l(n=9,20%) and neurological (n=6, 13.3%).

We also observed 20 (44.44%) patients had pancreatitis, 16 (35.55%) had cholelithiasis, 9 (20%) had gall bladder sludge, 10(22.22%) had nephrolithiasis, 1 (2.22%) had nephrocalcinosis and ureteric stones were also found in 1 (2.22%) patient on USG abdomen.

Mithal et al[8] studied 50 patients and found 62% patients were symptomatic and rest were asymptomatic. He observed bone pains in 48.4% cases, renal calculi in 32.3%, fractures in 25.8%. Muscle weakness in 19.4%, pancreatitis in 16.1% cases.

In the study conducted by Misgar RA et al[54], most common symptoms in patients of primary hyperparathyroidism (PHPT) were found to be renal (64.1%) followed by bony pain(44.1%), abdominal pain (39%), constipation (26%) and myopathy (14.10%) .

Bhadada et al[85] retrospectively studied 464 patients and observed the most common symptom to be weakness and fatigability (58.7%) followed by bone pain (56%), renal stone disease (31%), pancreatitis (12.3%) and gallstone disease (11%).

Yadav SK et al[45] studied 333 patients divided into three subgroups [(1990-1999(n=34), 2000-2009(n=112), 2010-2016(n=187)] and observed a progressive increase in age at presentation (35 vs 39vs 43.8) over years. He also observed a declining trend in musculoskeletal symptoms (85.3 % vs 76.8% vs 61%) and biochemical parameters such as mean PTH (837.5 vs 812.8 vs 635.7pg/ml) and ALP levels (1393 vs 965 vs 414.8 IU/ml).

Jha S et al[44] studied 110 patients divided in two time frames i.e 1334-2007 (n=51)and 2007-2015 (n=59). They observed a declining trend in the severity of musculoskeletal symptoms.

Zhao et al[47] studied 249 patients with hyperparathyroidism between 2000-2010 and observed an increase in the presentation of asymptomatic hyperpararhyroidism after 2007.

Although the musculoskeletal and renal symptoms used to be the major symptoms associated with hyperparathyroidism, yet the incidence of these symptoms is declining in the developing countries like India. Majority of the patients in our study had gastrointestinal symptoms rather than musculoskeletal or renal symptoms. Pancreatitis was seen as an emerging presentation of parathyroid adenoma in our study. Hence, this changing pattern of hyperparathyroidism must be kept in mind while evaluating the patient.

In our study, 32 (71.1%) patients were found to have parathyroid adenoma on USG neck whereas additional 13 patients were localized on sestamibi scan. Hence, sestamibi scan is a better modality than USG neck for localization.

Most of the adenomas were found on left-inferior location in our study, (n=50% on USG neck and n=44.4% on sestamibi scan).

The findings were comparable with other studies done by Aslam M et al [86] and Bhansali A et al[87]. They also found left-inferior location as the most common site of parathyroid adenoma in 37.7% and 56% patients respectively on radionuclear imaging.

2.Lithium induced hypercalcemia

In our study only one patient was found to have lithium induced hypercalcemia who was consuming lithium for some psychiatric illness since 1972 in the dose of 800mg per day. PTH levels were found to be high normal in this patient.

Outcome associated with hypercalcemia:

In our study outcome was found to be fairly good except in cases of malignancy where maximum mortality was observed. A total of 22 patients died by the end of three months of follow up in our study and most of the patients died of malignancy (n=15,68.2%). This can be attributed to the fact that most of the patients with malignancy were referred to us at a very late stage.

Two patients (9.1%) died of multiorgan dysfunction secondary to pancreatitis in hyperparathyroidism group in hospital. Overall the prognosis was found to be good in hyperparathyroidism patients especially post parathyroidectomy. One patient died of chronic liver disease (CLD) in hospital due to decompensation. Two patients with vitamin D intoxication died. One had inhospital mortality due to multiorgan dysfunction secondary to sepsis and the other one expired within a month of discharge but the cause could not be determined. One patient with thyrotoxicosis died of aspiration of variceal bleed as she had underlying CLD.

Management of hypercalcemia:

First line of treatment for all the patients with hypercalcemia was aimed at providing symptomatic relief by reducing serum calcium levels by medical management followed by definitive management of the underlying etiology. Initial step was to discontinue all the vitamin D and calcium supplements. It was followed by resuscitation of the patient with i.v. fluids (95.0%) because already the patients with hypercalcemia are dehydrated. Care was taken to avoid fluid overload especially in patients with chronic kidney disease and coronary artery disease. Further calcitonin and loop

diuretics were given in 95.5% and 91.0 % patients respectively. Bisphosphonates were given especially in the patients with malignancy for long term control of calcium in 14.5% cases. In our study only one patient was prescribed denosumab because of its higher cost and lower affordability. In refractory cases of hypercalcemia as well as in patients with underlying chronic kidney disease, dialysis was done (16.5%). Steroids have a role in treatment of vitamin D intoxication, lymphoma and multiple myeloma and were used in 30% cases. Chemotherapy and radiotherapy were given in 49 (24.5%) patients with malignancy whereas surgical procedures (debulking surgery or palliative procedures like PTBD) were done in 10 (5%) cases of malignancy. In 24 (12%) patients parathyroidectomy was done for hyperparathyroidism during hospital stay whereas additional 14(31.1%) patients got it done by end of 3months of follow up.

To conclude serum calcium levels should be included in the routine health check up which might help in picking up the underlying etiology at an early stage and thus, improve outcome. Malignancy and hyperparathyroidism are the two most common etiologies associated with hypercalcemia in hospital settings whereas in outpatients hyperparathyroidism is seen more commonly. Majority of the patients with hyperparathyroidism are diagnosed in asymptomatic stage in the western countries whereas in India most of the patients are diagnosed when symptomatic. This difference can be attributed to the increased awareness in the western countries and routine biochemical screening of serum calcium.

Vitamin D intoxication cases are also increasing these days due to overcorrection of vitamin D deficiency as well as unnecessary prescription of vitamin D for non specific pains especially in elderly for general wellbeing. Irrational prescription of vitamin D formulations should be avoided on the part of physician. Patients as well as physicians should be educated regarding the potential toxicity of high doses of vitamin D. Therefore, various conferences and CME'S (continuing medical

education) should be organized periodically to keep the clinicians updated and aware of the changing profile of hypercalcemia.

There is paucity of data on the clinical profile of hypercalcemia in our country. More research work is needed in this field to decrease morbidity and mortality by early diagnosis and treatment of hypercalcemia.

SUMMARY

- The mean age of the cohort associated with hypercalcemia was found to be 58.3 years ± 13.6 (range 18.0 – 95.0 years) in our study.
- There were 103 (51.5%) males and 97 (48.5%) females.
- Majority of the cases in our study had mild hypercalcemia (n=82,41%) at admission while those with moderate and severe hypercalcemia were (n=62, 31%) and (n=56, 28%) respectively.
- Anorexia was found to be the most common clinical presentation present in 147 (73.5%) patients followed by nausea 123 (61.5%) and fatigue 91 (45.5%).
- In our study malignancy was found to be the most common cause of hypercalcemia (n= 85, 42.5%) followed by hyperparathyroidism (n=45,22.5%) and vitamin D intoxication (n=29,14.5%).
- The mean age of the patients associated with malignancy was found to be 60.3 years ± 11.1 (range 18.0 – 82.0 years)
- The most common malignancies observed were multiple myeloma (37.6%) followed by lymphoma (15.3%), breast cancer (11.8%) and ovarian cancer (8.2 %).
- The mean age associated with hyperparathyroidism was found to be 48.9 years ± 13.1 (range 18.0 – 72.0 years)
- In our study all the patients with hyperparathyroidism were symptomatic and the most common symptoms were gastrointestinal (n=43, 95.6%) followed by renal and generalised (n=10, 22.2% each) and musculoskeletal (n=9,20%).
- Amongst hyperparathyroidism patients, 20 patients were found to have pancreatitis , 16 had cholelithiasis , 9 had gall bladder sludge , 10 had nephrolithiasis, 1 had nephrocalcinosis and ureteric stones were also found in 1 patient.
- Most of the parathyroid adenomas were situated on left inferior location in our study, (n=50% on USG neck and n=44.4% on sestamibi scan).

- Median age associated with vitamin D intoxication was 65.0 years, range (54.0-82.0 years).
- Median cumulative dose and median dose of vitamin D per day required to cause vitamin D intoxication were found to be 300,000 IU (60,000-600,000) and 60,000IU respectively.
- Median duration of vitamin D supplements required to cause vitamin D intoxication was found to be 29.6 weeks (1.4-52.14).
- Other etiologies of hypercalcemia were – chronic liver disease (6%), thyrotoxicosis (3.5%) , granulomatous diseases (tuberculosis-2.5%, sarcoidosis-0.5%), thiazide (1%), lithium (0.5%), chronic kidney disease (0.5%), immobilization (0.5%) and idiopathic (3%).
- Goals of therapy were -
  a) To correct dehydration
  b) Enhance calcium excretion
  c) Inhibit bone resorption
  d) Treat underlying etiology
  e) Stop offending drug
- Total mortality observed at the end of 3 months of follow up-11%
- Most common cause of mortality in our study was malignancy, accounting for 68.2% mortality at the end of 3 months of follow up.

CONCLUSION

- Malignancy and hyperparathyroidism were the most common cause of hypercalcemia in our hospital setting
- Vitamin D intoxication was found to be an emerging cause of hypercalcemia because of-

1. Irrational prescription on part of physician for non specific complaints
2. Self consumption of over the counter available formulations of vitamin D
3. Prolonged intake of supplements beyond recommendation on the part of patients
4. wrong dose frequency , especially seen in elderly

- Symptomatic hyperparathyroidism still predominates in our country although the presentation has changed from symptomatic to asymptomatic in developed countries because of the incorporation of calcium screening in their routine health check up and more awareness among their physicians regarding the disease
- Pancreatitis is not an uncommon presentation of hyperparathyroidism these days
- Serum calcium levels should be included in routine health check up Which might help in picking up the underlying etiology at an early stage
- Various conferences and CME'S (continuing medical education) should be organized periodically to keep the clinicians updated and aware of the changing profile of hypercalcemia.

BIBLIOGRAPHY

1. Clapham DE. Calcium signaling. Cell. 2007;131(6):1047-58.
2. Ahmad S, Kuraganti G, Steenkamp D. Hypercalcemic crisis: a clinical review. The American journal of medicine. 2015;128(3):239-45.
3. Hall JE. 12th ed. Saunders; 2010. Guyton and Hall Textbook of Medical Physiology; pp. 955–972.
4. Carroll MF, Schade DS. A practical approach to hypercalcemia. Am Fam Physician. 2003;67(9):1959-66.
5. Kuchay MS, Kaur P, Mishra SK, Mithal A. The changing profile of hypercalcemia in a tertiary care setting in North India: an 18-month retrospective study. Clinical Cases in Mineral and Bone Metabolism. 2017;14(2):131.
6. Turner JJ. Hypercalcaemia–presentation and management. Clinical Medicine. 2017;17(3):270.
7. Mirrakhimov AE. Hypercalcemia of malignancy: an update on pathogenesis and management. North American journal of medical sciences. 2015;7(11):483.
8. Mithal A, Kaur P, Singh VP, Sarin D, Rao DS. Asymptomatic primary hyperparathyroidism exists in North India: Retrospective data from 2 tertiary care centers. Endocrine Practice. 2015;21(6):581-5.
9. Mishra SK, Agarwal G, Kar DK, Gupta SK, Mithal A, Rastad J. Unique clinical characteristics of primary hyperparathyroidism in India. British journal of surgery. 2001;88(5):708-14.
10. Parfitt MA, Rao DS, Kleerekoper M. Asymptomatic primary hyperparathyroidism discovered by multichannel biochemical screening: clinical course and considerations bearing on the need for surgical intervention. Journal of Bone and Mineral Research. 1991;6(S2):S97-101.
11. Marcocci C, Cetani F, Rubin MR, Silverberg SJ, Pinchera A, Bilezikian JP, et al. Parathyroid carcinoma. J Bone Miner Res. 2008;23:1869-80.

12. Minisola S, Pepe J, Piemonte S, Cipriani C. The diagnosis and management of hypercalcaemia. Bmj. 2015;350.
13. Galior K, Grebe S, Singh R. Development of vitamin D toxicity from overcorrection of vitamin D deficiency: a review of case reports. Nutrients. 2018;10(8):953.
14. Kaur P, Mishra SK, Mithal A. Vitamin D toxicity resulting from overzealous correction of vitamin D deficiency. Clinical endocrinology. 2015;83(3):327-31.
15. Koul PA, Ahmad SH, Ahmad F, Jan RA, Shah SU, Khan UH. Vitamin d toxicity in adults: a case series from an area with endemic hypovitaminosis d. Oman Medical Journal. 2011;26(3):201.
16. Bansal RK, Tyagi P, Sharma P, Singla V, Arora V, Bansal N, et al. Iatrogenic hypervitaminosis D as an unusual cause of persistent vomiting: a case report. Journal of medical case reports. 2014;8(1):1-4.
17. Pandita KK, Razdan S, Kudyar RP, Beigh A, Kuchay S, Banday T. “Excess gooD can be Dangerous”. A case series of iatrogenic symptomatic hypercalcemia due to hypervitaminosis D. Clinical cases in mineral and bone metabolism. 2012;9(2):118.
18. Delvin E, Souberbielle JC, Viard JP, Salle B. Role of vitamin D in acquired immune and autoimmune diseases. Critical reviews in clinical laboratory sciences. 2014;51(4):232-47.
19. C Brewer L, D Michos E, P Reis J. Vitamin D in atherosclerosis, vascular disease, and endothelial function. Current drug targets. 2011;12(1):54-60.
20. Rizzoli R. Nutritional aspects of bone health. Best Practice & Research Clinical Endocrinology & Metabolism. 2014;28(6):795-808.
21. Stewart AF. Hypercalcemia associated with cancer. New England Journal of Medicine. 2005;352(4):373-9.
22. Endres DB. Investigation of hypercalcemia. Clinical biochemistry. 2012;45(12):954-63.

23. Gardner Jr EC, Hersh TH. Primary hyperparathyroidism and the gastrointestinal tract. Southern medical journal. 1981;74(2):197-9.
24. Wynn D, Everett GD, Boothby RA. Small cell carcinoma of the ovary with hypercalcemia causes severe pancreatitis and altered mental status. Gynecol oncol. 2004;95:716–8. [PubMed]
25. Lins LE. Reversible renal failure caused by hypercalcemia: a retrospective study. Acta Medica Scandinavica. 1978;203(1-6):309-14.
26. Caruana RJ, Buckalew Jr VM. The syndrome of distal (type 1) renal tubular acidosis. Clinical and laboratory findings in 58 cases. Medicine. 1988;67(2):84-99.
27. Inzucchi SE. Understanding hypercalcemia: its metabolic basis, signs, and symptoms. Postgraduate medicine. 2004;115(4):69-76.
28. Kiewiet RM, Ponssen HH, Janssens EN, Fels PW. Ventricular fibrillation in hypercalcaemic crisis due to primary hyperparathyroidism. Neth J Med. 2004;62:94–6.
29. Vakiti A, Mewawalla P. Malignancy-related hypercalcemia. StatPearls [Internet]. 2019.
30. Baird GS. Ionized calcium. Clinica chimica acta. 2011;412(9-10):696-701.
31. Song L. Calcium and bone metabolism indices. Advances in clinical chemistry. 2017;82:1-46.
32. AZZABI S, KHALFALLAH N, BEN HASSINE L, OMAR S, KOOLI C. Les étiologies de l'hypercalcémie: Etude à propos de 47 cas dans un service de médecine interne. Tunisie médicale. 2001;79(6-7):348-52.
33. Frølich A. Prevalence of hypercalcaemia in normal and in hospital populations. Danish medical bulletin. 1998;45(4):436-9.
34. Pallan S, Khan A. Primary hyperparathyroidism: Update on presentation, diagnosis, and management in primary care. Canadian Family Physician. 2011;57(2):184-9.

35. Gupta CM. Evaluation and aetiopathogenesis of hypercalcaemia. A study of 89 patients. The Journal of the Association of Physicians of India. 1990;38(5):337-9.
36. Diamond WJ, TH B. Hypercalcaemia in the Johannesburg Hospital-differential diagnosis and physician awareness of primary hyperparathyroidism. South African Medical Journal. 1987;72(2):113-5.
37. Dent DM, Miller JL, Klaff L, Barron J. The incidence and causes of hypercalcaemia. Postgraduate medical journal. 1987;63(743):745-50.
38. Wijaya I, Oehadian A, Sumantri R. Hypercalcemia of malignancy: Clinical characteristics and treatment outcome. Majalah Kedokteran Bandung. 2014;46(2):111-7.
39. Lundgren E, Rastad J. Diagnosis, natural history and intervention in sporadic primary hyperparathyroidism. Surgical endocrinology. 2001:137-62.
40. Priya G, Jyotsna VP, Gupta N, Chumber S, Bal CS, Karak AK, et al. Clinical and laboratory profile of primary hyperparathyroidism in India. Postgraduate medical journal. 2008;84(987):34-9.
41. Pradeep PV, Jayashree B, Mishra A, Mishra SK. Systematic review of primary hyperparathyroidism in India: the past, present, and the future trends. International journal of Endocrinology. 2011;2011.
42. Yadav SK, Johri G, Bichoo RA, Jha CK, Kintu-Luwaga R, Mishra SK. Primary hyperparathyroidism in developing world: a systematic review on the changing clinical profile of the disease. Archives of endocrinology and metabolism. 2020;64(2):105-10.
43. Shah VN, Bhadada SK, Bhansali A, Behera A, Mittal BR. Changes in clinical & biochemical presentations of primary hyperparathyroidism in India over a period of 20 years. The Indian journal of medical research. 2014;139(5):694.

44. Jha S, Jayaraman M, Jha A, Jha R, Modi KD, Kelwadee JV. Primary hyperparathyroidism: A changing scenario in India. Indian journal of endocrinology and metabolism. 2016;20(1):80.
45. Yadav SK, Mishra SK, Mishra A, Mayilvagnan S, Chand G, Agarwal G, et al. Changing profile of primary hyperparathyroidism over two and half decades: A study in tertiary referral center of North India. World journal of surgery. 2018;42(9):2732-7.
46. Ohe, M.N., Santos, R.O., Barros, E.R., Lage, A., Kunii, I.S., Abrahão, M., Cervantes, O., et al., 2005. Changes in clinical and laboratory findings at the time of diagnosis of primary hyperparathyroidism in a University Hospital in São Paulo from 1985 to 2002. Brazilian Journal of Medical and Biological Research, 38(9), pp.1383-1387.
47. Zhao L, Liu JM, He XY, Zhao HY, Sun LH, Tao B, et al. The changing clinical patterns of primary hyperparathyroidism in Chinese patients: data from 2000 to 2010 in a single clinical center. The Journal of Clinical Endocrinology & Metabolism. 2013;98(2):721-8.
48. Yamashita H, Noguchi S, Uchino S, Watanabe S, Koike E, Murakami T, et al. Vitamin D status in Japanese patients with hyperparathyroidism: seasonal changes and effect on clinical presentation. World journal of surgery. 2002;26(8):937-41.
49. Carnevale V, Manfredi G, Romagnoli E, De Geronimo S, Paglia F, Pepe J, et al. Vitamin D status in female patients with primary hyperparathyroidism: does it play a role in skeletal damage?. Clinical endocrinology. 2004;60(1):81-6.
50. Mishra SK, Agarwal G, Kar DK, Gupta SK, Mithal A, Rastad J. Unique clinical characteristics of primary hyperparathyroidism in India. British journal of surgery. 2001;88(5):708-14.
51. Jacob JJ, John M, Thomas N, Chacko A, Cherian R, Selvan B, et al. Does hyperparathyroidism cause pancreatitis? A South Indian experience and a review of published work. ANZ journal of surgery. 2006;76(8):740-4.

52. Bhansali A, Masoodi SR, Reddy KS, Behera A, das Radotra B, Mittal BR, et al. Primary hyperparathyroidism in north India: a description of 52 cases. Annals of Saudi medicine. 2005;25(1):29-35.
53. Misgar RA, Sahu D, Bhat MH, Wani AI, Bashir MI. Vitamin D toxicity: a prospective study from a tertiary care centre in Kashmir Valley. Indian journal of endocrinology and metabolism. 2019;23(3):363.
54. Misgar RA, Dar PM, Masoodi SR, Ahmad M, Wani KA, Wani AI, et al. Clinical and laboratory profile of primary hyperparathyroidism in Kashmir Valley: A single-center experience. Indian journal of endocrinology and metabolism. 2016;20(5):696.
55. Gopal RA, Acharya SV, Bandgar T, Menon PS, Dalvi AN, Shah NS. Clinical profile of primary hyperparathyroidism from western India: a single center experience. Journal of postgraduate medicine. 2010;56(2):79.
56. Sadiq NM, Naganathan S, Badireddy M. Hypercalcemia. 2020.
57. Goltzman D. Approach to hypercalcemia. In: Arnold A, ed. Diseases of Bone and Calcium Metabolism. Accessed 2019
58. Lafferty FW. Differential diagnosis of hypercalcemia. Journal of Bone and Mineral Research. 1991;6(S2):S51-9.
59. Bilezikian JP. Management of acute hypercalcemia. New England Journal of Medicine. 1992;326(18):1196-203.
60. Vaughn CB, Vaitkevicius VK. The effects of calcitonin in hypercalcemia in patients with malignancy. Cancer. 1974;34(4):1268-71.
61. Wisneski LA. Salmon calcitonin in the acute management of hypercalcemia. Calcified tissue international. 1990;46(1):S26-30.
62. Austin LA, Heath III H. Calcitonin: physiology and pathophysiology. New England Journal of Medicine. 1981;304(5):269-78.
63. Xu XL, Gou WL, Wang AY, Wang Y, Guo QY, Lu Q, et al. Basic research and clinical applications of bisphosphonates in bone

disease: what have we learned over the last 40 years?. Journal of translational medicine. 2013;11(1):1-8.

64. Russell RG, Xia Z, Dunford JE, Oppermann UD, Kwaasi A, Hulley PA, et al. Bisphosphonates: an update on mechanisms of action and how these relate to clinical efficacy. Annals of the New York Academy of Sciences. 2007;1117(1):209-57.
65. Hanley DA, Adachi JD, Bell A, Brown V. Denosumab: mechanism of action and clinical outcomes. International journal of clinical practice. 2012;66(12):1139-46.
66. Hu MI, Glezerman IG, Leboulleux S, Insogna K, Gucalp R, Misiorowski W, et al. Denosumab for treatment of hypercalcemia of malignancy. The Journal of Clinical Endocrinology & Metabolism. 2014;99(9):3144-52.
67. Hu MI, Glezerman I, Leboulleux S, Insogna K, Gucalp R, Misiorowski W, et al. Denosumab for patients with persistent or relapsed hypercalcemia of malignancy despite recent bisphosphonate treatment. Journal of the National Cancer Institute. 2013;105(18):1417-20.
68. Adhikaree J, Newby Y, Sundar S. Denosumab should be the treatment of choice for bisphosphonate refractory hypercalcaemia of malignancy. Case Reports. 2014;2014:bcr2013202861.
69. Karuppiah D, Thanabalasingham G, Shine B, Wang LM, Sadler GP, Karavitaki N, et al. Refractory hypercalcaemia secondary to parathyroid carcinoma: response to high-dose denosumab. Eur J Endocrinol. 2014;171(1):K1-5.
70. Tong CV, Hussein Z, Noor NM, Mohamad M, Ng WF. Use of denosumab in parathyroid carcinoma with refractory hypercalcemia. QJM. 2015;108(1):49-50.
71. Collins MT, Skarulis MC, Bilezikian JP, Silverberg SJ, Spiegel AM, Marx SJ. Treatment of hypercalcemia secondary to parathyroid

carcinoma with a novel calcimimetic agent. The Journal of Clinical Endocrinology & Metabolism. 1998;83(4):1083-8.

72. Silverberg SJ, Rubin MR, Faiman C, Peacock M, Shoback DM, Smallridge RC, et al. Cinacalcet hydrochloride reduces the serum calcium concentration in inoperable parathyroid carcinoma. The Journal of Clinical Endocrinology & Metabolism. 2007;92(10):3803-8.
73. Catalano A, Chilà D, Bellone F, Nicocia G, Martino G, Loddo I, et al. Incidence of hypocalcemia and hypercalcemia in hospitalized patients: Is it changing?. Journal of clinical & translational endocrinology. 2018;13:9-13.
74. Lindner G, Felber R, Schwarz C, Marti G, Leichtle AB, Fiedler GM, Zimmermann H, et al. Hypercalcemia in the ED: prevalence, etiology, and outcome. The American journal of emergency medicine. 2013;31(4):657-60.
75. Lee CT, Yang CC, Lam KK, Kung CT, Tsai CJ, Chen HC. Hypercalcemia in the emergency department. The American journal of the medical sciences. 2006;331(3):119-23.
76. Mousseaux C, Dupont A, Rafat C, Ekpe K, Ghrenassia E, Kerhuel L, et al. Epidemiology, clinical features, and management of severe hypercalcemia in critically ill patients. Annals of intensive care. 2019;9(1):1-0.
77. Shek CC, Natkunam A, Tsang V, Cockram CS, Swaminathan R. Incidence, causes and mechanism of hypercalcaemia in a hospital population in Hong Kong. QJM: An International Journal of Medicine. 1990;77(3):1277-85.
78. Gastanaga VM, Schwartzberg LS, Jain RK, Pirolli M, Quach D, Quigley JM, et al. Prevalence of hypercalcemia among cancer patients in the United States. Cancer medicine. 2016;5(8):2091-100.
79. Gerhardt A, Greenberg A, Reilly JJ, Van Thiel DH. Hypercalcemia: A complication of advanced chronic liver disease. Archives of internal medicine. 1987;147(2):274-7.

80. Kaul A, Modwal R, Poorey K, Vijayvergia V. Hypercalcemia In Pulmonary Tuberculosis. Int J Res Med. 2017;6(1):38-41.
81. Griebeler ML, Kearns AE, Ryu E, Thapa P, Hathcock MA, Melton III LJ, et al. Thiazide-associated hypercalcemia: incidence and association with primary hyperparathyroidism over two decades. The Journal of Clinical Endocrinology & Metabolism. 2016;101(3):1166-73.
82. Cano-Torres EA, González-Cantú A, Hinojosa-Garza G, Castilleja-Leal F. Immobilization induced hypercalcemia. Clinical Cases in Mineral and Bone Metabolism. 2016;13(1):46.
83. Wick J. Immobilization hypercalcemia in the elderly. The Consultant Pharmacist®. 2007;22(11):892-905.
84. Pradeep PV, Mishra A, Agarwal G, Agarwal A, Verma AK, Mishra SK. Long-term outcome after parathyroidectomy in patients with advanced primary hyperparathyroidism and associated vitamin D deficiency. World journal of surgery. 2008;32(5):829-35.
85. Bhadada SK, Arya AK, Mukhopadhyay S, Khadgawat R, Sukumar S, Lodha S, et al. Primary hyperparathyroidism: insights from the Indian PHPT registry. Journal of bone and mineral metabolism. 2018;36(2):238-45.
86. Aslam M, Talukdar R, Jagtap N, Rao GV, Pradeep R, Rao U, et al. Clinical profile and outcome of parathyroid adenoma-associated pancreatitis. Saudi journal of medicine & medical sciences. 2018;6(2):95.
87. Bhansali A, Masoodi SR, Reddy KS, Behera A, das Radotra B, Mittal BR, et al. Primary hyperparathyroidism in north India: a description of 52 cases. Annals of Saudi medicine. 2005;25(1):29-35.
88. Bandeira F, Griz LH, Bandeira C, Pinho J, Lucena CS, Alencar C, et al. Prevalence of cortical osteoporosis in mild and severe primary hyperparathyroidism and its relationship with bone markers and vitamin D status. Journal of Clinical Densitometry. 2009;12(2):195-9.

sr no	mrd	initials	age	gender	address	urban/ rural	bmi	Gastrointestinal	Renal	Neurological	Generalised	Bony	nausea	duration	vomiting	duration	anorexia	duration	weight loss	value	duration	constipation	duration	abdominal pain	duration	dyspepsia	duration	renal stone	duration	polyuria	duration	nocturia	duration	bony pain	duration	fracture	duration	fatigue	duration
1	657560	rd	72	male	barnala	urban	27.3	y	n	y	y	n	y	20	y	20	y	60	y	15	60	n	0	n	0	n	0	n	0	n	0	n	0	n	0	n	0	y	0
2	620678	sd	50	female	jammu	rural	32.8	y	n	n	n	y	y	45	y	45	y	45	n	0	0	n	0	n	0	n	0	n	0	n	0	n	0	y	50	y	50	n	0
3	622323	sk	67	female	muktsar	rural	25.7	y	n	y	y	n	y	7	y	7	y	7	y	5	150	n	0	n	0	n	0	n	0	n	0	n	0	n	0	n	0	y	7
4	642273	bs	55	male	faridkot	urban	48	y	n	y	y	y	n	0	y	1	y	15	y	15	60	n	0	n	0	n	0	n	0	n	0	n	0	y	180	n	0	y	15
5	653016	ak	60	female	ludhiana	urban	27.4	y	n	n	y	y	n	0	n	0	y	365	n	0	0	y	60	n	0	n	0	n	0	n	0	n	0	y	180	n	0	y	365
6	652324	s	45	male	nadala,kapurthala	rural	22.3	y	n	y	y	y	y	60	n	0	y	60	y	5	30	n	0	y	1	n	0	n	0	n	0	n	0	y	30	n	0	y	7
7	634367	jc	70	male	hina nagar,kathua,j&k	rural	31	y	y	y	y	n	y	60	y	60	y	60	y	8	60	n	0	n	0	y	60	n	0	n	0	n	0	y	30	n	0	n	0	y	60
8	619369	gs	66	male	ludhiana	urban	20.7	y	n	n	y	n	n	0	n	0	n	0	y	4	60	n	0	y	2	n	0	n	0	n	0	n	0	n	0	n	0	n	0	y	60
9	479659	sc	28	male	ludhiana	urban	17.6	y	n	n	y	n	n	0	n	0	y	3	y	10	180	n	0	y	3	n	0	n	0	n	0	n	0	n	0	n	0	n	0	n	0
10	507990	ms	65	male	dala,moga	rural	28.3	y	n	y	y	n	y	30	y	30	y	30	y	3	30	n	0	y	30	y	30	n	0	n	0	n	0	n	0	n	0	n	0	n	0
11	114141	nb	20	male	hoshiarpur	urban	27.34	y	n	n	n	n	y	2	y	2	n	0	n	0	0	n	0	y	2	n	0	n	0	n	0	n	0	n	0	n	0	n	0	n	0
12	661028	cs	75	male	jangir,phillaur,jalandhar	rural	31.25	y	n	n	y	n	n	0	n	0	y	90	y	10	90	n	0	n	0	n	0	n	0	n	0	n	0	n	0	n	0	n	0	y	90
13	481154	ms	58	male	ludhiana	urban	28	y	n	n	y	y	n	0	n	0	n	0	n	0	0	y	120	y	120	n	0	n	0	n	0	n	0	y	60	n	0	y	120
14	661793	sd	70	female	bhatinda	urban	22	n	n	n	y	y	n	0	n	0	n	0	n	0	0	n	0	n	0	n	0	n	0	n	0	n	0	y	30	y	180	y	365
15	534702	jk	61	female	moga	urban	20.28	y	n	n	y	y	y	60	y	60	y	60	n	0	0	n	0	n	0	n	0	n	0	n	0	n	0	y	0	y	180	n	0
16	637317	jk	83	female	ludhiana	urban	26.6	y	n	n	y	n	n	0	n	0	y	120	y	5	120	n	0	n	0	n	0	y	120	n	0	n	0	n	0	n	0	y	120
17	660678	b	63	male	hoshiarpur	urban	24.8	y	n	y	y	n	y	7	n	0	y	7	y	2	120	n	0	n	0	n	0	n	0	n	0	n	0	n	0	n	0	n	0
18	678181	pc	61	male	garhi,udhampur, j&k	rural	29.4	y	n	y	y	n	y	3	y	3	y	90	y	10	365	n	0	n	0	n	0	n	0	n	0	n	0	n	0	n	0	n	0	n	0
19	471657	sd	55	female	ludhiana	urban	27.3	y	n	y	y	n	n	0	n	0	y	90	y	5	90	n	0	y	5	n	0	n	0	n	0	n	0	n	0	n	0	n	0	n	0
20	544686	ss	47	male	kishan pura kalan,moga	rural	27.6	n	y	n	y	n	n	0	n	0	n	0	n	0	0	n	0	n	0	n	0	y	120	y	120	y	0	n	0	n	0	n	0
21	547171	sq	51	male	kathua, j&k	urban	22.7	y	n	n	n	n	y	7	y	7	n	0	n	0	0	n	0	n	0	y	5	n	0	n	0	n	0	n	0	n	0	n	0	n	0
22	699422	h	65	male	barnala	urban	23.7	y	n	n	y	n	n	0	n	0	y	30	n	0	0	n	0	n	0	y	30	n	0	n	0	n	0	n	0	n	0	y	30
23	685762	k	65	male	rupewali, shahkot, jalandhar	rural	30.4	y	n	n	y	n	y	7	y	7	y	15	n	0	0	n	0	y	7	n	0	n	0	n	0	n	0	n	0	n	0	y	30
24	390146	ml	61	female	ludhiana	urban	24.8	y	n	y	n	n	y	5	y	5	n	0	n	0	0	n	0	n	0	y	5	y	5	n	0	n	0	n	0	n	0	n	0	n	0
25	696214	kk	70	female	pathankot	urban	20.2	y	n	n	y	n	n	0	n	0	y	90	y	5	90	n	0	n	0	n	0	n	0	n	0	n	0	n	0	n	0	n	0	y	90
26	689657	ys	75	male	jammu	urban	26.4	y	n	y	y	n	n	0	n	0	y	90	y	3	90	n	0	n	0	y	6	y	90	n	0	n	0	n	0	n	0	n	0	y	30
27	688609	s	55	female	ludhiana	urban	21.3	y	n	n	n	n	y	10	n	0	y	10	n	0	0	n	0	y	10	y	10	n	0	n	0	n	0	n	0	n	0	n	0	n	0
28	688263	sk	65	female	jalandhar	urban	19.7	y	n	n	y	n	y	1	n	0	y	7	y	5	90	n	0	y	1	y	2	n	0	n	0	n	0	n	0	n	0	y	90
29	549787	rr	75	female	amritsar	urban	19.5	y	n	y	y	y	n	0	n	0	y	60	y	10	180	n	0	n	0	y	180	n	0	n	0	n	0	y	60	y	30	y	180
30	884054	lw	58	female	jalandhar	rural	25	y	n	n	n	n	y	10	y	10	y	10	n	0	0	y	180	y	10	y	50	n	0	n	0	n	0	n	0	n	0	n	0	n	0
31	681615	lw	76	male	kathua, j&k	urban	27.5	y	y	n	y	y	y	15	n	15	n	0	y	5	120	n	0	y	15	n	0	n	0	y	30	y	30	y	30	n	0	y	15
32	681960	ln	71	male	kathua, j&k	urban	24.2	y	n	y	y	y	n	0	n	0	y	90	y	5	90	n	0	n	0	n	0	n	0	n	0	n	0	y	45	n	0	y	60
33	608658	ml	64	male	jalandhar	urban	20.2	y	n	n	y	n	n	0	n	0	y	30	y	5	120	n	0	n	0	n	0	n	0	n	0	n	0	n	0	n	0	y	120
34	704263	ds	63	male	lakhwal,nurpur,kangra	rural	32.4	y	n	y	y	y	n	30	n	0	y	30	y	4	30	n	0	n	0	n	0	n	0	n	0	n	0	y	90	n	0	y	90
35	616466	pk	70	female	ludhiana	urban	24.3	y	n	n	y	n	y	15	y	15	y	15	n	0	0	n	0	n	0	n	0	n	0	n	0	n	0	n	0	n	0	y	15
36	684353	s	72	female	jalandhar	urban	18.5	y	y	n	y	y	y	1	y	1	y	6	n	0	0	n	0	n	0	y	6	n	0	y	180	y	180	y	180	n	0	y	180
37	710294	bd	65	female	balachaur,nawashahar	rural	24.2	y	n	y	y	n	y	15	y	3	y	15	n	0	0	n	0	n	0	n	0	n	0	n	0	n	0	n	0	n	0	y	15
38	701237	qk	35	female	faridkot	urban	20.3	y	n	n	n	y	n	0	n	0	n	0	n	0	0	n	0	y	1	y	1	n	0	n	0	n	0	y	14	y	14	n	0
39	704363	sa	63	female	ludhiana	urban	25.5	y	n	y	y	n	n	0	n	0	y	150	y	5	150	n	0	n	0	n	0	n	0	n	0	n	0	n	0	n	0	n	0
40	714668	ds	70	male	ferozepur	urban	23.5	y	n	n	y	y	n	0	n	0	y	180	y	5	180	n	0	n	0	n	0	n	0	n	0	n	0	y	90	n	0	y	180
41	714055	ms	75	male	rajouri, j and k	urban	27.3	y	n	n	y	n	n	0	n	0	y	90	y	4	240	n	0	n	0	y	180	n	0	n	0	n	0	n	0	n	0	y	180
42	709161	dk	63	female	bhagta bhai,bhatinda	rural	19	y	n	n	y	y	y	60	y	60	y	60	y	5	120	n	0	n	0	n	0	n	0	n	0	n	0	n	0	y	90	n	0	n	0
43	705170	ik	55	female	mattan, j and k	rural	27.3	y	n	n	y	n	y	120	y	120	y	120	n	0	0	n	0	n	0	n	0	n	0	n	0	n	0	n	0	n	0	y	120
44	704346	ha	36	male	ludhiana	urban	25.39	y	n	n	y	y	n	0	n	0	y	30	n	0	0	n	0	y	30	n	0	n	0	n	0	n	0	y	0	n	0	y	15
45	701197	rr	60	female	ludhiana	urban	24.2	y	n	n	n	y	y	4	y	4	y	4	n	0	0	n	0	y	4	n	0	n	0	n	0	n	0	n	0	n	0	n	0
46	705939	mb	48	female	sarote,j and k	rural	24.3	y	n	n	n	n	y	8	y	8	n	0	n	0	0	n	0	y	8	n	0	n	0	n	0	n	0	n	0	n	0	n	0
47	716065	ss	44	male	panjagaran kalan,faridkot	rural	21.3	y	n	y	y	n	y	60	y	15	n	0	n	0	0	n	0	y	30	n	0	n	0	n	0	n	0	n	0	n	0	y	180
48	710294	bd	65	female	kukarsaha,ludhiana	rural	24.6	y	n	n	y	y	y	21	y	21	y	7	n	0	0	n	0	n	0	n	0	n	0	n	0	n	0	y	180	n	0	y	30
49	709534	gd	60	female	nathwal, jand k	rural	21.7	n	n	n	y	n	n	0	n	0	n	0	n	4	90	n	0	n	0	n	0	n	0	n	0	n	0	n	0	n	0	y	0
50	668636	ss	68	male	memdot,ferozepur	rural	24.7	y	n	y	y	n	n	0	n	0	y	15	y	8	180	n	0	n	0	n	0	n	0	n	0	n	0	n	0	n	0	y	60
51	24573	sd	42	female	dah kulara,kangra	rural	24.3	y	n	n	n	n	y	5	y	5	y	5	n	0	0	n	0	y	5	n	0	n	0	n	0	n	0	n	0	n	0	n	0
52	274445	mk	48	female	ludhiana	urban	17.7	y	n	n	y	y	n	0	n	0	y	90	y	10	90	n	0	n	0	n	0	n	0	n	0	n	0	y	90	n	0	y	90
53	715876	nr	52	female	qhuman,ludhiana	rural	24.1	y	n	n	y	n	y	15	y	15	y	60	y	8	100	n	0	n	0	y	7	n	0	n	0	n	0	n	0	n	0	y	180
54	82146	ms	70	male	qhana,dharamshala	rural	22.5	y	n	y	y	n	n	0	n	0	y	180	y	10	180	n	0	n	0	y	10	y	180	n	0	n	0	n	0	n	0	y	180
55	703014	ps	50	male	mohali	urban	20.7	y	n	n	n	y	n	0	n	0	y	30	n	0	0	n	0	n	0	n	0	n	0	n	0	n	0	y	30	n	0	n	0
56	688160	hs	45	male	mujara,ludhiana	rural	31.2	y	n	n	y	n	y	45	n	0	y	45	y	3	15	n	0	n	0	n	0	n	0	n	0	n	0	n	0	n	0	y	30
57	707264	sk	95	female	rurki muglan,nawashahar	rural	21.3	y	n	n	y	n	n	0	n	0	y	60	y	2	60	n	0	y	60	n	0	n	0	n	0	n	0	n	0	n	0	y	60
58	723943	dr	58	male	ludhiana	urban	28	y	n	n	n	y	y	10	y	2	n	0	n	0	0	n	0	n	0	n	0	n	0	n	0	n	0	y	10	n	0	n	0
59	721990	rs	18	male	chinqali,ferozepur	rural	24.5	y	n	n	y	n	y	4	y	4	y	4	y	4	120	n	0	n	0	n	0	n	0	n	0	n	0	n	0	n	0	y	30
60	735044	rs	59	male	yamunanagar	urban	29	y	n	n	n	n	y	180	n	0	n	0	n	0	0	n	0	n	0	n	0	n	0	n	0	n	0	n	0	n	0	n	0
61	720710	rr	47	female	patiala	urban	27.8	n	y	y	y	n	n	0	n	0	n	0	n	0	0	n	0	n	0	n	0	n	0	y	15	y	15	n	0	n	0	y	15
62	720710	rr	52	male	badhni kalan,moga	rural	22.8	y	n	y	y	n	y	10	y	1	n	0	n	0	0	n	0	n	0	y	10	n	0	n	0	n	0	n	0	n	0	y	0
63	728676	sk	38	male	suchi pind,jalandhar	rural	24.7	y	n	n	n	n	y	2	y	2	y	4	n	0	0	n	0	y	4	n	0	n	0	n	0	n	0	n	0	n	0	n	0
64	723902	ml	48	male	ludhiana	urban	27.6	y	n	y	n	n	y	3	y	3	y	3	n	0	0	n	0	n	0	n	0	n	0	n	0	n	0	n	0	n	0	n	0
65	724002	sk	72	female	khandwal, jand k	rural	23	y	n	n	y	n	n	0	n	0	y	30	n	0	0	n	0	n	0	n	0	n	0	n	0	n	0	n	0	n	0	y	30
66	615991	is	38	male	sadha chak,jalandhar	rural	29.7	y	n	n	n	n	n	0	n	0	y	15	n	0	0	n	0	n	0	n	0	n	0	n	0	n	0	n	0	n	0	n	0
67	729399	ks	67	male	ludhiana	urban	16	y	n	y	y	n	y	3	y	3	y	3	y	10	180	y	90	n	0	n	0	n	0	n	0	n	0	n	0	n	0	y	90
68	731537	rg	53	female	udhampur,j and k	urban	20.28	y	n	n	y	n	y	60	n	0	y	60	y	4	15	n	0	n	0	n	0	n	0	n	0	n	0	n	0	n	0	y	90
69	683750	kr	62	female	ferozepur	urban	24	y	n	y	y	y	y	120	n	0	y	120	y	10	120	n	0	y	4	n	0	n	0	n	0	n	0	n	0	y	90	n	0	y	90
70	739803	bs	65	male	dhinpanwali,fazilka	rural	23.7	y	n	y	y	n	n	0	n	0	y	15	y	3	90	n	0	y	15	n	0	n	0	n	0	n	0	n	0	n	0	y	90
71	736862	mk	70	female	ludhiana	urban	19	y	y	n	y	y	n	0	n	0	y	7	n	0	0	y	2	n	0	n	0	n	0	y	60	n	0	y	150	y	150	y	3
72	56701	hk	55	female	bangsi pura,jagraon	rural	21.5	y	n	n	n	y	y	20	y	20	y	20	n	0	0	n	0	n	0	y	20	n	0	n	0	n	0	n	0	n	0	n	0
73	699324	hs	82	male	ludhiana	urban	15	n	y	n	n	y	n	0	n	0	n	0	n	0	0	n	0	n	0	n	0	n	0	y	30	n	0	y	180	n	0	n	0
74	743426	ks	50	male	laliana,bhatinda	rural	23.4	n	n	n	y	n	n	0	n	0	n	0	n	0	0	n	0	n	0	n	0	n	0	n	0	n	0	n	0	n	0	y	10
75	342253	kk	77	female	ludhiana	urban	33.7	y	n	y	n	y	y	15	n	0	n	0	n	0	0	n	0	n	0	n	0	n	0	n	0	n	0	y	280	n	0	n	0
76	715875	sk	56	female	ludhiana	urban	20.3	y	n	y	y	n	y	30	y	1	y	30	y	2	120	n	0	n	0	n	0	n	0	n	0	n	0	n	0	n	0	y	150
77	740599	js	64	male	deep singh wala,faridkot	rural	24.6	y	n	y	y	n	y	5	n	0	y	20	y	11	180	n	0	n	0	n	0	n	0	n	0	n	0	n	0	n	0	y	120
78	743466	qk	69	female	jalandhar	urban	24.1	y	n	n	y	n	y	8	n	0	n	0	n	0	0	n	0	y	8	n	0	n	0	n	0	n	0	n	0	n	0	y	365
79	754136	sd	70	female	vpo sanura,j&k	rural	24.13	y	n	y	y	y	y	30	y	30	y	30	y	6	120	y	45	y	30	y	25	n	0	n	0	n	0	y	365	n	0	y	365
80	633010	rs	66	male	vpo karipur,bhatinda	rural	20.28	y	n	y	n	n	y	15	y	15	n	0	n	0	0	n	0	y	7	n	0	n	0	n	0	n	0	n	0	n	0	n	0
81	764175	js	59	male	vpo kasel,taran taran	rural	23.4	y	n	n	y	y	y	7	n	0	n	0	n	0	0	n	0	n	0	n	0	n	0	y	7	n	0	y	0	y	180	n	0
82	766536	tk	45	female	vpo bharsinghpur,jalandhar	rural	27.5	y	n	y	y	n	n	0	n	0	y	120	n	0	0	y	120	n	0	n	0	n	0	n	0	n	0	n	0	n	0	y	120
83	736862	mk	70	female	ludhiana	urban	28.8	y	n	n	y	y	n	0	n	0	y	120	n	2	150	n	0	n	0	y	120	n	0	n	0	n	0	n	0	y	150	n	0	y	150
84	765542	sk	52	female	pathankot	urban	26.6	y	n	y	n	n	n	0	n	0	y	7	n	0	0	n	0	n	0	n	0	n	0	n	0	n	0	n	0	n	0	n	0
85	772868	js	42	male	vpo pakki,ganganagar	rural	19.5	y	n	n	n	n	y	5	y	5	y	5	n	0	0	n	0	y	5	n	0	n	0	n	0	n	0	n	0	n	0	n	0
86	774306	hs	64	male	kotakapura	rural	19.5	y	n	y	n	n	y	7	y	7	y	7	n	0	0	n	0	y	7	n	0	n	0	n	0	n	0	n	0	n	0	n	0
87	787977	ts	60	male	pathankot	urban	27.6	y	n	y	n	y	y	45	y	45	y	45	n	10	60	y	60	n	0	n	0	n	0	n	0	n	0	n	0	n	0	y	0
88	759641	hs	75	male	muktsar	urban	31.25	y	y	y	y	n	y	15	y	12	y	180	y	10	240	n	0	y	20	n	0	n	0	y	15	y	15	n	0	n	0	n	0
89	765592	ss	62	male	pathankot	urban	29.2	y	n	y	y	n	y	20	n	0	y	25	n	0	0	n	0	n	0	n	0	n	0	n	0	n	0	n	0	n	0	y	15
90	768925	sk	74	female	ludhiana	urban	18.9	y	n	n	n	n	y	15	y	15	y	15	n	0	0	n	0	n	0	n	0	n	0	n	0	n	0	n	0	n	0	n	0
91	67452	aq	67	female	ludhiana	urban	24	y	n	n	y	y	y	7	y	7	y	150	y	8	180	n	0	n	0	n	0	n	0	n	0	y	150	n	0	n	0	n	0
92	704957	ak	52	female	ludhiana	urban	22.4	y	n	n	n	n	y	15	n	0	n	0	n	0	0	n	0	n	0	n	0	n	0	n	0	n	0	n	0	n	0	n	0
93	736862	mk	70	female	ludhiana	urban	22.6	y	n	n	y	n	y	7	n	0	y	7	n	0	0	n	0	n	0	n	0	n	0	n	0	n	0	n	0	n	0	y	15
94	770578	bk	54	female	vpo samalsar,moga	urban	19.5	y	n	n	y	n	y	60	y	60	n	0	y	5	120	n	0	y	60	y	60	n	0	n	0	n	0	n	0	n	0	y	60
95	770240	ss	65	male	ludhiana	urban	24	y	n	n	n	y	y	4	y	4	y	180	n	0	0	n	0	n	0	n	0	n	0	n	0	n	0	y	0	n	0	n	0
96	688217	hs	58	male	muktsar	urban	25.3	y	n	n	n	n	n	0	n	0	y	30	n	0	0	y	7	y	30	n	0	n	0	n	0	n	0	n	0	n	0	n	0
97	769542	jk	30	female	hoshiarpur	urban	19.5	y	n	n	y	n	y	4	y	4	y	10	n	0	0	n	0	n	0	n	0	n	0	n	0	n	0	n	0	n	0	n	0

sr no	mrd	altered sensorium	duration	depression	duration	vegetarian	smoker y/n	smoker duration(y)	smoker occasional	smoker reform yr	alcoholic y/n	alcoholic duration(y)	alcoholic occasional	alcoholic reformed (y)	menses regular	post menopausal	lithium y/n	lithium dose	lithium duration	lithium frequency	anti estrogen y/n	anti estrogen dose	anti estrogen duration	anti estrogen frequency	thiazide y/n	thiazide dose	thiazide duration	thiazide frequency	vit d supplement y/n	vit d supplement dose	vit d supplement duration	vit d supplement frequency	dose per day	ca supplement y/n
1	657560	y	1	n	0	y	n	0	-	-	n	-	-	-	na	na	n	0	0	0	n	0	0	0	n	0	0	0	n	600000iu	365	twice a month	40,000	n
2	620678	n	0	n	0	y	n	0	-	-	n	-	-	-	na	y	n	0	0	0	n	0	0	0	n	0	0	0	y	60000iu	45	od	60,000	y
3	622323	n	0	y	180	n	n	0	-	-	n	-	-	-	na	y	n	0	0	0	n	0	0	0	n	0	0	0	n	600000iu	>356	once a month	40,000	n
4	642273	y	15	y	365	n	n	0	-	-	n	-	-	-	na	na	y	400mg	365	bd	n	0	0	0	n	0	0	0	n	600000iu	60	twice a week	1,71,428	y
5	653016	n	0	n	0	y	n	0	-	-	n	-	-	-	na	y	n	0	0	0	n	0	0	0	n	0	0	0	n	60000iu	>365	od	60,000	n
6	652324	y	1	n	0	y	n	0	-	-	n	-	-	-	na	na	n	0	0	0	n	0	0	0	n	0	0	0	n	600000iu	180	once a month	40,000	n
7	634367	y	15	n	0	y	y	20	y	y	y	20	n	y	na	na	n	0	0	0	n	0	0	0	n	0	0	0	n	300000iu	150	twice a week	60,000	n
8	619369	n	0	n	0	y	n	0	-	-	n	-	-	0	na	na	n	0	0	0	n	0	0	0	n	0	0	0	n	60000	210	od	60,000	n
9	479659	n	0	n	0	y	n	0	-	-	n	-	-	0	na	na	n	0	0	0	n	0	0	0	n	0	0	0	n	60000iu	180	od	60,000	n
10	507990	y	2	n	0	n	n	0	-	-	y	10	y	n	na	na	n	0	0	0	n	0	0	0	n	0	0	0	n	60000iu	>365	od	60,000	n
11	114141	n	0	n	0	y	n	0	-	-	n	-	-	0	na	na	n	0	0	0	n	0	0	0	n	0	0	0	n	600000iu	60	once a week	85,714	n
12	661028	n	0	n	0	n	y	12	y	y	y	40	n	n	na	na	n	0	0	0	n	0	0	0	n	0	0	0	n	600000iu	>365	twice a month	40,000	n
13	481154	n	0	n	0	y	n	0	-	-	n	-	-	0	na	na	n	0	0	0	n	0	0	0	n	0	0	0	n	60000iu	>365	od	60,000	n
14	661793	n	0	n	0	y	n	0	-	-	n	-	-	0	na	y	n	0	0	0	n	0	0	0	n	0	0	0	y	600000iu	45	twice a week	1,71,428	y
15	534702	n	0	n	0	y	n	0	-	-	n	-	-	0	na	y	n	0	0	0	n	0	0	0	n	0	0	0	y	600000iu	90	once a week	85714	y
16	637317	n	0	n	0	y	n	0	-	-	n	-	-	0	na	y	n	0	0	0	n	0	0	0	n	0	0	0	n	300000iu	150	once a week	42,875	n
17	660678	y	1	n	0	y	n	0	-	-	n	-	-	0	na	na	n	0	0	0	n	0	0	0	n	0	0	0	n	60000iu	120	od	60,000	n
18	678181	y	7	n	0	y	y	5	y	y	y	5	y	n	na	na	n	0	0	0	n	0	0	0	n	0	0	0	n	60000iu	>365	od	60,000	n
19	471657	y	3	n	0	y	n	0	-	-	n	-	-	0	na	y	n	0	0	0	n	0	0	0	n	0	0	0	n	300000iu	>365	once a week	42,857	n
20	544686	n	0	n	0	n	y	4	y	n	y	4	y	n	na	na	n	0	0	0	n	0	0	0	n	0	0	0	y	600000iu	90	once a month	20000	y
21	547171	n	0	n	0	y	n	0	-	-	y	5	y	n	na	na	n	0	0	0	n	0	0	0	n	0	0	0	n	60000iu	>365	od	60,000	n
22	699422	n	0	n	0	y	n	0	-	-	n	-	-	0	na	na	n	0	0	0	n	0	0	0	n	0	0	0	n	600000iu	120	once a week	85,714	n
23	685762	n	0	n	0	y	n	0	-	-	n	-	-	0	na	na	n	0	0	0	n	0	0	0	n	0	0	0	n	0	0	0	-	n
24	390146	y	1	n	0	y	n	0	-	-	n	-	-	0	na	y	n	0	0	0	n	0	0	0	n	0	0	0	n	0	0	0	-	n
25	696214	n	0	n	0	y	n	0	-	-	n	-	-	0	na	y	n	0	0	0	n	0	0	0	n	0	0	0	n	0	0	0	-	n
26	689657	y	6	n	0	y	y	5	y	y	n	-	-	0	na	na	n	0	0	0	n	0	0	0	n	0	0	0	n	0	0	0	-	n
27	688609	n	0	n	0	y	n	0	-	-	n	-	-	-	na	y	n	0	0	0	n	0	0	0	n	0	0	0	y	60000iu	180	once a month	-	y
28	688263	n	0	n	0	y	n	0	-	-	n	-	-	-	na	y	n	0	0	0	n	0	0	0	n	0	0	0	n	0	0	0	-	n
29	549787	y	2	n	0	y	n	0	-	-	n	-	-	-	na	y	n	0	0	0	n	0	0	0	n	0	0	0	n	0	0	0	-	n
30	884054	n	0	n	0	y	n	0	-	-	n	-	-	-	na	y	n	0	0	0	n	0	0	0	n	0	0	0	n	0	0	0	-	n
31	681615	n	0	n	0	y	y	10	n	y	n	-	-	-	na	na	n	0	0	0	n	0	0	0	n	0	0	0	n	0	0	0	-	n
32	681960	y	3	n	0	n	y	50	n	n	y	4	y	y	na	na	n	0	0	0	n	0	0	0	n	0	0	0	n	0	0	0	-	n
33	608658	n	0	n	0	n	y	10	y	n	n	-	-	-	na	na	n	0	0	0	n	0	0	0	n	0	0	0	n	0	0	0	-	n
34	704263	y	30	n	0	y	y	10	y	n	n	-	-	-	na	na	n	0	0	0	n	0	0	0	n	0	0	0	n	0	0	0	-	n
35	616466	n	0	n	0	y	n	0	-	-	n	-	-	-	na	y	n	0	0	0	n	0	0	0	n	0	0	0	n	0	0	0	-	n
36	684353	n	0	n	0	y	n	0	-	-	n	-	-	-	na	y	n	0	0	0	n	0	0	0	y	25mg	>365	od	n	0	0	0	-	n
37	710294	y	1	n	0	y	n	0	-	-	n	-	-	-	na	y	n	0	0	0	n	0	0	0	n	0	0	0	n	0	0	0	-	n
38	701237	n	0	n	0	y	n	0	-	-	n	-	-	-	y	na	n	0	0	0	n	0	0	0	n	0	0	0	n	300000iu	10	od	300,000	n
39	704363	y	1	n	0	y	n	0	-	-	n	-	-	-	na	y	n	0	0	0	n	0	0	0	n	0	0	0	n	0	0	0	-	n
40	714668	n	0	n	0	n	y	25	y	y	n	-	-	-	na	na	n	0	0	0	n	0	0	0	n	0	0	0	n	0	0	0	-	n
41	714055	n	0	n	0	n	y	10	y	y	n	-	-	20	na	na	n	0	0	0	n	0	0	0	n	0	0	0	n	0	0	0	-	n
42	709161	n	0	n	0	y	n	0	-	-	n	-	-	-	na	y	n	0	0	0	n	0	0	0	n	0	0	0	n	0	0	0	-	n
43	705170	n	0	n	0	n	n	0	-	-	n	-	-	-	na	y	n	0	0	0	n	0	0	0	n	0	0	0	n	0	0	0	-	n
44	704346	n	0	n	0	y	y	10	y	n	n	-	-	-	na	na	n	0	0	0	n	0	0	0	n	0	0	0	y	600000iu	365	twice a month	40,000	y
45	701197	n	0	n	0	y	n	0	-	-	n	-	-	-	na	y	n	0	0	0	n	0	0	0	n	0	0	0	n	600000iu	>365	0	-	n
46	705939	n	0	n	0	y	n	0	-	-	n	-	-	-	y	y	n	0	0	0	n	0	0	0	n	0	0	0	n	600000iu	>356	0	-	n
47	716065	y	1	n	0	n	n	0	-	-	y	20	n	n	na	na	n	0	0	0	n	0	0	0	n	0	0	0	n	600000iu	60	0	-	n
48	710294	n	0	n	0	y	n	0	-	-	n	-	-	-	na	y	n	0	0	0	n	0	0	0	n	0	0	0	n	60000iu	>365	0	-	n
49	709534	n	4	n	0	y	n	0	-	-	n	-	-	-	na	y	n	0	0	0	n	0	0	0	n	0	0	0	y	600000iu	>365	twice a month	40,000	y
50	668636	y	4	n	0	y	y	20	y	y	y	20	y	y	na	na	n	0	0	0	n	0	0	0	n	0	0	0	n	300000iu	150	0	-	n
51	24573	n	0	n	0	y	n	0	-	-	n	-	-	-	na	y	n	0	0	0	n	0	0	0	n	0	0	0	n	60000	210	0	-	n
52	274445	n	0	n	0	y	n	0	-	-	n	-	-	-	na	y	n	0	0	0	n	0	0	0	n	0	0	0	n	60000iu	180	0	-	n
53	715876	n	0	n	0	y	n	0	-	-	n	-	-	-	na	y	n	0	0	0	n	0	0	0	n	0	0	0	n	60000iu	>365	0	-	n
54	82146	y	1	n	0	y	n	0	-	-	n	-	-	-	na	na	n	0	0	0	n	0	0	0	n	0	0	0	n	600000iu	60	0	-	n
55	703014	n	0	n	0	y	y	5	y	y	n	-	-	-	na	na	n	0	0	0	n	0	0	0	n	0	0	0	n	600000iu	>365	0	-	n
56	688160	n	0	n	0	n	n	0	-	-	n	-	-	-	na	na	n	0	0	0	n	0	0	0	n	0	0	0	n	60000iu	>365	0	-	n
57	707264	n	0	n	0	y	n	0	-	-	n	-	-	-	na	y	n	0	0	0	n	0	0	0	n	0	0	0	n	600000iu	45	0	-	n
58	723943	n	0	n	0	n	n	0	-	-	n	-	-	-	na	na	n	0	0	0	n	0	0	0	n	0	0	0	n	600000iu	240	0	-	n
59	721990	n	0	n	0	y	n	0	-	-	n	-	-	-	na	na	n	0	0	0	n	0	0	0	n	0	0	0	n	300000iu	150	0	-	n
60	735044	n	0	n	0	n	n	0	-	-	n	-	-	-	na	na	n	0	0	0	n	0	0	0	n	0	0	0	n	60000iu	120	0	-	n
61	720710	n	0	n	0	y	n	0	-	-	n	-	-	-	na	y	n	0	0	0	n	0	0	0	n	0	0	0	n	60000iu	>365	0	-	n
62	720710	n	0	y	3	y	y	10	y	n	n	-	-	-	na	na	n	0	0	0	n	0	0	0	n	0	0	0	n	300000iu	90	once a week	42857	n
63	728676	n	0	n	0	n	n	0	-	-	n	-	-	-	na	na	n	0	0	0	n	0	0	0	n	0	0	0	n	600000iu	>365	0	-	n
64	723902	y	10	n	0	n	n	0	-	-	y	2	y	n	na	na	n	0	0	0	n	0	0	0	n	0	0	0	n	60000iu	>365	0	-	n
65	724002	n	2	n	0	y	n	0	-	-	n	-	-	-	na	y	n	0	0	0	n	0	0	0	n	0	0	0	y	600000iu	>365	once a month	40,000	y
66	615991	y	15	n	0	n	n	0	-	-	y	10	n	n	na	na	n	0	0	0	n	0	0	0	n	0	0	0	y	60000iu	>365	once a month	-	n
67	729399	y	3	y	180	y	y	20	y	y	n	-	-	-	na	na	n	0	0	0	n	0	0	0	n	0	0	0	n	0	0	0	-	n
68	731537	n	0	n	0	y	n	0	-	-	n	-	-	-	na	y	n	0	0	0	n	0	0	0	n	0	0	0	n	0	0	0	-	n
69	683750	y	1	n	0	y	n	0	-	-	n	-	-	-	na	y	n	0	0	0	y	2.5mg	90	od	n	0	0	0	n	0	0	0	-	n
70	739803	y	5	n	0	y	n	0	-	-	y	30	n	n	na	na	n	0	0	0	n	0	0	0	n	0	0	0	n	0	0	0	-	n
71	736862	n	0	n	0	y	n	0	-	-	n	-	-	-	na	y	n	0	0	0	n	0	0	0	n	0	0	0	y	600000iu	60	twice a week	1,71,428	y
72	56701	n	0	n	0	y	n	0	-	-	n	-	-	-	na	y	n	0	0	0	n	0	0	0	n	0	0	0	n	0	0	0	-	n
73	699324	n	1	n	0	y	n	0	-	-	n	-	-	-	na	na	n	0	0	0	n	0	0	0	n	0	0	0	y	60000iu	>365	od	60,000	y
74	743426	n	0	n	0	n	n	0	-	-	n	-	-	-	na	na	n	0	0	0	n	0	0	0	y	12.5mg	180	0	n	0	0	0	-	n
75	342253	y	4	n	0	y	n	0	-	-	n	-	-	-	na	y	n	0	0	0	n	0	0	0	n	0	0	0	y	300000iu	>365	once every 6 monthly	-	y
76	715875	y	5	y	365	y	n	0	-	-	n	-	-	-	na	y	n	0	0	0	n	0	0	0	n	0	0	0	y	400iu	>365	od	-	y
77	740599	y	5	n	0	y	n	0	-	-	n	-	-	-	na	na	n	0	0	0	n	0	0	0	n	0	0	0	n	0	0	0	-	y
78	743466	n	0	n	0	y	n	0	-	-	n	-	-	-	na	y	n	0	0	0	n	0	0	0	n	0	0	0	n	0	0	0	-	n
79	754136	y	1	n	0	y	n	0	-	-	n	-	-	-	na	y	n	0	0	0	n	0	0	0	n	0	0	0	n	0	0	0	-	y
80	633010	y	2	n	0	y	n	0	-	-	n	-	-	-	na	na	n	0	0	0	n	0	0	0	n	0	0	0	y	1000iu	>365	od	-	y
81	764175	n	0	n	0	y	y	25	y	y	y	8	y	y	na	na	n	0	0	0	n	0	0	0	n	0	0	0	y	600000iu	180	once a month	40,000	y
82	766536	y	120	n	0	n	n	0	-	-	n	-	-	-	na	y	n	0	0	0	n	0	0	0	n	0	0	0	n	0	0	0	-	n
83	736862	n	30	n	0	y	n	0	-	-	n	-	-	-	na	y	n	0	0	0	n	0	0	0	n	0	0	0	y	300000iu	150	twice a week	60,000	y
84	765542	y	6	n	0	n	n	0	-	-	y	10	n	n	na	y	n	0	0	0	n	0	0	0	n	0	0	0	n	0	0	0	-	n
85	772868	n	0	n	0	n	n	0	-	-	n	-	-	-	na	na	n	0	0	0	n	0	0	0	n	0	0	0	n	0	0	0	-	n
86	774306	y	3	n	0	y	n	0	-	-	n	-	-	-	na	na	n	0	0	0	n	0	0	0	n	0	0	0	n	0	0	0	-	n
87	787977	n	0	n	0	n	n	0	-	-	n	-	-	-	na	na	n	0	0	0	n	0	0	0	n	0	0	0	y	60000iu	210	od	60,000	y
88	759641	y	2	n	0	y	n	0	-	-	n	-	-	-	na	na	n	0	0	0	n	0	0	0	n	0	0	0	n	0	0	0	-	n
89	765592	y	6	n	0	y	y	15	y	n	y	25	n	y	na	na	n	0	0	0	n	0	0	0	n	0	0	0	n	0	0	0	-	y
90	768925	n	0	n	0	y	n	0	-	-	n	-	-	-	na	y	n	0	0	0	n	0	0	0	y	25mg	>365	od	y	60000iu	15	od	-	y
91	67452	n	0	n	0	y	n	0	-	-	n	-	-	-	na	y	n	0	0	0	n	0	0	0	n	0	0	0	y	2000iu	90	od	-	y
92	704957	n	0	n	0	y	n	0	-	-	n	-	-	-	na	y	n	0	0	0	n	0	0	0	n	0	0	0	y	2000iu	>365	od	-	y
93	736862	n	1	n	0	y	n	0	-	-	n	-	-	-	na	y	n	0	0	0	n	0	0	0	y	12.5mg	180	od	y	60000iu	180	od	60,000	y
94	770578	n	0	n	0	y	n	0	-	-	n	-	-	-	na	y	n	0	0	0	n	0	0	0	n	0	0	0	n	0	0	0	-	n
95	770240	n	0	n	0	y	n	0	-	-	n	-	-	-	na	y	n	0	0	0	n	0	0	0	n	0	0	0	y	60000iu	>365	od	60,000	y
96	688217	n	0	n	0	y	n	0	-	-	y	15	y	y	na	na	n	0	0	0	n	0	0	0	n	0	0	0	n	0	0	0	-	n
97	769542	n	0	n	0	n	n	0	-	-	n	-	-	-	y	n	n	0	0	0	n	0	0	0	n	0	0	0	y	60000iu	150	twice a week	17142	y

sr no	mrd	ca supplement dose	ca supplement duration	ca supplement frequency	Past History y/n	DM	HTN	CKD	CAD	CLD	asthma/ COPD	arthritis	cancer	ca bladder	ca penis	ca ovary	ca cervix	ca esophagus	HCC	ca gb and bile duct	ca head and neck	multiple myeloma	breast	RCC	ca lung	lymphoma	TB	sarcoidosis	recurrent pancreatitis	hypothyroidism	hyperthyroidism	other	past treatment	hb(g/dl) adm	hb(g/dl) dis	TLC adm	TLC dis	platelets adm	platelets dis	urea adm
1	657560	0	0	0	y	y	y	n	n	n	n	n	n	n	n	n	n	n	n	n	n	n	n	n	-	n	n	n	-	-	-	-	-	12	12	20	18	242	248	22
2	620678	500mg	365	od	y	n	n	n	n	n	n	y	n	n	n	n	n	n	n	n	n	n	n	n	-	n	n	n	-	-	-	-	-	10	-	7	-	190	-	59
3	622323	0	0	0	n	y	y	n	n	n	n	n	n	n	n	n	n	n	n	n	n	n	n	n	-	n	n	n	-	-	-	-	-	5.2	9.2	18	20.6	251	116	110
4	642273	500mg	60	od	n	y	y	y	n	n	n	y	n	n	n	n	n	n	n	n	n	n	n	n	-	n	n	n	-	-	-	-	-	10.4	10	11.4	7.6	254	250	98
5	653016	0	0	0	y	y	n	n	n	n	n	n	n	n	n	n	n	n	n	n	n	n	n	n	-	n	n	n	-	-	-	-	-	6.4	-	8	-	50	-	110
6	652324	0	0	0	y	n	y	n	n	n	n	n	n	n	n	n	n	n	n	n	n	n	n	n	-	n	n	n	-	-	-	-	-	14.6	14.2	22.6	11.2	294	250	85
7	634367	0	0	0	y	y	y	n	n	y	y	n	n	n	n	n	n	n	n	n	n	n	n	n	-	n	n	n	-	-	-	-	-	8.4	8.4	7.7	8	85	90	38
8	619369	0	0	0	y	y	y	y	y	n	n	n	n	n	n	n	n	n	n	n	n	n	n	n	-	n	n	n	-	-	-	-	-	6.4	9.8	15.4	5.8	142	150	80
9	479659	0	0	0	n	n	n	n	n	n	n	n	y	n	n	n	n	n	n	n	n	y	n	n	n	n	n	n	-	-	-	-	-	10.7	9.4	22	20.3	556	486	61
10	507990	0	0	0	n	n	n	y	n	y	n	n	n	n	n	n	n	n	n	y	n	n	n	n	-	n	n	n	-	-	-	-	-	13	10.7	8	7.6	298	271	21
11	114141	0	0	0	y	n	n	n	n	n	n	n	n	n	n	n	n	n	n	n	n	n	n	n	-	n	n	n	-	-	-	-	-	15.4	13.7	16	7	230	245	25
12	661028	0	0	0	y	n	n	n	n	y	n	n	n	n	n	n	n	n	n	n	n	n	n	n	-	n	n	n	-	-	-	-	-	12.7	-	23	-	189	-	37
13	481154	0	0	0	n	n	y	n	n	n	n	n	n	n	n	n	n	n	n	n	n	n	n	n	-	n	n	n	-	-	-	-	-	12	8.8	9	6	120	146	42
14	661793	500mg	180	bd	n	y	y	y	n	n	n	n	n	n	n	n	n	n	n	n	n	n	n	n	-	n	n	n	-	-	-	-	-	8.6	8.4	13	9	232	242	132
15	534702	500mg	180	od	n	n	n	n	n	n	n	n	n	n	n	n	n	n	n	n	n	n	n	n	-	n	n	n	-	-	-	-	-	12.4	11.5	11.3	9.5	268	237	11
16	637317	0	0	0	n	n	n	n	n	n	n	n	n	n	n	n	n	n	n	n	n	n	n	n	-	n	n	n	-	-	-	-	-	7	-	8.8	-	261	-	38
17	660678	0	0	0	n	n	n	n	n	n	n	n	n	n	n	n	n	n	n	n	n	n	n	n	-	n	n	n	-	-	-	-	-	10.4	8.5	16.6	5.5	150	88	157
18	678181	0	0	0	n	n	n	n	n	n	n	n	y	y	n	n	n	n	n	n	n	n	n	n	n	n	n	n	-	-	-	-	-	15	13.4	18	20	239	171	100
19	471657	0	0	0	y	y	y	n	n	n	n	n	n	n	n	n	n	n	n	n	n	n	n	n	-	n	n	n	-	-	-	-	-	10	13	17.5	18.4	292	337	24
20	544686	500mg	180	od	y	y	n	n	n	n	n	n	n	n	n	n	n	n	n	n	n	n	n	n	-	n	n	n	-	-	-	-	-	9.5	8.4	10	10.5	513	499	83
21	547171	0	0	0	y	y	n	n	n	n	n	n	n	n	n	n	n	n	n	n	n	n	n	n	-	n	n	n	-	-	-	-	-	9	9.8	16.7	17.5	335	351	19
22	699422	0	0	0	n	n	n	y	n	y	n	n	n	n	n	n	n	n	n	n	n	n	n	n	-	n	n	n	-	-	-	-	-	12	12.7	17.5	27.5	182	250	82
23	685762	0	0	0	n	n	n	n	n	n	n	n	n	n	n	n	n	n	n	n	n	n	n	n	-	n	n	n	-	-	-	-	-	10.6	10.9	13	7	240	210	14
24	390146	0	0	0	y	y	y	n	y	n	n	n	n	n	n	n	n	n	n	n	n	n	n	n	-	n	n	n	-	-	-	-	-	8	7.3	23	27.4	395	349	129
25	696214	0	0	0	y	y	y	n	n	n	n	n	n	n	n	n	n	n	n	n	n	n	n	n	-	n	n	n	-	-	-	-	-	10	13.6	11	4.3	175	150	34
26	689657	0	0	0	y	n	y	n	n	n	n	n	n	n	n	n	n	n	n	n	n	n	n	n	-	n	n	n	-	-	-	-	-	9	7.8	13	8	214	209	103
27	688609	500mg	180	od	y	y	n	n	n	n	n	n	n	n	n	n	n	n	n	n	n	n	n	n	-	n	n	n	-	-	-	-	-	12	12	16	8	250	253	20
28	688263	0	0	0	y	y	n	n	y	n	n	n	n	n	n	n	n	n	n	n	n	n	n	n	-	n	n	n	-	-	-	-	-	10	10.4	6	4	423	333	85
29	549787	0	0	0	y	v	y	n	n	n	n	n	n	n	n	n	n	n	n	n	n	n	n	n	-	n	n	n	-	-	-	-	-	9.3	8.2	10.8	9	245	226	117
30	884054	0	0	0	y	y	y	n	n	n	n	n	n	n	n	n	n	n	n	n	n	n	n	n	-	n	n	n	-	-	-	-	-	8	8.4	13.3	13.7	263	138	154
31	681616	0	0	0	y	n	n	n	n	y	n	n	n	n	n	n	n	n	n	n	n	n	n	n	-	n	n	n	-	-	-	-	-	7.5	7.1	13	12	86	92	49
32	681960	0	0	0	y	y	n	n	y	n	n	n	y	n	n	n	n	n	n	n	n	n	n	n	y	n	n	n	-	-	-	-	-	8.5	9.5	30	18	536	603	78
33	608658	0	0	0	y	n	n	n	n	n	n	n	n	n	n	n	n	n	n	n	n	n	n	n	-	n	n	n	-	-	-	-	-	10.5	11.2	13.2	11	280	230	50
34	704263	0	0	0	y	y	y	n	y	n	n	n	n	n	n	n	n	n	n	n	n	n	n	n	-	n	n	n	-	-	-	-	-	6.4	8	9	8.8	162	120	198
35	616466	0	0	0	y	y	y	n	n	n	n	n	n	n	n	n	n	n	n	n	n	n	n	n	-	n	n	n	-	-	-	-	-	12	11	8.6	11.6	253	259	57
36	684353	0	0	0	y	y	y	y	n	y	n	n	n	n	n	n	n	n	n	n	n	n	n	n	-	n	n	n	-	-	-	-	-	10	12.2	15.5	17.5	336	374	75
37	710294	0	0	0	y	n	v	n	n	n	n	v	n	n	n	n	n	n	n	n	n	n	n	n	-	n	n	n	-	-	-	-	-	16	16	13.7	16.7	225	406	68
38	701237	0	0	0	n	n	n	n	n	n	n	n	n	n	n	n	n	n	n	n	n	n	n	n	-	n	n	n	-	-	-	-	-	10	10	27	36	120	101	143
39	704363	0	0	0	y	y	y	n	n	n	n	n	n	n	n	n	n	n	n	n	n	n	n	n	-	n	n	n	-	-	-	-	-	9.2	9.7	15	15	626	615	58
40	714668	0	0	0	n	n	n	n	n	n	n	n	n	n	n	n	n	n	n	n	n	n	n	n	-	n	n	n	-	-	-	-	-	6.5	7	14.8	14.7	172	175	94
41	714055	0	0	0	y	n	y	n	n	n	n	n	n	n	n	n	n	n	n	n	n	n	n	n	-	n	n	n	-	-	-	-	-	11	-	9.6	-	173	-	50
42	709161	0	0	0	y	n	n	n	n	n	n	n	n	n	n	n	n	n	n	n	n	n	n	n	-	n	n	n	-	-	y	-	-	8	-	12.4	-	100	-	75
43	705170	0	0	0	y	n	n	n	n	y	n	n	n	n	n	n	n	n	n	n	n	n	n	n	-	n	n	n	-	-	-	cva	-	8.5	8.2	5.8	6.7	150	149	124
44	704346	500mg	365	od	n	n	y	n	n	n	n	n	n	n	n	n	n	n	n	n	n	n	n	n	-	n	n	n	-	-	-	-	-	11	10.8	14.8	16	77	40	8.4
45	701197	0	0	0	n	n	n	n	n	n	n	n	n	n	n	n	n	n	n	n	n	n	n	n	-	n	n	n	-	-	-	-	-	11.7	10.4	17	10.8	416	454	14
46	705939	0	0	0	n	n	n	n	n	n	n	n	n	n	n	n	n	n	n	n	n	n	n	n	-	n	n	n	y	-	-	-	-	11	10.8	6.6	6.3	220	288	9
47	710065	0	0	0	y	n	n	n	n	y	n	n	n	n	n	n	n	n	n	n	n	n	n	n	-	n	n	n	-	-	-	-	-	11.5	7.1	22	25	84	60	86
48	710294	0	0	0	y	n	y	n	n	n	n	n	n	n	n	n	n	n	n	n	n	n	n	n	-	n	n	n	-	-	-	-	-	14	13.6	13.8	10.6	256	272	65
49	709534	500mg	365	irregular	y	y	n	n	n	n	n	n	n	n	n	n	n	n	n	n	n	n	n	n	-	n	n	n	-	-	-	-	-	10.2	9.9	31	17	524	590	60
50	668636	0	0	0	n	n	n	n	n	y	n	n	n	n	n	n	n	n	n	n	n	n	n	n	-	n	n	n	-	-	-	-	-	10.3	-	15.7	-	110	-	50
51	24573	0	0	0	n	n	n	n	n	n	n	n	y	n	n	y	n	n	n	n	n	n	n	n	n	n	n	n	-	-	-	-	-	9	8.8	13	31.5	200	147	95
52	274445	0	0	0	n	n	n	n	n	n	n	n	n	n	n	n	n	n	n	n	n	n	n	n	-	n	n	n	-	-	-	-	-	8.6	-	23	-	196	-	21
53	715876	0	0	0	y	n	v	n	y	n	n	n	y	n	n	n	y	n	n	n	n	n	n	n	n	n	n	n	-	-	-	-	post sx/ct/rt	9.4	9.7	6	7.5	204	165	41
54	82146	0	0	0	y	n	n	n	n	n	n	n	y	n	n	n	n	n	n	n	n	y	n	n	n	n	n	n	-	-	-	-	-	7	7.8	4	2.8	130	113	80
55	703014	0	0	0	n	n	n	n	n	n	n	n	n	n	n	n	n	n	n	n	n	n	n	n	-	n	n	n	-	-	-	-	-	8.4	9.5	6.4	8.2	86	111	36
56	688160	0	0	0	n	n	n	n	n	n	n	n	n	n	n	n	n	n	n	n	n	n	n	n	-	n	n	n	-	-	-	-	-	8.2	8.8	3.5	2.7	47	53	26
57	707264	0	0	0	n	y	y	n	n	n	n	n	n	n	n	n	n	n	n	n	n	n	n	n	-	n	n	n	-	-	-	-	-	9.8	10.5	15	10.8	400	369	58
58	723943	0	0	0	n	y	y	n	n	n	n	n	n	n	n	n	n	n	n	n	n	n	n	n	-	n	n	n	-	-	-	-	-	8	7.6	16	9.4	417	475	42
59	721990	0	0	0	n	n	n	n	n	n	n	n	n	n	n	n	n	n	n	n	n	n	n	n	-	n	n	n	-	-	-	-	-	12.3	12.7	55.6	46.3	1469	1488	40
60	735044	0	0	0	n	n	n	n	n	n	n	n	n	n	n	n	n	n	n	n	n	n	n	n	-	n	n	n	-	-	-	-	-	11.6	10.5	7.3	5.4	140	205	57
61	720710	0	0	0	n	y	n	n	n	n	n	n	n	n	n	n	n	n	n	n	n	n	n	n	-	n	n	n	-	-	-	-	-	6.4	8.1	8.4	4.5	104	46	34
62	720710	0	0	0	n	y	n	n	n	n	n	n	n	n	n	n	n	n	n	n	n	n	n	n	-	n	n	n	-	-	-	-	-	8	9	28	12	528	328	224
63	728676	0	0	0	n	n	n	n	n	n	n	n	n	n	n	n	n	n	n	n	n	n	n	n	-	n	n	n	-	-	-	-	-	11	11.5	11	9	210	677	102
64	723902	0	0	0	y	n	y	n	n	n	n	n	n	n	n	n	n	n	n	n	n	n	n	n	-	n	n	n	-	-	-	-	-	13	12	16.5	15.7	466	336	50
65	724002	500mg	365	irregular	y	n	y	n	n	n	n	n	n	n	n	n	n	n	n	n	n	n	n	n	-	n	n	n	-	-	-	-	#femur 2018	10.4	10	5	9.7	250	273	135
66	615991	0	0	0	y	n	n	n	y	n	n	n	n	n	n	n	n	n	n	n	n	n	n	n	-	n	y	n	-	y	-	hiv	-	12.8	9.1	10.6	4.7	66	70	71
67	729399	0	0	0	n	y	v	n	n	n	y	n	n	y	y	n	n	n	n	n	n	n	n	n	n	n	n	n	-	-	-	-	-	10.4	6.6	12	12	200	42	95
68	731537	0	0	0	n	n	y	n	n	n	n	n	y	n	n	n	n	n	n	n	n	y	n	n	n	n	n	n	-	y	-	-	-	8.4	12	15	4	198	163	156
69	683750	0	0	0	n	n	y	n	n	y	n	n	y	n	n	y	n	n	n	n	n	n	n	n	n	n	n	n	-	-	-	-	-	6.4	5.4	12.4	14.3	96	80	110
70	739803	0	0	0	n	n	n	y	n	y	n	n	y	n	n	n	n	n	y	n	n	n	n	n	n	n	n	n	-	-	-	-	-	12.3	13	16	13	37	34	127
71	736862	500mg	365	od	y	y	y	n	n	n	n	y	n	n	n	n	n	n	n	n	n	n	n	-	-	n	n	n	-	-	-	-	-	10.5	9.6	11.2	11.8	77	130	80
72	56701	0	0	0	y	n	y	n	n	n	n	n	n	n	n	n	n	n	n	n	n	n	n	n	-	n	n	n	-	-	-	-	-	9.4	8.7	6.5	6.7	190	243	35
73	699324	500mg	365	od	y	y	n	n	n	n	n	y	n	n	n	n	n	n	n	n	n	n	n	n	-	n	n	n	-	-	-	-	-	10.7	9.1	9.7	6.2	330	227	91
74	743426	0	0	0	n	y	y	n	n	n	n	n	n	n	n	n	n	n	n	n	n	n	n	n	-	n	y	n	-	-	-	-	-	14.8	14.6	12	11.7	72	86	118
75	342253	500mg	365	od	y	y	n	n	n	y	n	n	n	n	n	n	n	n	n	n	n	n	n	n	-	n	n	n	-	-	-	-	-	14	11.6	9.3	11.7	150	30	141
76	715875	50mg	365	od	y	n	n	n	y	n	n	n	y	n	n	y	n	n	n	n	n	n	n	n	n	n	n	n	-	-	-	-	-	8.6	9	22.3	63	276	314	95
77	740599	50mg	60	od	y	n	n	n	n	n	n	y	n	n	n	n	n	n	n	n	n	n	n	n	-	n	n	n	-	-	-	-	-	7.7	9	7.8	7.4	153	144	80
78	743466	0	0	0	y	n	n	n	n	n	y	y	n	n	n	n	n	n	n	n	n	n	n	n	-	n	n	n	-	-	y	-	-	7	7.5	9.4	10	695	645	53
79	754136	500mg	90	od	y	y	y	n	n	n	n	y	n	n	n	n	n	n	n	n	n	n	n	n	-	n	n	n	-	y	-	-	-	8	8.4	5.7	5	130	140	45
80	633010	16.3	365	od	y	n	n	n	n	n	n	n	y	n	y	n	n	n	n	n	n	n	n	n	n	n	n	n	-	-	-	-	-	11.6	10.8	56	22	282	340	41
81	764175	500mg	180	od	n	n	n	y	y	n	n	n	n	n	n	n	n	n	n	n	n	n	n	n	-	n	y	n	-	-	-	-	att	10.8	12.6	10.4	11	239	356	40
82	766536	0	0	0	y	n	v	n	n	n	n	n	n	n	n	n	n	n	n	n	n	n	n	n	-	n	n	n	-	-	-	-	-	13.8	-	10	-	166	-	26
83	736862	500mg	150	od	y	n	v	n	n	n	y	n	n	n	n	n	n	n	n	n	n	n	n	n	-	n	n	n	-	-	-	-	-	9.6	10.5	10	10.5	453	341	36
84	765542	0	0	0	n	n	y	n	n	y	n	n	n	n	n	n	n	n	n	n	n	n	n	n	-	n	n	n	-	-	-	-	-	12	10.5	4.3	28.3	60	140	187
85	772868	0	0	0	y	n	y	n	n	n	n	n	n	n	n	n	n	n	n	n	n	n	n	n	-	n	n	n	-	-	-	-	-	12.5	-	12.2	-	371	-	69
86	774306	0	0	0	y	y	y	y	n	n	n	n	n	n	n	n	n	n	n	n	n	n	n	n	-	n	n	n	-	-	-	-	-	10	7.4	13.4	18.5	194	204	30
87	787977	500mg	365	od	y	y	y	n	n	n	n	n	n	n	n	n	n	n	n	n	n	n	n	n	-	n	n	n	-	-	-	-	-	14.5	-	10.8	-	230	-	23
88	759641	0	0	0	y	y	n	y	n	n	n	n	n	n	n	n	n	n	n	n	n	n	n	n	-	n	n	n	-	-	-	-	-	8.3	8.5	12.2	8.3	310	264	187
89	765592	50mg	60	od	y	n	n	y	n	y	n	n	n	n	n	n	n	n	n	n	n	n	n	n	-	n	n	n	-	-	-	-	-	7.7	9.9	3.2	5.8	50	70	171
90	768925	16.3mq	15	od	y	n	y	n	y	n	n	n	n	n	n	n	n	n	n	n	n	n	n	n	-	n	n	n	-	y	-	-	-	11.5	9.7	14.4	11	325	337	44
91	67452	500mg	90	od	y	n	n	n	n	n	n	n	y	n	n	n	n	n	n	n	n	n	y	n	n	n	n	n	-	-	y	-	post mrm	13.7	13.4	11	13.8	226	263	23
92	704957	500mg	365	od	y	n	n	n	n	n	n	n	n	n	n	n	n	n	n	n	n	n	n	n	-	n	n	n	-	-	-	sle	-	8.6	12.9	5	13.4	90	50	55
93	736862	500mg	365	od	y	y	y	n	n	n	n	n	y	n	n	n	n	n	n	n	n	n	n	n	n	n	n	n	-	-	y	-	-	9.6	9	10.3	10.5	453	341	43
94	770578	0	0	0	y	n	n	n	n	n	n	n	n	n	n	n	n	n	n	n	n	n	n	n	-	n	n	n	-	-	-	-	-	9.4	7.8	29.3	25.7	502	227	14
95	770240	500mg	365	od	y	y	y	n	n	n	n	y	n	n	n	n	n	n	n	n	n	n	n	n	-	n	n	n	-	-	-	-	-	11.2	10.8	22.7	4.6	295	130	133
96	688217	0	0	0	y	y	n	n	n	y	n	n	n	n	n	n	n	n	n	n	n	n	n	n	-	n	n	n	-	-	-	-	-	8.7	8.5	8.2	6.2	110	155	58
97	769542	500mg	180	od	n	n	n	n	n	n	n	n	n	n	n	n	n	n	n	n	n	n	n	n	-	n	n	n	-	-	-	-	-	8.6	8.4	14.8	9	139	115	153

sr no	mrd	urea dis	creatinine adm	creatinine dis	Na adm	Na dis	K adm	K dis	Cl adm	Cl dis	total bilirubin adm	total bilirubin dis	direct bilirubin adm	direct bilirubin dis	SGOT adm	SGOT dis	SGPT adm	SGPT dis	ALP adm	ALP dis	total proteins adm	total proteins dis	s. albumin adm	s. albumin dis	s. calcium adm	s. calcium dis	Corrected Calcium adm	Corrected Calcium dis	phosphorus adm	phosphorus dis	urine r/e protein	rbc	pus cell	glucose	pth adm	pth dis	Vitamin D admission	Vitamin D dis	TSH	T3	T4	short qt in ecg	cxr nor=1/abn=2/ not done=3	cxr pleural effusion	cxr hilar lap	cxr s/o tb	cxr lytic lesion
1	657560	30	0.7	0.6	140	135	4	3.7	103	101	0.5	-	0.13	-	82	-	39	-	434	-	6.8	-	3	-	12.3	10.9	13.1	11.7	4.5	-	0	0	0	0	14	-	30	-	-	-	-	y	2	-	-	-	-
2	620678	-	1.6	-	133	-	3	-	101	-	0.6	-	0.2	-	36	-	28	-	113	-	6.1	-	3.2	-	12	11.2	12.64	11.84	4	-	0	0	0	0	14	-	115	-	-	-	-	y	1	-	-	-	-
3	622323	80	3	1.46	133	132	5.2	3.3	95	101	0.56	-	0.35	-	23	-	20	-	123	-	6.7	-	2.7	-	11.2	10.6	12.24	11.64	4.5	5.6	0	0	0	0	10.65	-	47	-	1.7	-	-	y	1	-	-	-	-
4	642273	95	7	5.4	129	135	4.2	4.1	94	103	0.33	-	0.13	-	17	-	16	-	207	-	7	-	4.2	-	13	11.6	12.84	11.44	4.4	4.7	2	2	0	0	65	-	21	-	1.5	-	-	y	1	-	-	-	-
5	653016	-	3.5	-	129	-	5.7	-	91	-	18	14.5	15.6	10.7	100	84	6	-	199	-	5.4	-	2.5	-	11.8	11.5	13	12.7	5.9	-	0	0	0	0	13.9	-	22.5	-	3.6	-	-	y	2	-	-	y	-
6	652324	80	2.8	1.4	133	141	2.85	3.6	97	98	1.05	0.98	0.55	0.3	17	20	15	21	572	370	7.2	6.4	4.1	3.1	17.6	13.2	17.52	13.92	4.7	5.2	1	4	0	0	164	1361	44.1	-	-	-	-	y	2	y	-	-	-
7	634367	40	145	134	145	134	2.6	3.3	108	102	1.3	1.01	0.5	0.7	88	33	38	11	154	117	6.2	7.5	2.1	3.3	12.1	8.4	13.62	8.96	3.2	3.5	1	0	0	0	10.17	-	87	-	-	-	-	y	3	-	y	-	-
8	619369	42	6.5	1.6	138	141	4.96	4.2	102	100	0.75	-	0.31	-	15	-	10	-	86	-	7.7	-	3.5	-	12.2	9.8	12.6	10.2	6.2	4.5	0	4	4	0	10.4	-	44	-	-	-	-	y	1	-	-	-	-
9	479659	45	1.5	1.2	123	150	3.5	3.9	81	107	0.4	-	0.1	-	38	-	40	-	95	-	4.5	-	3.1	-	11.4	11.6	12.12	12.32	4.5	4.3	0	3	0	0	6	-	-	-	-	-	-	y	3	-	-	-	-
10	507990	21	1.3	1.19	134	135	4.2	4.1	101	97	1.8	-	1.18	-	90	-	21	-	346	-	7.7	-	3.6	-	12.4	10.4	12.72	10.72	5	-	0	10	30	0	6	-	20	-	-	-	-	y	1	-	-	-	-
11	114141	15	0.7	0.7	139	141	4.6	4.1	100	97	1.5	-	0.3	-	53	-	24	-	565	500	6.5	-	5	-	10.5	10.4	9.7	9.6	4.5	4.6	0	0	0	0	214	-	12	-	3.2	-	-	y	1	-	-	-	-
12	661028	73	0.8	1.29	140	153	3.4	4.8	95	98	0.3	-	0.14	-	47	-	41	-	183	-	6.9	-	2.8	-	12.7	12	13.66	12.96	3	-	0	8	0	0	6.2	-	13.5	-	5	-	-	y	2	y	y	-	-
13	481154	40	1.5	1.7	140	135	5	4.8	106	99	0.5	-	0.18	-	17	-	17	-	787	650	8	-	4.8	-	15.4	7.4	14.76	6.76	4.6	7.4	-	-	-	-	505	-	18	-	5.12	-	-	y	1	-	-	-	-
14	661793	150	8.4	3.6	141	150	5.6	5.2	97	100	0.7	-	0.2	-	41	-	7	-	77	-	7	-	2.8	-	13.8	12.6	14.76	13.56	7	-	2	0	3	0	12.2	-	32	-	3.2	-	-	y	1	-	-	-	-
15	534702	-	0.6	-	137	-	2.7	4	96	100	0.5	-	0.2	-	30	-	14	-	108	-	5.4	-	3	-	13.6	10.2	14.4	11	3.2	-	0	0	0	0	9	-	125	-	1.17	-	-	y	1	-	-	-	-
16	637317	35	3	2.8	143	141	4	3.3	109	100	0.5	-	0.2	-	21	-	18	-	97	-	7	-	4.4	-	11	10	10.68	9.68	3	3.6	1	0	10	0	3.2	-	24	-	-	-	-	y	1	-	-	-	-
17	660678	138	5.8	3.3	154	141	3.3	4.5	108	109	0.8	0.3	0.5	0.2	24	22	17	24	120	120	7	5.8	2.4	1.7	17.8	19.7	19.08	21.54	4.7	4.1	3	0	0	0	13	-	32	-	1.3	2.5	9.4	y	2	y	-	-	-
18	678181	124	2.2	1.8	132	130	6.7	3.7	98	90	8.4	12.2	5.1	9.9	217	2.6	98	88	592	447	5.8	5.7	2.4	3.3	11.3	11.7	12.58	12.26	3.6	3.8	1	5	0	0	8	-	13	-	-	-	-	y	2	y	-	-	-
19	471657	31	0.6	0.5	138	141	3.8	3.7	101	102	11.3	-	12	-	46	-	55	-	2179	-	7.5	-	3.3	-	10.7	9.8	11.26	10.36	2.3	2.4	2	0	0	0	7.6	-	26	-	-	-	-	y	2	y	-	-	-
20	544686	80	2.3	2.4	130	133	4.4	5.5	94	105	0.6	0.3	0.4	0.1	67	31	277	6	667	546	6	5.4	2	1.4	12	8	13.6	10.08	5.5	-	2	10	4	0	7	-	110	-	-	-	-	y	2	y	-	-	-
21	547171	-	0.5	-	127	134	4.6	4.3	89	98	0.3	-	0.2	-	15	-	19	-	395	-	6.6	-	2.7	-	9.7	10.1	10.74	11.14	5	-	0	3	0	0	7.2	-	13	-	-	-	-	n	1	-	-	-	-
22	699422	-	1.6	-	132	-	5	-	98	-	4	2.8	3.5	2.7	555	615	348	70	413	421	6	6.1	2.5	2.5	13	12.5	14.2	13.7	5	4.5	0	0	0	0	3.5	-	29	-	-	-	-	y	2	y	-	-	-
23	685762	20	0.7	0.5	137	138	2.9	3.5	97	102	0.7	0.3	0.3	0.1	14	20	18	18	420	65	6	5.8	3	2.9	10.3	10.2	11.1	11.08	4	-	2	0	0	0	93	-	32	-	-	-	-	n	1	-	-	-	-
24	390146	100	5.3	3.6	133	134	6.2	4	104	103	0.17	-	0.05	-	18	-	12	-	165	-	6.6	-	3.3	-	11.9	8.8	12.46	9.36	5.5	-	0	0	25	0	14	-	18.5	-	0.3	-	-	y	1	-	-	-	-
25	696214	35	1.2	1.3	138	142	4.6	4.1	100	98	0.2	0.2	0.07	0.07	39	23	23	18	188	160	7.8	6.5	4.3	3.3	15	8.2	14.76	8.76	6.5	5.5	1	0	0	0	17	-	36	-	4.2	1.8	13.2	y	2	-	y	y	-
26	689657	70	6.5	4.5	136	143	2.9	3.7	97	108	0.2	-	0.09	-	17	-	9	-	93	-	7	-	3.7	-	15.3	8.5	15.54	8.74	4.5	-	1	10	0	0	11	-	24	-	2.6	-	-	y	1	-	-	-	-
27	688609	22	0.6	0.42	133	132	4.5	3.9	103	99	1.3	1.12	0.4	0.34	140	155	72	78	131	128	6	5.8	3.5	3.3	14	13.3	14.4	13.86	3.3	3.5	0	0	0	0	242	-	28	-	-	-	-	y	1	-	-	-	-
28	688263	80	1.9	2	140	137	3.8	3.7	101	105	0.8	0.6	0.8	0.1	17	22	10	24	123	125	6.5	6.4	2.5	2.6	10.6	10.2	11.8	11.32	4.5	4.5	1	0	0	0	5	-	13	-	-	-	-	y	1	-	-	-	-
29	549787	128	3.8	4.4	142	138	3	3	109	103	1.01	-	0.6	-	25	-	28	-	109	-	5.5	-	2.8	-	10.3	9.1	11.26	10.06	3	-	0	35	0	0	4.6	-	13	-	-	-	-	n	2	-	-	-	y
30	884054	115	3	1.78	146	124	3.46	3.5	115	105	0.23	1.8	0.16	1.48	20	16	11	2	451	350	5.7	4.8	2.5	2.2	10.4	7	11.6	8.44	5	-	0	0	0	0	1150	94	3.12	28	-	-	-	y	2	y	-	-	-
31	681661	40	0.9	0.7	138	139	4.4	3.1	92	97	0.8	-	0.3	-	69	-	53	-	106	-	7.7	-	3.2	-	13	9	13.64	9.64	1.5	-	0	20	0	0	11.2	-	23	-	2.6	12.6	3.7	y	2	y	-	-	-
32	681960	25	0.9	0.46	138	138	4.2	4.1	90	106	0.4	-	0.27	-	83	-	101	-	110	-	5.5	-	2.4	-	12.7	9.3	13.98	10.58	2.7	-	1	0	0	0	5	-	-	-	-	-	-	y	2	y	y	-	-
33	608658	-	0.9	-	131	136	3.1	4.2	9	101	0.6	-	0.3	-	70	-	53	-	106	-	6.5	-	3.2	-	12.8	12.2	13.44	12.84	3.5	-	0	0	0	0	4.2	-	36	-	-	-	-	y	2	-	y	-	y
34	704263	305	8.4	7.8	136	125	6.2	4.4	99	98	0.3	0.3	0.02	0.17	31	16	22	16	108	102	9.8	8.9	2.8	2.8	14	9.2	14.96	10.16	5.2	-	1	5	5	0	4.6	-	21	-	-	-	-	y	1	-	-	-	-
35	616466	72	2.6	2	133	129	3.6	3.6	93	94	0.26	-	0.13	-	16	-	15	-	65	-	8.7	-	4	-	16.7	8.4	16.7	8.4	6.7	-	1	0	0	0	12	-	22	-	-	-	-	y	1	-	-	-	y
36	684353	82	2	2.9	133	143	4.2	3.6	97	114	1.8	-	1.38	-	35	-	70	-	97	-	6.2	-	2.8	-	12.4	10.5	13.36	11.46	4.8	4.5	2	-	0	0	10	-	25	-	2.3	-	-	y	1	-	-	-	-
37	710294	38	1.15	0.9	121	138	4.6	3.8	90	102	1.14	-	0.27	-	28	-	17	-	450	432	6.6	-	3.2	-	11.2	10.6	11.84	11.24	2.5	1.8	0	10	0	0	382	-	22	-	0.85	-	-	y	1	-	-	-	-
38	701237	118	3.2	7	144	143	4	4	106	110	5.7	12.5	0.3	10.37	11788	111	6507	129	70	136	4.9	5	2.2	2.8	9.8	10.5	11.24	11.46	4.5	2.4	0	0	0	0	60	-	163	-	-	-	-	y	1	y	-	-	-
39	704363	41	0.8	0.8	134	139	5.2	5	95	105	0.19	-	0.1	-	28	-	17	-	76	-	6.3	-	2.8	-	10.6	10	11.56	10.96	3.5	-	1	0	25	0	5	-	16	-	-	-	-	y	1	-	-	-	y
40	714668	110	6	7.16	94	110	4	4	98	97	0.3	-	0.16	-	31	-	17	-	128	-	6.5	-	2.8	-	14.5	12	15.46	12.96	4.8	-	2	25	50	0	9	-	70	-	-	-	-	y	1	-	-	-	-
41	714055	40	1.5	1.3	137	138	4.5	3.9	101	103	0.9	-	0.1	-	70	-	27	-	87	-	6.4	-	3	-	10.6	10.5	11.4	11.3	4.2	4.6	1	30	10	0	12	-	25	-	-	-	-	y	1	-	-	-	-
42	709161	-	1.46	-	137	-	4.4	-	100	-	0.5	-	0.09	-	27	-	42	-	192	-	6.4	-	3.4	-	12	11.2	12.48	11.68	-	-	1	0	0	0	2.4	-	19	-	-	-	-	y	2	-	-	-	-
43	705170	94	7.6	5.3	136	135	4.3	5.1	94	100	0.8	-	0.3	-	20	-	6	-	109	-	7.2	-	2.6	-	16.3	8.8	17.42	9.92	2.23	2.5	1	10	3	0	6	-	14.3	-	-	-	-	y	1	-	-	-	-
44	704346	3.7	2.3	3.7	129	146	5.9	3.6	5.2	-	5.37	-	416	-	205	-	205	-	235	-	5	-	2.03	2.01	10.2	11.2	11.776	12.792	4.5	6.4	1	0	15	0	34	-	163	-	-	-	-	y	2	-	-	-	-
45	701197	18	0.47	0.6	138	136	3	3.6	97	97	0.7	-	0.5	-	46	-	77	-	665	520	6.9	-	3.6	-	10.5	9.5	10.82	9.82	3.8	-	0	0	0	0	125	20	29	-	0.5	-	-	y	1	-	-	-	-
46	705939	6	0.34	0.23	139	141	4.1	3.5	105	106	0.33	-	0.17	-	98	-	59	-	655	650	6	-	3.4	-	10.6	10.9	11.08	11.38	4.5	4.6	0	0	0	0	281	-	13.2	-	-	-	-	y	1	-	-	-	-
47	716065	3.1	1.6	2.8	118	122	4.7	4.5	83	88	36	38	32.6	33.5	191	130	77	77	255	111	5.8	-	3.3	3.7	9.6	10.9	10.16	11.14	5.1	-	0	0	0	0	19	-	21	-	2.3	-	-	y	2	y	-	-	-
48	710294	38	1.2	0.9	125	140	4.1	4.2	93	101	1.1	-	0.27	-	28	-	17	-	290	344	6.2	-	3.2	-	11.2	10.6	11.84	11.24	2	2.5	0	0	0	0	382	-	22	-	8.2	22	0.8	y	1	-	-	-	-
49	709534	48	2.5	1.8	126	134	3.3	3.4	83	84	0.3	-	0.16	-	11	-	12	-	67	-	5.4	-	2.5	-	11.2	11.9	12.4	13.1	5.6	-	1	10	0	0	20	-	163	-	-	-	-	y	1	-	-	-	-
50	668636	52	1	1.2	117	130	4.8	5	88	96	12	10.2	8.5	8.1	70	75	19	20	107	-	6.3	-	2.6	-	10.2	10.3	11.32	11.42	2.16	1	-	0	20	18	-	36	-	-	-	-	-	-	y	2	y	-	-	-
51	24573	73	6.1	2.2	135	141	3.2	3	99	110	0.4	-	-	0.32	45	-	20	-	141	-	5.5	-	1.9	-	13.4	14.2	15.08	15.88	6.5	-	2	35	45	0	1.08	-	4.7	-	-	-	-	y	2	y	-	-	-
52	274445	-	0.6	-	141	-	3.6	-	104	-	0.4	-	0.2	-	24	-	17	-	103	-	5.6	-	2.4	-	13.2	13.5	14.48	14.78	5.6	-	1	0	3	0	4.3	-	31.5	-	-	-	-	y	2	y	-	y	y
53	715876	31	0.8	0.9	133	133	4.9	4.1	96	95	0.45	0.3	0.18	0.16	16	18	8	10	120	137	5.8	5.7	2.7	2.5	14.1	11	15.14	12.2	5.2	4.6	1	25	2	0	5.4	-	16	-	-	-	-	y	2	y	-	-	-
54	82146	85	2.38	2.48	137	140	4	3.9	104	102	0.6	-	0.5	-	20	-	29	-	317	-	7.7	-	3.2	-	11.6	8.1	12.24	8.74	4.5	4.6	1	20	20	0	10	-	22	-	-	-	-	y	1	y	-	-	-
55	703014	65	1.34	1.23	128	129	3.7	3.9	96	97	0.9	-	0.3	-	46	-	18	-	69	-	11	-	3	-	10.7	10.4	11.5	11.2	6.2	-	2	0	0	0	4.4	-	24	-	-	-	-	y	2	-	-	-	y
56	688160	35	1.05	0.58	138	136	3.8	4.3	106	101	0.6	0.5	0.15	0.2	110	75	12	11	102	70	6	5.8	3	2.8	10.5	10.7	11.3	11.66	5	4.6	0	0	0	0	3.6	-	11	-	2.1	-	-	y	2	-	-	-	-
57	707264	72	1.3	1.4	135	132	5.2	4.6	94	100	0.3	-	0.1	-	20	-	6	-	107	-	5.8	-	4	-	10.3	9.8	10.3	9.8	6	-	0	20	0	0	8	-	22	-	1.2	-	-	y	1	-	-	-	-
58	723943	89	2	1.3	140	145	5	3.1	97	101	0.3	-	0.15	-	32	-	19	-	50	-	6	-	3.5	-	13.2	9.1	13.6	9.5	4.8	2.6	0	0	20	0	13	-	40.8	-	-	-	-	y	1	-	-	-	-
59	721990	42	0.6	0.7	135	138	4	3.8	102	101	0.4	-	0.1	-	20	-	25	-	90	-	4.3	-	2.3	-	10.3	10	11.666	11.36	4.6	-	0	0	0	0	11.2	-	-	-	-	-	-	n	1	-	-	-	-
60	735044	64	1.6	1.4	137	138	5.2	4	94	97	0.4	-	0.3	-	20	-	13	-	206	230	5.6	-	3.6	-	10.3	10.6	10.62	10.92	3.6	-	0	0	0	0	388	-	55.7	-	0.6	2.7	14.2	n	2	y	-	-	-
61	720732	56	2.7	1.1	140	138	3	4	102	108	0.3	-	0.1	-	24	-	11	-	51	-	7.3	-	4	-	13.4	8	13.4	8	4	-	1	0	0	0	14	-	9	-	-	-	-	y	1	-	-	-	-
62	730710	198	13	5.2	111	130	7.1	4.4	82	105	1.36	-	0.7	-	43	-	18	-	195	-	5	-	1.8	-	8.6	10.6	10.36	12.36	3.4	2.5	0	2	20	0	14	-	121	-	2.6	4.3	18.4	y	1	-	-	-	-
63	728676	22	2	0.5	150	132	4	3.6	110	98	0.9	-	0.3	-	600	-	700	-	620	-	5	-	3.1	-	11	11.4	11.72	12.12	2.36	-	1	12	0	2	237	-	7	-	-	-	-	y	1	-	-	-	-
64	723902	56	1.6	0.7	156	142	3.6	5.2	121	109	0.5	-	0.4	-	49	-	21	-	64	-	6.5	-	2.8	-	11.7	7	12.66	7.96	4.6	-	1	20	0	0	11.4	-	17	-	0.9	-	-	y	2	-	-	-	-
65	724002	120	1.6	1	135	132	4.2	4	105	101	1.4	-	0.7	-	18	-	10	-	63	-	6.7	-	2.5	2.9	10.2	8	11.4	8.88	5.4	3.6	0	10	80	0	18	-	163	-	6.6	-	-	y	1	-	-	-	-
66	615991	29	1.5	1.5	120	128	4	3.5	90	94	36	13.6	30.5	11.6	140	132	65	18	97	140	4.6	5	4.8	3.5	10.5	11.8	9.86	12.2	4.5	-	0	0	0	0	12	-	63	-	-	-	-	y	2	y	-	-	-
67	729399	140	0.9	2	131	143	5.3	5.7	100	112	1.8	1.6	1.4	0.9	364	749	241	371	366	252	6.8	6.4	3.24	3	13	13.2	13.608	14	2.5	5	1	2	0	0	12.3	-	-	-	-	-	-	y	1	-	-	-	-
68	731537	109	5.8	5.6	138	148	3.4	4.5	100	114	0.38	0.8	0.2	0.3	31	46	25	58	270	484	5.5	4	1.2	2	8.6	8	10.84	9.6	4	-	1	0	0	0	14.2	-	-	-	-	-	-	y	2	y	-	-	-
69	683750	166	1.8	2.1	131	128	4.8	4.1	97	88	7.6	6.7	2.2	3.4	316	466	72	126	220	296	7.4	6.7	3.6	3	10.4	10.1	10.72	10.9	5.8	-	1	0	0	0	8	-	12	-	0.1	-	-	n	1	-	-	-	-
70	739803	178	1.3	2.3	135	136	5	6.4	97	98	7	9	5.8	7	1258	1896	347	445	254	307	5.7	5.3	3	2.4	14	14	14.8	15.28	6	-	1	12	0	0	12	-	21.6	-	-	-	-	y	1	-	-	-	-
71	736862	70	3.3	2.3	125	140	4.7	3	86	96	0.4	-	0.07	-	52	-	42	-	70	-	6.5	-	4	-	14.5	10.8	14.5	10.8	3	-	0	0	4	-	18	-	168	-	-	-	-	y	1	-	-	-	-
72	56701	40	0.7	0.3	138	140	4.1	3.4	108	105	0.3	-	0.05	-	18	-	16	-	413	420	6.7	-	3.8	3	11	10.3	11.16	11.1	2.2	-	0	0	0	0	159	-	29	-	3.8	3.4	18.8	y	1	-	-	-	-
73	699324	41	2.7	1.7	140	138	3.6	3.5	99	102	0.5	-	0.2	-	23	-	12	-	83	-	7.6	-	4	-	13.3	9.3	13.3	9.3	3.3	-	0	0	50	0	9	-	163	-	-	-	-	y	1	-	-	-	-
74	743426	134	1.4	1.5	135	134	4.6	4.3	93	94	4.8	-	3.7	-	770	-	900	-	857	-	5.6	-	3	-	15	15.2	15.8	16	5.7	-	0	15	0	0	12	-	21	-	1.8	-	-	y	2	y	-	-	-
75	342253	150	2.1	1.4	124	122	3.1	5	90	92	14.2	10.6	11.4	8	170	150	40	44	165	-	6.4	-	2.5	-	13.4	9	14.6	10.2	1.8	-	0	0	0	0	2.3	-	90	-	-	-	-	y	1	y	-	-	-
76	715875	212	2.1	3.2	124	133	4	4.5	90	97	0.6	-	0.5	-	46	-	50	-	97	-	4.5	-	2.5	-	13.8	11	15	12.2	4.3	-	0	0	0	0	8	-	30	-	-	-	-	y	2	y	-	-	-
77	740599	74	3.5	1.1	140	135	3.7	5.7	101	109	0.4	-	0.2	-	18	-	13	-	86	-	4.5	-	2.4	-	13	9.7	14.28	10.98	2.9	2.8	0	0	0	0	8.4	-	65	-	-	-	-	y	1	-	-	-	-
78	743466	65	3.1	3.3	142	146	5.3	4.6	100	99	0.2	-	0.09	-	9	-	11	-	57	-	5.6	-	3.1	-	12	11.2	12.72	11.92	7	-	0	0	0	0	8.25	-	-	-	-	-	-	y	1	-	-	-	-
79	754136	75	0.7	1.2	119	128	45	75	85	95	0.86	3.09	0.18	2.6	44	41	20	18	224	169	6.1	5	2.6	2.4	11.2	10.7	12.32	11.98	2.6	1.8	0	0	0	0	10.9	-	16.3	-	-	-	-	y	2	-	-	-	-
80	633010	62	1.2	1.06	127	137	4	3.4	92	97	0.57	-	0.12	-	29	-	19	-	192	-	7.4	-	2.16	-	13.8	15.2	15.272	16.672	2.2	-	0	0	0	0	12.1	-	-	-	-	-	-	y	2	-	-	-	-
81	764175	73	1.2	1.8	140	137	3.1	3.8	106	100	0.5	-	0.2	-	0.2	-	13	-	10	-	6.3	-	4.2	-	11.2	8.8	11.04	8.64	3.4	-	0	0	0	0	9.9	-	163	-	0.23	-	-	y	1	-	-	-	-
82	766536	-	2	-	139	-	4.8	-	100	-	1	-	0.8	-

sr no	mrd	cxr metastasis/ sol	cxr other	USG nor=1/ abn=2/ not done=3	USG fatty liver	USG rpcg	USG cld	USG ascites	USG pleural effusion	USG gb sludge	USG lap	USG cholelithiasis	USG nephrolithiasis	USG nephrocalcinosis	USG sol/ metastasis	USG hepatomegaly	USG spleenomegaly	USG pancreatitis	USG s/o tb	USG_other	ct chest_nor=1/abn=2/not done=3	ct chest pleural effusion	ct chest mass lesion	ct chest lytic lesion	ct chest lap	ct chest metastasis	ct chest tubercular changes
1	657560	y	-	2	-	-	-	-	-	-	-	-	-	-	y	-	-	-	-	-	2	y	-	-	y	y	-
2	620678	-	-	2	-	y	-	-	-	-	y	-	-	-	-	-	-	-	-	-	3	-	-	-	-	-	-
3	622323	-	-	2	-	y	-	y	-	-	y	-	-	-	-	-	-	-	-	-	2	y	-	-	y	-	-
4	642273	-	-	2	-	y	-	-	-	-	-	-	-	-	-	-	-	-	-	-	3	-	-	-	-	-	-
5	653016	-	-	2	-	-	y	-	-	-	-	-	-	-	-	-	y	-	-	-	3	-	-	-	-	-	-
6	652324	-	-	2	-	y	-	-	-	y	-	-	-	-	-	-	-	-	-	-	3	-	-	-	-	-	-
7	634367	-	-	2	-	y	y	y	-	-	-	-	-	-	-	-	y	-	-	-	2	-	-	-	-	-	y
8	619369	-	-	2	-	y	-	-	-	-	-	-	-	-	-	-	-	-	-	-	3	-	-	-	-	-	-
9	479659	-	air under diaphragm	3	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	3	-	-	-	-	-	-
10	507990	-	-	2	-	-	y	-	-	-	-	-	-	-	-	-	y	-	-	hcc with pv involvement	3	-	-	-	-	-	-
11	114141	-	-	2	-	-	-	-	-	-	-	-	-	-	-	-	-	y	-	-	3	-	-	-	-	-	-
12	661028	?	-	2	-	y	-	-	-	-	-	-	-	-	-	-	y	-	-	-	2	y	y	-	y	-	-
13	481154	-	-	2	-	y	-	-	-	-	y	y	-	-	-	-	-	-	-	-	3	-	-	-	-	-	-
14	661793	-	-	2	-	y	-	-	-	-	-	-	-	-	-	-	-	-	-	-	3	-	-	-	-	-	-
15	534702	-	-	1	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	3	-	-	-	-	-	-
16	637317	-	-	1	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	3	-	-	-	-	-	-
17	660678	-	-	2	-	y	-	-	-	-	-	-	-	-	-	-	-	-	-	-	3	-	-	-	-	-	-
18	678181	-	-	2	-	y	y	y	-	-	-	-	-	-	-	-	y	-	-	-	3	-	-	-	-	-	-
19	471657	-	-	2	-	-	-	-	-	-	y	-	-	-	y	-	-	-	-	cholangiocarcinoma	3	-	-	-	-	-	-
20	544686	-	-	1	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	3	-	-	-	-	-	-
21	547171	-	-	2	-	-	-	-	-	-	-	-	-	-	v	-	v	-	-	-	3	-	-	-	-	-	-
22	699422	-	-	2	-	-	v	y	-	-	-	-	-	-	-	v	v	-	-	-	3	-	-	-	-	-	-
23	685762	-	-	2	-	-	-	-	-	-	-	-	-	-	y	-	-	-	-	liver abcess	3	-	-	-	-	-	-
24	390146	-	-	2	-	y	-	-	-	-	-	y	-	-	-	-	-	-	-	-	3	-	-	-	-	-	-
25	696214	-	-	2	-	-	-	y	-	y	y	-	-	-	-	-	-	-	-	-	3	-	-	-	-	-	-
26	689657	-	-	1	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	3	-	-	-	-	-	-
27	688609	-	-	2	-	-	-	-	-	-	-	y	-	-	-	-	-	y	-	-	3	-	-	-	-	-	-
28	688263	-	-	2	-	-	y	y	-	-	y	-	-	-	-	-	y	-	y	-	2	-	-	-	-	-	-
29	549787	-	-	2	-	y	-	-	-	-	-	-	-	-	-	-	-	-	-	-	3	-	-	-	-	-	-
30	884054	-	-	2	-	y	-	y	-	-	-	-	-	-	-	-	-	y	-	-	3	-	-	-	-	-	-
31	681615	-	consolidation	3	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	2	y	-	-	y	-	-
32	681960	-	ggo's	3	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	3	-	-	-	-	-	-
33	608658	-	ggo's	2	-	-	-	y	-	-	y	-	-	-	-	-	-	-	-	-	2	-	-	y	y	-	-
34	704263	-	-	2	-	y	-	-	-	-	-	-	-	-	-	-	-	-	-	-	3	-	-	-	-	-	-
35	616466	-	-	2	-	y	-	-	-	-	-	-	-	-	-	-	-	-	-	-	3	-	-	-	-	-	-
36	684353	-	-	2	-	y	-	-	-	-	-	-	-	-	-	-	-	-	-	-	3	-	-	-	-	-	-
37	710294	-	-	1	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	3	-	-	-	-	-	-
38	701237	-	-	2	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	aki	3	-	-	-	-	-	-
39	704363	-	-	2	-	-	-	-	-	-	-	-	-	-	y	-	-	-	-	-	3	-	-	-	-	-	-
40	714668	-	-	2	-	-	-	-	-	-	-	-	y	-	-	-	-	-	-	-	3	-	-	-	-	-	-
41	714055	-	-	2	-	y	-	-	-	-	-	-	-	-	-	-	-	-	-	-	3	-	-	-	-	-	-
42	709161	y	-	2	-	y	-	-	-	-	-	-	-	-	-	-	-	-	-	-	3	-	-	-	-	-	-
43	705170	-	-	2	-	y	-	-	-	-	-	-	-	-	-	-	-	-	-	-	3	-	-	-	-	-	-
44	704346	-	ggo's	2	-	y	-	y	-	-	-	-	-	-	-	-	-	-	-	-	3	-	-	-	-	-	-
45	701197	-	-	1	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	3	-	-	-	-	-	-
46	705939	-	-	2	-	-	-	-	-	v	-	v	-	-	-	-	-	y	-	-	3	-	-	-	-	-	-
47	716065	-	-	2	-	-	y	y	y	-	-	-	-	-	-	-	y	-	-	-	3	-	-	-	-	-	-
48	710294	-	-	2	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	3	-	-	-	-	-	-
49	709534	-	-	2	y	y	-	-	-	-	-	-	-	-	-	-	-	-	-	-	3	-	-	-	-	-	-
50	668636	-	-	2	-	-	y	y	-	-	-	-	-	-	-	-	y	-	-	-	3	-	-	-	-	-	-
51	24573	-	-	2	-	-	-	-	-	-	-	-	-	-	-	-	-	y	-	-	3	-	-	-	-	-	-
52	274445	y	-	2	y	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	3	-	-	-	-	-	-
53	715876	-	-	2	-	-	-	-	y	-	-	-	-	-	-	-	y	-	-	rt hun	3	-	-	-	-	-	-
54	82146	-	-	2	-	y	-	-	y	-	-	-	-	-	-	-	-	-	-	-	3	-	-	-	-	-	-
55	703014	-	-	2	-	y	-	-	-	-	-	-	-	-	-	-	-	-	-	-	3	-	-	-	-	-	-
56	688160	-	inhomogenous opacities	2	-	-	-	-	-	-	-	-	-	-	-	-	y	-	-	-	2	-	-	-	y	-	-
57	707264	-	-	2	y	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	3	-	-	-	-	-	-
58	723943	-	-	2	y	y	-	-	-	-	-	-	-	-	-	-	-	-	-	-	3	-	-	-	-	-	-
59	721990	-	-	2	-	-	-	-	-	-	-	-	-	-	-	-	v	-	-	-	3	-	-	-	-	-	-
60	735044	-	-	2	-	y	-	-	y	-	-	-	-	-	-	-	-	-	-	-	3	-	-	-	-	-	-
61	720710	-	-	2	y	y	-	-	-	-	-	-	-	-	-	-	-	-	-	-	3	-	-	-	-	-	-
62	730710	-	-	2	-	y	-	-	-	-	-	-	-	-	-	-	-	-	-	pyelonephritis	3	-	-	-	-	-	-
63	728676	-	-	2	-	-	-	-	-	-	-	-	-	-	-	-	-	y	-	-	3	-	-	-	-	-	-
64	723902	-	inhomogenous opacities	2	y	-	-	-	-	y	-	-	-	-	-	-	-	-	-	-	3	-	-	-	-	-	-
65	724002	-	-	2	-	y	-	-	-	-	-	-	-	-	-	-	-	-	-	-	3	-	-	-	-	-	-
66	615991	-	-	2	-	-	v	-	-	-	-	-	-	-	-	-	v	-	-	-	3	-	-	-	-	-	-
67	729399	-	-	2	-	-	-	y	-	-	-	-	-	-	v	-	-	-	-	-	3	-	-	-	-	-	-
68	731537	-	-	2	-	-	y	-	-	-	-	-	-	-	-	-	y	-	-	-	3	-	-	-	-	-	-
69	683750	-	-	2	-	-	y	y	-	-	-	-	-	-	-	-	y	-	-	-	3	-	-	-	-	-	-
70	739803	-	-	2	-	-	y	y	-	-	-	-	-	-	y	-	y	-	-	-	3	-	-	-	-	-	-
71	736862	-	-	2	y	y	-	-	-	-	-	-	-	-	-	-	-	-	-	-	3	-	-	-	-	-	-
72	56701	-	-	2	-	-	-	-	-	-	-	y	-	-	-	-	-	-	-	-	3	-	-	-	-	-	-
73	699324	-	-	1	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	3	-	-	-	-	-	-
74	743426	-	-	2	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	qbwe	3	-	-	-	-	-	-
75	342253	-	-	2	-	-	y	y	-	-	-	-	-	-	-	-	y	-	-	-	3	-	-	-	-	-	-
76	715875	-	-	2	y	y	-	-	y	-	-	-	-	-	-	-	-	-	-	-	3	-	-	-	-	-	-
77	740599	-	-	2	y	y	-	-	-	-	y	-	-	-	-	-	y	-	-	-	3	-	-	-	-	-	-
78	743466	-	-	2	-	-	-	-	-	-	-	-	-	-	y	-	-	-	-	-	3	-	-	-	-	-	-
79	754136	-	mediastinal widening	2	-	-	-	y	-	y	-	-	-	-	-	-	-	-	-	bulky necrotic med lap	3	-	-	-	-	-	-
80	633010	y	-	2	-	-	-	-	-	-	y	-	-	-	y	-	-	-	-	-	3	-	-	-	-	-	-
81	764175	-	-	2	y	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	3	-	-	-	-	-	-
82	766536	-	-	1	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	3	-	-	-	-	-	-
83	736862	-	-	2	y	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	3	-	-	-	-	-	-
84	765542	-	-	2	-	-	y	y	-	-	-	-	-	-	-	-	y	-	-	-	3	-	-	-	-	-	-
85	772868	-	-	2	-	y	-	-	-	-	-	-	-	-	-	-	-	y	-	-	3	-	-	-	-	-	-
86	774306	-	-	2	-	y	-	y	y	y	-	-	-	-	-	-	-	y	-	-	3	-	-	-	-	-	-
87	787977	-	-	2	y	y	-	-	-	-	-	-	-	-	-	-	-	-	-	-	3	-	-	-	-	-	-
88	759641	-	-	2	-	y	-	-	-	-	-	-	y	-	-	-	-	-	-	ureteric stones	3	-	-	-	-	-	-
89	765592	-	-	2	-	-	y	y	-	-	-	-	-	-	-	-	y	-	-	-	2	y	-	-	-	-	-
90	768925	-	inhomogenous opacities	2	y	y	-	-	-	-	-	-	-	-	-	-	-	-	-	-	3	-	-	-	-	-	-
91	67452	-	-	2	-	-	-	-	-	-	-	-	-	-	y	-	-	-	-	-	2	y	-	y	-	-	-
92	704957	-	-	1	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	2	-	-	-	-	-	-
93	736862	-	-	2	y	y	-	-	y	-	-	-	-	-	-	-	-	-	-	b/l pyelitis	3	-	-	-	-	-	-
94	770578	-	-	2	-	-	y	y	y	-	y	-	-	-	y	-	-	-	-	gb mass	3	-	-	-	-	-	-
95	770240	-	-	2	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	3	-	-	-	-	-	-
96	688217	-	-	2	-	-	y	y	-	-	-	y	-	-	-	-	y	-	-	-	3	-	-	-	-	-	-
97	769542	-	-	2	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	aki	3	-	-	-	-	-	-

sr no	mrd	ct chest lymphangitis carcinomatosis	ct chest osseous metastasis	ct chest consolidation	ct chest other	ct abdomen nor=1/abn=2/not done=3	ct abdomen rpcg	ct abdomen cld	ct abdomen pleural effusion	ct abdomen ascites	ct abdomen lap	ct abdomen cholelithiasis	ct abdomen nephrolithiasis	ct abdomen nephrocalcinosis	ct abdomen sol/metastasis	ct abdomen s/o tb	ct abdomen pancreatitis	ct abdomen hcc	ct abdomen other	mri spine nor=1/abn=2/not done=3	mri spine vertebral collapse	mri spine lytic lesion	mri spine altered signal intensity	mri spine diffuse marrow infilteration	mri spine other
1	657560	-	-	-	-	2	-	-	-	-	y	y	-	-	y	-	-	-	-	3	-	-	-	-	-
2	620678	-	-	-	-	3	-	-	-	-	-	-	-	-	-	-	-	-	-	3	-	-	-	-	-
3	622323	-	-	-	-	2	y	-	-	y	y	-	-	-	-	-	-	-	-	3	-	-	-	-	-
4	642273	-	-	-	-	3	-	-	-	-	-	-	-	-	-	-	-	-	-	3	-	-	-	-	-
5	653016	-	-	-	-	3	-	-	-	-	-	-	-	-	-	-	-	-	-	3	-	-	-	-	-
6	652324	-	-	-	-	3	-	-	-	-	-	-	-	-	-	-	-	-	-	3	-	-	-	-	-
7	634367	-	-	-	-	3	-	-	-	-	-	-	-	-	-	-	-	-	-	3	-	-	-	-	-
8	619369	-	-	-	-	2	-	-	-	-	-	-	-	-	-	-	-	-	pyelonephritis	3	-	-	-	-	-
9	479659	-	-	-	-	2	-	-	-	-	-	-	-	-	-	-	-	-	pneumoperitoneum	3	-	-	-	-	-
10	507990	-	-	-	-	3	-	-	-	-	-	-	-	-	-	-	-	-	-	3	-	-	-	-	-
11	114141	-	-	-	-	2	-	-	-	-	-	-	-	-	-	-	y	-	-	3	-	-	-	-	-
12	661028	-	-	-	-	3	-	-	-	-	-	-	-	-	-	-	-	-	-	3	-	-	-	-	-
13	481154	-	-	-	-	3	-	-	-	-	-	-	-	-	-	-	-	-	-	3	-	-	-	-	-
14	661793	-	-	-	-	3	-	-	-	-	-	-	-	-	-	-	-	-	-	3	-	-	-	-	-
15	534702	-	-	-	-	3	-	-	-	-	-	-	-	-	-	-	-	-	-	3	-	-	-	-	-
16	637317	-	-	-	-	3	-	-	-	-	-	-	-	-	-	-	-	-	-	3	-	-	-	-	-
17	660678	-	-	-	-	3	-	-	-	-	-	-	-	-	-	-	-	-	-	2	y	y	-	-	-
18	678181	-	-	-	-	3	-	-	-	-	-	-	-	-	-	-	-	-	-	3	-	-	-	-	-
19	471657	-	-	-	-	2	-	-	-	-	y	-	-	-	y	-	-	-	cholangiocarcinoma	3	-	-	-	-	-
20	544686	-	-	-	-	3	-	-	-	-	-	-	-	-	-	-	-	-	-	3	-	-	-	-	-
21	547171	-	-	-	-	3	-	-	-	-	-	-	-	-	-	-	-	-	-	3	-	-	-	-	-
22	699422	-	-	-	-	2	-	y	-	y	y	-	-	-	y	-	-	y	-	3	-	-	-	-	-
23	685762	-	-	-	-	3	-	-	-	-	-	-	-	-	-	-	-	-	-	3	-	-	-	-	-
24	390146	-	-	-	-	3	-	-	-	-	-	-	-	-	-	-	-	-	-	2	y	y	-	-	-
25	696214	-	-	-	-	3	-	-	-	-	-	-	-	-	-	-	-	-	-	3	-	-	-	-	-
26	689657	-	-	-	-	3	-	-	-	-	-	-	-	-	-	-	-	-	-	3	-	-	-	-	-
27	688609	-	-	-	-	3	-	-	-	-	-	-	-	-	-	-	-	-	-	3	-	-	-	-	-
28	688263	-	-	-	oad	2	-	y	-	y	y	-	-	-	-	y	-	-	-	3	-	-	-	-	-
29	549787	-	-	-	-	3	-	-	-	-	-	-	-	-	-	-	-	-	-	3	-	-	-	-	-
30	884054	-	-	-	-	2	y	-	-	y	-	-	-	y	-	-	y	-	osseous changes spine	3	-	-	-	-	-
31	681615	-	-	y	-	2	-	-	-	-	-	-	y	-	-	-	-	-	-	3	-	-	-	-	-
32	681960	-	-	-	-	3	-	-	-	-	-	-	-	-	-	-	-	-	-	3	-	-	-	-	-
33	608658	-	-	y	-	2	-	-	-	y	y	-	-	-	-	-	-	-	-	3	-	-	-	-	-
34	704263	-	-	-	-	3	-	-	-	-	-	-	-	-	-	-	-	-	-	2	y	y	-	-	-
35	616466	-	-	-	-	3	-	-	-	-	-	-	-	-	-	-	-	-	-	2	y	-	-	-	-
36	684353	-	-	-	-	3	-	-	-	-	-	-	-	-	-	-	-	-	-	3	-	-	-	-	-
37	710294	-	-	-	-	3	-	-	-	-	-	-	-	-	-	-	-	-	-	3	-	-	-	-	-
38	701237	-	-	-	-	3	-	-	-	-	-	-	-	-	-	-	-	-	-	3	-	-	-	-	-
39	704363	-	-	-	-	3	-	-	-	-	-	-	-	-	-	-	-	-	-	2	y	-	-	-	-
40	714668	-	-	-	-	3	-	-	-	-	-	-	-	-	-	-	-	-	-	3	-	-	-	-	-
41	714055	-	-	-	-	3	-	-	-	-	-	-	-	-	-	-	-	-	-	3	-	-	-	-	-
42	709161	-	-	-	-	3	-	-	-	-	-	-	-	-	-	-	-	-	-	2	y	-	y	-	-
43	705170	-	-	-	-	3	-	-	-	-	-	-	-	-	-	-	-	-	-	2	y	y	-	y	-
44	704346	-	-	-	-	3	-	-	-	-	-	-	-	-	-	-	-	-	-	3	-	-	-	-	-
45	701197	-	-	-	-	2	-	-	-	-	-	-	-	-	-	-	y	-	-	3	-	-	-	-	-
46	705939	-	-	-	-	3	-	-	-	-	-	-	-	-	-	-	-	-	-	3	-	-	-	-	-
47	716065	-	-	-	-	3	-	-	-	-	-	-	-	-	-	-	-	-	-	3	-	-	-	-	-
48	710294	-	-	-	-	3	-	-	-	-	-	-	-	-	-	-	-	-	-	3	-	-	-	-	-
49	709534	-	-	-	-	3	-	-	-	-	-	-	-	-	-	-	-	-	-	3	-	-	-	-	-
50	668636	-	-	-	-	3	-	-	-	-	-	-	-	-	-	-	-	-	-	3	-	-	-	-	-
51	24573	-	-	-	-	3	-	-	-	-	-	-	-	-	-	-	-	-	-	3	-	-	-	-	-
52	274445	-	-	-	-	3	-	-	-	-	-	-	-	-	-	-	-	-	-	3	-	-	-	-	-
53	715876	-	-	-	-	3	-	-	-	-	-	-	-	-	-	-	-	-	-	3	-	-	-	-	-
54	82146	-	-	-	-	3	-	-	-	-	-	-	-	-	-	-	-	-	-	2	y	y	-	-	-
55	703014	-	-	-	-	3	-	-	-	-	-	-	-	-	-	-	-	-	-	3	-	-	-	-	-
56	688160	-	-	-	atelectic bands	3	-	-	-	-	-	-	-	-	-	-	-	-	-	3	-	-	-	-	-
57	707264	-	-	-	-	3	-	-	-	-	-	-	-	-	-	-	-	-	-	3	-	-	-	-	-
58	723943	-	-	-	-	3	-	-	-	-	-	-	-	-	-	-	-	-	-	3	-	-	-	-	-
59	721990	-	-	-	-	3	-	-	-	-	-	-	-	-	-	-	-	-	-	3	-	-	-	-	-
60	735044	-	-	-	-	3	-	-	-	-	-	-	-	-	-	-	-	-	-	3	-	-	-	-	-
61	720710	-	-	-	-	3	-	-	-	-	-	-	-	-	-	-	-	-	-	3	-	-	-	-	-
62	730710	-	-	-	-	3	-	-	-	-	-	-	-	-	-	-	-	-	-	3	-	-	-	-	-
63	728676	-	-	-	-	3	-	-	-	-	-	-	-	-	-	-	-	-	-	3	-	-	-	-	-
64	723902	-	-	-	-	3	-	-	-	-	-	-	-	-	-	-	-	-	-	3	-	-	-	-	-
65	724002	-	-	-	-	3	-	-	-	-	-	-	-	-	-	-	-	-	-	3	-	-	-	-	-
66	615991	-	-	-	-	2	-	-	-	-	-	-	y	-	-	-	-	-	-	3	-	-	-	-	-
67	729399	-	-	-	-	3	-	-	-	-	-	-	-	-	-	-	-	-	-	3	-	-	-	-	-
68	731537	-	-	-	-	3	-	-	-	-	-	-	-	-	-	-	-	-	-	3	-	-	-	-	-
69	683750	-	-	-	-	3	-	-	-	-	-	-	-	-	-	-	-	-	-	3	-	-	-	-	-
70	739803	-	-	-	-	2	-	-	-	-	-	-	-	-	y	-	-	y	-	3	-	-	-	-	-
71	736862	-	-	-	-	3	-	-	-	-	-	-	-	-	-	-	-	-	-	3	-	-	-	-	-
72	56701	-	-	-	-	3	-	-	-	-	-	-	-	-	-	-	-	-	-	3	-	-	-	-	-
73	699324	-	-	-	-	3	-	-	-	-	-	-	-	-	-	-	-	-	-	3	-	-	-	-	-
74	743426	-	-	-	-	3	-	-	-	-	-	-	-	-	-	-	-	-	-	3	-	-	-	-	-
75	342253	-	-	-	-	3	-	-	-	-	-	-	-	-	-	-	-	-	-	3	-	-	-	-	-
76	715875	-	-	-	-	3	-	-	-	-	-	-	-	-	-	-	-	-	-	3	-	-	-	-	-
77	740599	-	-	-	-	3	-	-	-	-	-	-	-	-	-	-	-	-	-	3	-	-	-	-	-
78	743466	-	-	-	-	3	-	-	-	-	-	-	-	-	-	-	-	-	-	3	-	-	-	-	-
79	754136	-	-	-	-	3	-	-	-	-	-	-	-	-	-	-	-	-	-	3	-	-	-	-	-
80	633010	-	-	-	-	3	-	-	-	-	-	-	-	-	-	-	-	-	-	3	-	-	-	-	-
81	764175	-	-	-	-	3	-	-	-	-	-	-	-	-	-	-	-	-	-	3	-	-	-	-	-
82	766536	-	-	-	-	3	-	-	-	-	-	-	-	-	-	-	-	-	-	3	-	-	-	-	-
83	736862	-	-	-	-	3	-	-	-	-	-	-	-	-	-	-	-	-	-	3	-	-	-	-	-
84	765542	-	-	-	-	3	-	-	-	-	-	-	-	-	-	-	-	-	-	3	-	-	-	-	-
85	772868	-	-	-	-	3	-	-	-	-	-	-	-	-	-	-	-	-	-	3	-	-	-	-	-
86	774306	-	-	-	-	3	-	-	-	-	-	-	-	-	-	-	-	-	-	3	-	-	-	-	-
87	787977	-	-	-	-	3	-	-	-	-	-	-	-	-	-	-	-	-	-	3	-	-	-	-	-
88	759641	-	-	-	-	2	-	-	-	-	-	-	y	-	-	-	-	-	ureteric stones,pyelonephritis	3	-	-	-	-	-
89	765592	-	-	-	-	3	-	-	-	-	-	-	-	-	-	-	-	-	-	3	-	-	-	-	-
90	768925	-	-	-	-	3	-	-	-	-	-	-	-	-	-	-	-	-	-	3	-	-	-	-	-
91	67452	-	-	-	-	2	-	-	-	-	-	-	-	-	y	-	-	-	-	3	-	-	-	-	-
92	704957	-	-	-	infective bronchiolitis	3	-	-	-	-	-	-	-	-	-	-	-	-	-	3	-	-	-	-	-
93	736862	-	-	-	-	3	-	-	-	-	-	-	-	-	-	-	-	-	-	3	-	-	-	-	-
94	770578	-	-	-	-	3	-	-	-	-	-	-	-	-	-	-	-	-	-	3	-	-	-	-	-
95	770240	-	-	-	-	3	-	-	-	-	-	-	-	-	-	-	-	-	-	3	-	-	-	-	-
96	688217	-	-	-	-	3	-	-	-	-	-	-	-	-	-	-	-	-	-	1	-	-	-	-	-
97	769542	-	-	-	-	3	-	-	-	-	-	-	-	-	-	-	-	-	-	3	-	-	-	-	-

sr no	mrd	ncct head nor/abn/ not done-1/2/3	mri brain nor/abn/not done-1/2/3	bone scan-nor/abn/not done-1/2/3	pet scan nor=1/abn=2/not done=3	pet scan inc fdg uptake in	usg neck parathyroid adenoma yes/no/not done-1/2/3	usg neck parathyroid adenoma right-1,left-2	usg neck parathyroid adenoma superior-1, inferior-2	sestamibi scan y/n/not done-1/2/3	sestamibi scan right-1,left-2	sestamibi scan superior-1,inferior-2	sestamibi scan other	xray skull punched out lesions y/n/not done-1/2/3	24 hr urinary calcium	spep m band y/n/not done-1/2/3	bma & biopsy nor/abn/not done-1/2/3	plasma cell dyscrasia	other
1	657560	3	3	3	3	-	3	-	-	3	-	-	-	3	-	3	3	-	-
2	620678	3	3	3	3	-	3	-	-	3	-	-	-	3	-	3	3	-	-
3	622323	3	3	3	3	-	3	-	-	3	-	-	-	3	-	3	3	-	-
4	642273	3	3	3	3	-	2	-	-	2	-	-	-	3	-	2	3	-	-
5	653016	3	3	3	3	-	3	-	-	3	-	-	-	3	-	3	3	-	-
6	652324	3	3	3	3	-	2	-	-	1	2	2	-	3	96	1	3	-	-
7	634367	3	3	3	3	-	3	-	-	3	-	-	-	3	-	1	3	-	-
8	619369	3	3	3	3	-	3	-	-	3	-	-	-	3	-	1	2	y	-
9	479659	3	3	3	3	-	3	-	-	3	-	-	-	3	-	3	3	-	-
10	507990	3	3	3	3	-	3	-	-	3	-	-	-	3	-	3	3	-	-
11	114141	3	3	3	3	-	1	2	2	1	2	2	-	3	-	3	3	-	-
12	661028	3	3	3	3	-	3	-	-	3	-	-	-	3	-	3	3	-	-
13	481154	3	3	3	3	-	2	-	-	1	1	2	-	3	-	3	3	-	-
14	661793	3	3	3	3	-	3	-	-	3	-	-	-	1	-	1	2	y	-
15	534702	3	3	3	3	-	3	-	-	3	-	-	-	3	-	3	3	-	-
16	637317	3	3	3	3	-	3	-	-	3	-	-	-	3	-	1	3	-	-
17	660678	3	3	3	3	-	3	-	-	3	-	-	-	3	-	1	2	y	-
18	678181	3	3	3	3	-	3	-	-	3	-	-	-	3	-	3	3	-	-
19	471657	3	3	3	3	-	3	-	-	3	-	-	-	3	-	3	3	-	-
20	544686	3	3	3	3	-	3	-	-	3	-	-	-	3	-	3	3	-	-
21	547171	3	3	3	3	-	3	-	-	3	-	-	-	3	-	3	3	-	-
22	699422	3	3	3	3	-	3	-	-	3	-	-	-	3	-	3	3	-	-
23	685762	3	3	3	3	-	1	2	2	1	2	2	-	3	-	3	3	-	-
24	390146	1	3	2	3	-	3	-	-	3	-	-	-	3	-	1	2	y	-
25	696214	3	3	3	3	-	3	-	-	3	-	-	-	3	-	3	3	-	-
26	689657	1	3	3	3	-	3	-	-	3	-	-	-	3	-	1	2	y	-
27	688609	3	3	3	3	-	1	2	2	1	2	2	-	3	-	3	3	-	-
28	688263	3	3	3	3	-	3	-	-	3	-	-	-	3	-	3	3	-	-
29	549787	3	1	2	3	-	3	-	-	3	-	-	-	2	-	1	1	-	-
30	884054	3	3	3	3	-	2	-	-	1	1	2	-	3	-	3	3	-	-
31	681615	3	3	3	3	-	3	-	-	3	-	-	-	1	-	1	2	y	-
32	681960	1	3	3	3	-	3	-	-	3	-	-	-	3	-	3	3	-	-
33	608658	3	3	3	2	-	3	-	-	3	-	-	-	3	-	3	3	-	-
34	704263	3	3	3	3	-	3	-	-	3	-	-	-	1	-	1	2	y	-
35	616466	3	3	3	3	-	3	-	-	3	-	-	-	3	-	3	3	-	-
36	684353	3	3	3	3	-	2	-	-	2	-	-	-	3	-	2	3	-	-
37	710294	3	3	3	3	-	1	2	2	1	2	2	-	3	-	2	3	-	-
38	701237	3	3	3	3	-	3	-	-	3	-	-	-	3	-	3	3	-	-
39	704363	3	3	3	3	-	3	-	-	3	-	-	-	3	-	1	2	y	-
40	714668	3	3	3	3	-	3	-	-	3	-	-	-	1	-	1	2	y	-
41	714055	3	left mca infarc	3	3	-	3	-	-	3	-	-	-	3	-	3	3	-	-
42	709161	3	3	3	2	bones and lymph nodes	3	-	-	3	-	-	-	1	-	3	3	-	-
43	705170	3	3	3	3	-	3	-	-	3	-	-	-	1	-	1	2	y	-
44	704346	3	3	3	3	-	3	-	-	3	-	-	-	3	-	3	3	-	-
45	701197	3	3	3	3	-	1	2	1	1	2	1	-	3	-	3	3	-	-
46	705939	3	3	3	3	-	1	2	2	1	2	2	-	3	-	3	3	-	-
47	716065	3	multifocal infa	3	3	-	3	-	-	3	-	-	-	3	-	3	3	-	-
48	710294	3	multifocal infa	3	3	-	2	-	-	1	2	2	-	3	-	3	3	-	-
49	709534	3	3	3	3	-	3	-	-	3	-	-	-	3	-	3	3	-	-
50	668636	3	3	3	3	-	3	-	-	3	-	-	-	3	-	3	3	-	-
51	24573	3	3	3	3	-	3	-	-	3	-	-	-	3	-	3	3	-	-
52	274445	3	3	3	2	bones and axillary lymph nodes	3	-	-	3	-	-	-	3	-	3	3	-	-
53	715876	3	3	3	3	-	3	-	-	3	-	-	-	3	-	3	3	-	-
54	82146	3	3	3	3	-	3	-	-	3	-	-	-	1	-	3	3	-	-
55	703014	3	3	3	3	-	3	-	-	3	-	-	-	1	-	1	2	y	-
56	688160	3	3	3	3	-	3	-	-	3	-	-	-	3	-	3	2	-	nhl
57	707264	3	3	3	3	-	3	-	-	3	-	-	-	3	-	3	3	-	-
58	723943	3	3	3	3	-	3	-	-	3	-	-	-	3	-	2	2	y	-
59	721990	3	3	3	3	-	3	-	-	3	-	-	-	3	-	3	2	-	leukamoid reaction
60	735044	3	3	3	3	-	1	2	2	1	1	1	-	3	-	2	3	-	-
61	720710	3	calvarial meta	3	3	-	3	-	-	3	-	-	-	1	-	1	2	y	-
62	730710	3	3	3	3	-	3	-	-	3	-	-	-	3	-	3	3	-	-
63	728676	3	3	3	3	-	1	2	2	1	2	2	-	3	-	3	3	-	-
64	723902	3	3	3	3	-	3	-	-	3	-	-	-	3	-	3	3	-	-
65	724002	3	3	3	3	-	3	-	-	3	-	-	-	3	-	2	1	-	-
66	615991	3	3	3	3	-	3	-	-	3	-	-	-	3	-	3	3	-	-
67	729399	3	1	3	2	bones and liver	3	-	-	3	-	-	-	3	-	3	3	-	-
68	731537	3	3	3	3	-	3	-	-	3	-	-	-	3	-	3	3	-	-
69	683750	3	3	2	3	-	3	-	-	3	-	-	-	3	-	3	3	-	-
70	739803	3	3	3	3	-	3	-	-	3	-	-	-	3	-	3	3	-	-
71	736862	3	3	3	3	-	3	-	-	3	-	-	-	3	-	2	3	-	-
72	56701	3	3	3	3	-	1	2	2	1	2	1	-	3	-	3	3	-	-
73	699324	3	3	3	3	-	3	-	-	3	-	-	-	3	-	3	3	-	-
74	743426	3	3	3	3	-	3	-	-	3	-	-	-	3	-	3	3	-	-
75	342253	3	3	3	3	-	3	-	-	3	-	-	-	3	-	3	3	-	-
76	715875	3	3	3	3	-	3	-	-	3	-	-	-	3	-	3	3	-	-
77	740599	3	3	3	3	-	3	-	-	3	-	-	-	3	-	3	3	-	-
78	743466	3	3	3	3	-	3	-	-	3	-	-	-	3	-	3	3	-	-
79	754136	3	3	3	3	-	3	-	-	3	-	-	-	3	-	3	3	-	-
80	633010	3	3	3	3	-	3	-	-	3	-	-	-	3	-	3	3	-	-
81	764175	3	3	3	3	-	3	-	-	3	-	-	-	3	-	3	3	-	-
82	766536	3	1	3	3	-	3	-	-	3	-	-	-	3	-	3	3	-	-
83	736862	3	3	3	3	-	3	-	-	3	-	-	-	3	-	2	1	n	-
84	765542	3	3	3	3	-	3	-	-	3	-	-	-	3	-	3	3	-	-
85	772868	3	3	3	3	-	1	1	2	1	1	2	-	3	-	3	3	-	-
86	774306	3	3	3	3	-	2	-	-	1	2	2	-	3	-	3	3	-	-
87	787977	3	3	3	3	-	3	-	-	3	-	-	-	3	-	3	3	-	-
88	759641	3	3	3	3	-	3	-	-	3	-	-	-	3	-	1	2	y	-
89	765592	3	3	3	3	-	3	-	-	3	-	-	-	3	-	3	3	-	-
90	768925	3	3	3	3	-	2	-	-	2	-	-	-	3	-	2	3	-	-
91	67452	3	3	3	3	-	3	-	-	3	-	-	-	3	-	3	3	-	-
92	704957	3	3	3	3	-	3	-	-	3	-	-	-	3	-	3	3	-	-
93	736862	3	3	3	3	-	3	-	-	3	-	-	-	3	-	2	3	-	-
94	770578	3	3	3	3	-	3	-	-	3	-	-	-	3	-	3	3	-	-
95	770240	3	3	3	3	-	3	-	-	3	-	-	-	3	-	3	3	-	-
96	688217	3	3	3	3	-	1	1	2	1	1	2	-	3	-	3	3	-	-
97	769542	3	3	3	3	-	3	-	-	3	-	-	-	3	-	3	3	-	-

sr no	mrd	24hr urine for light chain assay y/n/not done-1/2/3	24hr urine for light chain assay	other	fnac/biosy other part_y/n/not done-1/2/3	atypical cells	area	malignancy	Probable malignancy	malignancy ca bladder	malignancy ca penis	malignancy ca ovary	malignancy ca cervix	malignancy ca esophagus	malignancy hcc	malignancy ca head and neck	malignancy ca gall bladder and bile ducts	malignancy multiple myeloma	malignancy breast	malignancy rcc	malignancy lymphoma	malignancy cml
1	657560	3	-	-	3	-	-	y	n	-	-	-	-	-	-	-	-	-	-	-	-	-
2	620678	3	-	-	3	-	-	n	n	-	-	-	-	-	-	-	-	-	-	-	-	-
3	622323	3	-	-	2	lymphoid	lymph node	y	n	-	-	-	-	-	-	-	-	-	-	-	y	-
4	642273	3	-	-	3	-	-	n	n	-	-	-	-	-	-	-	-	-	-	-	-	-
5	653016	3	-	-	3	-	-	n	n	-	-	-	-	-	-	-	-	-	-	-	-	-
6	652324	3	-	-	3	-	-	n	n	-	-	-	-	-	-	-	-	-	-	-	-	-
7	634367	3	-	-	3	-	-	n	n	-	-	-	-	-	-	-	-	-	-	-	-	-
8	619369	3	-	-	3	-	-	y	n	-	-	-	-	-	-	-	-	y	-	-	-	-
9	479659	3	-	-	3	-	-	y	n	-	-	-	-	-	-	y	-	-	-	-	-	-
10	507990	3	-	-	3	-	-	y	n	-	-	-	-	-	y	-	-	-	-	-	-	-
11	114141	3	-	-	3	-	-	n	n	-	-	-	-	-	-	-	-	-	-	-	-	-
12	661028	3	-	-	2	lymphoid	lymph node	y	n	-	-	-	-	-	-	-	-	-	-	-	y	-
13	481154	3	-	-	3	-	-	n	n	-	-	-	-	-	-	-	-	-	-	-	-	-
14	661793	3	-	-	3	-	-	y	n	-	-	-	-	-	-	-	-	y	-	-	-	-
15	534702	3	-	-	3	-	-	n	n	-	-	-	-	-	-	-	-	-	-	-	-	-
16	637317	3	-	-	3	-	-	n	y	-	-	-	-	-	-	-	-	?	-	-	-	-
17	660678	2	1.8g	-	3	-	-	y	n	-	-	-	-	-	-	-	-	y	-	-	-	-
18	678181	3	-	-	3	-	-	y	n	y	-	-	-	-	-	-	-	-	-	-	-	-
19	471657	3	-	-	3	-	-	y	n	-	-	-	-	-	-	-	y	-	-	-	-	-
20	544686	3	-	-	3	-	-	n	n	-	-	-	-	-	-	-	-	-	-	-	-	-
21	547171	3	-	-	2	scc	gej growth	y	n	-	-	-	-	y	-	-	-	-	-	-	-	-
22	699422	3	-	-	3	-	-	y	n	-	-	-	-	-	y	-	-	-	-	-	-	-
23	685762	3	-	-	3	-	-	n	n	-	-	-	-	-	-	-	-	-	-	-	-	-
24	390146	3	-	-	3	-	-	y	n	-	-	-	-	-	-	-	-	y	-	-	-	-
25	696214	3	-	-	3	-	-	n	n	-	-	-	-	-	-	-	-	-	-	-	-	-
26	689657	3	-	-	3	-	-	y	n	-	-	-	-	-	-	-	-	y	-	-	-	-
27	688609	3	-	-	3	-	-	n	n	-	-	-	-	-	-	-	-	-	-	-	-	-
28	688263	3	-	-	2	tubercular	colon	n	n	-	-	-	-	-	-	-	-	-	-	-	-	-
29	549787	3	-	-	2	malignant aspirate	breast	y	n	-	-	-	-	-	-	-	-	-	y	-	-	-
30	884054	3	-	-	3	-	-	n	n	-	-	-	-	-	-	-	-	-	-	-	-	-
31	681615	3	-	-	3	-	-	y	n	-	-	-	-	-	-	-	-	y	-	-	-	-
32	681960	3	-	-	3	-	-	y	n	-	-	-	-	-	-	-	-	-	-	-	-	-
33	608658	3	-	-	2	lymphoid	lymph node	y	n	-	-	-	-	-	-	-	-	-	-	-	y	-
34	704263	2	1.7g	-	3	-	-	y	n	-	-	-	-	-	-	-	-	y	-	-	-	-
35	616466	3	-	-	3	-	-	y	n	-	-	-	-	-	-	-	-	y	-	-	-	-
36	684353	3	-	-	3	-	-	n	n	-	-	-	-	-	-	-	-	-	-	-	-	-
37	710294	3	-	-	3	-	-	n	n	-	-	-	-	-	-	-	-	-	-	-	-	-
38	701237	3	-	fracture femur	3	-	-	n	n	-	-	-	-	-	-	-	-	-	-	-	-	-
39	704363	3	-	-	3	-	-	y	n	-	-	-	-	-	-	-	-	y	-	-	-	-
40	714668	3	-	-	3	-	-	y	n	-	-	-	-	-	-	-	-	y	-	-	-	-
41	714055	3	-	-	3	-	-	n	y	-	-	-	-	-	-	-	-	?	-	-	-	-
42	709161	3	-	-	3	-	-	n	y	-	-	-	-	-	-	-	-	?	-	-	-	-
43	705170	3	-	-	3	-	-	y	n	-	-	-	-	-	-	-	-	y	-	-	-	-
44	704346	3	-	-	3	-	-	n	n	-	-	-	-	-	-	-	-	-	-	-	-	-
45	701197	3	-	-	3	-	-	n	n	-	-	-	-	-	-	-	-	-	-	-	-	-
46	705939	3	-	-	3	-	-	n	n	-	-	-	-	-	-	-	-	-	-	-	-	-
47	716065	3	-	-	3	-	-	n	n	-	-	-	-	-	-	-	-	-	-	-	-	-
48	710294	3	-	ct neck-pth adenoma(2,2)	3	-	-	n	n	-	-	-	-	-	-	-	-	-	-	-	-	-
49	709534	3	-	-	3	-	-	n	n	-	-	-	-	-	-	-	-	-	-	-	-	-
50	668636	3	-	-	3	-	-	n	n	-	-	-	-	-	-	-	-	-	-	-	-	-
51	24573	3	-	-	3	-	-	y	n	-	-	y	-	-	-	-	-	-	-	-	-	-
52	274445	3	-	xray spine-vertebral collapse	2	malignant aspirate	breast	y	n	-	-	-	-	-	-	-	-	-	y	-	-	-
53	715876	3	-	-	3	-	-	y	n	-	-	-	y	-	-	-	-	-	-	-	-	-
54	82146	3	-	-	3	-	-	y	n	-	-	-	-	-	-	-	-	y	-	-	-	-
55	703014	3	-	-	3	-	-	y	n	-	-	-	-	-	-	-	-	y	-	-	-	-
56	688160	3	-	-	3	-	-	y	n	-	-	-	-	-	-	-	-	-	-	-	y	-
57	707264	3	-	-	3	-	-	n	n	-	-	-	-	-	-	-	-	-	-	-	-	-
58	723943	3	-	-	3	-	-	y	n	-	-	-	-	-	-	-	-	y	-	-	-	-
59	721990	3	-	biopsy-cml	3	-	-	y	n	-	-	-	-	-	-	-	-	-	-	-	-	y
60	735044	3	-	-	3	-	-	n	n	-	-	-	-	-	-	-	-	-	-	-	-	-
61	720710	3	-	-	3	-	-	y	n	-	-	-	-	-	-	-	-	y	-	-	-	-
62	730710	3	-	-	3	-	-	n	n	-	-	-	-	-	-	-	-	-	-	-	-	-
63	728676	3	-	-	3	-	-	n	n	-	-	-	-	-	-	-	-	-	-	-	-	-
64	723902	3	-	-	3	-	-	n	n	-	-	-	-	-	-	-	-	-	-	-	-	-
65	724002	3	-	-	3	-	-	n	n	-	-	-	-	-	-	-	-	-	-	-	-	-
66	615991	3	-	-	3	-	-	n	n	-	-	-	-	-	-	-	-	-	-	-	-	-
67	729399	3	-	-	3	-	-	y	n	y	-	-	-	-	-	-	-	-	-	-	-	-
68	731537	3	-	-	3	-	-	y	n	-	-	-	-	-	-	-	-	y	-	-	-	-
69	683750	3	-	-	3	-	-	y	n	-	-	y	-	-	-	-	-	-	-	-	-	-
70	739803	3	-	-	3	-	-	y	n	-	-	-	-	-	y	-	-	-	-	-	-	-
71	736862	3	-	-	3	-	-	n	n	-	-	-	-	-	-	-	-	-	-	-	-	-
72	56701	3	-	-	3	-	-	n	n	-	-	-	-	-	-	-	-	-	-	-	-	-
73	699324	3	-	-	3	-	-	n	n	-	-	-	-	-	-	-	-	-	-	-	-	-
74	743426	3	-	-	3	-	-	n	n	-	-	-	-	-	-	-	-	-	-	-	-	-
75	342253	3	-	-	3	-	-	n	n	-	-	-	-	-	-	-	-	-	-	-	-	-
76	715875	3	-	malignant pleural effusion	3	-	-	y	n	-	-	y	-	-	-	-	-	-	-	-	-	-
77	740599	3	-	-	2	lymphoid	-	y	n	-	-	-	-	-	-	-	-	-	-	-	y	-
78	743466	3	-	-	2	lymphoid	retroperitoneal mass	y	n	-	-	-	-	-	-	-	-	-	-	-	y	-
79	754136	3	-	-	2	lymphoid	lymph node	y	n	-	-	-	-	-	-	-	-	-	-	-	y	-
80	633010	3	-	-	3	-	-	y	n	-	y	-	-	-	-	-	-	-	-	-	-	-
81	764175	3	-	-	3	-	-	n	n	-	-	-	-	-	-	-	-	-	-	-	-	-
82	766536	3	-	-	3	-	-	n	n	-	-	-	-	-	-	-	-	-	-	-	-	-
83	736862	3	-	-	3	-	-	n	n	-	-	-	-	-	-	-	-	-	-	-	-	-
84	765542	3	-	-	3	-	-	n	n	-	-	-	-	-	-	-	-	-	-	-	-	-
85	772868	3	-	-	3	-	-	n	n	-	-	-	-	-	-	-	-	-	-	-	-	-
86	774306	3	-	-	3	-	-	n	n	-	-	-	-	-	-	-	-	-	-	-	-	-
87	787977	3	-	-	3	-	-	n	n	-	-	-	-	-	-	-	-	-	-	-	-	-
88	759641	3	-	-	3	-	-	y	n	-	-	-	-	-	-	-	-	y	-	-	-	-
89	765592	3	-	-	3	-	-	n	n	-	-	-	-	-	-	-	-	-	-	-	-	-
90	768925	3	-	-	3	-	-	n	n	-	-	-	-	-	-	-	-	-	-	-	-	-
91	67452	3	-	-	3	-	-	y	n	-	-	-	-	-	-	-	-	-	y	-	-	-
92	704957	3	-	-	3	-	-	n	n	-	-	-	-	-	-	-	-	-	-	-	-	-
93	736862	3	-	-	3	-	-	n	n	-	-	-	-	-	-	-	-	-	-	-	-	-
94	770578	3	-	-	3	-	-	y	n	-	-	-	-	-	-	-	y	-	-	-	-	-
95	770240	3	-	-	3	-	-	n	n	-	-	-	-	-	-	-	-	-	-	-	-	-
96	688217	3	-	-	3	-	-	n	n	-	-	-	-	-	-	-	-	-	-	-	-	-
97	769542	3	-	-	3	-	-	n	n	-	-	-	-	-	-	-	-	-	-	-	-	-

sr no	mrd	malignancy ca lung	malignancy unknown primary	hyperparathyroidism	tb	sarcoidosis	vit d intox	drug responsible	thyrotoxicosis	exclusive cld	drug induced	exclusive ckd	bedridden exclusive	other	medical lasix	medical iv fluids	medical calcitonin	medical bisphosphonates	medical steroids	medical dialysis	medical denosumab	medical ct/rt	surgery parathyroidectomy	surgery procedure	surgery mastectomy	surgery debulking surgery	outcome symptoms	outcome calcium	discharge/ dor /dama /death - 1/2/3/4	1month constitutional symptoms
1	657560	-	y	-	-	-	-	-	-	-	-	-	-	-	y	y	y	n	n	n	-	na	n	-	na	n	n	y	3	-
2	620678	-	-	-	-	-	y	-	-	-	y	-	-	-	y	y	y	n	y	n	-	na	na	-	na	na	y	y	1	n
3	622323	-	-	-	-	-	-	-	-	-	-	-	-	-	y	y	y	n	y	y	-	n	na	-	na	na	y	y	2	n
4	642273	-	-	-	-	-	-	lithium	-	-	y	-	-	-	y	y	y	n	y	y	-	na	na	-	na	na	y	y	1	n
5	653016	-	-	-	-	-	-	-	-	y	-	-	-	-	n	y	y	n	n	n	-	na	na	-	na	na	y	y	1	n
6	652324	-	-	y	-	-	-	-	-	-	-	-	-	-	y	y	y	y	n	n	-	na	y	-	na	na	y	y	2	n
7	634367	-	-	-	y	-	-	-	-	-	-	-	-	-	y	y	y	n	y	n	-	na	na	-	na	na	y	y	1	y
8	619369	-	-	-	-	-	-	-	-	-	-	-	-	-	y	y	y	n	y	y	-	y	na	-	na	na	y	y	1	y
9	479659	-	-	-	-	-	-	-	-	-	-	-	-	-	y	y	y	n	y	n	-	y	na	-	na	na	n	n	3	-
10	507990	-	-	-	-	-	-	-	-	-	-	-	-	-	n	y	y	n	n	n	-	n	na	-	na	na	y	y	1	y
11	114141	-	-	y	-	-	-	-	-	-	-	-	-	-	y	y	y	n	n	n	-	na	n	-	na	na	y	y	1	y
12	661028	-	-	-	-	-	-	-	-	-	-	-	-	-	y	y	y	n	y	n	-	n	na	-	na	na	n	y	3	-
13	481154	-	-	y	-	-	-	-	-	-	-	-	-	-	y	y	y	n	n	n	-	na	y	-	na	na	y	y	1	y
14	661793	-	-	-	-	-	-	-	-	-	-	-	-	-	y	n	y	n	y	y	-	na	na	-	na	na	y	y	1	y
15	534702	-	-	-	-	-	y	-	-	-	y	-	-	-	y	y	y	n	y	n	-	na	na	-	na	na	y	y	1	y
16	637317	-	-	-	-	-	-	-	-	-	-	-	-	-	y	y	y	n	n	n	-	n	na	-	na	na	n	y	2	y
17	660678	-	-	-	-	-	-	-	-	-	-	-	-	-	y	y	y	y	n	y	-	n	na	-	na	na	y	y	1	y
18	678181	-	-	-	-	-	-	-	-	-	-	-	-	-	y	y	y	n	n	n	-	y	na	-	na	na	n	n	3	-
19	471657	-	-	-	-	-	-	-	-	-	-	-	-	-	y	y	y	n	n	n	-	n	na	-	na	n	n	n	3	-
20	544686	-	-	-	-	-	y	-	-	-	y	-	-	-	y	y	y	n	y	n	-	n	na	-	na	na	y	y	3	y
21	547171	-	-	-	-	-	-	-	-	-	-	-	-	-	y	y	y	n	n	n	-	y	na	-	na	n	y	n	1	y
22	699422	-	-	-	-	-	-	-	-	-	-	-	-	-	n	y	y	n	n	n	-	n	n	-	na	n	n	n	2	y
23	685762	-	-	y	-	-	-	-	-	-	-	-	-	-	y	y	y	n	n	n	-	na	n	-	na	na	y	y	2	y
24	390146	-	-	-	-	-	-	-	-	-	-	-	-	-	y	y	n	n	n	y	-	y	na	-	na	na	y	y	1	y
25	696214	-	-	-	y	-	-	-	-	-	-	-	-	-	y	y	y	n	y	n	-	na	na	-	na	na	y	y	1	y
26	689657	-	-	-	-	-	-	-	-	-	-	-	-	-	y	y	y	n	n	y	-	n	na	-	na	na	y	y	1	y
27	688609	-	-	y	-	-	-	-	-	-	-	-	-	-	y	y	y	n	n	n	-	na	n	-	na	na	y	y	2	y
28	688263	-	-	-	y	-	-	-	-	-	-	-	-	-	y	y	y	n	n	n	-	na	na	-	na	na	y	y	2	y
29	549787	-	-	-	-	-	-	-	-	-	-	-	-	-	y	y	y	n	n	n	-	n	na	-	n	n	y	y	2	y
30	884054	-	-	y	-	-	-	-	-	-	-	-	-	-	y	y	y	y	n	y	-	n	y	-	na	na	y	y	1	y
31	881615	-	-	-	-	-	-	-	-	-	-	-	-	-	y	y	y	y	y	n	-	n	na	-	na	na	y	y	1	y
32	681960	y	-	-	-	-	-	-	-	-	-	-	-	-	y	y	y	y	n	n	-	y	na	-	na	na	n	y	2	y
33	608658	-	-	-	-	-	-	-	-	-	-	-	-	-	y	y	y	y	y	n	-	n	na	-	na	na	y	y	2	y
34	704263	-	-	-	-	-	-	-	-	-	-	-	-	-	y	y	y	y	y	y	-	y	na	-	na	na	y	y	1	y
35	616466	-	-	-	-	-	-	-	-	-	-	-	-	-	y	y	y	y	n	n	-	na	na	-	na	na	y	y	1	n
36	684353	-	-	-	-	-	-	thiazide	-	-	y	-	-	-	y	y	y	n	n	n	-	n	na	-	na	na	y	y	1	y
37	710294	-	-	y	-	-	-	-	-	-	-	-	-	-	y	y	y	n	n	n	-	na	n	-	na	na	y	y	1	y
38	701237	-	-	-	-	-	y	-	-	-	y	-	-	-	y	y	y	n	y	y	-	na	na	-	na	na	y	y	1	n
39	704363	-	-	-	-	-	-	-	-	-	-	-	-	-	y	y	y	n	n	n	-	n	na	-	na	na	y	y	1	y
40	714668	-	-	-	-	-	-	-	-	-	-	-	-	-	y	y	y	n	y	y	-	n	na	-	na	na	n	y	4	-
41	714055	-	-	-	-	-	-	-	-	-	-	-	-	-	y	y	n	n	n	n	-	n	n	-	na	na	y	y	1	y
42	709161	-	-	-	-	-	-	-	-	-	-	-	-	-	y	y	y	y	n	n	-	n	na	-	na	na	n	y	2	y
43	705170	-	-	-	-	-	-	-	-	-	-	-	-	-	y	n	y	n	n	y	-	y	na	-	na	na	y	y	1	y
44	704346	-	-	-	-	-	y	-	-	-	y	-	-	-	y	n	y	n	y	y	-	na	na	-	na	na	n	n	1	y
45	701197	-	-	y	-	-	-	-	-	-	-	-	-	-	y	y	y	n	n	n	-	na	y	-	na	na	y	y	1	n
46	705939	-	-	y	-	-	-	-	-	-	-	-	-	-	y	y	y	n	n	n	-	na	n	-	na	na	y	y	1	y
47	716065	-	-	-	-	-	-	-	-	y	-	-	-	-	y	y	y	n	y	y	-	na	na	-	na	na	n	n	4	-
48	710294	-	-	y	-	-	-	-	-	-	-	-	-	-	y	y	y	n	n	n	-	na	n	-	y	y	n	y	3	y
49	709534	-	-	-	-	-	y	-	-	-	y	-	-	-	y	y	y	n	n	n	-	na	na	-	na	na	y	n	1	y
50	668636	-	-	-	-	-	-	-	-	y	-	-	-	-	y	y	y	n	n	n	-	n	na	-	na	n	n	n	2	y
51	24573	-	-	-	-	-	-	-	-	-	-	-	-	-	y	y	y	y	n	n	-	n	n	-	na	na	y	n	2	y
52	274445	-	-	-	-	-	-	-	-	-	-	-	-	-	y	y	y	y	y	n	-	n	na	-	n	n	y	n	2	y
53	715876	-	-	-	-	-	-	-	-	-	-	-	-	-	y	y	y	y	n	n	-	n	na	-	na	n	n	y	3	y
54	82146	-	-	-	-	-	-	-	-	-	-	-	-	-	y	y	y	n	n	n	-	n	na	-	na	na	y	y	2	y
55	703014	-	-	-	-	-	-	-	-	-	-	-	-	-	y	y	y	n	y	n	-	y	na	-	na	na	y	y	1	y
56	688160	-	-	-	-	-	-	-	-	-	-	-	-	-	y	y	y	n	y	n	-	y	na	-	na	na	y	y	1	y
57	707264	-	-	-	-	-	-	-	-	-	-	-	y	-	y	y	y	n	n	n	-	na	na	-	na	na	n	n	2	y
58	723943	-	-	-	-	-	-	-	-	-	-	-	-	-	y	y	y	n	n	n	-	y	na	-	na	na	y	y	1	y
59	721990	-	-	-	-	-	-	-	-	-	-	-	-	-	y	y	y	n	n	n	-	y	na	-	na	na	y	y	1	n
60	735044	-	-	y	-	-	-	-	-	-	-	-	-	-	y	y	y	n	n	n	-	y	n	-	na	na	y	y	1	n
61	720710	-	-	-	-	-	-	-	-	-	-	-	-	-	y	y	y	n	y	n	-	y	na	-	na	na	y	y	1	y
62	720710	-	-	-	-	-	y	-	-	-	y	-	-	-	y	y	y	n	n	y	-	na	na	-	na	na	y	y	1	-
63	728676	-	-	y	-	-	-	-	-	-	-	-	-	-	y	y	y	n	n	n	-	na	n	-	na	na	y	n	1	y
64	723902	-	-	-	-	-	-	-	-	-	-	-	-	idiopathic	y	y	y	n	n	n	-	na	na	-	na	na	y	y	1	y
65	724002	-	-	-	-	-	y	-	-	-	y	-	-	-	y	y	y	n	y	n	-	na	na	-	na	na	y	y	2	y
66	615991	-	-	-	-	-	-	-	-	y	-	-	-	-	n	y	y	n	n	n	-	na	na	-	na	na	y	y	1	y
67	729399	-	-	-	-	-	-	-	-	-	-	-	-	-	y	y	y	y	n	n	-	n	na	-	na	na	n	n	4	-
68	731537	-	-	-	-	-	-	-	-	-	-	-	-	-	n	y	y	n	n	n	-	na	na	-	na	na	n	y	3	-
69	683750	-	-	-	-	-	-	-	-	-	-	-	-	-	y	y	y	n	n	n	-	y	na	-	na	n	n	y	3	-
70	739803	-	-	-	-	-	-	-	-	-	-	-	-	-	n	y	y	n	n	n	-	n	na	-	na	n	n	n	4	-
71	736862	-	-	-	-	-	y	-	-	-	y	-	-	-	y	y	y	n	y	n	-	na	na	-	na	na	y	y	1	y
72	56701	-	-	y	-	-	-	-	-	-	-	-	-	-	y	y	y	n	n	n	-	na	n	-	na	na	y	y	1	n
73	699324	-	-	-	-	-	y	-	-	-	y	-	-	-	y	y	y	n	y	n	-	na	na	-	na	na	y	y	1	y
74	743426	-	-	-	-	-	-	-	-	-	-	-	-	idiopathic	y	y	y	n	n	n	-	na	na	-	na	na	n	n	4	-
75	342253	-	-	-	-	-	-	-	-	y	-	-	-	-	n	y	y	n	n	n	-	n	na	-	na	na	y	y	1	y
76	715875	-	-	-	-	-	-	-	-	-	-	-	-	-	y	y	y	n	n	n	-	y	na	-	na	na	n	y	3	-
77	740599	-	-	-	-	-	-	-	-	-	-	-	-	-	y	y	y	n	y	n	-	y	na	-	na	na	y	y	1	y
78	743466	-	-	-	-	-	-	-	-	-	-	-	-	-	y	y	y	n	n	n	-	n	na	-	na	n	n	y	2	y
79	754136	-	-	-	-	-	-	-	-	-	-	-	-	-	y	y	y	n	y	n	-	n	na	-	na	n	y	y	1	y
80	633010	-	-	-	-	-	-	-	-	-	-	-	-	-	y	y	y	n	n	n	-	n	na	-	na	n	n	n	3	-
81	764175	-	-	-	-	-	y	-	-	-	y	-	-	-	y	y	y	n	y	n	-	na	na	-	na	na	y	y	1	n
82	766536	-	-	-	-	-	-	-	-	-	-	-	-	idiopathic	y	y	y	n	n	n	-	na	na	-	na	na	y	y	1	n
83	736862	-	-	-	-	-	y	-	-	-	y	-	-	-	y	y	y	n	y	n	-	na	na	-	na	na	y	y	1	y
84	765542	-	-	-	-	-	-	-	y	-	-	-	-	-	n	y	n	n	n	n	-	na	na	-	na	na	n	y	3	-
85	772868	-	-	y	-	-	-	-	-	-	-	-	-	-	y	y	y	n	n	n	-	na	y	-	na	na	y	y	1	n
86	774306	-	-	y	-	-	-	-	-	-	-	-	-	-	y	y	y	n	n	n	-	na	n	-	na	na	y	y	1	y
87	787977	-	-	-	-	-	y	-	-	-	y	-	-	-	y	y	y	n	n	n	-	na	na	-	na	na	y	y	2	y
88	759641	-	-	-	-	-	-	-	-	-	-	-	-	-	y	y	y	n	n	y	-	na	n	-	na	na	y	y	1	n
89	765592	-	-	-	-	-	-	-	y	-	-	-	-	-	n	y	y	n	n	n	-	na	na	-	na	na	y	y	1	y
90	768925	-	-	-	-	-	-	thiazide	-	-	y	-	-	-	y	n	n	n	n	n	-	na	na	-	na	na	y	y	1	n
91	67452	-	-	-	-	-	-	-	-	-	-	-	-	-	y	y	y	n	n	n	-	y	na	-	n	na	y	y	1	y
92	704957	-	-	-	-	-	-	-	-	-	-	-	-	idiopathic	n	y	n	n	y	n	-	na	na	-	na	na	y	y	1	y
93	736862	-	-	-	-	-	y	-	-	-	y	-	-	-	y	y	n	n	y	n	-	na	na	-	na	na	y	y	1	y
94	770578	-	-	-	-	-	-	-	-	-	-	-	-	-	y	y	y	n	n	n	-	na	na	-	na	na	y	y	1	y
95	770240	-	-	-	-	-	y	-	-	-	y	-	-	-	y	y	y	n	y	y	-	na	na	-	na	na	y	y	1	y
96	688217	-	-	y	-	-	-	-	-	-	-	-	-	-	n	y	y	n	n	n	-	na	n	-	na	na	y	y	1	n
97	769542	-	-	-	-	-	y	-	-	-	y	-	-	-	y	y	y	n	y	y	-	na	na	-	na	na	y	y	3	-

sr no	mrd	1month improvement in symptoms	1month new symptom	1month symptom	1month s.calcium	1month albumin	1month corrected calcium	1month vit d	1month PTH	1month tlc	1month HB	1month platelets	1month creatinine	1month other	1month alive	1month loss to f/u	1month interval pathyroidectomy	3month constitutional symptoms	3month improvement in symptoms	3month new symptom	-	3month s.calcium	3month albumin	3month corrected calcium	3month tlc	3month PTH	3month HB	3month platelets
1	657560	-	-	-	-	-	-	-	-	-	-	-	-	-	n1	-	-	-	-	-	-	-	-	-	-	-	-	-
2	620678	y	n	-	10.2	-	10.84	-	-	-	-	-	-	-	y	-	-	n	y	y	irrelevant talks,insomnia	12.4	-	-	-	-	-	-
3	622323	n	y	dec urine output	10.2	2.3	11.56	-	-	-	7	-	1.4	-	y	-	-	n	n	y	anasarca	10.3	2.5	-	-	-	6.5	-
4	642273	n	n	-	12.6	-	12.44	-	-	-	-	-	5.4	-	y	-	-	n	y	n	-	11	4.2	10.8	10	-	11	250
5	653016	y	n	-	11	2.5	12.2	-	-	8	8	120	2.6	-	y	-	-	n	y	y	irrelevant talks	10	2.5	11.2	8.5	-	7.6	124
6	652324	y	n	-	12.8	3.6	13.12	-	1361	-	14.2	-	0.76	-	y	-	-	n	y	n	-	9.9	3.6	10.22	-	743	-	-
7	634367	y	n	-	8.6	3.3	9.16	-	-	-	-	-	-	-	y	-	-	y	y	n	-	-	-	-	-	-	-	-
8	619369	y	n	-	9.4	2.5	10.6	-	-	9.5	8.4	150	2	-	y	-	-	n	y	n	-	9.8	2.6	10.9	5.4	-	8	120
9	479659	-	-	-	-	-	-	-	-	-	-	-	-	-	n1	-	-	-	-	-	-	-	-	-	-	-	-	-
10	507990	n	y	jaundice,irrelevant talks	10.2	3.4	10.68	-	-	-	10.6	-	1.2	-	y	-	-	y	n	n	-	11.2	2.3	12.56	-	-	8.3	-
11	114141	y	n	-	10.8	4.8	10.2	-	-	-	15.4	-	0.8	-	y	-	y	n	y	n	-	8.3	4.5	7.9	-	24	-	-
12	661028	-	-	-	-	-	-	-	-	-	-	-	-	-	n1	-	-	-	-	-	-	-	-	-	-	-	-	-
13	481154	y	n	-	9	4.3	8.76	-	69	-	11.5	-	-	-	y	-	-	n	y	n	-	9.4	-	-	-	-	-	-
14	661793	y	n	-	11.4	2.8	11.8	-	-	8.5	8.5	231	3.7	-	y	-	-	y	y	n	-	10	3	10.8	6.5	-	8.6	212
15	534702	n	n	-	9.8	3	9	-	-	-	10	-	-	-	y	-	-	y	y	n	-	9.2	2.98	9.19	-	-	-	-
16	637317	n	y	irrelevant talks	11.2	3.4	11.6	-	-	7.5	7	240	2.5	-	y	-	-	y	n	y	abdominal pain	11	3	11.8	10.5	-	7.2	200
17	660678	y	y	bony pains	10.7	-	12.54	-	-	-	-	-	-	-	y	-	-	y	n	n	-	12.6	-	-	-	-	6.8	-
18	678181	-	-	-	-	-	-	-	-	-	-	-	-	-	n1	-	-	-	-	-	-	-	-	-	-	-	-	-
19	471657	-	-	-	-	-	-	-	-	-	-	-	-	-	n1	-	-	-	-	-	-	-	-	-	-	-	-	-
20	544686	n	n	-	9.4	2	10	-	-	-	-	-	-	-	y	-	-	y	y	n	-	-	-	-	-	-	-	-
21	547171	y	y	malena,jaundice,anasarca	8.3	2.5	9.5	-	72	-	7.3	-	0.55	-	y	-	-	y	n	y	depression	9.5	1.8	11.26	13	-	8	250
22	699422	y	n	-	11	3	11.8	-	-	13	11	155	1.1	bilirubin 1.4	y	-	-	y	y	y	abdominal distension	-	-	-	8	-	10	150
23	685762	n	-	-	11.2	3	12	-	14	-	9.7	-	0.7	-	y	-	y	n	y	n	-	9	3.8	9.16	-	30	-	-
24	390146	y	n	-	9	3	9.8	-	-	-	-	-	-	-	y	-	-	n	y	n	-	8.9	3.2	9.5	-	-	-	-
25	696214	y	n	-	9.3	3.7	9.5	-	-	-	-	-	-	-	y	-	-	y	y	y	pain abdomen	9	3.7	9.2	-	-	-	-
26	689657	y	n	-	9.3	3.7	9.5	-	-	-	8.8	-	4.2	-	y	-	-	y	y	n	-	8.6	2.8	9.2	-	-	8.4	-
27	688609	y	n	-	10.1	3.2	10.7	-	-	-	12.5	-	0.34	-	y	-	n	y	n	y	alt sensorium, dec urine output,renal stones	11.3	3	12.1	-	-	-	-
28	688263	n	y	sob	10.5	2.3	11	-	-	-	9.8	-	2.3	-	y	-	-	y	y	n	-	10.5	2.5	10.9	-	-	-	-
29	549787	y	n	-	9.5	3	10.3	-	-	9.5	9	250	3	-	y	-	-	y	y	y	depression	10.8	3	11.6	10	-	8.8	210
30	884054	y	n	-	7.5	2.8	8.4	-	-	10.5	8.5	150	0.8	-	y	-	-	n	y	n	-	8.4	3	9.2	-	44	9	174
31	681615	y	n	-	9	-	9.64	-	-	-	-	-	-	-	y	-	-	n	y	n	-	10.6	2.5	11.8	14.5	-	6.5	100
32	681960	y	y	depression	10	2.4	11.6	-	-	12	9	642	0.5	-	y	-	-	y	y	y	sob	10.5	2.6	11.6	13	-	8	540
33	608658	n	n	-	12.6	3.5	13	-	-	-	13	-	1	-	y	-	-	y	y	n	-	10.5	3.5	10.9	9	-	9.5	180
34	704263	y	n	-	10	3	10.8	-	-	5.5	7.8	125	4.5	-	y	-	-	y	y	n	-	9	2.5	10.2	6.5	-	7.5	110
35	616466	y	n	-	9	-	9	-	-	-	-	-	-	-	y	-	-	n	y	n	-	9	-	-	-	-	-	-
36	684353	y	n	-	9	-	9.96	-	-	-	-	-	-	-	y	-	-	y	n	y	difficulty walking,bony pains	-	-	-	-	-	-	-
37	710294	y	n	-	10.2	-	10.84	-	74	-	-	-	-	-	y	-	y	n	y	n	-	8.6	3.4	9.1	-	-	-	-
38	701237	y	n	-	9	-	9.96	-	-	-	-	-	-	-	y	-	-	n	y	-	-	9	-	-	-	-	-	-
39	704363	y	y	fatigue	10.1	3	10.9	-	-	10	9	600	0.6	-	y	-	-	y	y	y	fatigue	10	3.2	10.6	6	-	8.5	550
40	714668	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
41	714055	y	n	-	9.5	3	10.3	-	-	6.4	11	180	1.2	-	y	-	-	y	y	n	-	-	-	-	5.5	-	11.2	200
42	709161	y	y	bed sores	11	3	11.8	-	-	12	7.5	150	1.2	-	y	-	-	y	n	y	fever,bed sore, constipation,uti	10.5	2.8	11.4	12	-	8	142
43	705170	y	n	-	9	3.6	9.3	-	-	-	7.6	-	4.3	-	y	-	-	y	y	n	-	9	2.6	10.1	-	-	-	-
44	704346	y	n	-	10	2.8	10.9	88	-	4.5	8	120	2.2	-	y	-	-	y	y	y	sob	9.5	2.6	10.6	5.6	-	7.8	158
45	701197	y	n	-	9.2	3.6	9.5	-	-	-	-	-	-	-	y	-	-	n	y	n	-	8.5	3.6	8.8	-	-	-	-
46	705939	y	y	fatigue	11.5	3.8	11.8	-	26	-	10	-	0.23	-	y	-	y	n	y	n	-	8.3	3.8	8.6	-	-	-	-
47	716065	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
48	710294	y	n	-	11.6	3	12.4	-	379	-	12	-	1.06	-	y	-	y	n	y	n	-	8.6	-	9.4	-	17.5	-	-
49	709534	y	n	-	10.8	2.3	12.4	-	-	-	10	-	0.5	-	y	-	-	y	y	n	-	10.2	2.3	11.8	-	-	-	-
50	668636	y	y	depression	10.6	2.6	11.7	-	-	12	9.5	300	0.6	-	y	-	-	y	y	y	sob	10.5	2.8	11.6	9.3	-	7.6	321
51	24573	y	y	abdominal distension,sob	14	1.9	15.6	-	-	-	11	-	1.4	-	y	-	-	y	y	y	abdominal distension,sob	10.6	2.4	11.8	12	-	9.5	120
52	274445	n	y	depression	12.3	2.4	13.5	-	-	-	-	-	-	-	y	-	-	y	y	y	irrelevant talks	13	2.5	14.2	15	-	9.5	182
53	715876	n	y	hematuria,sob, drowsy	13.2	2.3	14.56	-	-	-	8.4	-	1.2	-	y	-	-	y	n	y	sob	11.5	2.8	12.4	12.4	-	8.5	220
54	82146	y	y	constipation	10.3	3	11	-	-	4.2	6.5	100	2.6	-	y	-	-	y	y	y	irrelevant talks, bed sore	10.8	2.4	12	14	-	7.2	123
55	703014	y	y	leg pain	11.2	3	12	-	-	4.3	7.8	150	0.9	mri-paravertebral mass, fnac-malignant	y	-	-	y	n	y	encephalopathy,pain abdomen	13.4	2.4	14.6	-	-	-	-
56	688160	y	n	-	11	3	11.8	-	-	2	10	23	0.7	-	y	-	-	y	y	n	-	9.3	4	9.3	4	-	12	150
57	707264	y	n	-	10.3	3	11	-	-	8.6	8	650	1.2	-	y	-	-	y	y	n	-	-	-	-	10	-	8	241
58	723943	y	n	-	10.2	2.5	11.4	-	-	4.6	7.5	140	2.6	-	y	-	-	n	y	n	-	10.5	2.6	11.62	-	-	12	-
59	721990	y	n	-	9	2.5	10.2	-	-	43	10	1200	1.1	-	y	-	-	y	y	n	-	9.2	2.5	10.4	43	-	8.5	16
60	735044	y	n	-	-	-	-	-	-	-	-	-	-	-	y	-	-	n	y	n	-	-	-	-	-	-	-	-
61	720710	y	n	-	8.4	3.5	9.6	-	-	5	6	80	2.5	-	y	-	-	y	y	y	fever	-	-	-	20	-	6.5	-
62	720710	-	-	-	-	-	-	-	-	-	-	-	-	-	n1	-	-	-	-	-	-	-	-	-	-	-	-	-
63	728676	y	y	joint pains	11.5	3	12.7	-	-	9	12	250	-	-	y	-	n	y	y	n	-	8	3	8.8	-	20	-	-
64	723902	y	n	-	9.4	3	10.4	-	-	-	-	-	-	-	y	-	-	-	-	-	-	-	-	-	-	-	-	-
65	724002	n	y	uti	-	-	-	-	-	-	-	-	5	-	y	-	-	y	y	n	-	-	-	-	-	-	-	-
66	615991	y	n	-	9	2.5	10.2	-	-	6	8.5	140	0.8	-	y	-	-	y	y	y	ugi bleed	-	-	-	-	-	6	-
67	729399	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
68	731537	-	-	-	-	-	-	-	-	-	-	-	-	-	n1	-	-	-	-	-	-	-	-	-	-	-	-	-
69	683750	-	-	-	-	-	-	-	-	-	-	-	-	-	n1	-	-	-	-	-	-	-	-	-	-	-	-	-
70	739803	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
71	736862	y	y	edema	11	3.6	11.8	114	-	10.5	9	340	4.5	-	y	-	-	y	y	y	dec urine output	10.4	2.6	11.5	-	-	-	-
72	56701	y	n	-	11.5	3	12.3	-	-	9	9	2	-	-	y	-	n	n	y	n	-	-	-	-	-	-	-	-
73	699324	y	n	-	9	4	9.8	86	-	-	-	-	-	-	y	-	-	y	y	n	-	-	-	-	-	-	-	-
74	743426	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
75	342253	y	y	uti	9	3.5	10.2	-	-	5	8	40	-	-	y	-	-	y	n	y	abdominal distension,jaundice	-	2.5	-	12	-	7.5	45
76	715875	-	-	-	-	-	-	-	-	-	-	-	-	-	n1	-	-	-	-	-	-	-	-	-	-	-	-	-
77	740599	n	y	pain lumbar area	11.4	2	13	-	-	4.3	9	130	1.36	-	y	-	-	y	y	y	bedsore	11	2.3	12.3	5.2	-	8.5	126
78	743466	n	y	back pain, drowsy, anorexia	11	3	11.8	-	-	11	7.5	684	5.5	-	y	-	-	y	n	y	fever	-	-	-	20	-	7	654
79	754136	y	n	-	10.5	2.8	11.7	-	-	3.2	7.6	80	0.9	-	y	-	-	y	y	y	fever	9.8	2.8	10.7	4.6	-	7.5	86
80	633010	-	-	-	-	-	-	-	-	-	-	-	-	-	n1	-	-	-	-	-	-	-	-	-	-	-	-	-
81	764175	y	n	-	9	4	9	-	-	-	-	-	-	-	y	-	n	n	y	n	-	9	-	-	-	-	-	-
82	766536	y	n	-	9	2.6	10.1	-	-	-	-	-	-	-	y	-	-	n	y	n	-	-	-	-	-	-	-	-
83	736862	n	n	-	11	3.6	11.3	89	63	-	-	-	-	-	y	-	-	y	y	n	-	10	3	10.8	8	-	10.5	350
84	765542	-	-	-	-	-	-	-	-	-	-	-	-	-	n1	-	-	-	-	-	-	-	-	-	-	-	-	-
85	772868	y	n	-	8	3.5	8.4	-	-	8	10	250	1.6	-	y	-	-	n	y	n	-	8.5	4	8.5	6	-	10.5	250
86	774306	y	n	-	7.5	3	8.3	-	52	8.6	10.5	194	0.8	-	y	-	y	n	y	n	-	8	3	8.8	6.5	-	9	200
87	787977	y	n	-	-	-	-	-	-	-	-	-	-	-	y	-	-	y	y	y	fatigue	-	-	-	-	-	-	-
88	759641	y	n	-	9	3	9.8	-	-	-	-	-	3.2	-	y	-	-	n	y	n	-	-	-	-	-	-	-	-
89	765592	y	n	-	9.4	2.8	10.3	-	-	8.6	8.5	120	0.8	-	y	-	-	n	y	n	-	-	-	-	-	-	9	-
90	768925	y	n	-	8.2	4	8.2	-	-	-	10	-	-	-	y	-	-	n	y	n	-	-	-	-	-	-	-	-
91	67452	n	y	depression	8.7	2	11.5	-	-	-	11.6	-	-	-	y	-	-	y	y	n	-	-	-	-	9.6	-	10.5	200
92	704957	y	n	-	-	-	-	-	-	-	-	-	0.2	-	y	-	-	n	y	n	-	-	-	-	6	-	10	98
93	736862	n	y	uti,pain abdomen	8.7	3.5	9	-	-	-	9	-	6.7	-	y	-	-	y	y	n	-	-	-	-	8	-	9.5	265
94	770578	n	y	drowsy	8.7	2.3	9.3	-	-	-	9	-	0.9	-	y	-	-	y	y	y	anorexia	9.5	2.3	10.8	13.2	-	8.5	220
95	770240	y	n	-	-	-	-	-	-	-	10	-	3.4	-	y	-	-	y	n	y	sob	-	-	-	-	-	8	-
96	688217	y	n	-	9.2	3	10	-	-	-	10	-	-	-	y	-	-	n	y	n	-	9.8	2.6	10.1	-	-	-	-
97	769542	n	n	-	9	2.8	9.9	-	-	-	-	-	8	-	y	-	-	y	n	n	-	-	-	-	-	-	-	-

sr no	mrd	3month creatinine	3month vit d	3month alive	3month loss to f/u	3month interval parathyroidectomy
1	657560	-	-	n1	-	-
2	620678	-	-	y	-	-
3	622323	4	-	y	-	-
4	642273	-	-	y	-	-
5	653016	2.8	-	y	-	-
6	652324	-	-	y	-	-
7	634367	-	-	y	-	-
8	619369	-	-	y	-	-
9	479659	-	-	n1	-	-
10	507990	5.6	-	y	-	-
11	114141	-	-	y	-	-
12	661028	-	-	n1	-	-
13	481154	-	-	y	-	-
14	661793	-	86	y	-	-
15	534702	-	-	y	-	-
16	637317	-	-	y	-	-
17	660678	-	-	y	-	-
18	678181	-	-	n1	-	-
19	471657	-	-	n1	-	-
20	544686	-	-	y	-	-
21	547171	0.6	-	y	-	-
22	699422	0.9	-	y	-	-
23	685762	-	-	y	-	-
24	390146	-	-	y	-	-
25	696214	-	-	y	-	-
26	689657	-	-	y	-	-
27	688609	-	-	y	-	n
28	688263	-	-	y	-	-
29	549787	-	-	y	-	-
30	884054	-	-	y	-	-
31	681615	1.2	-	y	-	-
32	681960	1.1	-	y	-	-
33	608658	0.6	-	y	-	-
34	704263	-	-	y	-	-
35	616466	-	-	y	-	-
36	684353	-	-	y	-	-
37	710294	-	-	y	-	-
38	701237	-	-	y	-	-
39	704363	1.2	-	y	-	-
40	714668	-	-	-	-	-
41	714055	-	-	y	-	-
42	709161	2.5	-	y	-	-
43	705170	4.8	-	y	-	-
44	704346	8.4	-	y	-	-
45	701197	-	-	y	-	-
46	705939	-	-	y	-	-
47	716065	-	-	-	-	-
48	710294	-	-	y	-	-
49	709534	-	-	y	-	-
50	668636	1.3	-	y	-	-
51	24573	1.5	-	y	-	-
52	274445	0.5	-	y	-	-
53	715876	0.78	-	y	-	-
54	82146	3.5	-	y	-	-
55	703014	-	-	y	-	-
56	688160	0.7	-	y	-	-
57	707264	-	-	y	-	-
58	723943	2	-	y	-	-
59	721990	1.5	-	y	-	-
60	735044	-	-	y	-	-
61	720710	5	-	y	-	-
62	730710	-	-	n1	-	-
63	728676	-	-	y	-	y
64	723902	-	-	y	-	-
65	724002	-	-	y	-	-
66	615991	-	-	y	-	-
67	729399	-	-	-	-	-
68	731537	-	-	n1	-	-
69	683750	-	-	n1	-	-
70	739803	-	-	-	-	-
71	736862	5.4	-	y	-	-
72	56701	-	-	y	-	-
73	699324	-	-	y	-	-
74	743426	-	-	-	-	-
75	342253	1.6	-	y	-	-
76	715875	-	-	n1	-	-
77	740599	1.4	-	y	-	-
78	743466	7.2	-	y	-	-
79	754136	1.6	-	y	-	-
80	633010	-	-	n1	-	-
81	764175	-	-	y	-	-
82	766536	-	-	y	-	-
83	736862	1	42	y	-	-
84	765542	-	-	n1	-	-
85	772868	1.5	-	y	-	-
86	774306	-	-	y	-	-
87	787977	-	-	y	-	-
88	759641	-	-	y	-	-
89	765592	-	-	y	-	-
90	768925	-	-	y	-	-
91	67452	0.5	-	y	-	-
92	704957	0.7	-	y	-	-
93	736862	2.5	-	y	-	-
94	770578	8	-	y	-	-
95	770240	8	-	y	-	-
96	688217	-	-	y	-	-
97	769542	10.4	-	y	-	-

sr no	mrd	initials	age	gender	address	urban/ rural	bmi	Gastrointestinal	Renal	Neurological	Generalised	Bony	nausea	duration	vomiting	duration	anorexia	duration	weight loss	value	duration	constipation	duration	abdominal pain	duration	dyspepsia	duration	renal stone	duration	polyuria	duration	nocturia	duration	bony pain	duration	fracture	duration	fatigue	duration
98	768710	tr	65	male	ludhiana	urban	23.8	y	n	y	y	n	y	7	n	0	y	120	y	5	120	n	0	n	0	n	0	n	0	n	0	n	0	n	0	n	0	y	60
99	758074	ss	70	male	barnala	urban	22	y	n	n	y	n	y	60	n	0	y	90	y	5	60	n	0	y	20	n	0	n	0	n	0	n	0	n	0	n	0	y	20
100	483498	cr	56	female	vpo kaloh,una	rural	22	y	n	n	y	y	y	14	n	0	y	120	n	6	120	n	0	y	5	n	0	n	0	n	0	n	0	y	14	y	14	y	150
101	772868	js	60	female	vpo pakki,jamnagar	rural	27	y	n	y	y	n	n	0	n	0	n	0	y	5	120	y	5	n	0	n	0	n	0	n	0	n	0	n	0	n	0	y	60
102	937061	sk	70	female	ludhiana	urban	19	y	n	y	y	n	y	180	y	180	y	180	y	10	180	n	0	n	0	n	0	n	0	n	0	n	0	n	0	n	0	y	180
103	961780	gk	43	female	ludhiana	urban	29	y	n	n	y	n	n	0	n	0	n	0	y	1.5	60	n	0	y	60	n	0	n	0	n	0	n	0	n	0	n	0	y	60
104	794384	rk	63	female	ludhiana	urban	20.6	y	n	n	y	n	y	15	n	0	y	30	y	5	30	n	0	n	0	n	0	n	0	n	0	n	0	n	0	n	0	y	7
105	800496	sk	34	male	bhatinda	urban	26.6	y	n	n	y	n	y	30	y	30	y	30	y	5	60	n	0	y	30	y	30	n	0	n	0	n	0	n	0	n	0	y	15
106	797701	nr	35	female	ludhiana	urban	22.4	y	n	n	n	n	n	0	n	0	n	0	n	0	0	n	0	y	15	y	15	n	0	n	0	n	0	n	0	n	0	n	0
107	784819	sl	58	male	ferozepur	urban	25.2	y	n	n	y	y	y	3	y	3	y	150	n	5	150	n	0	n	0	n	0	n	0	n	0	n	0	y	60	y	60	y	120
108	795785	sd	72	female	chamba	urban	22.2	y	y	n	y	n	y	2	y	2	y	30	n	0	0	n	0	n	0	n	0	n	0	y	5	y	5	n	0	n	0	y	15
109	803042	ns	50	male	malikpur,j and k	rural	25	y	y	y	y	y	y	7	n	0	y	14	n	0	0	n	0	y	7	n	0	n	0	y	7	y	7	y	30	n	0	y	7
110	715766	rk	49	male	jalandhar	urban	16.6	y	n	y	y	n	n	0	n	0	y	150	y	10	180	n	0	n	0	n	0	n	0	n	0	n	0	n	0	n	0	n	0
111	801466	am	54	male	ludhiana	urban	21.6	y	n	y	n	n	y	1	y	1	n	0	n	0	0	n	0	y	1	n	0	n	0	n	0	n	0	n	0	n	0	n	0
112	757988	rg	82	male	ludhiana	urban	25	y	n	y	y	n	n	0	n	0	y	15	n	0	0	n	0	n	0	n	0	n	0	n	0	n	0	n	0	n	0	y	180
113	806528	pm	54	male	gurdaspur	urban	25.3	y	n	n	y	n	n	0	n	0	y	30	y	6	60	n	0	n	0	n	0	n	0	n	0	n	0	n	0	n	0	y	60
114	78322	gs	67	male	ludhiana	urban	22.1	y	n	y	n	y	y	14	y	14	y	14	n	0	0	n	0	n	0	n	0	n	0	n	0	n	0	y	0	n	0	n	0
115	800002	ba	74	male	ludhiana	urban	18.5	y	n	y	y	y	y	7	y	7	y	180	y	5	240	n	0	n	0	n	0	n	0	n	0	n	0	y	180	y	60	y	180
116	808782	kk	50	female	jalandhar	urban	28	y	n	n	y	n	y	30	y	30	y	30	y	1	30	n	0	n	0	y	30	n	0	n	0	n	0	n	0	n	0	n	0
117	758074	ss	70	male	barnala	urban	28.5	y	n	n	y	n	y	4	y	4	y	4	y	2	60	n	0	n	0	n	0	n	0	n	0	n	0	n	0	n	0	n	0
118	808924	a	44	female	vpo darsopur, j and k	rural	26	n	y	n	n	y	n	0	n	0	n	0	n	0	0	n	0	n	0	n	0	n	0	y	30	y	30	y	30	n	0	n	0
119	813129	kd	73	female	vpo dharha, j and k	rural	22.2	y	n	n	n	y	y	15	y	15	y	20	n	0	0	y	20	n	0	n	0	n	0	n	0	n	0	n	0	y	60	y	60	n	0
120	120235	jk	39	female	ludhiana	urban	26.5	y	y	n	n	n	y	7	y	7	n	0	n	0	0	n	0	y	10	n	0	y	150	n	0	n	0	n	0	n	0	n	0
121	815300	hr	64	male	gurdaspur	urban	24.4	y	n	y	y	n	y	4	n	0	y	30	n	0	0	n	0	n	0	n	0	n	0	n	0	n	0	n	0	n	0	y	90
122	806598	mk	60	female	nawashahar	urban	21.7	y	n	n	n	n	y	3	y	3	y	3	n	0	0	n	0	y	3	n	0	n	0	n	0	n	0	n	0	n	0	n	0
123	202821	nd	70	female	sangrur	urban	34.8	y	n	n	n	n	y	120	n	0	y	120	n	0	0	y	120	y	20	y	120	n	0	n	0	n	0	n	0	n	0	n	0
124	676387	dk	71	female	sangrur	urban	28	y	n	n	n	n	y	60	y	60	y	60	n	0	0	n	0	n	0	y	60	n	0	n	0	n	0	n	0	n	0	n	0
125	816494	ak	60	male	hoshiarpur	urban	21	y	n	n	y	y	y	30	n	0	y	30	y	10	180	n	0	n	0	n	0	n	0	n	0	n	0	n	0	y	60	y	20	n	0
126	815505	ak	60	male	bhatinda	urban	26.3	y	n	n	n	n	n	0	n	0	n	0	n	0	0	n	0	n	0	y	30	n	0	n	0	n	0	n	0	n	0	n	0
127	816596	nl	37	male	ludhiana	urban	28	y	n	n	n	n	y	4	y	4	y	4	n	0	0	n	0	y	4	n	0	n	0	n	0	n	0	n	0	n	0	n	0
128	518576	sd	60	female	hoshiarpur	urban	21.5	y	n	n	y	y	y	45	n	0	y	60	y	4	60	n	0	n	0	n	0	n	0	n	0	n	0	n	0	y	60	n	0	y	60
129	868046	sk	56	female	fatehgarh sahib	rural	26.6	n	n	n	y	y	n	0	n	0	n	0	y	5	120	n	0	n	0	n	0	n	0	n	0	n	0	n	0	y	30	n	0	y	30
130	867305	ks	48	male	ludhiana	urban	29	n	n	y	y	n	n	0	n	0	n	0	n	0	8	90	n	0	n	0	n	0	n	0	n	0	n	0	n	0	n	0	y	60
131	487433	bk	47	female	ludhiana	urban	24.4	y	n	y	n	n	y	15	y	15	y	15	n	0	0	n	0	n	0	n	0	n	0	n	0	n	0	n	0	n	0	n	0
132	860301	js	45	male	vpo sadhupatti, mansa	rural	27.3	y	y	n	n	n	y	5	n	0	n	0	n	0	0	n	0	n	0	y	5	n	0	n	0	y	365	n	0	y	365	n	0	n	0
133	870491	nd	56	female	fatehgarh sahib	rural	26.6	y	n	n	y	n	y	15	y	15	n	0	y	4	30	n	0	y	7	n	0	n	0	n	0	n	0	n	0	n	0	y	30
134	870616	ds	65	male	vpo jargari,ludhiana	rural	27.3	y	n	n	n	n	y	3	y	3	y	3	n	0	0	n	0	n	0	y	3	n	0	n	0	n	0	n	0	n	0	n	0
135	870526	as	57	male	vpo qidhar pindi,jalandhar	rural	28	y	n	n	n	y	y	30	y	30	y	90	n	0	0	n	0	n	0	n	0	n	0	n	0	n	0	n	0	y	90	n	0
136	868092	ss	40	male	vpo qulabqarh,bhatinda	rural	26.5	y	y	n	n	n	y	7	y	7	n	0	n	0	0	n	0	n	0	y	7	n	0	n	0	y	3	n	0	n	0	n	0	n	0
137	730279	rs	43	male	khanna	urban	25.4	y	n	n	n	n	y	5	n	0	n	0	n	0	0	n	0	n	0	y	5	n	0	n	0	n	0	n	0	n	0	n	0
138	873183	rg	49	male	bhatinda	urban	22.2	y	y	n	n	n	n	0	n	0	n	0	n	0	0	n	0	n	0	y	90	n	0	y	90	n	0	y	90	n	0	n	0	n	0
139	863874	pk	47	male	sohawal,gurdaspur	rural	27.2	y	n	n	y	n	y	60	n	0	y	60	n	0	0	n	0	n	0	n	0	n	0	n	0	n	0	n	0	n	0	n	0	y	0
140	874227	tcs	83	male	kathua, j&k	urban	19.5	y	y	n	y	y	y	150	y	150	y	365	n	5	210	y	120	n	0	n	0	n	0	y	30	n	0	y	150	y	150	y	365
141	874222	gk	65	female	vpo atalgarh,hoshiarpur	rural	22.2	y	n	y	n	n	y	2	n	0	n	0	n	0	0	n	0	y	2	n	0	n	0	n	0	n	0	n	0	n	0	n	0	n	0
142	874605	pw	78	female	sangrur	urban	23.4	y	n	n	n	n	y	15	n	0	y	15	n	0	0	n	0	n	0	y	25	y	15	n	0	n	0	n	0	n	0	n	0	n	0
143	837754	bk	47	male	vpo faizgarh,khanna	urban	22.2	y	n	n	n	n	y	10	n	0	y	10	n	0	0	n	0	n	0	y	10	n	0	n	0	n	0	n	0	n	0	n	0	n	0
144	839395	ss	76	male	nawashahar	urban	22.2	y	n	n	n	n	y	20	n	0	y	20	n	0	0	n	0	n	0	n	0	n	0	n	0	n	0	n	0	n	0	n	0	n	0
145	648486	bs	44	male	patiala	urban	28	y	n	n	n	n	y	3	y	3	y	3	n	0	0	n	0	n	0	y	3	n	0	n	0	n	0	n	0	n	0	n	0	n	0
146	639722	ss	69	male	moga	urban	27.3	y	n	n	y	n	n	0	n	0	y	60	n	0	0	n	0	n	0	n	0	n	0	n	0	n	0	n	0	n	0	n	0	y	180
147	840633	gk	47	male	ludhiana	urban	26.6	y	n	n	n	n	y	5	y	5	y	5	n	0	0	n	0	y	5	n	0	n	0	n	0	n	0	n	0	n	0	n	0	n	0
148	681164	js	51	male	jarnala, ludhiana	rural	22	y	n	n	y	n	y	60	y	60	y	60	y	10	180	n	0	n	0	n	0	n	0	n	0	n	0	n	0	n	0	n	0	n	0
149	736950	ps	55	female	ludhiana	urban	22	y	n	n	n	n	n	0	n	0	y	120	n	0	0	n	0	y	60	n	0	n	0	n	0	n	0	n	0	n	0	n	0	n	0
150	844350	gs	62	male	bhatinda	urban	19	y	n	y	n	n	y	14	y	14	y	14	n	0	0	n	0	n	0	n	0	n	0	n	0	n	0	n	0	n	0	n	0	n	0
151	838640	mk	53	male	kokri,moga	rural	27	y	n	n	n	n	y	15	y	15	n	0	n	0	0	n	0	y	15	n	0	n	0	n	0	n	0	n	0	n	0	n	0	n	0
152	457005	gk	62	female	vpo malsian,jalandhar	rural	22	y	n	n	n	n	y	7	n	0	y	7	n	0	0	n	0	n	0	y	7	n	0	n	0	n	0	n	0	n	0	n	0	n	0
153	93021	mr	48	female	jalandhar	urban	22	y	n	n	n	n	n	0	y	5	y	5	n	0	0	n	0	n	0	y	5	n	0	n	0	n	0	n	0	n	0	n	0	n	0
154	582848	gs	38	male	ludhiana	urban	27	y	n	n	n	y	n	5	y	5	n	0	n	0	0	n	0	n	0	n	0	n	0	n	0	n	0	n	0	y	5	n	0	n	0
155	834904	ak	61	male	gurdaspur	urban	31.2	y	n	n	n	n	y	60	n	0	y	20	n	0	0	n	0	n	0	n	0	n	0	n	0	n	0	n	0	n	0	n	0	n	0
156	824096	rr	72	female	ludhiana	urban	20	y	n	y	y	n	n	0	n	0	y	365	y	8	180	n	0	n	0	n	0	n	0	n	0	n	0	n	0	n	0	n	0	n	0
157	800091	sd	69	female	vpo ghoral,kangra	rural	22	y	n	y	n	n	n	0	n	0	y	3	n	0	0	n	0	n	0	n	0	n	0	n	0	n	0	n	0	n	0	n	0	n	0
158	884091	js	38	male	vpo sekhwan,gurdaspur	rural	27	y	n	n	n	n	y	6	y	6	n	0	n	0	0	n	0	y	6	n	0	n	0	n	0	n	0	n	0	n	0	n	0	n	0
159	746917	nk	56	female	vpo dolo nagar nangal,amritsar	rural	27	y	n	n	y	n	y	30	n	0	y	30	n	0	0	n	0	n	0	n	0	n	0	n	0	n	0	n	0	n	0	y	0	n	0
160	776677	k	18	female	jalandhar	urban	23.4	y	n	n	n	n	y	3	y	3	y	3	n	0	0	n	0	y	3	n	0	n	0	n	0	n	0	n	0	n	0	n	0	n	0
161	836002	bs	55	male	vpo padori,jaalandhar	rural	27	y	n	n	y	n	n	0	n	0	y	60	y	4	60	n	0	n	0	n	0	n	0	n	0	n	0	n	0	n	0	n	0	n	0
162	849333	bk	75	female	ludhiana	urban	22	y	n	y	y	n	n	0	n	0	y	30	n	0	0	n	0	n	0	n	0	n	0	n	0	n	0	n	0	n	0	n	0	y	14
163	851055	ss	60	male	vpo bhucho kalan, bhatinda	rural	26.6	y	n	n	n	n	n	0	n	0	y	30	n	0	0	n	0	n	0	n	0	n	0	n	0	n	0	n	0	n	0	n	0	n	0
164	845069	s	56	female	jalandhar	urban	27	y	n	n	n	y	y	3	y	3	n	0	n	0	0	n	0	n	0	n	0	n	0	n	0	n	0	n	0	y	120	n	0	n	0
165	531317	as	20	male	ludhiana	urban	22	n	n	n	y	y	n	0	n	0	n	0	n	0	0	n	0	n	0	n	0	n	0	n	0	n	0	n	0	y	150	y	150	y	90
166	849455	ls	52	male	vpo mohanpur,ludhiana	rural	25	y	n	n	n	y	y	30	y	30	y	30	n	0	0	n	0	n	0	n	0	n	0	n	0	n	0	n	0	y	60	n	0	n	0
167	383444	ss	60	female	ludhiana	urban	19	y	y	n	y	n	n	0	n	0	y	30	y	10	240	n	0	y	10	y	180	n	0	y	15	y	15	n	0	n	0	n	0	n	0
168	849152	rk	53	female	ludhiana	urban	20	y	n	y	n	n	y	6	y	6	y	6	n	0	0	n	0	n	0	n	0	n	0	n	0	n	0	n	0	n	0	n	0	n	0
169	853509	id	80	female	bhatinda	urban	22	y	n	n	y	y	y	15	n	0	y	180	n	0	0	n	0	n	0	n	0	n	0	n	0	n	0	n	0	y	15	n	0	y	15
170	856156	hk	54	female	ludhiana	urban	20	y	y	n	y	n	n	0	n	0	y	150	y	8	150	n	0	n	0	n	0	n	0	n	0	n	0	n	0	n	0	n	0	y	365
171	36273	pk	78	male	amritsar	urban	25	y	n	n	n	n	y	5	y	5	y	5	n	0	0	n	0	n	0	n	0	n	0	n	0	n	0	n	0	n	0	n	0	n	0
172	897187	fcq	75	male	bhatinda	urban	24	y	n	n	n	y	n	0	n	0	y	4	n	0	0	n	0	n	0	n	0	n	0	n	0	n	0	n	0	y	45	n	0	n	0
173	892695	ms	21	male	vpo kalu,batala	rural	18	y	n	y	n	n	y	7	y	7	y	90	n	0	0	n	0	n	0	n	0	n	0	n	0	n	0	n	0	n	0	n	0	n	0
174	383444	ss	60	female	ludhiana	urban	21	y	n	y	y	n	y	4	y	4	y	4	y	4	180	n	0	n	0	n	0	n	0	n	0	n	0	n	0	n	0	n	0	n	0
175	907933	mk	60	female	jammu	urban	22	y	n	n	n	y	y	3	y	3	y	3	n	0	0	n	0	n	0	n	0	n	0	n	0	n	0	n	0	y	90	n	0	n	0
176	150185	mj	48	female	sangrur	urban	24	y	n	n	n	y	y	10	y	10	y	30	n	0	0	n	0	n	0	n	0	y	30	n	0	n	0	n	0	y	30	n	0	n	0
177	902832	i	60	male	vpo kindi, j and k	rural	25	y	n	y	y	n	n	0	n	0	y	20	y	2	20	n	0	n	0	n	0	n	0	n	0	n	0	n	0	n	0	y	6
178	888867	js	57	male	vpo,baran,patiala	rural	27	y	n	n	n	y	n	0	y	1	n	0	n	0	0	n	0	n	0	n	0	n	0	n	0	n	0	n	0	y	15	n	0	n	0
179	891164	gs	39	male	vpo allowal,taran taran,amritsar	rural	24	y	n	n	n	y	n	0	n	0	y	60	n	0	0	n	0	n	0	n	0	n	0	n	0	n	0	n	0	y	60	n	0	n	0
180	881651	ak	62	female	fatehgarh sahib	rural	28	y	n	n	y	y	n	0	n	0	y	90	y	6	90	n	0	n	0	n	0	n	0	n	0	n	0	n	0	y	90	n	0	y	90
181	874012	ns	53	male	ferozepur	urban	24	y	n	n	y	n	y	15	n	0	y	180	n	0	0	y	5	n	0	n	0	n	0	n	0	n	0	n	0	n	0	y	180
182	666086	sk	69	male	mansa	urban	26	y	y	n	n	y	y	5	y	5	n	0	n	0	0	y	30	n	0	n	0	n	0	y	120	y	120	y	150	n	0	n	0
183	873183	rg	49	male	bhatinda	urban	28	y	y	n	y	n	y	0	y	3	y	150	n	0	0	n	0	n	0	n	0	y	365	n	0	n	0	y	365	n	0	n	0
184	876104	kk	59	female	vpo rurka khurd, jalandhar	rural	25	y	y	n	n	n	n	0	n	0	y	90	n	10	90	n	0	n	0	n	0	n	0	y	90	y	90	n	0	n	0	n	0
185	882709	js	55	female	sangrur	urban	20	n	n	n	y	n	n	150	n	150	n	150	n	0	0	n	0	n	0	n	0	n	0	n	0	n	0	n	0	n	0	y	180
186	849332	bk	74	female	karnal	urban	21	y	n	n	y	y	n	0	n	0	y	7	n	0	0	n	0	n	0	n	0	n	0	n	0	n	0	y	0	n	0	y	7
187	759614	ms	79	male	ludhiana	urban	26	n	n	y	n	n	n	0	n	0	n	0	n	0	0	n	0	n	0	n	0	n	0	n	0	n	0	n	0	n	0	n	0	n	0
188	893454	hk	30	female	vpo deon, bhatinda	urban	23	y	y	n	n	n	y	30	n	0	y	30	n	0	0	n	0	y	15	y	30	y	90	y	90	y	90	n	0	n	0	n	0	n	0
189	568835	ss	73	male	ludhiana	urban	25	y	n	y	y	n	y	15	y	15	n	0	n	0	0	y	30	y	7	n	0	n	0	n	0	n	0	n	0	n	0	n	0	y	15
190	787977	t	61	male	pathankot	urban	25	y	n	n	y	n	n	0	n	0	y	60	y	10	150	n	0	n	0	n	0	n	0	n	0	n	0	n	0	n	0	y	150
191	848737	sd	70	female	kangra	urban	22	n	n	y	y	y	n	0	n	0	n	0	n	4	90	n	0	n	0	n	0	n	0	n	0	n	0	n	0	y	0	n	0	y	0

sr no	mrd	altered sensorium	duration	depression	duration	vegetarian	smoker y/n	smoker duration(y)	smoker occasional	smoker reform yr	alcoholic y/n	alcoholic duration(y)	alcoholic occasional	alcoholic reformed (y)	menses regular	post menopausal	lithium y/n	lithium dose	lithium duration	lithium frequency	anti estrogen y/n	anti estrogen dose	anti estrogen duration	anti estrogen frequency	thiazide y/n	thiazide dose	thiazide duration	thiazide frequency	vit d supplement y/n	vit d supplement dose	vit d supplement duration	vit d supplement frequency	dose per day	ca supplement y/n
98	768710	y	4	n	0	n	y	15	n	y	n	-	-	-	na	na	n	0	0	0	n	0	0	0	n	0	0	0	n	0	0	0	-	n
99	758074	n	0	n	0	y	y	20	n	y	y	10	y	y	na	na	n	0	0	0	n	0	0	0	n	0	0	0	n	0	0	0	-	n
100	483498	n	0	n	0	y	n	0	-	-	n	-	-	-	na	y	n	0	0	0	n	0	0	0	n	0	0	0	n	0	0	0	-	n
101	772868	y	4	n	0	n	n	0	-	-	-	-	-	-	na	y	n	0	0	0	n	0	0	0	n	0	0	0	n	0	0	0	-	n
102	937061	y	7	n	0	y	n	0	-	-	n	-	-	-	na	y	n	0	0	0	n	0	0	0	n	0	0	0	y	0.25mg	180	od	-	y
103	961780	n	0	n	0	y	n	0	-	-	n	-	-	-	y	na	n	0	0	0	n	0	0	0	n	0	0	0	n	0	0	0	-	n
104	794384	n	0	n	0	y	n	0	-	-	n	-	-	-	na	y	n	0	0	0	n	0	0	0	n	0	0	0	y	600000iu	180	once a month	-	y
105	800496	n	0	n	0	y	n	0	-	-	y	5	y	n	na	na	n	0	0	0	n	0	0	0	n	0	0	0	n	0	0	0	-	n
106	797701	n	0	n	0	y	n	0	-	-	n	-	-	-	y	na	n	0	0	0	n	0	0	0	n	0	0	0	n	0	0	0	-	n
107	784819	n	1	n	0	n	y	10	y	n	n	-	-	-	na	na	n	0	0	0	n	0	0	0	n	0	0	0	y	600000iu	60	once a week	85,714	y
108	795785	n	0	n	0	y	n	0	-	-	n	-	-	-	na	y	n	0	0	0	n	0	0	0	n	0	0	0	y	-	-	-	-	y
109	803042	y	2	n	0	y	n	0	-	-	n	-	-	-	na	na	n	0	0	0	n	0	0	0	n	0	0	0	n	0	0	0	-	n
110	715766	n	0	y	30	y	y	20	n	n	n	-	-	-	na	na	n	0	0	0	n	0	0	0	n	0	0	0	n	0	0	0	-	n
111	801466	y	1	n	0	n	n	0	-	-	n	-	-	y	na	na	n	0	0	0	n	0	0	0	n	0	0	0	n	0	0	0	-	n
112	757988	y	15	n	0	n	n	0	-	-	n	-	-	-	na	na	n	0	0	0	n	0	0	0	n	0	0	0	y	2000iu	60	od	-	y
113	806528	n	0	n	0	n	y	10	y	y	n	-	-	-	na	na	n	0	0	0	n	0	0	0	n	0	0	0	n	0	0	0	-	n
114	78322	y	10	n	0	n	n	0	-	-	n	-	-	-	na	na	n	0	0	0	n	0	0	0	n	0	0	0	y	60000iu	>365	od	60,000	y
115	800002	y	3	n	0	n	n	0	-	-	n	-	-	-	na	na	n	0	0	0	n	0	0	0	n	0	0	0	y	2000iu	60	od	-	y
116	808782	n	0	n	0	y	n	0	-	-	n	-	-	-	na	y	n	0	0	0	n	0	0	0	n	0	0	0	n	0	0	0	-	n
117	758074	n	0	n	0	n	n	0	-	-	y	5	y	y	na	na	n	0	0	0	n	0	0	0	n	0	0	0	n	0	0	0	-	n
118	808924	n	0	n	0	n	n	0	-	-	n	-	-	-	y	na	n	0	0	0	n	0	0	0	n	0	0	0	n	0	0	0	-	n
119	813129	n	4	n	0	y	n	0	-	-	n	-	-	-	na	y	n	0	0	0	n	0	0	0	n	0	0	0	y	600000iu	45	twice a week	1,71,428	y
120	120235	n	0	n	0	y	n	0	-	-	n	-	-	-	y	na	n	0	0	0	n	0	0	0	n	0	0	0	n	0	0	0	-	n
121	815300	y	2	n	0	n	n	0	-	-	n	-	-	-	na	na	n	0	0	0	n	0	0	0	n	0	0	0	y	0.25mg	30	od	-	y
122	806598	n	0	n	0	n	n	0	-	-	n	-	-	-	na	y	n	0	0	0	n	0	0	0	n	0	0	0	n	0	0	0	-	y
123	202821	n	0	n	0	y	n	0	-	-	n	-	-	-	na	y	n	0	0	0	n	0	0	0	y	12.5mg	>365	od	y	2000iu	120	od	-	y
124	676387	n	0	n	0	y	n	0	-	-	n	-	-	-	na	y	n	0	0	0	n	0	0	0	n	0	0	0	n	0	0	0	-	n
125	816494	n	0	n	0	y	n	0	-	-	n	-	-	-	na	na	n	0	0	0	n	0	0	0	n	0	0	0	n	0	0	0	-	n
126	815505	n	0	n	0	n	n	0	-	-	y	25	y	n	na	na	n	0	0	0	n	0	0	0	n	0	0	0	n	0	0	0	-	n
127	816596	n	0	n	0	n	n	0	-	-	n	-	-	-	na	na	n	0	0	0	n	0	0	0	n	0	0	0	n	0	0	0	-	n
128	518576	n	0	n	0	y	n	0	-	-	n	-	-	-	na	y	n	0	0	0	n	0	0	0	n	0	0	0	n	0	0	0	-	n
129	868046	n	0	n	0	y	n	0	-	-	n	-	-	-	na	y	n	0	0	0	n	0	0	0	n	0	0	0	y	1000iu	60	od	-	y
130	867305	y	1	n	0	n	n	0	-	-	n	-	-	-	na	na	n	0	0	0	n	0	0	0	n	0	0	0	n	0	0	0	-	n
131	487433	y	1	n	0	y	n	0	-	-	n	-	-	-	na	y	n	0	0	0	n	0	0	0	n	0	0	0	n	0	0	0	-	n
132	860301	n	0	n	0	y	n	0	-	-	n	-	-	-	na	na	n	0	0	0	n	0	0	0	n	0	0	0	n	0	0	0	-	n
133	870491	n	0	n	0	n	n	0	-	-	n	-	-	-	na	y	n	0	0	0	n	0	0	0	n	0	0	0	n	0	0	0	-	n
134	870616	n	0	n	0	n	n	0	-	-	n	-	-	-	na	na	n	0	0	0	n	0	0	0	n	0	0	0	n	0	0	0	-	n
135	870526	n	0	n	0	n	n	0	-	-	y	25	n	n	na	na	n	0	0	0	n	0	0	0	y	12.5mg	180	od	y	600000iu	240	twice a month	40,000	y
136	868092	n	0	n	0	n	n	0	-	-	n	-	-	-	na	na	n	0	0	0	n	0	0	0	n	0	0	0	n	0	0	0	-	n
137	730279	n	0	n	0	n	y	2	y	n	y	5	y	n	na	na	n	0	0	0	n	0	0	0	n	0	0	0	n	0	0	0	-	n
138	873183	n	0	n	0	y	n	0	-	-	n	-	-	-	na	na	n	0	0	0	n	0	0	0	n	0	0	0	n	0	0	0	-	n
139	863874	n	0	n	0	n	n	0	-	-	n	-	-	-	na	na	n	0	0	0	n	0	0	0	n	0	0	0	y	60000iu	180	once a month	60,000	y
140	874227	n	0	n	0	y	n	0	-	-	n	-	-	-	na	na	n	0	0	0	n	0	0	0	n	0	0	0	y	300000iu	150	once a week	42,875	y
141	874222	y	2	n	0	y	n	0	-	-	n	-	-	-	na	y	n	0	0	0	n	0	0	0	n	0	0	0	n	0	0	0	-	n
142	874605	n	0	n	0	n	n	0	-	-	n	-	-	-	na	y	n	0	0	0	n	0	0	0	n	0	0	0	n	0	0	0	-	y
143	837754	n	0	n	0	y	n	0	-	-	n	-	-	-	na	y	n	0	0	0	n	0	0	0	n	0	0	0	n	0	0	0	-	n
144	839395	n	0	n	0	y	n	0	-	-	n	-	-	-	na	y	n	0	0	0	n	0	0	0	n	0	0	0	y	60000iu	120	od	60,000	y
145	648486	n	0	n	0	y	n	0	-	-	n	-	-	-	na	na	n	0	0	0	n	0	0	0	n	0	0	0	n	0	0	0	-	n
146	639722	n	0	n	0	y	n	0	-	-	n	-	-	-	na	na	n	0	0	0	n	0	0	0	n	0	0	0	n	0	0	0	-	n
147	840633	n	0	n	0	n	n	0	-	-	n	-	-	-	na	na	n	0	0	0	n	0	0	0	n	0	0	0	n	0	0	0	-	n
148	681164	n	0	n	0	y	y	30	y	y	y	4	y	y	na	na	n	0	0	0	n	0	0	0	n	0	0	0	n	0	0	0	-	y
149	736950	n	0	n	0	n	n	0	-	-	n	-	-	-	na	y	n	0	0	0	n	0	0	0	n	0	0	0	n	0	0	0	-	y
150	844350	y	7	n	0	y	n	0	-	-	n	-	-	-	na	na	n	0	0	0	n	0	0	0	n	0	0	0	n	0	0	0	-	n
151	838640	n	0	n	0	n	n	0	-	-	y	20	n	n	na	na	n	0	0	0	n	0	0	0	n	0	0	0	n	0	0	0	-	n
152	457005	n	0	n	0	y	n	0	-	-	n	-	-	-	na	y	n	0	0	0	n	0	0	0	n	0	0	0	n	0	0	0	-	n
153	93021	n	0	n	0	n	n	0	-	-	n	-	-	-	na	y	n	0	0	0	n	0	0	0	n	0	0	0	n	0	0	0	-	n
154	582848	n	0	n	0	n	n	0	-	-	n	-	-	-	na	na	n	0	0	0	n	0	0	0	y	12.5mg	180	od	n	0	0	0	-	n
155	834904	n	0	n	0	n	n	0	-	-	n	-	-	-	na	na	n	0	0	0	n	0	0	0	n	0	0	0	n	0	0	0	-	n
156	824096	y	1	n	0	y	n	0	-	-	n	-	-	-	na	y	n	0	0	0	n	0	0	0	n	0	0	0	n	0	0	0	-	n
157	840091	y	1	n	0	y	n	0	-	-	n	-	-	-	na	y	n	0	0	0	n	0	0	0	n	0	0	0	n	0	0	0	-	n
158	884091	n	0	n	0	y	n	0	-	-	n	-	-	-	na	na	n	0	0	0	n	0	0	0	n	0	0	0	n	0	0	0	-	n
159	746917	n	0	n	0	y	n	0	-	-	n	-	-	-	na	y	n	0	0	0	n	0	0	0	n	0	0	0	y	600000iu	>365	od	60,000	y
160	776677	n	0	n	0	y	n	0	-	-	n	-	-	-	y	na	n	0	0	0	n	0	0	0	n	0	0	0	n	0	0	0	-	n
161	836002	n	0	n	0	y	n	0	-	-	n	-	-	-	na	na	n	0	0	0	n	0	0	0	n	0	0	0	n	0	0	0	-	n
162	849333	y	5	n	0	y	n	0	-	-	n	-	-	-	na	y	n	0	0	0	n	0	0	0	n	0	0	0	y	300000iu	>365	once a week	42,875	y
163	851055	n	0	n	0	y	n	0	-	-	n	-	-	-	na	na	n	0	0	0	n	0	0	0	n	0	0	0	n	0	0	0	-	n
164	845069	n	0	n	0	n	n	0	-	-	n	-	-	-	na	y	n	0	0	0	n	0	0	0	n	0	0	0	y	2000iu	365	od	-	y
165	531317	n	0	n	0	n	n	0	-	-	n	-	-	-	na	na	n	0	0	0	n	0	0	0	n	0	0	0	n	0	0	0	-	n
166	849455	n	0	n	0	n	n	0	-	-	n	-	-	-	na	na	n	0	0	0	n	0	0	0	n	0	0	0	y	1000iu	>365	od	-	y
167	383444	n	0	n	0	n	n	0	-	-	n	-	-	-	na	y	n	0	0	0	n	0	0	0	n	0	0	0	n	0	0	0	-	n
168	849152	y	1	n	0	y	n	0	-	-	n	-	-	-	na	y	n	0	0	0	n	0	0	0	n	0	0	0	n	0	0	0	-	y
169	853509	n	0	n	0	y	n	0	-	-	n	-	-	-	na	y	n	0	0	0	n	0	0	0	n	0	0	0	y	250iu	15	od	-	y
170	856156	y	3	n	0	n	n	0	-	-	n	-	-	-	na	y	n	0	0	0	n	0	0	0	n	0	0	0	n	0	0	0	-	n
171	36273	y	3	n	0	n	y	10	y	y	y	5	y	y	na	na	n	0	0	0	n	0	0	0	n	0	0	0	y	600000iu	190	once a month	40000	y
172	897187	n	0	n	0	y	n	0	-	-	n	-	-	-	na	na	n	0	0	0	n	0	0	0	n	0	0	0	n	0	0	0	-	n
173	892695	y	7	n	0	n	n	0	-	-	n	-	-	-	na	na	n	0	0	0	n	0	0	0	n	0	0	0	n	0	0	0	-	n
174	383444	y	3	n	0	y	n	0	-	-	n	-	-	-	na	y	n	0	0	0	n	0	0	0	n	0	0	0	n	0	0	0	-	n
175	907933	n	0	n	0	y	n	0	-	-	n	-	-	-	na	y	n	0	0	0	n	0	0	0	n	0	0	0	y	60000iu	90	once a week	-	y
176	150185	n	0	n	0	y	n	0	-	-	n	-	-	-	na	y	n	0	0	0	n	0	0	0	n	0	0	0	n	0	0	0	-	n
177	902832	y	6	n	0	y	n	0	-	-	n	-	-	-	na	na	n	0	0	0	n	0	0	0	n	0	0	0	n	0	0	0	-	n
178	888867	n	0	n	0	y	n	0	-	-	n	-	-	-	na	na	n	0	0	0	n	0	0	0	n	0	0	0	n	0	0	0	-	n
179	891164	n	0	n	0	n	n	0	-	-	n	-	-	-	na	na	n	0	0	0	n	0	0	0	n	0	0	0	n	0	0	0	-	n
180	881651	n	0	n	0	n	n	0	-	-	n	-	-	-	na	y	n	0	0	0	n	0	0	0	n	0	0	0	y	60000iu	90	once a week	-	y
181	874012	n	0	n	0	y	n	0	-	-	n	-	-	-	na	na	n	0	0	0	n	0	0	0	n	0	0	0	n	0	0	0	-	n
182	666086	n	0	n	0	y	n	0	-	-	n	-	-	-	na	na	n	0	0	0	n	0	0	0	n	0	0	0	n	0	0	0	-	n
183	873183	n	0	n	0	y	n	0	-	-	n	-	-	-	na	na	n	0	0	0	n	0	0	0	n	0	0	0	n	0	0	0	-	n
184	876104	n	0	n	0	y	n	0	-	-	n	-	-	-	na	y	n	0	0	0	n	0	0	0	n	0	0	0	n	0	0	0	-	n
185	882709	n	0	n	0	n	n	0	-	-	n	-	-	-	y	na	n	0	0	0	n	0	0	0	n	0	0	0	n	0	0	0	-	n
186	849332	n	0	n	0	n	n	0	-	-	n	-	-	-	na	y	n	0	0	0	n	0	0	0	n	0	0	0	y	600000iu	>365	once a week	85,714	y
187	759614	y	1	n	0	n	n	0	-	-	y	20	n	y	na	na	n	0	0	0	n	0	0	0	n	0	0	0	n	0	0	0	-	n
188	893454	n	0	n	0	y	n	0	-	-	n	-	-	-	y	na	n	0	0	0	n	0	0	0	n	0	0	0	n	0	0	0	-	n
189	568835	y	3	n	0	n	n	0	-	-	y	45	n	y	na	na	n	0	0	0	n	0	0	0	n	0	0	0	n	0	0	0	-	n
190	787977	n	0	n	0	n	n	0	-	-	n	-	-	-	na	na	n	0	0	0	n	0	0	0	n	0	0	0	n	0	0	0	-	n
191	848737	y	4	n	0	y	n	0	-	-	n	-	-	-	na	y	n	0	0	0	n	0	0	0	n	0	0	0	y	60000iu	>365	once a month	60,000	y

sr no	mrd	ca supplement dose	ca supplement duration	ca supplement frequency	Past History y/n	DM	HTN	CKD	CAD	CLD	asthma/ COPD	arthritis	cancer	ca bladder	ca penis	ca ovary	ca cervix	ca esophagus	HCC	ca gb and bile duct	ca head and neck	multiple myeloma	breast	RCC	ca lung	lymphoma	TB	sarcoidosis	recurrent pancreatitis	hypothyroidism	hyperthyroidism	other	past treatment	hb(g/dl) adm	hb(g/dl) dis	TLC adm	TLC dis	platelets adm	platelets dis	urea adm
98	768710	0	0	0	n	n	n	n	n	n	n	n	n	n	n	n	n	n	n	n	n	n	n	n	-	n	n	n	-	-	-	-	att	10.5	9.9	13.6	16.7	370	310	150
99	758074	0	0	0	n	n	n	n	n	n	n	n	n	n	n	n	n	n	n	n	n	n	n	n	-	n	n	n	-	-	-	-	-	11	10	5.6	7.4	81	100	107
100	483498	0	0	0	y	n	n	n	n	n	n	n	y	n	n	n	n	n	n	n	n	y	n	n	n	n	n	n	-	-	-	-	-	6	6.8	2.6	2.4	85	110	93
101	772868	0	0	0	y	n	y	n	n	n	n	n	y	n	n	n	n	n	n	n	n	n	y	n	n	n	n	n	-	-	-	-	post mrm	9.2	9.5	9	9.5	345	330	69
102	937061	500mg	180	od	y	y	y	n	n	n	n	n	y	n	n	y	n	n	n	n	n	n	n	n	n	n	n	n	-	-	-	-	post hysterectomy and b/l soo	8.8	8	29.5	47	448	353	66
103	961780	0	0	0	y	y	n	n	n	n	n	n	n	n	n	n	n	n	n	n	n	n	n	n	-	n	n	n	-	-	-	-	-	10.7	-	7.4	-	150	-	34
104	794384	500mg	180	od	y	n	n	n	n	n	y	n	n	n	n	n	n	n	n	n	n	n	n	n	-	n	n	n	-	-	-	-	-	11	12.1	10.6	7.4	290	280	23
105	800496	0	0	0	n	n	n	n	n	n	n	n	n	n	n	n	n	n	n	n	n	n	n	n	-	n	n	n	-	-	-	-	-	13.2	12	5.5	7.6	333	334	27
106	797701	0	0	0	n	n	n	n	n	n	n	n	n	n	n	n	n	n	n	n	n	n	n	n	-	n	n	n	-	-	-	-	-	12.3	10.4	6.4	7.8	272	234	20
107	784819	500mg	180	od	y	y	y	n	n	n	y	n	n	n	n	n	n	n	n	n	n	n	n	n	-	n	y	n	-	-	-	-	-	10.2	10	14.2	10.2	150	140	130
108	795785	500mg	365	od	y	y	y	n	n	n	y	n	n	n	n	n	n	n	n	n	n	n	n	n	-	n	n	n	-	-	-	cva	-	8.5	9.5	11.3	18.3	150	130	172
109	803042	0	0	0	y	n	y	n	n	n	n	n	n	n	n	n	n	n	n	n	n	n	n	n	-	n	n	n	-	-	-	-	-	11.7	10.3	28	12.3	302	263	166
110	715766	0	0	0	n	n	n	n	n	y	n	n	n	n	n	n	n	n	n	n	n	n	n	n	-	n	n	n	-	-	-	-	-	13	11	15.7	20.3	392	190	59
111	801466	0	0	0	n	n	n	n	n	n	n	n	n	n	n	n	n	n	n	n	n	n	n	n	-	n	n	n	-	-	-	-	-	17.7	8.8	17.3	10.7	160	317	28
112	757988	500mg	60	od	y	y	n	n	n	n	n	n	y	n	n	n	n	n	n	y	n	n	n	n	n	n	n	n	-	-	-	-	post sems	9.4	9.7	47	34.6	284	155	57
113	806528	0	0	0	n	n	n	n	n	n	y	n	n	n	n	n	n	n	n	n	n	n	n	n	-	n	n	n	-	-	-	-	-	13.8	14	25	36	143	150	63
114	78322	500mg	365	od	y	y	y	n	y	n	n	n	n	n	n	n	n	n	n	n	n	n	n	n	-	n	n	n	-	-	-	-	-	9.8	10.4	7.6	7.2	256	253	89
115	800002	500mg	60	od	y	y	n	n	n	n	n	y	n	n	n	n	n	n	n	n	n	y	n	n	n	n	n	n	-	-	-	-	-	9	8	1.8	3.5	36	31	44
116	808782	0	0	0	y	y	n	n	n	n	n	n	n	n	n	n	n	n	n	n	n	n	n	n	-	n	n	n	-	-	-	-	-	8.8	9.6	11	23	117	125	108
117	758074	0	0	0	n	n	n	n	n	n	n	n	n	n	n	n	n	n	n	n	n	n	n	n	-	n	n	n	-	-	-	-	-	8.6	-	7.7	-	88	-	89
118	808924	0	0	0	n	n	n	n	n	n	n	n	n	n	n	n	n	n	n	n	n	n	n	n	-	n	n	n	-	-	-	-	-	13	13	9.4	9.3	110	112	19
119	813129	500mg	45	od	n	n	n	n	n	n	y	n	n	n	n	n	n	n	n	n	n	n	n	n	-	n	n	n	-	-	-	-	-	11.3	10	9	17	183	165	45
120	120235	0	0	0	n	n	n	n	n	n	n	n	n	n	n	n	n	n	n	n	n	n	n	n	-	n	n	n	-	-	-	-	-	13.2	12.5	11.5	11.4	314	378	68
121	815300	500mg	30	od	y	y	y	n	n	n	n	n	n	n	n	n	n	n	n	n	n	n	n	n	-	n	n	n	-	-	-	-	-	6.5	8.5	24.5	12	236	200	129
122	806598	50mg	60	od	y	y	n	n	n	n	n	n	n	n	n	n	n	n	n	n	n	n	n	n	-	n	n	n	-	-	-	-	-	10.2	10.1	11	10.3	488	537	33
123	202821	500mg	120	od	y	n	y	n	n	n	n	n	n	n	n	n	n	n	n	n	n	n	n	n	-	n	n	n	-	-	-	-	-	10.7	10.8	9.2	18	267	215	106
124	676387	0	0	0	y	y	y	y	n	n	n	y	n	n	n	n	n	n	n	n	n	n	n	n	-	n	n	n	-	-	-	-	-	7.4	9.4	15	8.4	455	200	116
125	816494	0	0	0	n	n	n	n	n	n	n	n	n	n	n	n	n	n	n	n	n	n	n	n	-	n	n	n	-	-	-	-	-	7	7.5	10	9.5	300	302	210
126	815505	0	0	0	y	y	n	n	n	n	y	n	n	n	n	n	n	n	n	n	n	n	n	n	-	n	n	n	-	-	-	-	-	11	11.5	2.3	2.2	72	75	105
127	816596	0	0	0	n	n	n	n	n	n	n	n	n	n	n	n	n	n	n	n	n	n	n	n	-	n	n	n	-	-	-	-	-	13	12	7	6.3	282	252	18
128	518576	0	0	0	y	n	y	y	n	n	n	n	n	n	n	n	n	n	n	n	n	n	n	n	-	n	n	n	-	-	-	-	-	7.2	8	5.7	6.4	223	230	212
129	868046	16.3mg	60	od	y	n	n	n	n	n	n	n	n	n	n	n	n	n	n	n	n	n	n	n	-	n	n	n	-	-	-	-	-	11	12.9	6.3	5.2	220	223	27
130	867305	0	0	0	y	n	n	n	n	n	n	n	n	n	n	n	n	n	n	n	n	n	n	n	-	n	y	n	-	-	-	-	att	12	11.2	7.6	9.4	271	251	40
131	487433	0	0	0	n	n	n	n	n	n	n	n	n	n	n	n	n	n	n	n	n	n	n	n	-	n	n	n	-	-	-	-	-	5.3	9.6	7.8	11	120	116	150
132	860301	0	0	0	y	y	n	n	n	n	n	n	n	n	n	n	n	n	n	n	n	n	n	n	-	n	n	n	-	-	-	-	-	8.3	10	9	10	205	249	13
133	870491	0	0	0	n	n	n	n	n	n	n	n	n	n	n	n	n	n	n	n	n	n	n	n	-	n	n	n	-	-	-	-	-	12	-	6.4	-	228	-	29
134	870616	0	0	0	n	n	n	n	n	n	n	n	n	n	n	n	n	n	n	n	n	n	n	n	-	n	n	n	-	-	-	-	-	14	-	14	-	187	-	33
135	870526	500mg	90	od	y	y	y	y	n	y	n	n	n	n	n	n	n	n	n	n	n	n	n	n	-	n	n	n	-	-	-	-	-	10.5	9.6	5.7	7.9	163	150	19
136	868092	0	0	0	n	n	n	n	n	n	n	n	n	n	n	n	n	n	n	n	n	n	n	n	-	n	n	n	-	-	-	-	-	17	12.6	17.7	7.9	385	360	40
137	730279	0	0	0	y	y	n	n	n	n	n	n	n	n	n	n	n	n	n	n	n	n	n	n	-	n	n	n	y	-	-	-	-	12.7	-	13.2	-	378	-	39
138	873183	0	0	0	y	n	y	n	n	n	n	n	n	n	n	n	n	n	n	n	n	n	n	n	-	n	n	n	-	-	-	-	-	13.3	10.5	7.6	6.8	265	237	55
139	863874	500mg	365	od	n	y	n	n	n	n	n	n	n	n	n	n	n	n	n	n	n	n	n	n	-	n	n	n	-	-	-	-	-	7.2	7.3	10.4	7.8	323	276	39
140	874227	500mg	150	od	y	y	y	n	n	n	n	y	n	n	n	n	n	n	n	n	n	n	n	n	-	n	n	n	-	-	-	-	femur #	10.9	10.7	11	14.7	259	209	146
141	874222	0	0	0	n	n	n	n	n	n	n	n	n	n	n	n	n	n	n	n	n	n	n	n	-	n	n	n	-	-	-	restrictive cmp	-	11.2	10.9	9.8	8.5	157	170	304
142	874605	50mg	150	od	y	n	n	n	n	y	n	n	n	n	n	n	n	n	n	n	n	n	n	n	-	n	n	n	-	-	-	-	-	9.8	12.3	7.2	18.9	70	66	111
143	837754	0	0	0	n	n	n	n	n	n	n	n	n	n	n	n	n	n	n	n	n	n	n	n	-	n	n	n	-	-	-	-	hysterectomy for fibroids	11.6	9	17	8	242	238	131
144	839395	500mg	365	od	y	y	y	y	y	n	n	n	n	n	n	n	n	n	n	n	n	n	n	n	-	n	n	n	-	-	-	-	post cabg	12	12	12.2	11.8	367	381	34
145	648486	0	0	0	n	n	n	n	n	n	n	n	n	n	n	n	n	n	n	n	n	n	n	n	-	n	n	n	-	-	-	-	-	16	14.6	12.1	10.2	308	310	21
146	639722	0	0	0	y	y	n	n	y	n	n	n	n	n	n	n	n	n	n	n	n	n	n	n	-	n	n	n	-	-	-	-	post cabg	11	9.8	13	10.6	188	178	84
147	840633	0	0	0	n	n	n	n	n	n	n	n	n	n	n	n	n	n	n	n	n	n	n	n	-	n	n	n	-	-	-	-	-	8	10	12	8	241	150	36
148	681164	50mg	20	od	n	n	n	n	n	n	n	n	y	n	n	n	n	n	y	n	n	n	n	n	n	n	n	n	-	-	-	-	-	10.3	6.8	9.4	5.3	100	60	137
149	736950	50mg	365	od	y	n	y	n	n	n	n	n	y	n	n	y	n	n	n	n	n	n	n	n	n	n	n	n	-	y	-	-	palliative radiotherapy	5.6	8.6	6.6	9.7	192	317	42
150	844350	0	0	0	y	n	n	n	n	n	n	n	y	n	n	n	n	n	n	n	n	n	n	y	n	n	n	n	-	-	-	-	left nephrectomy	7	7.2	31.5	29.4	394	342	58
151	838640	0	0	0	y	n	n	n	n	y	n	n	n	n	n	n	n	n	n	n	n	n	n	n	-	n	n	n	-	-	-	-	-	7	11.4	7	5.7	50	60	198
152	457005	0	0	0	y	n	n	n	n	n	n	n	y	n	n	y	n	n	n	n	n	n	n	n	-	n	n	n	-	-	-	-	post hysterectomy and b/l soo	8.2	7.5	5.6	4.2	45	40	0.7
153	93021	0	0	0	n	n	n	n	n	n	n	n	n	n	n	n	n	n	n	n	n	n	n	n	-	n	n	n	-	-	-	-	-	11	10.6	11	12	340	321	8
154	582848	0	0	0	y	n	y	n	n	n	n	n	y	n	n	n	n	n	n	n	n	y	n	n	-	n	n	n	-	-	-	-	-	7	7.4	3.5	4	120	100	102
155	834904	0	0	0	y	n	n	n	n	n	n	n	n	n	n	n	n	n	n	n	n	n	n	n	-	n	n	n	-	-	-	-	-	10.8	8.4	4.8	4.5	60	47	17
156	824096	0	0	0	y	y	y	n	n	n	n	n	y	n	n	n	n	n	n	n	n	n	y	n	n	n	n	n	-	-	-	-	post mrm	8.5	8.4	8	10	295	248	104
157	840091	0	0	0	n	n	n	n	n	n	n	n	n	n	n	n	n	n	n	n	n	n	n	n	-	n	n	n	-	-	-	-	-	10.3	8.3	26.4	14	290	365	137
158	884091	0	0	0	n	n	n	n	n	n	n	n	n	n	n	n	n	n	n	n	n	n	n	n	-	n	n	n	-	-	-	-	-	9.2	8.7	24	12.4	333	368	35
159	746917	500mg	365	od	y	y	y	n	n	n	n	n	n	n	n	n	n	n	n	n	n	n	n	n	-	n	n	n	-	y	-	-	-	9.5	-	15.3	-	248	-	61
160	776677	0	0	0	n	n	n	n	n	n	n	n	n	n	n	n	n	n	n	n	n	n	n	n	-	n	n	n	-	-	-	-	-	13	11.8	9.3	9.2	291	319	18
161	836002	0	0	0	n	n	n	n	n	n	n	n	n	n	n	n	n	n	n	n	n	n	n	n	-	n	n	n	-	-	-	-	-	10.3	-	5	-	140	-	40
162	849333	500mg	365	od	y	y	y	n	n	n	n	n	n	n	n	n	n	n	n	n	n	n	n	n	-	n	n	n	-	y	-	-	-	9.4	9	10.7	9.6	182	238	132
163	851055	0	0	0	n	n	n	n	n	n	n	n	n	n	n	n	n	n	n	n	n	n	n	n	-	n	n	n	-	-	-	-	-	11	10.5	4.2	18	85	60	62
164	845069	500mg	365	od	y	n	n	n	n	n	n	n	y	n	n	n	n	n	n	n	n	y	n	n	n	n	n	n	-	-	-	-	-	10.7	-	11.3	-	150	-	115
165	531317	0	0	0	n	n	n	n	n	n	n	n	n	n	n	n	n	n	n	n	n	n	n	n	-	n	n	n	-	-	-	-	-	13	13.3	9	9.1	345	321	24
166	849455	16.3mg	365	od	y	y	y	y	n	n	n	n	n	n	n	n	n	n	n	n	n	n	n	n	-	n	n	n	-	-	-	-	-	9	7	7	7.4	170	130	75
167	383444	0	0	0	y	n	n	n	n	n	n	n	y	y	n	n	n	n	n	n	n	n	n	n	n	n	n	n	-	-	-	-	post sx/ct/rt	8	8.4	10.7	11	398	350	70
168	849152	50mg	6	od	y	y	n	n	n	n	n	n	n	n	n	n	n	n	n	n	n	n	n	n	-	n	n	n	-	-	-	-	-	14	7.7	5.5	7	33	150	70
169	853509	500mg	15	od	y	y	y	y	n	n	n	n	n	n	n	n	n	n	n	n	n	n	n	n	-	n	n	n	-	-	-	-	-	7.8	8	7	7.8	2	196	110
170	856156	0	0	0	y	n	n	y	n	n	n	n	y	n	n	n	n	n	n	n	n	y	n	n	-	n	n	n	-	-	-	-	-	7.4	8.5	22.5	16	150	125	123
171	36273	500mg	365	od	y	y	n	y	n	n	n	n	n	n	n	n	n	n	n	n	n	n	n	n	-	n	n	n	-	-	-	-	-	10	8.5	36	18.8	150	104	128
172	897187	0	0	0	y	n	n	n	y	n	n	n	n	n	n	n	n	n	n	n	n	n	n	n	-	n	n	n	-	-	-	-	-	7.5	9	9	11.3	162	257	118
173	892695	0	0	0	n	n	n	n	n	n	n	n	n	n	n	n	n	n	n	n	n	n	n	n	-	n	y	n	-	-	-	-	-	10.3	10.4	9.6	10.4	123	207	55
174	383444	0	0	0	n	n	n	n	n	n	n	n	y	n	n	n	n	n	n	y	n	n	n	n	n	n	n	n	-	-	-	-	chemotherapy, post cbd stenting	6.7	6	23.3	15.7	190	80	21
175	907933	500mg	90	od	n	n	y	n	n	n	n	n	n	n	n	n	n	n	n	n	n	n	n	n	-	n	n	n	-	-	-	-	-	8	9	9.6	11	133	130	136
176	150185	0	0	0	n	n	n	n	n	n	n	n	n	n	n	n	n	n	n	n	n	n	n	n	-	n	n	n	-	-	-	-	-	8.4	8.3	10	9	261	205	20
177	902832	0	0	0	y	n	n	n	y	n	n	n	n	n	n	n	n	n	n	n	n	n	n	n	-	n	n	n	-	-	-	-	post cabg	7.8	8	6	6.7	145	150	55
178	888867	0	0	0	n	n	n	n	n	n	n	n	n	n	n	n	n	n	n	n	n	n	n	n	-	n	n	n	-	-	-	-	-	10	10.4	6.8	11.4	150	165	64
179	891164	0	0	0	n	n	n	n	n	n	n	n	n	n	n	n	n	n	n	n	n	n	n	n	-	n	n	n	-	-	-	-	-	6	6.5	18	16.5	32	27	120
180	881651	500mg	90	od	y	n	n	n	n	n	n	n	n	n	n	n	n	n	n	n	n	n	n	n	-	n	n	n	-	-	-	-	-	10	8.6	14.4	11	176	236	105
181	874012	0	0	0	y	n	y	n	n	n	n	n	n	n	n	n	n	n	n	n	n	n	n	n	-	n	n	n	-	-	-	-	-	9	9.5	7.6	8.8	282	262	57
182	666086	0	0	0	n	n	n	n	n	n	n	n	n	n	n	n	n	n	n	n	n	n	n	n	-	n	n	n	-	-	-	-	-	12	12	12.4	10.7	150	164	155
183	873183	0	0	0	n	n	n	n	n	n	n	n	n	n	n	n	n	n	n	n	n	n	n	n	-	n	n	n	-	-	-	-	-	11	11.4	8	6.8	214	240	55
184	876104	0	0	0	n	n	n	n	n	n	n	n	n	n	n	n	n	n	n	n	n	n	n	n	-	n	n	n	-	-	-	-	-	9.5	9.8	12	9	457	387	120
185	882709	0	0	0	y	n	n	n	n	n	n	n	y	n	n	n	n	n	n	n	n	n	n	n	n	n	n	n	-	-	y	-	post sems	12.6	10	14	15.5	535	381	16
186	849332	500mg	365	od	y	y	y	n	n	n	n	n	n	n	n	n	n	n	n	n	n	n	n	n	-	n	n	n	-	y	-	-	-	10	10.5	7.6	8.2	285	258	44
187	759614	0	0	0	y	y	y	y	y	y	n	n	n	n	n	n	n	n	n	n	n	n	n	n	-	n	n	n	-	-	-	-	-	8	8.2	13.8	10.2	134	120	171
188	893454	0	0	0	n	n	n	n	n	n	n	n	n	n	n	n	n	n	n	n	n	n	n	n	-	n	n	n	-	-	-	-	dj stenting	13	12.5	9.5	10.2	256	230	40
189	568835	0	0	0	y	y	n	y	n	n	y	n	n	n	n	n	n	n	n	n	n	n	n	n	-	n	n	n	-	-	-	-	-	8.5	7.6	31	14	85	70	84
190	787977	0	0	0	n	n	n	n	n	n	n	n	n	n	n	n	n	n	n	n	n	n	n	n	-	n	n	n	-	-	-	-	att	14	13	10.5	9.8	230	234	14
191	848737	500mg	365	irregular	y	y	n	n	n	n	n	n	n	n	n	n	n	n	n	n	n	n	n	n	-	n	n	n	-	-	-	-	-	10.2	9.9	31	17	524	590	41

sr no	mrd	urea dis	creatinine adm	creatinine dis	Na adm	Na dis	K adm	K dis	Cl adm	Cl dis	total bilirubin adm	total bilirubin dis	direct bilirubin adm	direct bilirubin dis	SGOT adm	SGOT dis	SGPT adm	SGPT dis	ALP adm	ALP dis	total proteins adm	total proteins dis	s. albumin adm	s. albumin dis	s. calcium adm	s. calcium dis	Corrected Calcium adm	Corrected Calcium dis	phosphorus adm	phosphorus dis	urine r/e protein	rbc	pus cell	glucose	pth adm	pth dis	Vitamin D admission	Vitamin D dis	TSH	T3	T4	short qt in ecg	cxr nor=1/abn=2/ not done=3	cxr pleural effusion	cxr hilar lap	cxr s/o tb	cxr lytic lesion
98	768710	161	2.39	2.3	137	130	5.7	5.3	106	103	0.6	-	0.5	-	108	-	31	-	626	-	6.6	-	3	-	10.9	10.8	11.7	11.6	5.5	-	2	20	120	0	6	-	9.4	-	2.9	-	-	y	2	-	-	-	-
99	758074	82	1.6	0.9	128	126	3.8	4	99	127	1.26	1.16	0.3	0.6	28	25	13	9	268	204	5.2	5	2.3	3	9	8.9	10.36	9.7	2.3	1.9	0	0	0	0	4	-	19	-	2.3	-	-	y	1	-	-	-	-
100	483498	58	1.3	6.8	133	133	5.6	5	105	103	0.7	-	0.2	-	18	-	20	-	119	-	9.4	-	4	-	12	12.3	12	12.3	3.2	-	3	10	0	0	11	-	16.3	-	-	-	-	y	1	-	-	-	-
101	772868	52	2	1.3	137	134	4.6	3.7	100	94	0.6	-	0.14	-	27	-	12	-	89	-	6.7	-	3.6	-	11.5	9.3	11.82	9.62	8	4.9	0	0	0	0	12	-	21	-	2.4	-	-	y	1	-	-	-	-
102	937061	97	1.26	2.76	129	97	5.3	5.1	95	106	0.2	-	0.12	-	19	-	11	-	56	-	5.4	-	2.6	-	11.1	10.1	12.22	11.22	4.8	4.9	0	30	10	0	14.8	-	11.23	-	10.7	-	-	y	2	y	-	-	-
103	961780	-	0.3	-	142	-	3.4	-	105	-	0.4	-	0.3	-	136	-	99	-	63	-	5.5	-	2.6	-	9.7	10.8	10.82	11.92	1.3	-	0	12	0	1	11	-	22	-	0.005	19.7	100	y	2	y	-	-	-
104	794384	26	0.7	0.8	146	145	2.7	2.6	104	104	0.3	-	0.1	-	15	-	20	-	63	-	6.1	-	3.24	-	12.2	10.1	12.808	10.708	3	-	0	0	0	0	20	-	54	-	0.008	12	52.7	y	1	-	-	-	-
105	800496	23	1.1	0.6	137	137	5.8	3.8	97	100	0.5	-	0.03	-	43	-	12	-	64	-	7.3	-	3	-	10.5	9.4	11.3	10.2	4.17	-	0	0	0	0	3.2	-	21	-	-	-	-	y	2	y	-	-	-
106	797701	-	0.4	-	132	-	3.5	-	111	-	0.3	-	0.2	-	50	-	42	-	380	176	6.3	-	3.5	-	11.2	8	11.6	8.4	2.8	-	0	2	0	0	554	90	28	-	5.1	-	-	1	1	-	-	-	-
107	784819	122	1.2	2.85	135	132	4.8	4.6	102	101	0.4	-	0.1	-	50	-	55	-	72	-	6.2	-	3	-	12.5	9.4	13.3	10.2	4.6	-	1	0	0	0	12	-	163	-	3.2	-	-	y	1	-	-	-	-
108	795785	73	5.5	4.1	129	127	4	3.5	92	96	0.5	-	0.35	-	24	-	4	-	420	-	6.8	-	3.8	-	10.7	9.3	10.86	9.46	4	-	1	15	100	2	219	-	21	-	2.1	-	-	y	2	y	-	-	-
109	803042	85	3.6	1.2	156	145	3.4	3.6	113	103	0.4	0.23	0.1	0.09	33	28	18	25	160	113	5.9	5.8	2.6	2.7	18.8	6.5	19.92	7.54	3.12	-	0	0	0	0	328	-	11	-	0.18	2.3	9.2	y	1	-	-	-	-
110	715766	117	0.9	1.02	137	144	5.3	3.4	98	105	0.2	-	0.07	-	24	-	15	-	427	-	8	-	3.4	-	15.8	8.8	16.28	9.28	4.7	-	0	0	0	0	12	-	18	-	0.5	-	-	y	2	y	-	-	-
111	801466	52	1.7	1.06	136	131	4	4.9	101	99	7.7	2.7	4.5	2.3	155	61	116	27	460	310	7	5.2	3.6	1.6	10.9	8.7	11.22	10.62	5	-	0	4	0	0	136	-	13.1	-	2.6	13.3	7.5	y	1	-	-	-	-
112	757988	58	0.9	0.65	157	131	4	4.3	101	103	0.36	-	0.31	-	53	-	68	-	211	-	4.4	-	2.24	-	9.7	10.6	11.108	12.008	1.3	-	1	2	12	0	4	-	21	-	2.1	-	-	y	2	y	-	-	-
113	806528	53	0.8	0.5	138	136	4	3.8	101	104	0.5	-	0.08	-	19	-	34	-	100	-	5.3	-	2.7	-	11.4	7.8	12.44	8.84	1.8	-	0	0	0	0	12.4	-	-	-	-	-	-	y	2	y	-	-	-
114	78322	59	3.2	7.1	131	134	4.7	4	101	99	0.6	-	0.1	-	35	-	41	-	250	287	6	-	2.3	-	11.5	10	12.86	11.36	4.2	-	0	10	50	0	15	-	163	-	-	-	-	y	2	y	-	-	-
115	800002	49	1.2	1.48	137	141	2.5	3.2	106	116	0.6	-	0.1	-	12	-	9	-	139	-	5	-	2.7	-	14.2	13.6	15.24	14.64	4.8	-	1	0	0	0	4	-	13	-	-	-	-	y	2	-	-	-	y
116	808782	145	1.29	2.6	168	145	4.1	4.3	127	113	0.4	1.2	0.2	1	20	65	9	80	147	136	5.4	4.7	1.9	-	13	12	14.68	13.68	4.7	-	2	0	0	0	339	-	6.7	-	-	-	-	y	2	y	-	-	-
117	758074	-	4	-	131	-	3.6	-	94	-	0	-	0.2	-	22	-	14	-	195	-	5.4	-	3.1	-	13.4	5.3	14.12	6.02	-	-	0	0	0	0	4	-	13	-	-	-	-	y	2	-	-	-	-
118	808924	21	0.7	0.6	133	135	4.3	4.08	103	106	0.4	-	0.1	-	20	-	12	-	210	140	7.6	-	4.6	-	11	10.8	10.52	10.32	2.5	2.8	0	0	0	0	169	-	15.6	-	5	-	-	y	1	-	-	-	-
119	813129	28	2.8	1.12	134	141	3.1	2.8	96	107	0.5	-	0.2	-	23	-	15	-	81	-	7	-	3.5	-	16	9.3	16.4	9.7	4.3	-	0	0	30	0	7.36	-	163	-	-	-	-	y	1	-	-	-	-
120	120235	65	1.3	1.1	136	141	3.8	3.7	106	108	0.3	-	0.2	-	4	-	33	-	332	265	6.3	-	3.3	-	15.6	9.5	16.16	10.06	3.5	-	0	0	0	0	741	48.6	21.4	-	2.4	-	-	y	1	-	-	-	-
121	815300	65	7.2	3.5	136	133	5.1	3.6	104	95	0.8	-	0.2	-	40	-	6	-	87	-	7.2	-	2.57	-	11.4	11.3	12.544	12.444	6.7	3.5	0	0	0	0	12	-	22	-	2.1	-	-	y	2	y	-	-	-
122	806598	28	0.7	0.9	128	132	4	4	94	99	0.4	-	0.12	-	31	-	20	-	272	280	6.5	-	2.7	-	11	10	12.04	11.04	1.5	-	1	0	0	1	127	-	22	-	-	-	-	y	1	-	-	-	-
123	202821	157	4.1	3.4	138	135	5.4	3.7	100	97	0.6	-	0.13	-	48	-	112	-	110	-	7	-	3.5	-	14	11.5	14.4	11.9	5.5	-	0	10	100	0	12.3	-	78	-	1.38	-	-	y	1	y	-	-	-
124	676387	40	3	0.7	136	137	4	3.3	106	99	0.3	-	0.1	-	15	-	20	-	63	-	6	-	2.5	-	10.3	9.3	11.5	10.5	7.2	-	0	10	18	0	7.7	-	21	-	1.1	-	-	y	2	-	-	-	-
125	816494	265	5	5.6	134	135	5.7	5.6	91	93	0.4	-	0.3	-	56	-	65	-	84	-	7.6	-	2.8	-	11.7	11.9	12.66	12.86	5.6	-	3	10	25	0	6	-	16	-	-	-	-	y	1	-	-	-	-
126	815505	67	2.8	1.38	121	128	4.3	3.8	84	94	26.4	20.8	22.6	17.6	94	96	64	42	95	-	6.2	-	3.4	-	13.2	9.9	13.68	10.38	3.5	-	0	10	5	1	7.7	-	38.8	-	1.6	-	-	y	1	-	-	-	-
127	816596	17	0.8	0.7	140	139	4.5	4.1	103	104	0.4	-	0.13	-	39	-	44	-	450	224	7	-	4	-	11.4	8.7	11.4	8.7	2.4	-	0	0	0	0	152	40	3.2	-	2.1	-	-	y	1	-	-	-	-
128	518576	60	17	3	141	141	6.5	3.8	94	101	104	0.5	-	0.08	-	19	-	34	-	100	-	5.3	-	2.7	-	11.4	7.8	12.44	8.84	1.8	-	0	0	0	0	12.4	-	-	-	-	-	-	y	2	y	-	-	-
129	868046	71	1.5	1.8	130	154	3.7	4	92	122	1.2	-	0.6	-	40	-	46	-	120	-	6.4	-	3.2	3.6	15.3	8.6	15.94	8.92	2.3	2.8	0	0	0	0	3	-	22.6	-	-	-	-	y	2	y	-	-	-
130	867305	15	0.4	0.34	12.3	13.5	3.4	3.6	87	100	0.1	-	0.4	-	58	-	64	-	68	-	7.3	-	1.3	2.4	9.8	9.9	11.96	11.18	2.1	2.6	0	0	0	0	22	-	18.3	-	2.1	-	-	y	2	-	-	y	-
131	487433	60	9.5	5.7	115	126	6.16	4.2	82	88	18.6	16.4	15.4	12.2	120	124	84	62	273	-	5.5	-	3.78	-	12.9	10.7	13.076	10.876	7.6	-	2	2	10	0	21	-	8.49	-	2.5	3.1	11.1	y	2	y	-	-	y
132	860301	-	0.53	-	135	-	5.1	-	103	-	0.9	-	0.3	-	35	-	17	-	452	330	6.9	-	4.3	-	12.2	11.1	11.96	10.86	3.1	-	0	0	3	0	112	-	19.4	-	0.8	-	-	y	1	-	-	-	-
133	870491	-	0.84	-	137	-	4.3	-	101	-	0.3	-	0.2	-	64	-	46	-	147	-	7.4	-	3.6	-	10.8	10.3	11.12	10.62	4.2	-	0	0	0	0	21	-	28	-	0.0001	7.4	14.2	y	1	-	-	-	-
134	870616	18	1.18	1.06	138	142	4.5	3.4	105	107	1.18	1.05	0.25	0.4	27	62	32	104	108	109	6.8	5.4	3.2	3.3	13	7.7	13.64	8.26	1.1	2.3	0	0	0	0	307	64	33.8	-	1.2	-	-	y	2	y	-	-	-
135	870526	-	1.35	2.2	138	-	4.2	-	105	-	3.5	-	3.04	-	89	-	32	-	187	-	6.2	-	2.3	-	12.8	9.6	14.16	10.96	2.4	-	0	2	0	0	11.9	-	178	-	-	-	-	y	1	-	-	-	-
136	868092	20	1.6	0.9	136	138	3.5	3.8	101	107	2.5	-	0.4	-	30	-	36	-	820	650	6.8	-	3.3	-	21.3	8.8	21.86	9.36	4.3	-	0	0	0	0	2252	81	10.06	-	-	-	-	y	1	-	-	-	-
137	730279	38	1.2	1.2	140	142	4	3.6	98	102	0.7	-	0.19	-	48	-	26	-	368	320	7.4	-	3.4	-	13	12.6	13.48	13.08	-	-	0	0	0	0	296	-	9.8	-	4.7	-	-	y	1	y	-	-	-
138	873183	24	1.9	1.36	136	140	3.2	3.8	100	111	0.8	-	0.3	-	20	-	24	-	230	150	7.8	-	4.3	3.28	16.6	8.9	16.36	9.476	2.23	1	-	-	-	-	158	264	27	-	-	-	-	y	1	-	-	-	-
139	863874	40	4.46	4.3	141	142	4.23	4.1	102	101	0.3	-	0.08	-	19	-	13	-	82	-	6.2	-	3.74	-	10.9	10.6	11.108	10.808	7.3	3.8	2	12	5	1	20	-	112	-	-	-	-	y	2	y	-	-	-
140	874227	112	2.3	2.2	145	142	4	3.6	105	108	0.14	-	0.3	-	21	-	23	-	58	-	6.6	-	3.3	3.14	15.5	10.1	16.06	10.788	5.2	4	1	2	5	0	9.48	-	166.3	-	7	6.2	14.3	y	1	-	-	-	-
141	874222	206	4.2	5.5	128	128	4.2	4.3	85	94	0.8	-	0.6	-	42	-	45	-	94	-	6.8	-	2.6	-	10.6	10.4	11.72	11.52	6.2	-	0	0	0	0	14	-	28	-	4	2	16	n	2	-	-	-	-
142	874605	-	1.45	-	126	130	5.5	4.9	91	96	24.9	16.2	20.6	12	108	93	74	70	461	-	5.6	-	3.28	-	10.9	10.3	11.476	10.876	-	-	0	3	20	2	43	-	39	-	1.2	-	-	y	1	-	-	-	-
143	837754	18	2.6	1.4	128	140	3.1	3.04	89	112	0.3	-	0.09	-	23	-	22	-	287	280	7.6	-	3.4	-	17.6	7	18.08	7.48	2.9	2.1	0	0	100	0	1422	52.4	23	-	1.35	5.4	9.6	y	1	-	-	-	-
144	839395	17	1.1	1	133	132	4	3.2	95	94	0.3	-	0.2	-	23	-	23	-	69	-	6.6	-	3.9	-	11.4	-	11.48	#VALUE!	4	-	0	0	0	0	65	-	158	-	2.2	-	-	y	2	y	-	-	-
145	648486	23	0.8	1.1	139	140	4.3	3.8	102	98	1.12	-	0.22	-	20	-	31	-	465	460	7.3	-	4.19	-	11.2	10.8	11.048	10.648	2.5	-	0	0	0	0	95	-	18.7	-	2.3	-	-	y	1	-	-	-	-
146	639722	55	1.6	1.13	134	137	3.8	4.2	101	103	0.5	-	0.16	-	32	-	45	-	435	336	4.8	-	2.5	-	9.2	7.3	10.4	8.5	2.5	-	0	0	40	0	464	-	19	-	1.6	-	-	y	1	-	-	-	-
147	840633	35	0.7	0.6	142	138	3.7	3.6	104	107	1.3	0.5	0.75	0.4	132	30	140	36	314	260	5.6	5	2.6	2.15	12.4	10.2	13.52	11.68	3	-	0	0	0	0	1782	324	33	-	1.7	-	-	y	2	y	-	-	-
148	681164	129	1.5	1.7	144	145	3.1	3.4	108	115	5.9	-	4.6	-	237	-	72	-	673	-	6	-	2.8	-	12.4	7.6	13.36	8.56	3.7	5.3	0	0	0	0	13.7	-	31	-	2.3	-	-	y	2	-	-	-	-
149	736950	-	0.7	-	136	-	4.4	-	104	-	0.3	-	0.2	-	41	-	40	-	85	-	6.1	-	3.2	-	11	8.6	11.64	9.24	5.5	-	0	0	0	0	4	-	13	-	0.6	-	-	y	1	y	-	-	-
150	844350	-	1.17	-	146	-	4	-	109	-	0.2	-	0.09	-	31	-	32	-	240	-	5.5	-	2.3	-	11.7	9	13.06	10.36	5.5	-	1	0	0	0	7.19	-	21	-	1.6	1.8	7.3	y	1	-	-	-	-
151	838640	177	1.4	0.9	124	126	5	4.4	94	92	8.9	6.5	6.4	4.2	90	74	60	45	68	84	6	5.8	2.5	2.7	10.7	10.4	11.9	11.44	2.5	-	0	0	0	0	35	-	64	-	7.3	-	-	y	2	y	-	-	-
152	457005	-	0.24	-	130	-	4.7	-	100	-	0.7	-	0.24	-	17	-	7	-	105	-	5	-	3	-	10.7	10.8	11.5	11.6	3.3	-	0	0	0	0	4	-	9	-	1.6	-	-	y	2	y	-	-	-
153	93021	12	0.6	0.4	140	141	4.3	4	106	102	0.3	-	0.1	-	15	-	16	-	70	-	6.7	-	2.7	-	10.5	10.7	11.54	11.74	3.1	-	0	0	0	0	97	67	7	-	0.8	4	19	y	1	-	-	-	-
154	582848	-	2.5	2.1	136	-	4.5	-	105	-	0.6	-	0.2	-	136	-	166	-	110	-	7	-	2.8	-	11	10.6	11.96	11.56	1.3	-	0	0	0	0	10.2	-	12	-	-	-	-	y	1	-	-	-	-
155	834904	106	0.6	2.1	110	130	4.3	3.8	86	90	14.6	16.8	11.2	12.6	140	124	42	98	149	86	5.2	5.5	2.5	2.7	9.5	9.6	10.7	10.64	3	-	0	10	2	0	19	-	9	-	0.5	-	-	n	1	y	-	-	-
156	824096	117	3	3.1	136	151	2.8	3.9	94	108	2	-	1.3	-	81	-	19	-	283	-	6.8	-	3.6	-	17.3	14.3	17.62	14.62	5	-	0	0	0	0	8.6	-	21	-	-	-	-	y	2	-	-	-	-
157	84009	76	5.5	3.8	143	136	3.7	3.9	103	103	0.3	-	0.1	-	14	-	10	-	99	-	6.8	-	3.1	-	10.4	8	11.12	8.72	5.6	-	3	8	6	0	15	-	10.6	-	1.02	11.4	9	y	2	-	-	-	-
158	884091	14	0.6	0.5	143	137	5.8	4.1	105	101	0.9	-	0.4	-	30	-	16	-	740	667	5.2	-	2.3	-	8.7	8.6	10.06	9.96	7.8	-	0	0	3	0	720	-	20	-	1.2	-	-	y	2	y	-	-	-
159	746917	105	2.3	2.4	131	135	4.5	4	97	93	0.5	-	0.2	-	68	-	35	-	323	-	5.4	-	2.3	-	10.7	10.4	12.06	11.76	4.3	-	0	0	30	0	11	-	163	-	5.2	-	-	y	1	-	-	-	-
160	776677	20	0.6	0.8	136	134	4.4	4.2	98	101	0.58	-	0.12	-	28	-	24	-	265	250	8.1	-	2.03	-	10.4	10.1	11.976	11.676	5.7	-	0	0	0	0	600	-	10	-	-	-	-	y	1	-	-	-	-
161	836002	69	1.7	2.3	138	136	4	3.4	101	103	0.8	-	0.3	-	24	-	44	-	153	-	7.3	-	4.6	-	14	11	13.52	10.52	4.6	-	0	0	0	0	4	-	16	-	-	-	-	y	2	-	-	-	-
162	849333	96	2.1	2.7	131	143	2.3	2.9	85	108	0.3	-	0.2	-	29	-	7	-	55	-	6.5	-	3.7	-	16	8	16.24	8.24	5	-	0	4	0	0	10	-	175	-	-	-	-	y	2	y	-	-	-
163	851055	95	0.9	1.35	154	146	3	2.7	128	100	0.6	-	0.3	-	28	-	20	-	299	-	9.6	-	2	-	14.6	10.8	16.2	12.4	4.8	-	3	20	8	0	13	-	10.6	-	-	-	-	y	2	-	-	-	-
164	845069	125	4.8	3	136	140	3.8	3.6	101	106	0.5	0.9	0.23	0.1	15	10	9	12	83	173	12.4	9.8	1.8	1.5	13.6	10	15.36	12	6	3.8	1	10	4	0	12.5	-	25	-	-	-	-	y	2	y	-	-	-
165	531317	20	0.6	0.5	139	138	3.3	4	98	96	1.08	-	0.5	-	40	-	24	-	800	798	5.5	-	4.4	4.6	12.7	7.2	12.38	6.72	2.7	2.2	0	0	2	0	741	25	32	-	2.1	-	-	y	1	y	-	-	-
166	849455	116	6.4	3.2	139	140	4	4.3	98	109	0.9	-	0.36	-	35	-	17	-	136	-	8	-	4.3	-	14.2	9.3	13.96	9.06	6.2	-	2	4	2	0	14.4	-	12.25	-	0.5	-	-	y	1	-	-	-	-
167	383444	84	0.6	1.2	138	136	2.7	3.5	98	100	0.7	-	0.4	-	17	-	8	-	102	-	6.5	-	3.3	-	11	10.5	11.56	11.06	5.6	-	0	0	0	0	12.2	-	12	-	1.2	-	-	y	1	y	-	-	-
168	849152	130	1.3	1.18	136	150	5.4	3.6	99	102	1.5	1.05	1.4	0.89	2700	141	1300	178	500	436	6	5.8	2.7	2.14	11.5	8	12.54	9.488	0.7	2.8	1	25	0	0	315	-	21	-	-	-	-	y	2	-	-	-	-
169	853509	90	4.6	4.5	135	137	4.3	4.2	96	94	0.36	-	0.07	-	24	-	12	-	92	-	7	-	2.6	-	10.2	9.2	11.32	10.32	4.5	-	0	0	0	0	13	-	64	-	-	-	-	y	1	-	-	-	-
170	856156	76	9.4	5.13	139	125	4.1	4.6	94	94	0.6	-	0.27	-	94	-	25	-	84	-	6.7	-	2.4	-	11	7.8	12.28	9.08	4.5	3.3	2	12	100	0	12.7	-	-	-	-	-	-	y	2	-	-	-	-
171	36273	205	8.4	4.4	143	142	5.6	5.1	108	109	0.3	-	0.13	-	30	-	9	-	118	-	5.7	-	2.5	-	13	9.2	14.2	10.4	8.4	-	2	0	0	0	48	-	116	-	-	-	-	y	2	-	-	-	-
172	897187	75	2.18	1.6	136	141	4.2	3.14	96	103	1.03	-	0.2	-	48	-	28	-	102	-	6.7	-	3.26	-	15.3	9.2	15.892	9.792	5.2	-	0	0	0	0	8.7	-	29.7	-	4.5	-	-	y	1	-	-	-	-
173	892695	40	1.48	1.09	154	140	3.5	5.3	107	95	11.3	3.2	9.5	1.6	200	60	160	40	86	92	8	5.2	3	2.28	11.3	10.1	12.1	11.476	2.5	-	1	55	0	0	8.8	-	65.7	-	0.05	-	-	y	2	y	-	-	-
174	383444	34	0.6	0.5	133	132	4	3.15	102	86	4.5	8	3.4	7	55	41	27	12	134	105	6.2	5.8	1.8	2.4	11.2	10.9	12.96	12.18	2.7	-	0	0	0	0	7	-	-	-	-	-	-	y	1	-	-	-	-
175	907933	66	2.2	1.8	145	141	2.9	4.2	107	108	0.6	-	0.4	-	43	-	28	-	149	-	5.8	-	2.6	-	16.2	14.8	17.32	15.92	6.7	-	0	0	0	0	8	-	13.4	-	1.6	3.7	7	y	2	y	-	-	y
176	150185	-	0.5	-	138	135	4.5	4.6	103	106	0.3	-	0.12	-	22	-	23	-	487	-	7	-	4	-	11.6	12	11.6	12	2.3	-	0	0	0	0	300	-	27.9	-	1.7	-	-	y	1	-	-	-	-
177	902832	141	5	3.49	144	147	3.3	3.5	108	118	0.8	-	0.3	-	17	-	14	-	60	-	11.4	-	2.8	-	11.3	10	12.26	10.96	6.15	-	2	0	0	0	13	-	8.4	-	-	-	-	y	1	-	-	-	-
178	888867	65	2.5	1.48	140	141	3.8	1.41	95	110	0.5	-	0.2	-	71	-	37	-	84	-	10.6	-	2.5	-	12.7	8	13.9	9.2	5.5	-	1	10	4	0	13	-	31	-	1.5	-	-	y	2	-	-	-	y
179	891164	104	2.6	2.4	130	129	5.8	3.4	103	89	0.9	-	0.4	-	70	-	17	-	93	-	6.8	-	3.2	-	10.6	10	11.24	10

sr no	mrd	cxr metastasis/ sol	cxr other	USG nor=1/ abn=2/ not done=3	USG fatty liver	USG rpcg	USG cld	USG ascites	USG pleural effusion	USG gb sludge	USG lap	USG cholelithiasis	USG nephrolithiasis	USG nephrocalcinosis	USG sol/ metastasis	USG hepatomegaly	USG spleenomegaly	USG pancreatitis	USG s/o tb	USG_other	ct chest_nor=1/abn=2/not done=3	ct chest pleural effusion	ct chest mass lesion	ct chest lytic lesion	ct chest lap	ct chest metastasis	ct chest tubercular changes
98	768710	-	inhomogenous opacities	2	y	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	2	-	-	-	y	-	-
99	758074	-	-	2	-	-	-	-	-	-	y	-	-	-	-	-	y	-	-	-	3	-	-	-	-	-	-
100	483498	-	-	2	-	y	-	-	-	-	-	-	-	-	-	-	-	-	-	-	3	-	-	-	-	-	-
101	772868	-	-	1	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	3	-	-	-	-	-	-
102	937061	y	-	2	-	-	-	y	-	-	y	-	-	-	y	-	-	-	-	-	3	-	-	-	-	-	-
103	961780	-	pulmonary edema	2	y	-	-	-	y	-	-	-	-	-	-	-	-	-	-	-	3	-	-	-	-	-	-
104	794384	-	-	1	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	3	-	-	-	-	-	-
105	800496	-	-	2	-	-	-	-	y	-	-	-	-	-	y	-	-	-	-	-	3	-	-	-	-	-	-
106	797701	-	-	2	-	-	-	-	-	-	-	y	y	-	-	-	-	-	-	-	3	-	-	-	-	-	-
107	784819	-	-	2	-	y	-	-	-	-	-	-	-	-	-	-	-	-	-	-	3	-	-	-	-	-	-
108	795785	-	-	2	-	y	-	-	-	-	-	-	-	-	-	-	-	-	-	pyelonephritis	3	-	-	-	-	-	-
109	803042	-	-	2	y	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	3	-	-	-	-	-	-
110	715766	-	-	2	-	y	-	-	y	-	-	-	-	-	-	-	-	-	-	-	2	y	y	-	-	y	-
111	801466	-	-	2	-	-	-	y	y	y	-	-	-	-	-	-	-	y	-	-	3	-	-	-	-	-	-
112	757988	-	-	2	-	-	-	y	-	-	-	-	-	-	y	-	-	-	-	-	3	-	-	-	-	-	-
113	806528	y	-	2	-	-	-	-	y	-	-	-	-	-	-	-	-	-	-	-	3	-	-	-	-	-	-
114	78322	-	-	2	-	-	-	-	y	-	-	-	-	-	-	-	-	-	-	cystitis	3	-	-	-	-	-	-
115	800002	-	-	2	-	y	-	-	-	-	-	-	-	-	-	-	-	-	-	-	3	-	-	-	-	-	-
116	808782	-	-	2	-	-	-	-	-	-	-	-	-	-	-	-	-	y	-	-	3	-	-	-	-	-	-
117	758074	y	-	2	-	-	-	-	-	-	y	-	-	-	y	-	-	-	-	-	3	-	-	-	-	-	-
118	808924	-	-	2	-	-	-	-	-	-	-	y	-	-	-	-	-	-	-	-	3	-	-	-	-	-	-
119	813129	-	-	2	-	y	-	-	-	-	-	-	-	-	-	-	-	-	-	cystitis	1	-	-	-	-	-	-
120	120235	-	-	2	-	-	-	-	-	-	-	y	y	-	-	-	-	-	-	ureteric stones	3	-	-	-	-	-	-
121	815300	-	pulmonary edema	2	-	y	-	y	y	y	-	-	-	-	-	-	-	-	-	-	3	-	-	-	-	-	-
122	806598	-	-	2	-	-	-	-	-	-	-	y	-	-	-	-	-	y	-	-	3	-	-	-	-	-	-
123	202821	-	-	2	y	y	-	-	-	-	-	-	-	-	-	-	-	-	-	-	2	y	-	-	y	-	-
124	676387	-	ild	1	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	3	-	-	-	-	-	-
125	816494	-	-	2	-	y	-	-	-	-	-	-	-	-	-	-	-	-	-	-	3	-	-	-	-	-	-
126	815505	-	-	2	-	y	y	y	-	-	-	-	-	-	-	-	y	-	-	-	3	-	-	-	-	-	-
127	816596	-	-	2	-	-	-	-	-	-	-	y	y	-	-	-	-	y	-	-	3	-	-	-	-	-	-
128	518576	-	-	2	-	y	-	-	-	-	-	-	-	-	-	-	-	-	-	-	3	-	-	-	-	-	-
129	868046	-	-	2	-	y	-	-	y	-	-	-	-	-	y	-	-	-	-	-	3	-	-	-	-	-	-
130	867305	-	-	2	y	-	-	-	-	-	-	-	-	-	-	-	-	-	y	-	3	-	-	-	-	-	-
131	487433	-	-	2	-	-	y	y	y	-	-	-	-	-	-	-	y	-	-	-	3	-	-	-	-	-	-
132	860301	-	-	2	-	y	-	-	-	-	-	-	y	y	-	-	-	-	-	-	3	-	-	-	-	-	-
133	870491	-	-	1	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	3	-	-	-	-	-	-
134	870616	-	-	2	-	-	-	-	y	-	-	-	-	-	-	-	-	y	-	-	3	-	-	-	-	-	-
135	870526	-	-	2	y	y	y	-	-	-	-	-	-	-	-	-	y	-	-	-	3	-	-	-	-	-	-
136	868092	-	-	2	-	-	-	-	-	-	-	-	y	-	-	-	-	y	-	-	3	-	-	-	-	-	-
137	730279	-	-	2	-	-	-	-	y	-	-	-	-	-	-	-	-	y	-	phlegmonous changes, peripancreatic collection	3	-	-	-	-	-	-
138	873183	-	-	2	y	y	-	-	-	-	-	y	y	-	-	-	-	-	-	-	3	-	-	-	-	-	-
139	863874	-	-	2	y	y	-	-	y	-	-	-	-	-	-	-	-	-	-	-	3	-	-	-	-	-	-
140	874227	-	-	2	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	3	-	-	-	-	-	-
141	874222	-	pulmonary edema	2	y	y	-	-	-	-	-	-	-	-	-	-	-	-	-	-	3	-	-	-	-	-	-
142	874605	-	-	2	-	-	y	y	-	-	-	y	-	-	-	-	y	-	-	-	3	-	-	-	-	-	-
143	837754	-	-	1	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	3	-	-	-	-	-	-
144	839395	-	-	1	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	3	-	-	-	-	-	-
145	648486	-	-	2	y	-	-	-	-	-	-	-	-	-	-	-	-	y	-	-	3	-	-	-	-	-	-
146	639722	-	-	1	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	3	-	-	-	-	-	-
147	840633	-	-	2	-	-	-	y	y	-	-	y	-	-	-	-	-	y	-	-	3	-	-	-	-	-	-
148	681164	-	?aspiration pneumonitis	2	-	y	-	-	-	-	-	-	-	-	y	-	-	-	-	-	3	-	-	-	-	-	-
149	736950	-	-	3	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	3	-	-	-	y	-	-
150	844350	-	-	2	-	y	-	-	-	-	-	-	-	-	-	-	-	-	-	-	3	-	-	-	-	-	-
151	838640	-	-	2	-	-	y	y	y	-	-	-	-	-	-	-	y	-	-	-	3	-	-	-	-	-	-
152	457005	-	-	2	-	-	-	y	-	-	-	-	-	-	-	-	-	-	-	-	3	-	-	-	-	-	-
153	93021	-	-	2	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	3	-	-	-	-	-	-
154	582848	-	-	1	y	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	3	-	-	-	-	-	-
155	834904	-	-	2	-	-	y	y	y	-	-	-	-	-	-	-	y	-	-	-	3	-	-	-	-	-	-
156	824096	-	?aspiration pneumonitis	2	y	y	-	-	-	-	-	-	-	-	-	-	-	-	-	-	3	-	-	-	-	-	-
157	840091	-	cavitatory nodules	2	-	y	-	y	-	-	-	-	-	-	-	-	-	-	-	-	3	-	-	-	-	-	-
158	884091	-	-	2	-	-	-	y	y	y	-	-	-	-	-	-	-	y	-	-	3	-	-	-	-	-	-
159	746917	-	-	2	y	y	-	-	-	-	-	-	-	-	-	y	-	-	-	-	3	-	-	-	-	-	-
160	776677	-	-	2	-	-	-	-	-	y	-	-	-	-	-	-	-	y	-	-	3	-	-	-	-	-	-
161	836002	-	mediastinal widening	2	-	-	-	-	-	-	-	-	-	-	-	y	y	-	-	-	2	-	-	-	-	-	-
162	849333	-	-	2	y	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	3	-	-	-	-	-	-
163	851055	-	inhomogenous opacities	2	-	y	-	-	-	-	-	-	-	-	-	-	-	-	-	-	2	-	-	-	-	-	-
164	845069	-	-	2	-	y	-	-	-	-	-	-	-	-	-	-	-	y	-	-	3	-	-	-	-	-	-
165	531317	-	-	2	y	-	-	-	y	-	-	-	-	-	-	-	-	-	-	-	3	-	-	-	-	-	-
166	849455	-	-	2	y	y	-	-	-	-	-	-	-	-	-	-	-	-	-	-	3	-	-	-	-	-	-
167	383444	-	-	2	-	-	-	y	-	-	-	-	-	-	y	-	-	-	-	-	3	-	-	-	-	-	-
168	849152	-	?aspiration pneumonitis	2	-	y	-	y	-	-	-	-	-	-	-	-	-	-	-	gbwe	3	-	-	-	-	-	-
169	853509	-	-	2	-	y	-	-	-	-	-	-	-	y	-	-	-	-	-	?lymph nodal mass	3	-	-	-	-	-	-
170	856156	-	left pneumothorax	2	-	y	-	-	-	-	-	-	-	-	-	-	-	-	-	pyelonephritis	3	-	-	-	-	-	-
171	36273	-	?aspiration pneumonitis	2	-	y	-	-	y	y	-	-	-	-	-	-	-	-	-	emphysematous pyelonephritis	3	-	-	-	-	-	-
172	897187	-	-	2	-	-	-	-	-	-	-	y	-	-	-	-	y	-	-	aki	3	-	-	-	-	-	-
173	892695	-	-	2	-	-	-	y	y	-	-	-	-	-	-	-	y	-	-	-	2	y	-	-	-	-	-
174	383444	-	-	2	-	-	-	-	-	-	y	-	-	-	y	-	-	-	-	obstructive biliopathy	3	-	-	-	-	-	-
175	907933	-	-	2	y	y	-	y	y	y	-	-	-	-	-	-	-	-	-	thick endometrium	2	y	y	y	y	y	-
176	150185	-	-	2	y	-	-	-	-	-	-	y	-	-	-	-	-	-	-	-	3	-	-	-	-	-	-
177	902832	-	-	2	-	y	-	-	-	-	-	-	-	-	-	-	-	-	-	-	3	-	-	-	-	-	-
178	888867	-	-	2	y	y	-	-	-	-	-	-	-	-	-	-	-	-	-	-	3	-	-	-	-	-	-
179	891164	-	inhomogenous opacities	2	-	-	-	-	-	-	-	-	-	-	-	y	y	-	-	-	2	-	-	-	-	-	-
180	881651	y	-	2	y	-	-	-	-	-	y	-	-	-	-	-	-	-	-	-	2	-	y	-	-	y	-
181	874012	-	-	2	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	prostatomegaly,umblical hernia	2	-	-	y	-	-	-
182	666086	-	-	2	-	-	-	-	-	-	-	y	-	-	-	-	-	-	-	-	3	-	-	-	-	-	-
183	873183	-	-	2	-	-	-	-	-	-	-	y	y	-	-	-	-	-	-	-	3	-	-	-	-	-	-
184	876104	y	-	2	-	-	-	y	-	-	-	-	-	-	y	-	-	-	-	adnexal mass	3	-	-	-	-	-	-
185	882709	-	inhomogenous opacities	3	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	2	-	-	-	-	y	-
186	849332	-	-	2	y	y	-	-	-	-	-	-	-	-	-	-	-	-	-	-	3	-	-	-	-	-	-
187	759614	-	-	2	-	-	y	-	-	-	-	-	-	-	-	-	y	-	-	-	3	-	-	-	-	-	-
188	893454	-	-	2	-	-	-	-	-	-	-	y	y	-	-	-	-	-	-	-	3	-	-	-	-	-	-
189	568835	-	-	2	-	-	y	y	y	-	-	-	-	-	-	-	y	-	-	-	3	-	-	-	-	-	-
190	787977	-	-	2	-	y	-	y	-	-	-	-	-	-	-	-	-	-	-	-	2	-	-	-	y	-	-
191	848737	-	-	2	y	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	3	-	-	-	-	-	-

sr no	mrd	ct chest lymphangitis carcinomatosis	ct chest osseous metastasis	ct chest consolidation	ct chest other	ct abdomen nor=1/abn=2/not done=3	ct abdomen rpcg	ct abdomen cld	ct abdomen pleural effusion	ct abdomen ascites	ct abdomen lap	ct abdomen cholelithiasis	ct abdomen nephrolithiasis	ct abdomen nephrocalcinosis	ct abdomen sol/metastasis	ct abdomen s/o tb	ct abdomen pancreatitis	ct abdomen hcc	ct abdomen other	mri spine nor=1/abn=2/not done=3	mri spine vertebral collapse	mri spine lytic lesion	mri spine altered signal intensity	mri spine diffuse marrow infilteration	mri spine other
98	768710	y	-	-	-	3	-	-	-	-	-	-	-	-	-	-	-	-	-	3	-	-	-	-	-
99	758074	-	-	-	-	3	-	-	-	-	-	-	-	-	-	-	-	-	-	3	-	-	-	-	-
100	483498	-	-	-	-	3	-	-	-	-	-	-	-	-	-	-	-	-	-	3	-	-	-	-	-
101	772868	-	-	-	-	3	-	-	-	-	-	-	-	-	-	-	-	-	-	3	-	-	-	-	-
102	937061	-	-	-	-	3	-	-	-	-	-	-	-	-	-	-	-	-	-	3	-	-	-	-	-
103	961780	-	-	-	-	3	-	-	-	-	-	-	-	-	-	-	-	-	-	3	-	-	-	-	-
104	794384	-	-	-	-	3	-	-	-	-	-	-	-	-	-	-	-	-	-	3	-	-	-	-	-
105	800496	-	-	-	-	2	-	-	y	-	-	-	-	-	y	-	-	-	-	3	-	-	-	-	-
106	797701	-	-	-	-	3	-	-	-	-	-	-	-	-	-	-	-	-	-	3	-	-	-	-	-
107	784819	-	-	-	-	3	-	-	-	-	-	-	-	-	-	-	-	-	-	3	-	-	-	-	-
108	795785	-	-	-	-	3	-	-	-	-	-	-	-	-	-	-	-	-	-	3	-	-	-	-	-
109	803042	-	-	-	-	3	-	-	-	-	-	-	-	-	-	-	-	-	-	3	-	-	-	-	-
110	715766	y	-	-	-	3	-	-	-	-	-	-	-	-	-	-	-	-	-	3	-	-	-	-	-
111	801466	-	-	-	-	3	-	-	-	-	-	-	-	-	-	-	-	-	-	3	-	-	-	-	-
112	757988	-	-	-	-	3	-	-	-	-	-	-	-	-	-	-	-	-	-	3	-	-	-	-	-
113	806528	-	-	-	-	3	-	-	-	-	-	-	-	-	-	-	-	-	-	3	-	-	-	-	-
114	78322	-	-	-	-	3	-	-	-	-	-	-	-	-	-	-	-	-	-	3	-	-	-	-	-
115	800002	-	-	-	-	3	-	-	-	-	-	-	-	-	-	-	-	-	-	3	-	-	-	-	-
116	808782	-	-	-	-	2	-	-	y	y	-	-	-	-	-	-	y	-	-	3	-	-	-	-	-
117	758074	-	-	-	-	3	-	-	-	-	-	-	-	-	-	-	-	-	-	3	-	-	-	-	-
118	808924	-	-	-	-	3	-	-	-	-	-	-	-	-	-	-	-	-	-	3	-	-	-	-	-
119	813129	-	-	-	-	1	-	-	-	-	-	-	-	-	-	-	-	-	-	3	-	-	-	-	-
120	120235	-	-	-	-	3	-	-	-	-	-	-	-	-	-	-	-	-	-	3	-	-	-	-	-
121	815300	-	-	-	-	3	-	-	-	-	-	-	-	-	-	-	-	-	-	3	-	-	-	-	-
122	806598	-	-	-	-	3	-	-	-	-	-	-	-	-	-	-	-	-	-	3	-	-	-	-	-
123	202821	-	-	y	-	3	-	-	-	-	-	-	-	-	-	-	-	-	-	3	-	-	-	-	-
124	676387	-	-	-	-	3	-	-	-	-	-	-	-	-	-	-	-	-	-	3	-	-	-	-	-
125	816494	-	-	-	-	3	-	-	-	-	-	-	-	-	-	-	-	-	-	3	-	-	-	-	-
126	815505	-	-	-	-	3	-	-	-	-	-	-	-	-	-	-	-	-	-	3	-	-	-	-	-
127	816596	-	-	-	-	3	-	-	-	-	-	-	-	-	-	-	-	-	-	3	-	-	-	-	-
128	518576	-	-	-	-	3	-	-	-	-	-	-	-	-	-	-	-	-	-	2	y	-	-	y	-
129	868046	-	-	-	-	3	-	-	-	-	-	-	-	-	-	-	-	-	-	3	-	-	-	-	-
130	867305	-	-	-	-	3	-	-	-	-	-	-	-	-	-	-	-	-	-	3	-	-	-	-	-
131	487433	-	-	-	-	3	-	-	-	-	-	-	-	-	-	-	-	-	-	3	-	-	-	-	-
132	860301	-	-	-	-	3	-	-	-	-	-	-	-	-	-	-	-	-	-	3	-	-	-	-	-
133	870491	-	-	-	-	3	-	-	-	-	-	-	-	-	-	-	-	-	-	3	-	-	-	-	-
134	870616	-	-	-	-	3	-	-	-	-	-	-	-	-	-	-	-	-	-	3	-	-	-	-	-
135	870526	-	-	-	-	3	-	-	-	-	-	-	-	-	-	-	-	-	-	3	-	-	-	-	-
136	868092	-	-	-	-	3	-	-	-	-	-	-	-	-	-	-	-	-	-	3	-	-	-	-	-
137	730279	-	-	-	-	3	-	-	-	-	-	-	-	-	-	-	-	-	-	3	-	-	-	-	-
138	873183	-	-	-	-	3	-	-	-	-	-	-	-	-	-	-	-	-	-	3	-	-	-	-	-
139	863874	-	-	-	-	3	-	-	-	-	-	-	-	-	-	-	-	-	-	3	-	-	-	-	-
140	874227	-	-	-	-	3	-	-	-	-	-	-	-	-	-	-	-	-	-	3	-	-	-	-	-
141	874222	-	-	-	-	3	-	-	-	-	-	-	-	-	-	-	-	-	-	3	-	-	-	-	-
142	874605	-	-	-	-	3	-	-	-	-	-	-	-	-	-	-	-	-	-	3	-	-	-	-	-
143	837754	-	-	-	-	3	-	-	-	-	-	-	-	-	-	-	-	-	-	3	-	-	-	-	-
144	839395	-	-	-	-	3	-	-	-	-	-	-	-	-	-	-	-	-	-	3	-	-	-	-	-
145	648486	-	-	-	-	3	-	-	-	-	-	-	-	-	-	-	-	-	-	3	-	-	-	-	-
146	639722	-	-	-	-	3	-	-	-	-	-	-	-	-	-	-	-	-	-	3	-	-	-	-	-
147	840633	-	-	-	-	2	-	-	-	-	-	-	-	-	-	-	y	-	walled off pancreatic necrosis	3	-	-	-	-	-
148	681164	-	-	-	-	3	-	-	-	-	-	-	-	-	-	-	-	-	-	3	-	-	3	-	-
149	736950	-	-	-	-	3	-	-	-	-	-	-	-	-	-	-	-	-	-	3	-	-	-	-	-
150	844350	-	-	-	-	3	-	-	-	-	-	-	-	-	-	-	-	-	-	3	-	-	-	-	-
151	838640	-	-	-	-	3	-	-	-	-	-	-	-	-	-	-	-	-	-	3	-	-	-	-	-
152	457005	-	-	-	-	3	-	-	-	-	-	-	-	-	-	-	-	-	-	3	-	-	-	-	-
153	93021	-	-	-	-	3	-	-	-	-	-	-	-	-	-	-	-	-	-	3	-	-	-	-	-
154	582848	-	-	-	-	3	-	-	-	-	-	-	-	-	-	-	-	-	-	3	-	-	-	-	-
155	834904	-	-	-	-	3	-	-	-	-	-	-	-	-	-	-	-	-	-	3	-	-	-	-	-
156	824096	-	-	-	-	3	-	-	-	-	-	-	-	-	-	-	-	-	-	3	-	-	-	-	-
157	840091	-	-	-	-	3	-	-	-	-	-	-	-	-	-	-	-	-	-	3	-	-	-	-	-
158	884091	-	-	-	-	3	-	-	-	-	-	-	-	-	-	-	-	-	-	3	-	-	-	-	-
159	746917	-	-	-	-	3	-	-	-	-	-	-	-	-	-	-	-	-	-	3	-	-	-	-	-
160	776677	-	-	-	-	3	-	-	-	-	-	-	-	-	-	-	-	-	-	3	-	-	-	-	-
161	836002	-	-	-	lymphoma	3	-	-	-	-	-	-	-	-	-	-	-	-	-	3	-	-	-	-	-
162	849333	-	-	-	-	3	-	-	-	-	-	-	-	-	-	-	-	-	-	3	-	-	-	-	-
163	851055	-	-	-	ggo's	3	-	-	-	-	-	-	-	-	-	-	-	-	-	2	y	y	-	-	-
164	845069	-	-	-	-	2	-	-	-	-	-	-	-	-	-	-	y	-	-	3	-	-	-	-	-
165	531317	-	-	-	-	3	-	-	-	-	-	-	-	-	-	-	-	-	-	3	-	-	-	-	-
166	849455	-	-	-	-	3	-	-	-	-	-	-	-	-	-	-	-	-	-	2	y	-	-	-	-
167	383444	-	-	-	-	3	-	-	-	-	-	-	-	-	-	-	-	-	-	3	-	-	-	-	-
168	849152	-	-	-	-	3	-	-	-	-	-	-	-	-	-	-	-	-	-	3	-	-	-	-	-
169	853509	-	-	-	-	3	-	-	-	-	-	-	-	-	-	-	-	-	-	3	-	-	-	-	-
170	856156	-	-	-	-	3	-	-	-	-	-	-	-	-	-	-	-	-	-	3	-	-	-	-	-
171	36273	-	-	-	-	3	-	-	-	-	-	-	-	-	-	-	-	-	-	3	-	-	-	-	-
172	897187	-	-	-	-	3	-	-	-	-	-	-	-	-	-	-	-	-	-	2	y	-	y	-	-
173	892695	-	-	y	-	3	-	-	-	-	-	-	-	-	-	-	-	-	-	3	-	-	-	-	-
174	383444	-	-	-	-	3	-	-	-	-	-	-	-	-	-	-	-	-	-	3	-	-	-	-	-
175	907933	-	-	-	-	3	-	-	-	-	-	-	-	-	-	-	-	-	-	3	-	-	-	-	-
176	150185	-	-	-	-	3	-	-	-	-	-	-	-	-	-	-	-	-	-	3	-	-	-	-	-
177	902832	-	-	-	-	3	-	-	-	-	-	-	-	-	-	-	-	-	-	3	-	-	-	-	-
178	888867	-	-	-	-	3	-	-	-	-	-	-	-	-	-	-	-	-	-	2	y	y	-	-	-
179	891164	-	-	y	-	3	-	-	-	-	-	-	-	-	-	-	-	-	-	3	-	-	-	-	-
180	881651	y	y	-	pleural mets, patho#d10	3	-	-	-	-	-	-	-	-	-	-	-	-	-	3	-	-	-	-	-
181	874012	-	y	-	-	3	-	-	-	-	-	-	-	-	-	-	-	-	-	3	-	-	-	-	-
182	666086	-	-	-	-	3	-	-	-	-	-	-	-	-	-	-	-	-	-	3	-	-	-	-	-
183	873183	-	-	-	-	3	-	-	-	-	-	-	-	-	-	-	-	-	-	3	-	-	-	-	-
184	876104	-	-	-	-	3	-	-	-	-	-	-	-	-	-	-	-	-	-	3	-	-	-	-	-
185	882709	-	-	-	tracheo-esophageal communication	3	-	-	-	-	-	-	-	-	-	-	-	-	-	3	-	-	-	-	-
186	849332	-	-	-	-	3	-	-	-	-	-	-	-	-	-	-	-	-	-	3	-	-	-	-	-
187	759614	-	-	-	-	3	-	-	-	-	-	-	-	-	-	-	-	-	-	3	-	-	-	-	-
188	893454	-	-	-	-	3	-	-	-	-	-	-	-	-	-	-	-	-	-	3	-	-	-	-	-
189	568835	-	-	-	-	3	-	-	-	-	-	-	-	-	-	-	-	-	-	3	-	-	-	-	-
190	787977	-	-	-	?granulomatous	3	-	-	-	-	-	-	-	-	-	-	-	-	-	3	-	-	-	-	-
191	848737	-	-	-	-	3	-	-	-	-	-	-	-	-	-	-	-	-	-	3	-	-	-	-	-

sr no	mrd	ncct head nor/abn/ not done-1/2/3	mri brain nor/abn/not done-1/2/3	bone scan-nor/abn/not done-1/2/3	pet scan nor=1/abn=2/not done=3	pet scan inc fdg uptake in	usg neck parathyroid adenoma yes/no/not done-1/2/3	usg neck parathyroid adenoma right-1,left-2	usg neck parathyroid adenoma superior-1, inferior-2	sestamibi scan y/n/not done-1/2/3	sestamibi scan right-1,left-2	sestamibi scan superior-1,inferior-2	sestamibi scan other	xray skull punched out lesions y/n/not done-1/2/3	24 hr urinary calcium	spep m band y/n/not done-1/2/3	bma & biopsy nor/abn/not done-1/2/3	plasma cell dyscrasia	other
98	768710	3	3	3	3	-	-	-	-	3	-	-	-	3	-	3	3	-	-
99	758074	3	3	3	2	thoracic and abdominal lymph nodes	3	-	-	3	-	-	-	3	-	3	3	-	-
100	483498	3	3	3	3	-	3	-	-	3	-	-	-	1	-	1	2	y	-
101	772868	3	3	2	3	-	3	-	-	3	-	-	-	3	-	3	3	-	-
102	937061	3	3	3	3	-	3	-	-	3	-	-	-	3	-	3	3	-	-
103	961780	3	3	3	3	-	3	-	-	2	-	-	toxic nodular goitre	3	-	3	3	-	-
104	794384	3	1	3	3	-	2	-	-	2	-	-	toxic nodular goitre	3	-	3	3	-	-
105	800496	3	3	3	3	-	3	-	-	3	-	-	-	3	-	3	3	-	-
106	797701	3	3	3	3	-	1	2	2	1	2	2	-	3	-	3	3	-	-
107	784819	3	3	3	3	-	3	-	-	3	-	-	-	3	-	3	3	-	-
108	795785	1	3	3	3	-	2	-	-	1	2	2	-	3	-	3	3	-	-
109	803042	3	3	3	3	-	1	1	1	1	1	1	-	3	-	3	3	-	-
110	715766	3	3	3	3	-	3	-	-	3	-	-	-	3	-	3	3	-	-
111	801466	3	3	3	3	-	2	-	-	1	2	1	-	3	-	2	3	-	-
112	757988	3	3	3	3	-	3	-	-	3	-	-	-	3	-	3	3	-	-
113	806528	3	3	3	3	-	3	-	-	3	-	-	-	3	-	3	3	-	-
114	78322	3	3	3	3	-	3	-	-	3	-	-	-	3	-	3	3	-	-
115	800002	3	3	3	3	-	3	-	-	3	-	-	-	3	-	1	2	y	-
116	808782	3	3	3	3	-	1	1	2	1	1	2	-	3	-	3	3	-	-
117	758074	3	3	3	3	-	3	-	-	3	-	-	-	3	-	3	3	-	-
118	808924	3	3	3	3	-	1	2	2	1	2	2	-	3	-	3	3	-	-
119	813129	3	3	3	3	-	3	-	-	3	-	-	-	3	-	3	3	-	-
120	120235	3	3	3	3	-	1	1	1	1	1	2	-	3	-	3	3	-	-
121	815300	3	3	3	3	-	3	-	-	3	-	-	-	3	-	1	2	y	-
122	806598	3	3	3	3	-	1	2	2	1	2	2	-	3	-	3	3	-	-
123	202821	3	3	3	3	-	3	-	-	3	-	-	-	3	-	2	3	-	-
124	676387	3	htn angiopath	3	3	-	3	-	-	3	-	-	-	3	-	3	3	-	-
125	816494	1	3	3	3	-	3	-	-	3	-	-	-	3	-	3	2	y	-
126	815505	3	3	3	3	-	3	-	-	3	-	-	-	3	-	3	3	-	-
127	816596	3	3	3	3	-	1	1	2	1	1	2	-	3	-	3	3	-	-
128	518576	3	3	1	3	-	3	-	-	3	-	-	-	3	-	1	2	y	-
129	868046	3	3	3	2	bones	3	-	-	3	-	-	-	3	-	3	3	-	-
130	867305	3	tbm	3	3	-	3	-	-	3	-	-	-	3	-	3	3	-	-
131	487433	3	3	3	3	-	3	-	-	3	-	-	-	1	-	2	1	-	-
132	860301	3	3	3	3	-	1	1	2	1	1	2	-	3	-	3	3	-	-
133	870491	3	3	3	3	-	3	-	-	2	-	-	acute thyroiditis-grave's	3	-	3	3	-	-
134	870616	3	3	3	3	-	2	-	-	1	2	2	-	3	-	3	3	-	-
135	870526	3	3	3	3	-	3	-	-	3	-	-	-	3	-	2	3	-	-
136	868092	3	3	3	3	-	1	1	2	1	1	2	-	3	-	3	3	-	-
137	730279	3	3	3	3	-	1	2	2	1	2	2	-	3	-	3	3	-	-
138	873183	3	3	3	3	-	1	1	2	1	1	2	-	3	-	3	3	-	-
139	863874	3	3	3	3	-	3	-	-	3	-	-	-	3	-	3	3	-	-
140	874227	1	3	3	3	-	3	-	-	3	-	-	-	3	-	3	3	-	-
141	874222	calvarial metas	3	3	3	-	3	-	-	3	-	-	-	3	-	2	3	-	-
142	874605	3	3	3	3	-	3	-	-	3	-	-	-	3	-	3	3	-	-
143	837754	3	3	3	3	-	1	2	2	1	2	2	-	3	-	3	3	-	-
144	839395	3	3	3	3	-	3	-	-	3	-	-	-	3	-	3	3	-	-
145	648486	3	3	3	3	-	2	-	-	1	2	2	-	3	-	3	3	-	-
146	639722	3	3	3	3	-	2	-	-	1	2	2	-	3	-	3	3	-	-
147	840633	3	3	3	3	-	1	1	2	1	1	2	-	3	-	3	3	-	-
148	681164	3	3	3	3	-	3	-	-	3	-	-	-	3	-	3	3	-	-
149	736950	3	3	3	3	-	3	-	-	3	-	-	-	3	-	3	3	-	-
150	844350	3	1	3	3	-	3	-	-	3	-	-	-	3	-	3	3	-	-
151	838640	3	pachymening	3	3	-	3	-	-	3	-	-	-	3	-	3	3	-	-
152	457005	3	3	3	3	-	3	-	-	3	-	-	-	3	-	3	3	-	-
153	93021	3	3	3	3	-	2	-	-	2	-	-	acute thyroiditis-grave's	3	-	3	3	-	-
154	582848	3	3	3	3	-	3	-	-	3	-	-	-	3	-	3	3	-	-
155	834904	3	3	3	3	-	3	-	-	3	-	-	-	3	-	3	3	-	-
156	824096	3	3	3	3	-	3	-	-	3	-	-	-	3	-	3	3	-	-
157	840091	3	3	3	3	-	3	-	-	3	-	-	-	3	-	3	3	-	-
158	884091	3	3	3	3	-	2	-	-	1	2	1	-	3	-	3	3	-	-
159	746917	3	3	3	3	-	3	-	-	3	-	-	-	3	-	3	3	-	-
160	776677	3	3	3	3	-	1	1	2	1	1	2	-	3	-	3	3	-	-
161	836002	3	3	3	2	lymph nodes and hsm	3	-	-	3	-	-	-	3	-	3	3	-	-
162	849333	3	3	3	3	-	3	-	-	3	-	-	-	3	-	2	3	-	-
163	851055	3	3	3	3	-	3	-	-	3	-	-	-	1	-	1	2	y	-
164	845069	3	3	3	3	-	3	-	-	3	-	-	-	3	-	3	3	-	-
165	531317	3	3	3	3	-	1	1	2	1	1	2	-	3	-	3	3	-	-
166	849455	3	3	3	3	-	3	-	-	3	-	-	-	3	-	1	2	y	-
167	383444	3	3	3	3	-	3	-	-	3	-	-	-	3	-	3	3	-	-
168	849152	3	3	3	3	-	1	2	2	1	2	2	-	3	-	3	3	-	-
169	853509	3	3	3	3	-	3	-	-	3	-	-	-	3	-	3	3	-	-
170	856156	3	3	3	3	-	3	-	-	3	-	-	-	3	-	3	3	-	-
171	36273	1	3	3	3	-	3	-	-	3	-	-	-	3	-	3	3	-	-
172	897187	3	3	3	2	L1 and L2	3	-	-	3	-	-	-	3	-	1	2	y	-
173	892695	3	3	3	3	-	3	-	-	3	-	-	-	3	-	3	3	-	-
174	383444	3	3	3	3	-	3	-	-	3	-	-	-	3	-	3	3	-	-
175	907933	3	3	3	3	-	3	-	-	3	-	-	-	3	-	3	2	n	metastatic carcinomatous deposits
176	150185	3	3	3	3	-	2	-	-	1	1	2	-	3	-	3	3	-	-
177	902832	3	chronic ischa	3	3	-	3	-	-	3	-	-	-	1	-	1	2	y	-
178	888867	3	3	3	3	-	3	-	-	3	-	-	-	3	-	3	2	y	-
179	891164	3	3	3	3	-	3	-	-	3	-	-	-	3	-	3	3	-	-
180	881651	3	3	3	3	-	3	-	-	3	-	-	-	3	-	3	3	-	-
181	874012	3	3	3	3	-	3	-	-	3	-	-	-	3	-	1	2	y	-
182	666086	3	3	3	3	-	1	2	2	1	2	2	-	3	-	3	3	-	-
183	873183	3	3	3	3	-	1	1	2	1	1	2	-	3	-	3	3	-	-
184	876104	3	3	3	3	-	3	-	-	3	-	-	-	3	-	2	3	-	-
185	882709	3	3	3	3	-	3	-	-	3	-	-	-	3	-	3	3	-	-
186	849332	3	3	3	3	-	3	-	-	3	-	-	-	3	-	3	3	-	-
187	759614	3	3	3	3	-	2	-	-	2	-	-	-	3	-	2	3	-	-
188	893454	3	3	3	3	-	1	2	1	1	2	1	-	3	-	3	3	-	-
189	568835	3	3	3	3	-	3	-	-	3	-	-	-	3	-	3	3	-	-
190	787977	3	3	3	3	-	3	-	-	3	-	-	-	3	-	3	3	-	-
191	848737	3	3	3	3	-	3	-	-	3	-	-	-	3	-	3	3	-	-

sr no	mrd	24hr urine for light chain assay y/n/not done-1/2/3	24hr urine for light chain assay	other	fnac/biosy other part_y/n/not done-1/2/3	atypical cells	area	malignancy	Probable malignancy	malignancy ca bladder	malignancy ca penis	malignancy ca ovary	malignancy ca cervix	malignancy ca esophagus	malignancy hcc	malignancy ca head and neck	malignancy ca gall bladder and bile ducts	malignancy multiple myeloma	malignancy breast	malignancy rcc	malignancy lymphoma	malignancy cml
98	768710	3	-	-	3	-	-	n	y	-	-	-	-	-	-	-	-	-	-	-	?	-
99	758074	3	-	-	2	lymphoid	lymph node	y	n	-	-	-	-	-	-	-	-	-	-	-	y	-
100	483498	3	-	-	3	-	-	y	n	-	-	-	-	-	-	-	-	y	-	-	-	-
101	772868	3	-	-	3	-	-	y	n	-	-	-	-	-	-	-	-	-	y	-	-	-
102	937061	3	-	-	3	-	-	y	n	-	-	y	-	-	-	-	-	-	-	-	-	-
103	961780	3	-	-	3	-	-	n	n	-	-	-	-	-	-	-	-	-	-	-	-	-
104	794384	3	-	-	3	-	-	n	n	-	-	-	-	-	-	-	-	-	-	-	-	-
105	800496	3	-	-	2	lymphoid	retroperitoneal mass	y	n	-	-	-	-	-	-	-	-	-	-	-	y	-
106	797701	3	-	-	3	-	-	n	n	-	-	-	-	-	-	-	-	-	-	-	-	-
107	784819	3	-	-	3	-	-	n	n	-	-	-	-	-	-	-	-	-	-	-	-	-
108	795785	3	-	-	3	-	-	n	n	-	-	-	-	-	-	-	-	-	-	-	-	-
109	803042	3	-	-	3	-	-	n	n	-	-	-	-	-	-	-	-	-	-	-	-	-
110	715766	3	-	ct head and neck-mass in retromolar area extend into masticator space	2	scc	retromolar mass	y	n	-	-	-	-	-	-	y	-	-	-	-	-	-
111	801466	3	-	-	3	-	-	n	n	-	-	-	-	-	-	-	-	-	-	-	-	-
112	757988	3	-	-	3	-	-	y	n	-	-	-	-	-	-	-	y	-	-	-	-	-
113	806528	3	-	malignant pleural effusion	3	-	-	y	n	-	-	-	-	-	-	-	-	-	-	-	-	-
114	78322	3	-	-	3	-	-	n	n	-	-	-	-	-	-	-	-	-	-	-	-	-
115	800002	3	-	-	3	-	-	y	n	-	-	-	-	-	-	-	-	y	-	-	-	-
116	808782	3	-	-	3	-	-	n	n	-	-	-	-	-	-	-	-	-	-	-	-	-
117	758074	3	-	-	2	lymphoid	lymph node	y	n	-	-	-	-	-	-	-	-	-	-	-	y	-
118	808924	3	-	-	3	-	-	n	n	-	-	-	-	-	-	-	-	-	-	-	-	-
119	813129	3	-	-	3	-	-	n	n	-	-	-	-	-	-	-	-	-	-	-	-	-
120	120235	3	-	-	3	-	-	n	n	-	-	-	-	-	-	-	-	-	-	-	-	-
121	815300	3	-	-	3	-	-	y	n	-	-	-	-	-	-	-	-	y	-	-	-	-
122	806598	3	-	-	3	-	-	n	n	-	-	-	-	-	-	-	-	-	-	-	-	-
123	202821	3	-	-	3	-	-	n	y	-	-	-	-	-	-	-	-	?	-	-	-	-
124	676387	3	-	-	3	-	-	n	n	-	-	-	-	-	-	-	-	-	-	-	-	-
125	816494	3	-	xray spine-vertebral collapse	3	-	-	y	n	-	-	-	-	-	-	-	-	y	-	-	-	-
126	815505	3	-	-	3	-	-	n	n	-	-	-	-	-	-	-	-	-	-	-	-	-
127	816596	3	-	-	3	-	-	n	n	-	-	-	-	-	-	-	-	-	-	-	-	-
128	518576	3	-	-	3	-	-	y	n	-	-	-	-	-	-	-	-	y	-	-	-	-
129	868046	3	-	-	2	malignant aspirate	breast	y	n	-	-	-	-	-	-	-	-	-	y	-	-	-
130	867305	3	-	csf cbnaat-mtb	3	-	-	n	n	-	-	-	-	-	-	-	-	-	-	-	-	-
131	487433	3	-	-	3	-	-	n	n	-	-	-	-	-	-	-	-	-	-	-	-	-
132	860301	3	-	-	3	-	-	n	n	-	-	-	-	-	-	-	-	-	-	-	-	-
133	870491	3	-	-	3	-	-	n	n	-	-	-	-	-	-	-	-	-	-	-	-	-
134	870616	3	-	-	3	-	-	n	n	-	-	-	-	-	-	-	-	-	-	-	-	-
135	870526	3	-	-	3	-	-	n	n	-	-	-	-	-	-	-	-	-	-	-	-	-
136	868092	3	-	-	3	-	-	n	n	-	-	-	-	-	-	-	-	-	-	-	-	-
137	730279	3	-	-	3	-	-	n	n	-	-	-	-	-	-	-	-	-	-	-	-	-
138	873183	3	-	-	3	-	-	n	n	-	-	-	-	-	-	-	-	-	-	-	-	-
139	863874	3	-	-	3	-	-	n	n	-	-	-	-	-	-	-	-	-	-	-	-	-
140	874227	3	-	-	3	-	-	n	n	-	-	-	-	-	-	-	-	-	-	-	-	-
141	874222	3	-	-	2	insufficient cellularity	lymph node	n	n	-	-	-	-	-	-	-	-	-	-	-	-	-
142	874605	3	-	-	3	-	-	n	n	-	-	-	-	-	-	-	-	-	-	-	-	-
143	837754	3	-	-	3	-	-	n	n	-	-	-	-	-	-	-	-	-	-	-	-	-
144	839395	3	-	-	3	-	-	n	n	-	-	-	-	-	-	-	-	-	-	-	-	-
145	648486	3	-	ct neck- parathyroid adenoma (2,1)	3	-	-	n	n	-	-	-	-	-	-	-	-	-	-	-	-	-
146	639722	3	-	-	3	-	-	n	n	-	-	-	-	-	-	-	-	-	-	-	-	-
147	840633	3	-	-	3	-	-	n	n	-	-	-	-	-	-	-	-	-	-	-	-	-
148	681164	3	-	-	3	-	-	y	n	-	-	-	-	y	-	-	-	-	-	-	-	-
149	736950	3	-	mri abdo- diffuse restriction in perineum,invol lower 1/2 vaginal stump? Deposits	3	-	-	y	n	-	-	y	-	-	-	-	-	-	-	-	-	-
150	844350	3	-	-	3	-	-	y	n	-	-	-	-	-	-	-	-	-	-	y	-	-
151	838640	3	-	-	3	-	-	n	n	-	-	-	-	-	-	-	-	-	-	-	-	-
152	457005	3	-	-	3	-	-	y	n	-	-	y	-	-	-	-	-	-	-	-	-	-
153	93021	3	-	-	3	-	-	n	n	-	-	-	-	-	-	-	-	-	-	-	-	-
154	582848	3	-	-	3	-	-	y	n	-	-	-	-	-	-	-	-	y	-	-	-	-
155	834904	3	-	-	3	-	-	n	n	-	-	-	-	-	-	-	-	-	-	-	-	-
156	824096	3	-	-	3	-	-	y	n	-	-	-	-	-	-	-	-	-	y	-	-	-
157	840091	3	-	canca-3+	3	-	-	n	n	-	-	-	-	-	-	-	-	-	-	-	-	-
158	884091	3	-	-	3	-	-	n	n	-	-	-	-	-	-	-	-	-	-	-	-	-
159	746917	3	-	-	3	-	-	n	n	-	-	-	-	-	-	-	-	-	-	-	-	-
160	776677	3	-	mri abdo-chronic pancreatitis with main pancreatic duct stricture	3	-	-	n	n	-	-	-	-	-	-	-	-	-	-	-	-	-
161	836002	3	-	-	3	-	-	y	n	-	-	-	-	-	-	-	-	-	-	-	y	-
162	849333	3	-	-	3	-	-	n	n	-	-	-	-	-	-	-	-	-	-	-	-	-
163	851055	3	-	-	3	-	-	y	n	-	-	-	-	-	-	-	-	y	-	-	-	-
164	845069	3	-	-	3	-	-	y	n	-	-	-	-	-	-	-	-	y	-	-	-	-
165	531317	3	-	-	3	-	-	n	n	-	-	-	-	-	-	-	-	-	-	-	-	-
166	849455	2	4.4g	-	3	-	-	y	n	-	-	-	-	-	-	-	-	y	-	-	-	-
167	383444	3	-	mri abdo-inc in size of lesion and collection in subhepatic space	3	-	-	y	n	y	-	-	-	-	-	-	-	-	-	-	-	-
168	849152	3	-	-	3	-	-	n	n	-	-	-	-	-	-	-	-	-	-	-	-	-
169	853509	3	-	mri abdo-retroperitoneal mass ? Lymphoma	2	lymphoid	retroperitoneal mass	y	n	-	-	-	-	-	-	-	-	-	-	-	y	-
170	856156	3	-	-	3	-	-	y	n	-	-	-	-	-	-	-	-	y	-	-	-	-
171	36273	3	-	-	3	-	-	n	n	-	-	-	-	-	-	-	-	-	-	-	-	-
172	897187	3	-	-	3	-	-	y	n	-	-	-	-	-	-	-	-	y	-	-	-	-
173	892695	3	-	-	3	-	-	n	n	-	-	-	-	-	-	-	-	-	-	-	-	-
174	383444	3	-	-	3	-	-	y	n	-	-	-	-	-	-	-	y	-	-	-	-	-
175	907933	3	-	-	2	malignant aspirate	breast	y	n	-	-	-	-	-	-	-	-	-	y	-	-	-
176	150185	3	-	-	3	-	-	n	n	-	-	-	-	-	-	-	-	-	-	-	-	-
177	902832	3	-	-	3	-	-	y	n	-	-	-	-	-	-	-	-	y	-	-	-	-
178	888867	3	-	-	2	plasmacytoma	vertebral mass	y	n	-	-	-	-	-	-	-	-	y	-	-	-	-
179	891164	3	-	immunophenotype-cd15,30+, pbf-atypical blast 55%	2	lymphoid	lymph node	y	n	-	-	-	-	-	-	-	-	-	-	-	y	-
180	881651	3	-	-	2	malignant aspirate	breast	y	n	-	-	-	-	-	-	-	-	-	y	-	-	-
181	874012	2	1.4g	-	3	-	-	y	n	-	-	-	-	-	-	-	-	y	-	-	-	-
182	666086	3	-	-	3	-	-	n	n	-	-	-	-	-	-	-	-	-	-	-	-	-
183	873183	3	-	-	3	-	-	n	n	-	-	-	-	-	-	-	-	-	-	-	-	-
184	876104	3	-	-	3	-	-	y	n	-	-	y	-	-	-	-	-	-	-	-	-	-
185	882709	3	-	-	3	-	-	y	n	-	-	-	-	y	-	-	-	-	-	-	-	-
186	849332	3	-	-	3	-	-	n	n	-	-	-	-	-	-	-	-	-	-	-	-	-
187	759614	3	-	-	3	-	-	n	n	-	-	-	-	-	-	-	-	-	-	-	-	-
188	893454	3	-	-	3	-	-	n	n	-	-	-	-	-	-	-	-	-	-	-	-	-
189	568835	3	-	-	3	-	-	n	n	-	-	-	-	-	-	-	-	-	-	-	-	-
190	787977	3	-	-	3	-	-	n	n	-	-	-	-	-	-	-	-	-	-	-	-	-
191	848737	3	-	-	3	-	-	n	n	-	-	-	-	-	-	-	-	-	-	-	-	-

sr no	mrd	malignancy ca lung	malignancy unknown primary	hyperparathyroidism	tb	sarcoidosis	vit d intox	drug responsible	thyrotoxicosis	exclusive cld	drug induced	exclusive ckd	bedridden exclusive	other	medical lasix	medical iv fluids	medical calcitonin	medical bisphosphonates	medical steroids	medical dialysis	medical denosumab	medical ct/rt	surgery parathyroidectomy	surgery procedure	surgery mastectomy	surgery debulking surgery	outcome symptoms	outcome calcium	discharge/ dor /dama /death - 1/2/3/4	1month constitutional symptoms
98	768710	-	-	-	-	-	-	-	-	-	-	-	-	-	y	y	y	n	n	n	-	n	na	-	na	na	n	n	1	y
99	758074	-	-	-	-	-	-	-	-	-	-	-	-	-	y	y	y	n	y	n	-	y	na	-	na	na	y	y	1	y
100	483498	-	-	-	-	-	-	-	-	-	-	-	-	-	y	y	y	n	n	y	-	y	na	-	na	na	y	n	3	y
101	772868	-	-	-	-	-	-	-	-	-	-	-	-	-	y	y	y	y	n	n	-	y	na	-	na	na	y	y	1	y
102	937061	-	-	-	-	-	-	-	-	-	-	-	-	-	y	y	y	n	n	y	-	y	na	-	na	n	y	y	1	y
103	961780	-	-	-	-	-	-	-	y	-	-	-	-	-	y	y	y	n	n	n	-	n	na	-	na	na	y	y	1	n
104	794384	-	-	-	-	-	-	-	y	-	-	-	-	-	y	y	y	n	n	n	-	na	na	-	na	na	y	y	1	n
105	800496	-	-	-	-	-	-	-	-	-	-	-	-	-	y	y	y	n	y	n	-	y	na	-	na	na	y	y	1	y
106	797701	-	-	y	-	-	-	-	-	-	-	-	-	-	y	y	y	n	n	n	-	na	y	-	na	na	y	y	1	n
107	784819	-	-	-	-	-	y	-	-	-	y	-	-	-	y	y	y	n	y	n	-	na	n	-	na	na	y	y	1	y
108	795785	-	-	y	-	-	-	-	-	-	-	-	-	-	y	y	y	n	n	n	-	na	n	-	na	na	y	y	2	y
109	803042	-	-	y	-	-	-	-	-	-	-	-	-	-	y	y	y	y	n	n	-	na	y	-	na	na	y	y	1	n
110	715766	-	-	-	-	-	-	-	-	-	-	-	-	-	y	y	y	y	n	n	-	na	na	-	na	n	n	3	-	
111	801466	-	-	y	-	-	-	-	-	-	-	-	-	-	y	y	y	n	n	n	-	na	n	-	na	na	y	y	2	n
112	757988	-	-	-	-	-	-	-	-	-	-	-	-	-	y	y	n	n	n	n	-	n	na	-	na	na	n	n	1	y
113	806528	y	-	-	-	-	-	-	-	-	-	-	-	-	y	y	y	y	n	n	-	n	na	-	na	na	n	n	3	-
114	78322	-	-	-	-	-	y	-	-	-	y	-	-	-	y	n	y	n	y	y	-	na	n	-	na	na	y	y	1	y
115	800002	-	-	-	-	-	-	-	-	-	-	-	-	-	y	y	y	n	n	n	-	n	n	-	na	na	n	y	1	y
116	808782	-	-	y	-	-	-	-	-	-	-	-	-	-	y	y	y	n	n	n	-	na	n	-	na	na	n	y	4	-
117	758074	-	-	-	-	-	-	-	-	-	-	-	-	-	y	y	y	n	y	n	-	y	na	-	na	na	y	y	3	y
118	808924	-	-	y	-	-	-	-	-	-	-	-	-	-	y	y	y	n	n	n	-	na	y	-	na	na	y	y	1	n
119	813129	-	-	-	-	-	y	-	-	-	y	-	-	-	y	y	y	n	n	n	-	na	na	-	na	na	y	y	1	y
120	120235	-	-	y	-	-	-	-	-	-	-	-	-	-	y	y	y	n	n	n	-	na	y	-	na	na	y	y	1	n
121	815300	-	-	-	-	-	-	-	-	-	-	-	-	-	y	y	y	n	y	y	-	y	na	-	na	na	y	y	1	y
122	806598	-	-	y	-	-	-	-	-	-	-	-	-	-	y	y	y	n	n	n	-	na	n	-	na	na	y	y	1	n
123	202821	-	-	-	-	-	-	-	-	-	-	-	-	-	y	y	y	n	n	n	-	na	na	-	na	na	n	y	2	y
124	676387	-	-	-	-	-	-	-	-	-	-	y	-	-	y	n	y	n	y	n	-	na	na	-	na	na	y	y	1	y
125	816494	-	-	-	-	-	-	-	-	-	-	-	-	-	y	y	y	n	y	n	-	y	na	-	na	na	y	y	1	y
126	815505	-	-	-	-	-	-	-	-	y	-	-	-	-	n	y	y	n	n	n	-	na	na	-	na	na	y	y	1	n
127	816596	-	-	y	-	-	-	-	-	-	-	-	-	-	y	y	y	n	n	n	-	na	y	-	na	na	y	y	1	n
128	518576	-	-	-	-	-	-	-	-	-	-	-	-	-	y	y	y	n	y	y	-	y	na	-	na	na	y	y	1	y
129	868046	-	-	-	-	-	-	-	-	-	-	-	-	-	y	y	y	n	n	n	-	y	na	-	y	na	y	y	1	y
130	867305	-	-	-	y	-	-	-	-	-	-	-	-	-	y	y	y	n	y	n	-	n	na	-	na	na	y	y	1	n
131	487433	-	-	-	-	-	-	-	-	y	-	-	-	-	y	y	y	n	n	n	-	n	na	-	na	na	n	n	1	y
132	860301	-	-	y	-	-	-	-	-	-	-	-	-	-	y	y	y	n	n	n	-	na	y	-	na	na	y	y	2	n
133	870491	-	-	-	-	-	-	-	y	-	-	-	-	-	y	y	y	n	n	n	-	na	na	-	na	na	y	y	1	n
134	870616	-	-	y	-	-	-	-	-	-	-	-	-	-	y	y	y	n	n	n	-	na	y	-	na	na	y	y	1	n
135	870526	-	-	-	-	-	y	-	-	-	y	-	-	-	n	y	y	n	y	n	-	na	na	-	na	na	y	y	1	n
136	868092	-	-	y	-	-	-	-	-	-	-	-	-	-	y	y	y	n	n	n	-	na	y	-	na	na	y	y	1	n
137	730279	-	-	y	-	-	-	-	-	-	-	-	-	-	y	y	y	n	n	n	-	na	n	-	na	na	y	y	3	y
138	873183	-	-	y	-	-	-	-	-	-	-	-	-	-	y	y	y	n	n	n	-	n	y	-	na	na	y	y	1	n
139	863874	-	-	-	-	-	y	-	-	-	y	-	-	-	y	y	y	n	n	n	-	na	na	-	na	na	y	y	1	n
140	874227	-	-	-	-	-	y	-	-	-	y	-	-	-	y	n	y	n	n	y	-	na	na	-	na	na	y	y	1	y
141	874222	-	-	-	-	-	-	-	-	-	-	-	-	?amyloidosis	y	y	y	n	n	n	-	n	na	-	na	na	y	y	1	y
142	874605	-	-	-	-	-	-	-	-	y	-	-	-	-	n	y	y	n	n	n	-	na	na	-	na	na	y	y	1	n
143	837754	-	-	y	-	-	-	-	-	-	-	-	-	-	y	y	y	y	n	n	-	na	y	-	na	na	y	y	1	n
144	839395	-	-	-	-	-	y	-	-	-	y	-	-	-	y	n	y	n	y	n	-	na	na	-	na	na	y	y	1	y
145	648486	-	-	y	-	-	-	-	-	-	-	-	-	-	y	y	y	n	n	n	-	na	n	-	na	na	y	y	2	n
146	639722	-	-	y	-	-	-	-	-	-	-	-	-	-	y	y	y	n	n	n	-	na	y	-	na	na	y	y	1	n
147	840633	-	-	y	-	-	-	-	-	-	-	-	-	-	y	y	y	n	n	n	-	na	y	-	na	na	y	y	1	n
148	681164	-	-	-	-	-	-	-	-	-	-	-	-	-	y	y	y	n	n	n	-	y	n	-	na	na	y	y	1	y
149	736950	-	-	-	-	-	-	-	-	-	-	-	-	-	y	y	y	n	n	n	-	y	na	-	na	y	y	y	1	y
150	844350	-	-	-	-	-	-	-	-	-	-	-	-	-	y	y	y	n	n	n	-	y	na	-	na	y	y	y	1	y
151	838640	-	-	-	-	-	-	-	-	y	-	-	-	-	n	y	y	n	n	n	-	n	na	-	na	na	y	y	1	n
152	457005	-	-	-	-	-	-	-	-	-	-	-	-	-	y	y	y	n	n	n	-	y	na	-	na	y	n	n	2	y
153	93021	-	-	-	-	-	-	-	y	-	-	-	-	-	y	y	y	n	n	n	-	na	na	-	na	na	y	y	1	y
154	582848	-	-	-	-	-	-	-	-	-	-	-	-	-	y	y	n	n	n	n	-	y	na	-	na	na	y	y	1	n
155	834904	-	-	-	-	-	-	-	-	y	-	-	-	-	n	y	y	n	n	n	-	na	na	-	na	na	n	n	1	n
156	824096	-	-	-	-	-	-	-	-	-	-	-	-	-	y	y	y	n	n	n	-	y	na	-	y	na	n	n	4	-
157	840091	-	-	-	-	-	-	-	-	-	-	-	-	?wegener's granulomatosis	y	y	n	n	y	n	-	na	na	-	na	na	y	y	1	n
158	884091	-	-	y	-	-	-	-	-	-	-	-	-	-	y	y	y	n	n	n	-	na	n	-	na	na	y	y	1	n
159	746917	-	-	-	-	-	y	-	-	-	y	-	-	-	y	y	y	n	n	n	-	na	na	-	na	na	y	y	1	n
160	776677	-	-	y	-	-	-	-	-	-	-	-	-	-	y	y	y	n	n	n	-	na	y	-	na	na	y	y	1	n
161	836002	-	-	-	-	-	-	-	-	-	-	-	-	-	y	y	y	n	y	n	-	na	na	-	na	na	y	y	1	y
162	849333	-	-	-	-	-	y	-	-	-	y	-	-	-	y	y	y	n	y	y	-	na	na	-	na	na	y	y	1	y
163	851055	-	-	-	-	-	-	-	-	-	-	-	-	-	y	y	y	n	y	n	-	y	na	-	na	na	n	y	3	y
164	845069	-	-	-	-	-	-	-	-	-	-	-	-	-	y	y	y	n	n	n	-	y	na	-	na	na	y	y	2	n
165	531317	-	-	y	-	-	-	-	-	-	-	-	-	-	y	y	y	n	n	n	-	n	y	-	na	na	y	y	1	n
166	849455	-	-	-	-	-	-	-	-	-	-	-	-	-	y	y	y	n	y	y	-	y	na	-	na	na	y	y	1	y
167	383444	-	-	-	-	-	-	-	-	-	-	-	-	-	y	y	y	y	n	y	-	y	na	-	na	n	y	y	1	y
168	849152	-	-	y	-	-	-	-	-	-	-	-	-	-	y	y	y	y	n	n	-	na	n	-	na	na	y	y	1	n
169	853509	-	-	-	-	-	-	-	-	-	-	-	-	-	y	y	y	n	y	n	-	y	na	-	na	na	y	y	1	y
170	856156	-	-	-	-	-	-	-	-	-	-	-	-	-	y	y	y	n	y	y	-	y	na	-	na	na	y	y	1	n
171	36273	-	-	-	-	-	y	-	-	-	y	-	-	-	y	n	y	n	y	y	-	na	na	-	na	na	n	n	4	-
172	897187	-	-	-	-	-	-	-	-	-	-	-	-	-	y	y	y	n	y	n	-	y	na	-	na	na	y	y	1	y
173	892695	-	-	-	y	-	-	-	-	-	-	-	-	-	y	y	y	n	n	n	-	na	na	-	na	na	y	y	1	y
174	383444	-	-	-	-	-	-	-	-	-	-	-	-	-	y	y	y	n	n	n	-	n	na	ptbd	na	na	y	y	2	y
175	907933	-	-	-	-	-	-	-	-	-	-	-	-	-	y	y	y	n	n	n	-	n	na	-	n	n	n	y	2	-
176	150185	-	-	y	-	-	-	-	-	-	-	-	-	-	y	y	y	y	n	n	-	na	n	-	na	na	y	y	1	n
177	902832	-	-	-	-	-	-	-	-	-	-	-	-	-	y	y	y	n	y	y	-	y	na	-	na	na	y	y	1	y
178	888867	-	-	-	-	-	-	-	-	-	-	-	-	-	y	y	y	n	n	n	-	y	na	-	na	na	y	y	2	y
179	891164	-	-	-	-	-	-	-	-	-	-	-	-	-	y	y	y	n	y	n	-	n	na	-	na	na	y	y	3	y
180	881651	-	-	-	-	-	-	-	-	-	-	-	-	-	y	y	y	y	n	n	-	n	na	-	n	n	n	y	2	y
181	874012	-	-	-	-	-	-	-	-	-	-	-	-	-	y	y	y	n	y	n	y	y	na	-	na	na	y	y	1	y
182	666086	-	-	y	-	-	-	-	-	-	-	-	-	-	y	y	y	n	n	y	-	na	y	-	na	na	y	y	1	n
183	873183	-	-	y	-	-	-	-	-	-	-	-	-	-	y	y	y	n	n	n	-	na	y	-	na	na	y	y	1	n
184	876104	-	-	-	-	-	-	-	-	-	-	-	-	-	y	y	y	n	n	n	-	y	na	-	na	y	y	y	1	y
185	882709	-	-	-	-	-	-	-	-	-	-	-	-	-	y	y	y	y	n	n	-	y	na	-	na	n	n	y	1	y
186	849332	-	-	-	-	-	y	-	-	-	y	-	-	-	y	y	y	n	y	n	-	na	na	-	na	na	y	y	2	y
187	759614	-	-	-	-	-	-	-	-	y	-	-	-	-	n	y	y	n	n	n	-	na	na	-	na	na	y	y	1	n
188	893454	-	-	y	-	-	-	-	-	-	-	-	-	-	y	y	y	y	n	n	-	na	y	-	na	na	y	y	1	n
189	568835	-	-	-	-	-	-	-	-	y	-	-	-	-	n	y	y	n	n	n	-	na	na	-	na	na	y	y	1	y
190	787977	-	-	-	-	y	-	-	-	-	-	-	-	-	y	y	y	n	y	n	-	na	na	-	na	na	y	y	1	y
191	848737	-	-	-	-	-	y	-	-	-	y	-	-	-	y	y	y	n	n	n	-	na	na	-	na	na	y	n	1	y

sr no	mrd	1month improvement in symptoms	1month new symptom	1month symptom	1month s.calcium	1month albumin	1month corrected calcium	1month vit d	1month PTH	1month tlc	1month HB	1month platelets	1month creatinine	1month other	1month alive	1month loss to f/u	1month interval pathyroidectomy	3month constitutional symptoms	3month improvement in symptoms	3month new symptom	-	3month s.calcium	3month albumin	3month corrected calcium	3month tlc	3month PTH	3month HB	3month platelets
98	768710	y	y	sob,fatigue	10.5	2.5	11.7	-	-	12	8.5	300	2	-	y	-	-	y	n	y	bed sore	-	-	-	15	-	10	180
99	758074	y	y	fever	10.4	3	10.8	-	-	-	9.4	-	0.9	-	y	-	-	y	y	y	loose motions	13.4	3.2	14	-	-	9.4	-
100	483498	n	n	-	12.5	3.8	12.6	-	-	-	7.4	-	0.9	-	y	-	-	y	y	n	-	-	-	-	-	-	-	-
101	772868	y	y	drowsy	11.5	3	12.8	-	-	6.5	9.5	180	0.8	-	y	-	-	y	y	y	bodyaches, constipation	11.3	2.5	12.5	12	-	9.5	162
102	937061	y	n	-	10	2.5	11.2	-	-	12	8.5	120	0.6	-	y	-	-	y	y	y	sob	9.8	2.6	10.9	8	-	10	150
103	961780	y	n	-	-	-	-	-	-	-	-	-	-	-	y	-	-	n	y	n	-	-	-	-	-	-	-	-
104	794384	y	n	-	9	3.2	9.6	-	-	-	-	-	-	-	y	-	-	n	y	n	-	9	3.2	9.6	-	-	-	-
105	800496	y	y	vomitting,loose motions post ct	9.8	2.5	11	-	-	-	-	-	-	-	y	-	-	y	y	n	-	9.5	3.5	9.8	-	-	10	-
106	797701	y	n	-	9.5	3.5	9.8	-	25	-	12	-	0.6	-	y	-	-	n	y	n	-	9.5	3.5	9.8	-	16.5	10	-
107	784819	y	n	-	9	3	10.8	-	-	-	-	-	-	-	y	-	-	y	y	n	-	9	2.8	9.7	-	-	-	-
108	795785	y	y	bed sores	9.5	3.5	9.9	84	-	7.5	10.5	170	6.5	-	y	-	n	y	y	y	sob, uti	-	-	-	18	-	8	-
109	803042	y	n	-	8	2.7	9.04	-	65	-	11	-	-	-	y	-	-	n	y	n	-	9.7	3	10.5	-	-	13.3	-
110	715766	-	-	-	-	-	-	-	-	-	-	-	-	-	n1	-	-	-	-	-	-	-	-	-	-	-	-	-
111	801466	y	n	-	9	3	9.8	-	225	-	-	-	-	-	y	-	n	n	y	n	-	9	3	9.8	-	-	10	-
112	757988	y	y	jaundice,itching	10.3	2.5	11.5	-	-	16	9.5	174	1.2	total bilirubin-5, cbd stenting	y	-	-	y	y	y	anorexia	9.5	2.5	10.7	-	-	9.5	145
113	806528	-	-	-	-	-	-	-	-	-	-	-	-	-	n1	-	-	-	-	-	-	-	-	-	-	-	-	-
114	78322	y	n	-	-	-	-	-	-	-	-	-	10	-	y	-	-	n	y	n	-	-	-	-	-	-	-	-
115	800002	y	y	loose motions	12	2.7	13	-	-	4	7.5	50	2.3	-	y	-	-	y	y	y	depression	10	2.5	11.2	5.5	-	7.5	85
116	808782	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
117	758074	y	y	drowsy,fever	12.7	2.5	13.9	-	-	-	7.7	-	3.1	-	y	-	-	y	y	y	fever	9.6	2.4	10.8	3.5	-	7.5	100
118	808924	y	n	-	9	4.6	8.6	-	-	-	-	-	-	-	y	-	-	-	-	-	-	-	-	-	-	-	-	-
119	813129	n	n	-	12	3.2	12.4	-	-	-	-	-	-	-	y	-	-	n	y	n	-	10.2	3.5	10.7	-	-	-	-
120	120235	y	n	-	9	3	9.8	-	-	-	12.6	-	0.6	-	y	-	-	n	y	n	-	9.4	3.3	9.9	-	29	10	-
121	815300	y	n	-	10	2.8	10.9	-	-	11	8.5	150	5.9	-	y	-	-	y	y	y	anorexia	-	-	-	6	-	8	150
122	806598	y	n	-	9.8	2.7	10.6	-	200	-	12	-	0.6	-	y	-	n	n	y	n	-	7.4	3	8	-	16	12	-
123	202821	y	y	anorexia	9.5	3.5	9.9	-	-	11	10	200	2.5	-	y	-	-	y	y	n	-	-	-	-	-	-	8.5	-
124	676387	y	y	bed sores	10.2	2.5	11.4	-	-	-	10	-	-	-	y	-	-	y	y	y	bed sores	-	-	-	-	-	-	-
125	816494	y	n	-	10.5	2.5	11.7	-	-	10	7.5	285	3.5	-	y	-	-	y	y	n	-	9.8	2.8	10.7	14	-	8	184
126	815505	y	n	-	8.6	2.5	9.8	-	-	-	10	-	-	-	y	-	-	y	y	y	black stools	-	-	-	-	-	8	-
127	816596	y	n	-	9.4	4	9.4	-	16	-	12	-	-	-	y	-	-	n	y	n	-	9	4	9	-	-	-	-
128	518576	y	y	uti	10.2	2.6	11.3	-	-	-	9.6	-	2.8	-	y	-	-	y	y	n	-	8.5	2.5	9.7	-	-	9	-
129	868046	y	y	loose motions	9.4	2.3	10.76	-	-	-	10.4	-	1.4	-	y	-	-	y	n	y	loose motions, bodyaches	-	-	-	-	-	12	-
130	867305	y	n	-	9	2.8	9.7	-	-	-	12	-	0.5	-	y	-	-	n	y	n	-	-	-	-	-	-	11	-
131	487433	y	n	-	10.5	2.8	11.4	-	-	6.5	8.5	240	4.6	-	y	-	-	y	y	y	irrelevant talks, constipation	11	2.5	12.2	6.5	-	7.8	184
132	860301	y	n	-	7.2	4	7.2	-	21	-	9	-	0.6	-	y	-	-	n	y	n	-	8.4	4	8.4	-	-	10	-
133	870491	y	n	-	-	-	-	-	-	-	-	-	-	-	y	-	-	n	y	n	-	-	-	-	-	-	-	-
134	870616	y	n	-	8.9	3.2	9.5	-	24	-	13.8	-	0.5	-	y	-	-	n	y	n	-	9	3.5	9.3	-	-	-	-
135	870526	y	n	-	9.5	2.5	10.7	-	-	-	9	-	1.4	-	y	-	-	n	y	n	-	9.4	2.3	10.7	-	-	9.8	-
136	868092	y	n	-	9.2	3.3	9.7	-	24	-	12	-	0.6	-	y	-	-	n	y	n	-	9	3.5	9.4	-	-	12	-
137	730279	n	y	dysuria	15	3.5	15.4	-	-	-	13	-	1.4	-	y	-	n	n	y	n	-	10	3	10.8	-	40	12	-
138	873183	y	n	-	9	3.5	9.4	-	105	-	10	-	1.1	-	y	-	-	n	y	n	-	7.5	3.5	7.9	-	65	10.2	-
139	863874	y	n	-	-	-	-	-	-	-	-	-	2	-	y	-	-	n	y	n	-	10.7	3.8	10.8	-	-	8.5	-
140	874227	y	n	-	9.5	2.5	10.7	89	-	10.5	10.5	186	0.9	-	y	-	-	n	y	n	-	-	-	-	-	-	-	-
141	874222	y	y	irrelevant talks	10.2	2.2	11.6	-	-	9.5	10.5	200	4.2	-	y	-	-	y	y	y	anorexia	9.6	2.8	10.5	6.5	-	9.5	178
142	874605	y	n	-	9	2.5	10.2	-	-	-	12	-	-	-	y	-	-	n	y	y	constipation	-	-	-	-	-	12	-
143	837754	y	n	-	7.5	3.5	7.9	-	52.4	-	10	-	0.9	-	y	-	-	n	y	n	-	9	3.5	9.4	-	-	11	-
144	839395	y	n	-	10.5	3	11.3	96	-	-	8.5	-	0.5	-	y	-	-	y	y	n	-	-	-	-	-	-	-	-
145	648486	y	n	-	10	4.2	9.84	-	-	-	15	-	0.6	-	y	-	y	n	y	n	-	8.4	4	8.4	6.5	-	14	280
146	639722	n	n	-	9	2.5	10.2	-	64	-	9	-	1.5	-	y	-	-	n	y	n	-	8.6	2.8	9.5	-	-	-	-
147	840633	y	n	-	8.1	2.15	9.5	-	86	-	8.6	-	0.4	-	y	-	-	n	y	y	-	9.2	3	10	-	42	11.2	-
148	681164	y	n	-	9	3	9.8	-	-	6.5	8.5	100	1.2	-	y	-	-	y	y	n	-	-	-	-	8	-	9	85
149	736950	y	y	uti	9.4	3	10.2	-	-	6	8.5	200	0.6	-	y	-	-	y	y	n	-	-	-	-	4.5	-	7.9	155
150	844350	y	n	-	9.5	2.5	10.7	-	-	-	8	-	1.8	-	y	-	-	y	y	y	uti	-	-	-	14	-	7.6	180
151	838640	y	n	-	9.8	3	10.6	-	-	8	9.5	60	0.6	-	y	-	-	n	y	n	-	-	-	-	7.5	-	10.5	76
152	457005	y	y	depression	10.5	3	11.3	-	-	11.5	8	54	1.2	-	y	-	-	n	y	y	abdominal pain and distension	10.6	2.5	11.8	8.5	-	7.5	45
153	93021	y	y	palpitations,uti	9.5	2.7	10.5	-	-	-	11	-	0.6	-	y	-	-	n	y	n	-	-	-	-	-	-	12.6	-
154	582848	y	n	-	9	3.6	9.3	-	-	-	11.8	-	-	-	y	-	-	n	y	n	-	9	4	9	-	-	13	-
155	834904	y	n	-	-	-	-	-	-	6.5	9	65	1.5	-	y	-	-	n	y	y	black stools	-	2.6	-	8.6	-	6.5	55
156	824096	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
157	840091	y	n	-	9.5	3	10.3	-	-	12.5	9.5	245	2	-	y	-	-	n	y	n	-	-	-	-	8	-	8.5	200
158	884091	y	n	-	9	3.3	9.5	-	-	-	12	-	0.7	-	y	-	y	n	y	n	-	-	-	-	-	-	-	-
159	746917	y	n	-	10.3	3.5	10.7	75	-	-	-	-	-	-	y	-	-	n	y	n	-	-	-	-	-	-	-	-
160	776677	y	n	-	9.5	3.4	9.9	-	20	-	12	-	-	-	y	-	-	n	y	n	-	8.4	3.5	8.8	-	-	-	-
161	836002	y	n	-	10	2.8	10.9	-	-	4.3	9.6	144	1.5	-	y	-	-	y	y	y	fever,loose motions	-	-	-	3.3	-	10.1	90
162	849333	n	n	-	11.6	4	12.2	135	-	-	9.5	-	-	-	y	-	-	y	n	n	-	10.5	4	11.3	-	-	10	-
163	851055	y	y	fever	11	2	12.6	-	-	-	5	-	2.2	-	y	-	-	y	y	n	-	-	-	-	-	-	10	-
164	845069	y	n	-	-	-	-	-	-	-	9	-	3.8	-	y	-	-	n	y	n	-	9	2.5	10.2	-	-	10	-
165	531317	y	n	-	9.8	4	9.8	-	20	-	12	-	0.6	-	y	-	-	n	y	n	-	8.2	4	8.2	-	-	12.5	-
166	849455	y	n	-	8.2	2.5	9.4	-	-	-	11.7	-	-	-	y	-	-	y	y	n	-	9.4	2.5	10.6	-	-	10.3	-
167	383444	n	y	abdominal distension	10.2	3.3	10.7	-	-	-	6.7	-	-	-	y	-	-	y	n	y	jaundice, altered sensorium	11.2	2.6	12.3	-	-	6	-
168	849152	y	n	-	8.4	2.5	9.6	-	25	8	8.5	240	1.2	-	y	-	y	n	y	n	-	8.5	2.8	9.5	6.5	-	9	254
169	853509	n	n	-	9.5	2.6	10.6	-	-	-	8.5	-	-	-	y	-	-	y	n	y	uti	-	-	-	-	-	7	-
170	856156	y	n	-	8.6	2.5	9.8	-	-	10.5	7.6	140	3.6	-	y	-	-	n	y	y	sob	-	-	-	7.5	-	7	110
171	36273	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
172	897187	y	n	-	10	2.3	11.36	-	-	-	8.5	-	2.5	-	y	-	-	y	y	n	-	9	2.5	10.2	-	-	7.8	-
173	892695	y	n	-	9.6	2.8	10.6	-	-	7.5	11	175	0.6	-	y	-	-	n	y	n	-	-	-	-	7.5	-	10.8	200
174	383444	y	n	-	10.5	2.5	11.7	-	-	11	7.5	100	0.8	-	y	-	-	y	y	y	dyspepsia, abdominal mass	10.2	2.4	11.4	12	-	7.3	102
175	907933	-	-	-	10.6	3.1	11.3	-	-	10.5	8	110	0.4	-	y	-	-	n	y	n	anorexia, chronic bedridden	11	2.8	12	10.5	-	8.5	120
176	150185	y	n	-	12.4	4	12.4	-	450	-	9	-	0.5	-	y	-	n	y	n	n	-	8	3.5	9.2	-	20	10.4	-
177	902832	y	n	-	11.6	3	12.4	-	-	-	8.6	-	4.5	-	y	-	-	y	y	y	dec urine output	11.3	2.8	12	-	-	6.2	-
178	888867	y	y	depression	10	2.5	11.2	-	-	-	9.5	-	3.2	-	y	-	-	y	y	n	-	-	-	-	-	-	8.5	-
179	891164	n	y	fever,cough	-	-	-	-	-	36	10	20	1.2	b1,3 glucan +	y	-	-	y	y	n	-	-	-	-	14	-	8	18
180	881651	n	y	bedridden, depression, irrelevant talks	12	2.8	13	-	-	12	9.5	145	1	-	y	-	-	y	n	y	uti, bodyaches	12	2.5	13.2	20	-	8.5	100
181	874012	n	y	pain abdomen	8.4	2.5	9.6	3.7	-	4	7.5	338	5.6	-	y	-	-	y	y	y	dec urine output	9.2	2.5	10.4	4.5	-	6.4	291
182	666086	y	n	-	9.5	3	10.3	-	240	11.5	10.5	210	-	-	y	-	-	n	y	n	-	7.5	3.5	7.9	7.3	16	10.2	190
183	873183	y	n	-	7.4	3.3	8.7	-	6	7	10.5	230	1.1	-	y	-	-	n	y	n	-	9.2	3.5	9.6	-	-	-	-
184	876104	y	y	hair loss	9.5	3	10.3	-	-	8.5	10	480	1.6	-	y	-	-	y	y	y	hearing impairment	10	2.5	11.2	6.5	-	8.5	400
185	882709	y	y	cough	9.6	3	10.8	-	-	11	10	294	0.8	-	y	-	-	y	y	y	dyspepsia	10.4	2.8	11.4	15.4	-	8	250
186	849332	y	n	-	10.5	4	11.8	364	-	6	9.5	250	2.2	-	y	-	-	y	y	y	uti	-	-	-	18	-	10	-
187	759614	y	n	-	9	3	10.2	-	-	6	8.5	150	2.6	-	y	-	-	n	y	n	-	-	-	-	6.5	-	8.5	174
188	893454	y	n	-	8.4	3.5	9.6	-	34	11	12.5	240	-	-	y	-	-	n	y	n	-	9	3.4	9.4	-	-	-	-
189	568835	y	n	-	9	2.8	10	-	-	11	9.5	86	1.2	-	y	-	-	n	y	n	-	9.2	2.6	10.3	8.4	-	10	65
190	787977	y	n	-	10.4	3	11.2	150	-	-	-	-	-	-	y	-	-	n	y	n	-	9.6	2.8	10.8	6.5	-	11	250
191	848737	y	n	-	10.8	2.3	12.4	-	-	-	10	-	0.5	-	y	-	-	y	y	n	-	10.2	2.3	11.8	-	-	-	-

sr no	mrd	3month creatinine	3month vit d	3month alive	3month loss to f/u	3month interval parathyroidectomy
98	768710	1.8	-	y	-	-
99	758074	-	-	y	-	-
100	483498	-	-	y	-	-
101	772868	1.2	-	y	-	-
102	937061	0.6	-	y	-	-
103	961780	-	-	y	-	-
104	794384	-	-	y	-	-
105	800496	0.5	-	y	-	-
106	797701	-	-	y	-	-
107	784819	2.5	110	y	-	-
108	795785	8	-	y	-	n
109	803042	-	-	y	-	-
110	715766	-	-	n1	-	-
111	801466	1.2	-	y	-	n
112	757988	-	-	y	-	-
113	806528	-	-	n1	-	-
114	78322	8	-	y	-	-
115	800002	2.4	-	y	-	-
116	808782	-	-	-	-	-
117	758074	2.3	-	y	-	-
118	808924	-	-	y	-	-
119	813129	-	-	y	-	-
120	120235	0.7	-	y	-	-
121	815300	8	-	y	-	-
122	806598	0.5	-	y	-	y
123	202821	2.6	-	y	-	-
124	676387	-	-	y	-	-
125	816494	-	-	y	-	-
126	815505	-	-	y	-	-
127	816596	-	-	y	-	-
128	518576	2.56	-	y	-	-
129	868046	-	-	y	-	-
130	867305	-	-	y	-	-
131	487433	6.7	-	y	-	-
132	860301	-	-	y	-	-
133	870491	-	-	y	-	-
134	870616	-	-	y	-	-
135	870526	1.5	100	y	-	-
136	868092	0.5	-	y	-	-
137	730279	1	-	y	-	y
138	873183	1	-	y	-	-
139	863874	2.3	-	y	-	-
140	874227	-	-	y	-	-
141	874222	4.2	-	y	-	-
142	874605	1.2	-	y	-	-
143	837754	1	-	y	-	-
144	839395	-	-	y	-	-
145	648486	0.6	-	y	-	-
146	639722	-	-	y	-	-
147	840633	0.4	-	y	-	-
148	681164	-	-	y	-	-
149	736950	0.8	-	y	-	-
150	844350	2.4	-	y	-	-
151	838640	0.8	-	y	-	-
152	457005	1.6	-	y	-	-
153	93021	-	-	y	-	-
154	582848	-	-	y	-	-
155	834904	1.2	-	y	-	-
156	824096	-	-	-	-	-
157	840091	2.1	-	y	-	-
158	884091	-	-	y	-	-
159	746917	8.3	-	y	-	-
160	776677	-	-	y	-	-
161	836002	1.5	-	y	-	-
162	849333	2.4	90	y	-	-
163	851055	-	-	y	-	-
164	845069	2.1	-	y	-	-
165	531317	-	-	y	-	-
166	849455	2.7	-	y	-	-
167	383444	0.6	-	y	-	-
168	849152	0.8	-	y	-	-
169	853509	7	-	y	-	-
170	856156	8.4	-	y	-	-
171	36273	-	-	-	-	-
172	897187	3.6	-	y	-	-
173	892695	1	-	y	-	-
174	383444	0.5	-	y	-	-
175	907933	1.5	-	y	-	-
176	150185	0.5	-	y	-	y
177	902832	8	-	y	-	-
178	888867	3.5	-	y	-	-
179	891164	1.1	-	y	-	-
180	881651	1.5	-	y	-	-
181	874012	5.3	-	y	-	-
182	666086	-	-	y	-	-
183	873183	0.6	-	y	-	-
184	876104	0.6	-	y	-	-
185	882709	0.4	-	y	-	-
186	849332	5	-	y	-	-
187	759614	5.6	-	y	-	-
188	893454	-	-	y	-	-
189	568835	1.4	-	y	-	-
190	787977	0.4	-	y	-	-
191	848737	-	-	y	-	-

sr no	mrd	initials	age	gender	address	urban/ rural	bmi	Gastrointestinal	Renal	Neurological	Generalised	Bony	nausea	duration	vomiting	duration	anorexia	duration	weight loss	value	duration	constipation	duration	abdominal pain	duration	dyspepsia	duration	renal stone	duration	polyuria	duration	nocturia	duration	bony pain	duration	fracture	duration	fatigue	duration
192	848659	ak	71	female	moga	urban	25	y	n	y	y	n	n	0	n	0	y	6	y	10	90	n	0	n	0	n	0	n	0	n	0	n	0	n	0	n	0	y	365
193	882201	sd	85	female	ludhiana	urban	28	n	y	n	y	y	n	0	n	0	n	0	n	0	0	n	0	n	0	n	0	n	0	y	45	n	0	y	180	n	0	y	180
194	470330	kc	61	female	poonch	urban	22	y	n	n	y	n	y	30	n	0	y	30	y	3	30	n	0	n	0	y	30	n	0	n	0	n	0	n	0	n	0	y	30
195	576826	sk	65	female	kaithal	urban	24	y	y	n	y	y	n	0	n	0	n	0	n	0	0	y	365	n	0	n	0	n	0	y	180	y	180	y	90	n	0	y	180
196	697247	sk	58	female	rohira,sangrur	rural	25.7	y	n	n	n	n	y	10	y	10	y	10	n	0	0	y	180	y	10	n	0	n	0	n	0	n	0	n	0	n	0	n	0
197	847585	qs	37	male	vpo sekhwan,gurdaspur	rural	27	y	n	n	n	n	y	6	y	6	n	0	n	0	0	n	0	y	6	n	0	n	0	n	0	n	0	n	0	n	0	n	0
198	817544	bk	54	female	sangrur	urban	20	y	n	n	y	n	n	150	n	150	n	150	y	6	180	n	0	n	0	y	30	n	0	n	0	n	0	n	0	n	0	y	180
199	848094	mb	38	female	malerkotla	rural	27	y	n	n	n	n	y	5	y	5	n	0	n	0	0	n	0	y	5	n	0	n	0	n	0	n	0	n	0	n	0	n	0
200	813240	hk	60	female	hoshiarpur	urban	21.5	y	n	n	y	n	y	2	y	2	y	10	y	8	60	n	0	n	0	n	0	n	0	n	0	n	0	n	0	n	0	n	0

sr no	mrd	altered sensorium	duration	depression	duration	vegetarian	smoker y/n	smoker duration(y)	smoker occasional	smoker reform yr	alcoholic y/n	alcoholic duration(y)	alcoholic occasional	alcoholic reformed (y)	menses regular	post menopausal	lithium y/n	lithium dose	lithium duration	lithium frequency	anti estrogen y/n	anti estrogen dose	anti estrogen duration	anti estrogen frequency	thiazide y/n	thiazide dose	thiazide duration	thiazide frequency	vit d supplement y/n	vit d supplement dose	vit d supplement duration	vit d supplement frequency	dose per day	ca supplement y/n
192	848659	y	3	n	0	y	n	0	-	-	n	-	-	-	na	y	n	0	0	0	n	0	0	0	n	0	0	0	n	0	0	0	-	n
193	882201	n	1	n	0	y	n	0	-	-	n	-	-	-	na	y	n	0	0	0	n	0	0	0	n	0	0	0	y	600000iu	120	once a week	85,714	y
194	470330	n	0	n	0	y	n	0	-	-	n	-	-	-	na	y	n	0	0	0	n	0	0	0	n	0	0	0	n	0	0	0	-	n
195	576826	n	0	n	0	y	n	0	-	-	n	-	-	-	na	y	n	0	0	0	n	0	0	0	n	0	0	0	n	0	0	0	-	n
196	697247	n	0	n	0	y	n	0	-	-	n	-	-	-	na	y	n	0	0	0	n	0	0	0	n	0	0	0	n	0	0	0	-	n
197	847585	n	0	n	0	y	n	0	-	-	n	-	-	-	na	na	n	0	0	0	n	0	0	0	n	0	0	0	n	0	0	0	-	n
198	817544	n	0	n	0	n	n	0	-	-	n	-	-	-	na	y	n	0	0	0	n	0	0	0	n	0	0	0	n	0	0	0	-	n
199	848094	n	0	n	0	n	n	0	-	-	n	-	-	-	y	na	n	0	0	0	n	0	0	0	n	0	0	0	n	0	0	0	-	n
200	813240	n	0	n	0	y	n	0	-	-	n	-	-	-	na	y	n	0	0	0	n	0	0	0	n	0	0	0	n	0	0	0	-	n

sr no	mrd	ca supplement dose	ca supplement duration	ca supplement frequency	Past History y/n	DM	HTN	CKD	CAD	CLD	asthma/ COPD	arthritis	cancer	ca bladder	ca penis	ca ovary	ca cervix	ca esophagus	HCC	ca gb and bile duct	ca head and neck	multiple myeloma	breast	RCC	ca lung	lymphoma	TB	sarcoidosis	recurrent pancreatitis	hypothyroidism	hyperthyroidism	other	past treatment	hb(g/dl) adm	hb(g/dl) dis	TLC adm	TLC dis	platelets adm	platelets dis	urea adm
192	848659	0	0	0	n	n	y	n	n	n	n	n	y	n	n	n	n	n	n	n	n	n	y	n	n	n	n	n	-	-	-	-	post mrm	12	11.6	14.6	9.3	335	330	70
193	882201	500mg	365	od	y	y	n	n	n	n	n	y	n	n	n	n	n	n	n	n	n	n	n	n	-	n	n	n	-	-	-	-	-	10.7	9.1	9.7	6.2	330	227	91
194	470330	0	0	0	y	n	n	n	n	n	n	n	y	n	n	n	n	n	n	n	n	n	y	n	n	n	n	n	n	-	-	-	-	chemotherapy	10	9	20	6.7	210	150	122
195	576826	0	0	0	n	n	y	n	n	n	n	n	n	n	n	n	n	n	n	n	n	n	n	n	-	n	n	n	n	-	-	-	-	-	10	10.5	8.5	6.5	220	215	20
196	697247	0	0	0	y	y	n	y	n	n	n	n	n	n	n	n	n	n	n	n	n	n	n	n	-	n	n	n	n	-	-	-	-	-	8	8.4	14	24	120	70	154
197	847585	0	0	0	n	n	n	n	n	n	n	n	n	n	n	n	n	n	n	n	n	n	n	n	-	n	n	n	n	-	-	-	-	-	9.2	8.7	24	12.4	333	368	35
198	817544	0	0	0	y	n	n	n	n	n	n	n	y	n	n	n	n	y	n	n	n	n	n	n	n	n	n	n	n	-	-	y	-	post sx/ct/rt	12.6	10	14	10.5	535	381	16
199	848094	0	0	0	n	n	n	n	n	n	n	n	n	n	n	n	n	n	n	n	n	n	n	n	-	n	n	n	n	-	-	-	-	-	8	7.3	11.4	5.5	160	156	47
200	813240	0	0	0	y	y	y	y	n	n	n	n	n	n	n	n	n	n	n	n	n	n	n	n	-	n	n	n	n	-	-	-	-	-	9.4	10.1	10.4	10.1	285	206	68

sr no	mrd	urea dis	creatinine adm	creatinine dis	Na adm	Na dis	K adm	K dis	Cl adm	Cl dis	total bilirubin adm	total bilirubin dis	direct bilirubin adm	direct bilirubin dis	SGOT adm	SGOT dis	SGPT adm	SGPT dis	ALP adm	ALP dis	total proteins adm	total proteins dis	s. albumin adm	s. albumin dis	s. calcium adm	s. calcium dis	Corrected Calcium adm	Corrected Calcium dis	phosphorus adm	phosphorus dis	urine r/e protein	rbc	pus cell	glucose	pth adm	pth dis	Vitamin D admission	Vitamin D dis	TSH	T3	T4	short qt in ecg	cxr nor=1/abn=2/ not done=3	cxr pleural effusion	cxr hilar lap	cxr s/o tb	cxr lytic lesion
192	848659	58	1.6	1.3	138	145	3.8	3.3	92	108	0.4	-	0.1	-	28	-	20	-	88	-	6.4	-	3.5	-	14	9	14.4	9.4	3.5	-	0	20	25	0	10	-	26	-	0.9	3.8	22	y	1	-	-	-	-
193	882201	41	1.6	8.4	140	138	3.6	3.5	99	102	0.5	-	0.2	-	23	-	12	-	83	-	7.6	-	4	-	13.3	9.3	13.3	9.3	3.3	-	0	0	50	0	9	-	163	-	-	-	-	y	1	-	-	-	-
194	470330	86	3.7	2.6	130	134	6.5	4.6	103	96	0.4	-	0.3	-	27	-	8	-	186	-	5.4	-	2.7	-	11.3	9.3	12.34	10.34	3	-	3	20	50	0	8	-	12	-	0.6	-	-	y	1	-	-	-	-
195	576826	24	0.6	0.5	135	142	4.2	4.1	94	96	0.5	-	0.1	-	25	-	40	-	94	-	6.5	-	2.5	-	10.5	9	11.7	10.2	4	-	0	0	20	0	12	-	18	-	2.8	-	-	y	1	-	-	-	-
196	697247	160	3	6.5	146	124	3.46	3.5	115	105	0.23	2.4	0.16	1.48	20	84	11	75	560	451	5.7	4.8	2.5	2.2	10.4	7	11.6	8.44	5	-	0	0	0	0	1255	101	0.76	35	-	-	-	y	2	y	-	-	-
197	847585	14	0.6	0.5	143	137	3.8	4.1	105	101	0.9	-	0.4	-	30	-	16	-	361	-	5.2	-	2.3	-	8.7	8.6	10.06	9.96	7.8	-	0	0	0	3	720	-	20	-	1.2	-	-	y	2	y	-	-	-
198	817544	40	0.8	1.2	129	134	4.3	4.6	87	94	0.3	-	0.1	-	11	-	5	-	167	-	9	-	4.3	-	13.5	8	13.26	7.76	5.2	-	0	0	0	0	9	-	7.8	-	-	-	-	y	1	-	-	-	-
199	848094	40	1.7	1.2	139	138	3.3	4	98	107	1.08	-	0.5	-	80	-	140	-	258	-	8	-	4.4	-	16.5	8	16.18	7.68	2.7	1.1	0	0	12	0	1240	-	11.4	-	-	-	-	y	1	y	-	-	-
200	813240	132	2.6	2.9	132	133	4.2	3.06	100	104	0.23	-	0.1	-	17	-	16	-	51	-	7.5	-	4.5	-	14.5	10	14.1	9.6	4.3	-	1	10	100	0	27.4	-	17.23	-	0.056	5.8	26.8	y	1	-	-	-	-

sr no	mrd	cxr metastasis/ sol	cxr other	USG nor=1/ abn=2/ not done=3	USG fatty liver	USG rpcg	USG cld	USG ascites	USG pleural effusion	USG gb sludge	USG lap	USG cholelithiasis	USG nephrolithiasis	USG nephrocalcinosis	USG sol/ metastasis	USG hepatomegaly	USG spleenomegaly	USG pancreatitis	USG s/o tb	USG_other	ct chest_nor=1/abn=2/not done=3	ct chest pleural effusion	ct chest mass lesion	ct chest lytic lesion	ct chest lap	ct chest metastasis	ct chest tubercular changes
192	848659	-	-	2	-	-	-	-	-	-	-	y	-	-	-	-	-	-	-	-	3	-	-	-	-	-	-
193	882201	-	-	2	-	y	-	-	-	-	-	-	-	-	-	-	-	-	-	-	3	-	-	-	-	-	-
194	470330	-	-	2	-	y	-	-	-	-	-	-	-	-	-	-	-	-	-	-	3	-	-	-	-	-	-
195	576826	-	-	2	y	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	1	-	-	-	-	-	-
196	697247	-	-	2	-	y	-	y	-	-	-	-	-	-	-	-	-	y	-	-	3	-	-	-	-	-	-
197	847585	-	-	2	-	-	-	y	y	y	-	-	-	-	-	-	-	y	-	-	3	-	-	-	-	-	-
198	817544	-	-	3	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	2	-	-	-	y	-	-
199	848094	-	-	2	-	-	-	-	-	y	-	-	y	-	-	-	-	-	-	-	3	-	-	-	-	-	-
200	813240	-	-	2	-	y	-	-	-	-	-	-	-	-	-	-	-	-	-	-	3	-	-	-	-	-	-

sr no	mrd	ct chest lymphangitis carcinomatosis	ct chest osseous metastasis	ct chest consolidation	ct chest other	ct abdomen nor=1/abn=2/not done=3	ct abdomen rpcg	ct abdomen cld	ct abdomen pleural effusion	ct abdomen ascites	ct abdomen lap	ct abdomen cholelithiasis	ct abdomen nephrolithiasis	ct abdomen nephrocalcinosis	ct abdomen sol/metastasis	ct abdomen s/o tb	ct abdomen pancreatitis	ct abdomen hcc	ct abdomen other	mri spine nor=1/abn=2/not done=3	mri spine vertebral collapse	mri spine lytic lesion	mri spine altered signal intensity	mri spine diffuse marrow infilteration	mri spine other
192	848659	-	-	-	-	3	-	-	-	-	-	-	-	-	-	-	-	-	-	3	-	-	-	-	-
193	882201	-	-	-	-	3	-	-	-	-	-	-	-	-	-	-	-	-	-	3	-	-	-	-	-
194	470330	-	-	-	-	3	-	-	-	-	-	-	-	-	-	-	-	-	-	3	-	-	-	-	-
195	576826	-	-	-	-	2	-	-	-	-	-	-	-	-	-	-	-	-	renal abcess	3	-	-	-	-	-
196	697247	-	-	-	-	2	y	-	-	y	-	-	-	y	-	-	y	-	-	3	-	-	-	-	-
197	847585	-	-	-	-	3	-	-	-	-	-	-	-	-	-	-	-	-	-	3	-	-	-	-	-
198	817544	-	-	-	-	3	-	-	-	-	-	-	-	-	-	-	-	-	-	3	-	-	-	-	-
199	848094	-	-	-	-	3	-	-	-	-	-	-	-	-	-	-	-	-	-	3	-	-	-	-	-
200	813240	-	-	-	-	3	-	-	-	-	-	-	-	-	-	-	-	-	-	3	-	-	-	-	-

sr no	mrd	ncct head nor/abn/ not done-1/2/3	mri brain nor/abn/not done-1/2/3	bone scan-nor/abn/not done-1/2/3	pet scan nor=1/abn=2/not done=3	pet scan inc fdg uptake in	usg neck parathyroid adenoma yes/no/not done-1/2/3	usg neck parathyroid adenoma right-1,left-2	usg neck parathyroid adenoma superior-1, inferior-2	sestamibi scan y/n/not done-1/2/3	sestamibi scan right-1,left-2	sestamibi scan superior-1,inferior-2	sestamibi scan other	xray skull punched out lesions y/n/not done-1/2/3	24 hr urinary calcium	spep m band y/n/not done-1/2/3	bma & biopsy nor/abn/not done-1/2/3	plasma cell dyscrasia	other
192	848659	3	3	1	3	-	3	-	-	3	-	-	-	3	-	3	3	-	-
193	882201	3	3	3	3	-	3	-	-	3	-	-	-	3	-	3	3	-	-
194	470330	3	3	3	3	-	3	-	-	3	-	-	-	3	-	3	3	-	-
195	576826	3	3	1	3	-	3	-	-	3	-	-	-	3	-	3	3	-	-
196	697247	3	3	3	3	-	1	1	2	1	1	2	-	3	-	3	3	-	-
197	847585	3	3	3	3	-	1	2	2	1	1	1	-	3	-	3	3	-	-
198	817544	3	3	3	3	-	3	-	-	3	-	-	-	3	-	3	3	-	-
199	848094	3	1	3	3	-	2	-	-	1	1	1	-	3	-	3	3	-	-
200	813240	3	3	1	3	-	3	-	-	2	-	-	toxic nodular goitre	3	-	2	3	-	-

sr no	mrd	24hr urine for light chain assay y/n/not done-1/2/3	24hr urine for light chain assay	other	fnac/biosy other part_y/n/not done-1/2/3	atypical cells	area	malignancy	Probable malignancy	malignancy ca bladder	malignancy ca penis	malignancy ca ovary	malignancy ca cervix	malignancy ca esophagus	malignancy hcc	malignancy ca head and neck	malignancy ca gall bladder and bile ducts	malignancy multiple myeloma	malignancy breast	malignancy rcc	malignancy lymphoma	malignancy cml
192	848659	3	-	-	3	-	-	y	n	-	-	-	-	-	-	-	-	-	y	-	-	-
193	882201	3	-	-	3	-	-	n	n	-	-	-	-	-	-	-	-	-	-	-	-	-
194	470330	3	-	-	3	-	-	y	n	-	-	-	-	-	-	-	-	y	-	-	-	-
195	576826	3	-	-	2	invasive lobular carcinoma	breast	y	n	-	-	-	-	-	-	-	-	-	y	-	-	-
196	697247	3	-	-	3	-	-	n	n	-	-	-	-	-	-	-	-	-	-	-	-	-
197	847585	3	-	-	3	-	-	n	n	-	-	-	-	-	-	-	-	-	-	-	-	-
198	817544	3	-	-	3	-	-	y	n	-	-	-	-	y	-	-	-	-	-	-	-	-
199	848094	3	-	-	3	-	-	n	n	-	-	-	-	-	-	-	-	-	-	-	-	-
200	813240	3	-	-	3	-	-	n	n	-	-	-	-	-	-	-	-	-	-	-	-	-

sr no	mrd	malignancy ca lung	malignancy unknown primary	hyperparathyroidism	tb	sarcoidosis	vit d intox	drug responsible	thyrotoxicosis	exclusive cld	drug induced	exclusive ckd	bedridden exclusive	other	medical lasix	medical iv fluids	medical calcitonin	medical bisphosphonates	medical steroids	medical dialysis	medical denosumab	medical ct/rt	surgery parathyroidectomy	surgery procedure	surgery mastectomy	surgery debulking surgery	outcome symptoms	outcome calcium	discharge/ dor /dama /death - 1/2/3/4	1month constitutional symptoms
192	848659	-	-	-	-	-	-	-	-	-	-	-	-	-	y	y	y	y	n	n	-	y	na	-	na	na	y	y	1	y
193	882201	-	-	-	-	-	y	-	-	-	y	-	-	-	y	n	y	n	y	y	-	na	na	-	na	na	y	y	1	y
194	470330	-	-	-	-	-	-	-	-	-	-	-	-	-	y	y	y	n	n	n	-	y	na	-	na	na	y	y	1	y
195	576826	-	-	-	-	-	-	-	-	-	-	-	-	-	y	y	y	y	n	n	-	y	n	-	y	na	y	y	1	y
196	697247	-	-	y	-	-	-	-	-	-	-	-	-	-	y	y	y	y	n	y	-	n	y	-	na	na	y	y	4	-
197	847585	-	-	y	-	-	-	-	-	-	-	-	-	-	y	y	y	n	n	n	-	na	n	-	na	na	y	y	1	n
198	817544	-	-	-	-	-	-	-	-	-	-	-	-	-	y	y	y	y	n	n	-	y	na	-	na	n	y	y	1	y
199	848094	-	-	y	-	-	-	-	-	-	-	-	-	-	y	y	y	n	n	n	-	n	y	-	na	na	y	y	1	n
200	813240	-	-	-	-	-	-	-	y	-	-	-	-	-	y	y	y	n	n	n	-	na	na	-	na	na	y	y	3	n

sr no	mrd	1month improvement in symptoms	1month new symptom	1month symptom	1month s.calcium	1month albumin	1month corrected calcium	1month vit d	1month PTH	1month tlc	1month HB	1month platelets	1month creatinine	1month other	1month alive	1month loss to f/u	1month interval pathyroidectomy	3month constitutional symptoms	3month improvement in symptoms	3month new symptom	-	3month s.calcium	3month albumin	3month corrected calcium	3month tlc	3month PTH	3month HB	3month platelets
192	848659	y	n	-	8.5	2.5	9.7	-	-	-	12	-	-	-	y	-	-	y	y	n	-	10.1	3.5	10.4	8	-	10.8	240
193	882201	y	n	-	9	4	9.8	86	-	-	-	-	3.5	-	y	-	-	y	y	n	-	9.1	2.6	10.2	8.5	-	9.5	200
194	470330	y	n	-	9.5	2.8	10.7	-	-	10	9.5	150	2.1	-	y	-	-	n	y	n	-	9.6	2.8	10.8	9	-	9	145
195	576826	y	n	-	8.5	3.5	8.9	-	-	6	10	190	0.5	-	y	-	-	y	y	n	-	-	-	-	12	-	9.5	180
196	697247	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
197	847585	y	n	-	9	3.3	9.5	-	-	-	12	-	0.7	-	y	-	y	n	y	n	-	-	-	-	-	-	-	-
198	817544	y	n	-	9.5	2.6	10.6	-	-	10.5	9.5	156	0.5	-	y	-	-	n	y	n	-	10	2.9	10.8	-	-	9	140
199	848094	y	n	-	9.8	4	9.8	-	124	-	8	-	0.6	-	y	-	-	n	y	n	-	8.2	4	8.2	-	16	8.5	-
200	813240	y	y	uti	10.2	4	9.4	-	-	-	9.6	-	2.8	-	y	-	-	n	y	n	-	9.9	-	9.1	-	-	9	-

sr no	mrd	3month creatinine	3month vit d	3month alive	3month loss to f/u	3month interval parathyroidectomy
192	848659	0.6	-	y	-	-
193	882201	2.1	-	y	-	-
194	470330	2.3	-	y	-	-
195	576826	0.6	-	y	-	-
196	697247	-	-	-	-	-
197	847585	-	-	y	-	-
198	817544	0.6	-	y	-	-
199	848094	-	-	y	-	-
200	813240	2.56	-	y	-	-

Baba Farid University
of Health Sciences
Sadiq Road
Faridkot-151 203 (Pb). INDIA.
Phone : 01639-256232,256236
Tele/Fax : 01639-256235
Email – Examination@bfuhs.ac.in

No. BFUHS/2K19p-TH/ 1723

Date 15/9/19

The Principal,
DMC, Ludhiana.

Subject: Approval of Plan of Thesis.

This is to inform you that the Faculty of Medical Sciences in its meeting held on 29.05.2019 has approved the plan of thesis of **Taniya Sukhija**, a student of your college for **MD General Medicine** along with the names of Supervisor/Co-Supervisor as under:-

Topic Plan of Thesis

Clinical profile and outcome in patients with hypercalcemia in a tertiary care centre

Supervisor
Dr. Vandana Midha
Prof.,
Dept. of Medicine,
DMCH, Ludhiana.

Co-Supervisor
Dr. Naveen Mittal Prof
Dept of Endocrinology,
DMCH, Ludhiana.

Dr. Navjot Bajwa
Prof. & Head,
Dept. of Biochemistry,
DMCH, Ludhiana.

The student has to submit the four copies of thesis (along with PDF format) , to the Controller of Examinations, BFUHS, Faridkot, at least six months before the commencement of theory examination, if he/she is otherwise eligible to take the examination. He /She must directed to attach a photocopy of this letter with the forwarding letter while submitting thesis to the University along with the letter of approval of University for change of supervisor/Co-Supervisor, change of topic,(if any).

SP Singh

Dr. S P Singh MS(Oph)
Controller of Examinations

Note :

35. *If any discrepancy found regarding topic of thesis or Supervisor/Co-Supervisor, inform undersigned within one month after issue of this letter.*
36. *The student may submit the thesis as per the schedule already conveyed i.e for May/June examination 30th Nov of the preceding the year of examination and for Nov/Dec examinations 31st May of the year of examination.*

CLINICAL PROFILE AND OUTCOME IN PATIENTS WITH HYPERCALCEMIA IN A TERTIARY CARE CENTRE

THESIS PROPOSAL

FOR APPROVAL OF SUBJECT OF THESIS TO BE SUBMITTED

IN PARTIAL FULFILMENT OF THE REQUIREMENTS

FOR THE DEGREE OF

DOCTOR OF MEDICINE

IN

MEDICINE

OF THE

BABA FARID UNIVERSITY OF HEALTH SCIENCES
FARIDKOT

NOVEMBER, 2018

DR. TANIYA SUKHIJA

DEPARTMENT OF MEDICINE
DAYANAND MEDICAL COLLEGE & HOSPITAL
LUDHIANA

ABSTRACT OF PLAN OF THESIS

Title	CLINICAL PROFILE AND OUTCOME IN PATIENTS WITH HYPERCALCEMIA IN A TERTIARY CARE CENTRE
For the degree of	M.D. (Medicine)
Name of the candidate	Dr. Taniya Sukhija
Supervisor	Dr. Vandana Midha, Professor, Department of Medicine, DMCH, Ludhiana
Co-supervisor(s)	Dr. Parminder Singh, Professor and Head, Department of Endocrinology, DMCH, Ludhiana Dr. Navjot Bajwa, Professor and Head, Department of Biochemistry, DMCH, Ludhiana.
Institution	Dayanand Medical College and Hospital, Ludhiana
University	Baba Farid University of Health Sciences, Faridkot

Introduction: Calcium is an essential mineral in our body and is involved in many physiological and biochemical processes. Serum calcium levels are maintained in a narrow range by powerful homeostatic mechanisms. However, it is not uncommon to find calcium related metabolic abnormalities either hypercalcemia or hypocalcemia. The most common reasons for hypercalcemia are malignancies followed by symptomatic primary hyperparathyroidism (PHPT), granulomatous diseases like sarcoidosis and other rare causes.

Aim of Study: The aim of the study is to determine the clinical profile and the possible etiology of hypercalcemia based on the clinical signs, symptoms and investigations in patients presenting to Dayanand Medical College and Hospital, Ludhiana. Also the clinical status after one month and three months of follow up will be evaluated.

Materials & Methods: This prospective study will include all the patients (age>18years) presenting to Dayanand Medical College and Hospital, Ludhiana with verified hypercalcemia (total calcium corrected for albumin > 10.5mg/dl) , on atleast two occasions , from 1 st January 2019 to 31 st December 2019. The clinical profile and outcome of all the enrolled patients will be evaluated.

Clinical Significance: There are limited studies on hypercalcemia diagnosed in health care set ups in our country. Recently a changing trend has been observed in the symptomatology and etiology of hypercalcemia which is intended to be looked up in this study. Thus, a basic investigation like serum calcium level may change the outcome by helping in making diagnosis and guiding treatment (especially in case of malignancy).

Keywords: Hypercalcemia, Primary Hyperparathyroidism, Malignancy associated hypercalcemia, vitamin D

Taniya Sukhija

(Signature) Candidate | (Signature) Co-supervisor | (Signature) Co-supervisor | (Signature) Supervisor | (Signature) Principal

CERTIFICATE OF FACILITIES AVAILABLE

This is to certify that the facilities for work on the subject of thesis entitled "**CLINICAL PROFILE AND OUTCOME IN PATIENTS WITH HYPERCALCEMIA IN A TERTIARY CARE CENTRE**" exist in the Department of Medicine, Dayanand Medical College & Hospital, Ludhiana and will be provided to the candidate. We will see that the data being included in the thesis are genuine and is collected by the candidate herself under our supervision and guidance.

Supervisor

Dr. Vandana Midha
Professor
Department of Medicine
DMCH, Ludhiana

Co-Supervisor

Dr. Parminder Singh
Professor & Head
Department of Endocrinology
DMCH, Ludhiana

Dr. Navjot Bajwa
Professor & Head
Department of Biochemistry
DMCH, Ludhiana

Head of the Department

Dr. Dinesh Gupta
Professor & Head
Department of Medicine
DMCH, Ludhiana

Place : LUDHIANA

Date : 20/12/18

APPROVAL PROFORMA
BY RESEARCH & ETHICAL COMMITTEE
DAYANAND MEDICAL COLLEGE & HOSPITAL, LUDHIANA

Name of candidate	Dr. Taniya Sukhija
Department	Medicine
Topic of Thesis	CLINICAL PROFILE AND OUTCOME IN PATIENTS WITH HYPERCALCEMIA IN A TERTIARY CARE CENTRE
Likely date of appearing in PG examination	MAY-JUNE 2021
Date of enrollment	MAY 9, 2018
Name of Head of Department	Dr. Dinesh Gupta
1) Supervisor **2) Co-Supervisor(s)**	Dr. Vandana Midha Dr. Parminder Singh Dr. Navjot Bajwa
Signature of Members of Research Committee with Stamp	**Signature of Members of Ethics Committee with Stamp**
1. HOD Pharmacology	1. HOD Physiology
2. HOD Surgery	2. HOD Pathology
3. HOD Pathology	3. HOD Pharmacology
4. HOD Medicine	4. HOD SPM
5. Dean Academics	5. HOD Medicine
6. Vice Principal	6. HOD Surgery
	7. HOD Obst. & Gynae.
	8. Legal Expert
	9. Secretary, IEC
	10. Dean Academics
	11. Vice Principal
	12. Principal

Approved: Yes / No

Chairperson
Research Committee

Chairperson
Research Committee

Approved: Yes / No

Chairperson
Ethics Committee

Chairperson
Ethics Committee

BABA FARID UNIVERSITY OF HEALTH SCIENCES, FARIDKOT

PROFORMA FOR REGISTRATION OF SUBJECT FOR DISSERTATION

1	NAME OF THE CANDIDATE AND ADDRESS	TANIYA SUKHIJA 1253/11 Model Town, Kurukshetra Road, Kaithal, Haryana
2	NAME OF THE INSTITUTE	Dayanand Medical College and Hospital, Ludhiana
3	COURSE OF STUDY AND SUBJECT	MD Medicine
4	DATE OF ADMISSION OF COURSE	May 9, 2018
5	TITLE OF THE TOPIC	CLINICAL PROFILE AND OUTCOME OF PATIENTS WITH HYPERCALCEMIA IN A TERTIARY CARE CENTRE

6. BRIEF RESUME OF THE INTENDED WORK

6.1 NEED FOR THE STUDY

Hypercalcemia is defined as total serum calcium levels more than 10.5 mg/dl or 2.5 mmol/l. The hypercalcemia is further classified as

1. Mild- 10.5 to 11.9 mg/dl (2.5-3mmol/l)
2. Moderate- 12-13.9 mg/dl (3-3.5mmol/l)
3. Severe- >14 mg/dl (>3.5mmol/l)

The hypercalcemic crisis[1] is said when either severe neurological symptoms or cardiac arrhythmias are present in a patient with serum calcium levels more than 14 mg/dl or when serum calcium levels are more than 16 mg/dl.

The first step in evaluation of hypercalcemia is to verify the hypercalcemia with repeat measurement (total calcium corrected for albumin) on atleast two occasions.

Calcium ions play an important role in cellular function and signaling such as neuromuscular transmission, coagulation pathway, hormonal secretion etc.[2] Calcium homeostasis in body is maintained through a series of feedback mechanisms involving PTH, calcitonin and vitamin D via fluxes of calcium from git, kidney and bone. Mild hypercalcemia is usually asymptomatic and identified incidentally on routine blood testing.

Amongst the most common causes of hypercalcemia are malignancy and hyperparathyroidism. Hypercalcemia of malignancy is seen with squamous cell carcinoma (lung, head and neck, urothelial cancer), multiple myeloma, breast cancer, RCC, lymphoma's etc.[3] PHPT is a common endocrine condition.[4-6] Parathyroid adenoma accounts for 80%–85% of primary hyperparathyroidism cases whereas parathyroid carcinoma is very rare and

constitutes < 1% of cases.[7]Other causes of hypercalcemia includes granulomatous disorders (sarcoidosis, tuberculosis) ; medications (lithium, thiazides, antiestrogens, vitamin D and calcium supplements); milk alkali syndrome; hyperthyroidism; immobilization; benign familial hypocalciuric hypercalcemia.[8] Vitamin D intoxication has recently emerged as an important cause of hypercalcemia due to overcorrection of vitamin D deficiency.[9-13] This increase is due to a growing awareness of vitamin D deficiency in today's lifestyle and various researches suggesting the beneficial effects of vitamin D in immune system, cardiovascular health, bone health and cancer prevention, besides playing important roles in calcium homeostasis, that leads to overdosing by either patients or prescribers.[14-16]

Hypercalcemia can manifest as anorexia, nausea, vomiting, dyspepsia, constipation, pancreatitis, polyuria, polydipsia, nephrolithiasis, nephrocalcinosis, depression, confusion, stupor, coma, weakness, malaise, short QT interval, bradycardia, hypertension, bony pains, fractures, osteoporosis, osteitis fibrosa cystica etc.

Data on prevalence and clinical profile of hypercalcemia are scarce from Indian subcontinent. This study aims at studying the clinico-etiological profile of patients presenting to DMCH with hypercalcemia and accessing the short term outcome in these patients.

6.2 REVIEW OF LITERATURE

In a literature search for cases reporting intoxication of vitamin D done by Galior K, et al. (2018)[9]showed that inappropriate use of vitamin D supplements can lead to toxicity and life-threating hypercalcemia. The vitamin D doses reported in these cases were ranging from 50,000 IU/day to 2,604,000 IU/day resulting in hypercalcemia of range between 11.1 and 23.08 mg/dL and serum 25(OH)D concentrations greater than 150 ng/mL. The clinical features reported in these cases were a consequence of the hypercalcemia and included nausea, vomiting, weakness, polyuria, nephrocalcinosis, and renal failure. This study concluded that vitamin D levels above 150 ng/mL are more likely to be associated with toxicity and therefore should be avoided at all costs.

A retrospective study was done to determine the profile of hypercalcemia in all patients who presented to Medanta-The Medicity, a tertiary care hospital in North India by Mohammad Kuchay S, et al (2017).[3]In this out of total patients(26,297) presenting during 1 January 2014 to 30 June 2015 (18 months),in whom calcium measurement was done, a total of 552 patients were found to have hypercalcemia. Among them, the incidence of hypercalcemia was found to be 2.09%, being transient in 0.05% and sustained in 2.04%. The most common causes in the sustained group were malignancy (23.1%) followed by primary hyperparathyroidism (PHPT, 21.9%). Also they found emergence of two other causes of hypercalcemia, namely hypercalcemia of advanced chronic liver disease and vitamin D intoxication.

A study done in Kashmir valley by Misgar RA, et al (2015)[17] in which a total

of 78 patients were identified with PHPT during the two decades. Out of those 29 patients were studied retrospectively and 49 patients prospectively. They found the most common manifestation being renal either nephrolithiasis and/or nephrocalcinosis (64.10%) followed by bone pain (44.1%) followed by abdominal pain (39%) followed by constipation (26%) followed by myopathy (14.10%). Fractures were found only in 10.25%, and brown tumors in 6.41% patients. The cure rate after parathyroidectomy was remarkable being 96.15%. Mithal A (2015)[4] did a retrospective study conducted at 2 tertiary care centers in north India. All patients who underwent evaluation and surgery for primary hyperparathyroidism (PHPT) from January 2009 to December 2012 were included. In this study the asymptomatic form of PHPT was found in a significant percentage of north Indian patients. Asymptomatic PHPT patients were older in age and had lower parathyroid adenoma weights and iPTH levels compared to symptomatic PHPT patients. Positive correlations were found between parathyroid adenoma weight and serum calcium, iPTH, and ALP levels.

Another study done by Gopal RA et al.(2010)[18] described the clinical profile of primary hyperparathyroidism from western India in a retrospective study conducted at a tertiary care referral center. The most common symptoms at presentation were skeletal manifestations (75.5%), renal calculi (40.5%) and proximal muscle weakness (45.5%) with mean duration of symptoms being 33.70 (median: 24, range 1-120) months. The biochemistry revealed hypercalcemia (total corrected calcium 12.55+/-1.77 mg/dl), low inorganic phosphorus (1.81+/-0.682 mg/dl), elevated total alkaline phosphatase (mean: 762.2; median: 559; range: 50-4930IU/L) and high parathyroid hormone (PTH)

(mean+/-SD: 866.61+/-799.15; median: 639.5; range: 52-3820 pg/ml). Preoperative localization was achieved in 74 patients and single adenoma was found during surgery in 72 patients. Hungry bone disease was seen in 30.3% and transient hypoparathyroidism developed in 62% patients.

Azzabi S et al (2001)[19] studied the etiology of hypercalcemia in 47 cases at Charles Nicolle-Tunis hospital. Their result showed a positive significant correlation between the degree of hypercalcemia and the severity of clinical symptomatology. Multiple myeloma, hyperparathyroidism and the neoplasms accounted for 78% of the total etiology.

Frolich A et al.(1998)[20]reviewed the literature with respect to the prevalence of hypercalcaemia in normal and in hospital populations. Hypercalcemia of malignancy was the most common cause of hypercalcemia followed by primary hyperparathyroidism in hospital populations. The most common cause in normal populations was primary hyperparathyroidism followed by transient hypercalcemia. The prevalence of hypercalcemia showed a large variation in hospital populations ranging from 0.17% to 2.92%. The prevalence in normal populations varied between 1.07% and 3.9% and is more than the levels in hospital populations.

A study was conducted by Gupta CM (1990)[21] at AFMC, PUNE in which Eighty nine cases with hypercalcaemia were seen during the period 1975-87. Malignancy of nonparathyroid tissue was responsible in 72 cases (80.9%). The other causes were primary hyperparathyroidism (11 cases), hypervitaminosis D (5) and sarcoidosis (1). This study concluded that every patient with hypercalcaemia needs careful evaluation to establish the etiological basis so that specific treatment may be instituted.

Diamond T et al. (1987)[22] conducted a 1-year retrospective study of all serum profiles of patients with hypercalcemia analysed at the Johannesburg Hospital to ascertain the causes of hypercalcemia and physician awareness of primary hyperparathyroidism. Hypercalcemia was found in 560 subjects (2,9% of 19200), but in 147 of these (26%) this was not confirmed by repeat estimations. Malignant tumors were the commonest cause (38,4%) and accounted for the most severe hypercalcemia (mean serum calcium 2,93 mmol/l). Renal disease resulted in significant hypercalcemia, at times requiring parathyroidectomy. Drug-associated hypercalcemia was usually mild and reversible on drug withdrawal. Although primary hyperparathyroidism occurred in 21.3% of cases, overall physician awareness of the disease was poor (39%). 'Incidental' profile hypercalcaemia ($P < 0.005$) and hypertension ($P < 0.005$) were frequent presenting features in this study. Renal disease ($P < 0.001$) occurred infrequently.

Dent D, et al.(1987)[23] conducted a prospective screen for hypercalcaemia in 58,053 hospital in-patients over 12 months. The incidence of hypercalcaemia was 0.6%, being transient in 19.2% of patients and sustained in the remainder. The most common causes in the sustained group were malignancy (45%) and primary hyperparathyroidism (16.5%). The incidence of primary hyperparathyroidism was 78/100,000 hospital in-patients, and its discovery was directly attributable to the survey in over half the cases.

6.3 AIMS AND OBJECTIVES OF THE STUDY

The aim of the study is to determine the clinical profile and possible etiology of hypercalcemia based on the clinical signs, symptoms and investigations in patients presenting to the Dayanand Medical College and Hospital, Ludhiana. Also the clinical status after one month and three months of follow up will be evaluated.

7. MATERIALS AND METHODS

7.1 Source of Data

The study will be conducted at Dayanand Medical College and Hospital, Ludhiana from 1 st January 2019 to 31 st December 2019.

All the patients with verified hypercalcemia (total calcium corrected for albumin >10.5 mg/dl) atleast on two occasions will be enrolled.

Serum calcium levels will be analyzed using o-cresophthalein dye binding technique on an automated analyzer. Serum vitamin D and PTH levels will be measured using electrochemiluminescence immunoassay (ECLIA) as and when required on an automated analyzer.

7.2 METHOD OF COLLECTION OF DATA

Patients will be enrolled in the study based on the following inclusion and exclusion criteria.

INCLUSION CRITERIA

- Age >18years
- Serum calcium levels >10.5mg/dl
- Patient/legally authorized representative (LAR) giving consent to participate in the study

EXCLUSION CRITERIA

- Age < 18 years
- Patient/legally authorized representative (LAR) who are not willing to participate in the study

OUTCOME MEASURES

- Clinical features
- Etiology

- Clinical course within hospital and on follow up after 1 month and 3 months
- Discharge / Discharge at request (DOR) / Discharge against medical advice (DAMA)

STATISTICAL ANALYSIS

Data will be described in terms of range; mean ±standard deviation (± SD), median, frequencies (number of cases) and relative frequencies (percentages) as appropriate. All statistical calculations will be done using SPSS (Statistical Package for the Social Science) SPSS 21 version statistical program for Microsoft Windows.

7.3 DOES THE STUDY REQUIRE ANY INVESTIGATIONS OR INTERVENTIONS TO BE CONDUCTED ON PATIENTS OR OTHER HUMANS OR ANIMALS? IF SO, PLEASE DESCRIBE BRIEFLY.

No.

7.4 HAS ETHICAL CLEARANCE BEEN OBTAINED FROM YOUR INSTITUTION IN CASE OF 7.3?

Attached along with

LIST OF REFERENCES

1. Ahmad S, Kuraganti G, Steenkamp D. Hypercalcemic crisis: a clinical review. Am J Med. 2015;128:239-45.
2. David E. Clapham. Calcium Signaling. Cell. 2007;131:1047-58.
3. Kuchay MS, Kaur P, Mishra SK, Mithal A. The changing profile of hypercalcemia in a tertiary care setting in North India: an 18-month retrospective study. Clin Cases Miner Bone Metab. 2017;14:131-5.
4. Mithal A, Rao DS, Zaidi M. Role of Vitamin D and calcium nutrition in parathyroid growth and disease expression. In: Mithal A, Rao DS, Zaidi M, editors. Metabolism Bone Disorders Indian Social Bone MineralsResearch. New Delhi: Hindustan Book Depot, Lucknow; 1998. p. 25-8.
5. Mishra SK, Agarwal G, Kar DK, Gupta SK, Mithal A, Rastad J, et al. Unique clinical characteristics of primary hyperparathyroidsism in India.Br J Surg 2001;88:708-14.
6. Parfitt AM, Rao DS, Kleerekoper M. Asymptomatic primary hyperparathyroidism discovered by multichannel biochemical screening: Clinical course and considerations bearing on the need forsurgical intervention. J Bone Miner Res. 1991;6:S97-101.
7. Marcocci C, Cetani F, Rubin MR, Silverberg SJ, Pinchera A, Bilezikian JP, et al. Parathyroid carcinoma. J Bone Miner Res. 2008;23:1869-80.
8. Minisola S, Pepe J, Piemonte S, Cipriani C. The diagnosis and management of hypercalcaemia. BMJ. 2015;350:h2723.
9. Galior K, Grebe S, Singh R. Development of Vitamin D Toxicity from Overcorrection of Vitamin D Deficiency: A Review of Case

Reports.Nutrients.2018;10:E953.

10. Kaur P, Mishra SK, Mithal A. Vitamin D toxicity resulting from overzealous correction of vitamin D deficiency. Clin. Endocrinol. 2015;83:327–31.

11. Koul PA, Ahmad SH, Ahmad F, Jan RA, Shah SU, Khan UH. Vitamin d toxicity in adults: A case series from an area with endemic hypovitaminosis d. Oman Med. J. 2011;26:201–4.

12. Bansal RK, Tyagi P, Sharma P, Singla V, Arora V, Bansal N, et al. Iatrogenic hypervitaminosis D as an unusual cause of persistent vomiting: A case report. J. Med. Case Rep. 2014;8:74.

13. Pandita KK, Razdan S, Kudyar RP, Beigh A, Kuchay S, Banday T. Excess gooD can be Dangerous. A case series of iatrogenic symptomatic hypercalcemia due to hypervitaminosis D. Clin. Cases. Miner. Bone Metab. 2012;9:118–20.

14. Delvin E, Souberbielle JC, Viard JP, Salle B. Role of vitamin D in acquired immune and autoimmune diseases. Crit. Rev. Clin. Lab. Sci. 2014;51:232–47.

15. Brewer LC, Michos ED, Reis JP. Vitamin D in atherosclerosis, vascular disease, and endothelial function. Curr. Drug Targets. 2011;12:54–60.

16. Rizzoli R. Nutritional aspects of bone health. Best Pract. Res. Clin. Endocrinol. Metab. 2014;28:795–808.

17. Misgar RA, Dar PM, Masoodi SR, Ahmad M, Wani KA, Wani AI, et al. Clinical and laboratory profile of primary hyperparathyroidism in Kashmir Valley: A single-center experience. Indian J Endocrinol Metab. 2016;20:696–701.

18. Gopal RA, Acharya SV, Bandgar T, Menon PS, Dalvi AN, Shah NS.

Clinical profile of primary hyperparathyroidism from western India: a single center experience. J Postgrad Med. 2010;56:79-84.

19. Azzabi S, Khalfallah N, Ben Hassine L. The aetiology of hypercalcemia: a study of 47 cases in a hospital internal medicine service. Tunis Med. 2001;79:348-52.

20. Frolich A. Prevalence of hypercalcemia in normal and in hospital populations. Dan Med Bull. 1998;45:436–9.

21. Gupta CM. Evaluation and aetiopathogensis of hypercalcemia. A study of 89 patients. J Assoc Physicians India. 1990;38:337-9.

22. Diamond TH, Botha JR, Vermaak WJ, KalkWJ. Hypercalcemia in the Johannesburg Hospital. Differential diagnosis and physician awareness of primary hyperparathyroidism. S Afr Med J. 1987;72:113–5.

23. Dent DM, Miller JL, Klaff L, Barron J. The incidence and causes of hypercalcemia. Postgrad Med J. 1987;63:745–50.

PROFORMA

S. No.

Name **Age** **Gender**

MRD No. **Admn. No.** **Ward/Unit**

Address **Mobile No.**

Education status

Occupation

DOA **DOD**

Chief Complaints at admission :

Sr. No.	Complaint	Yes/No	Duration
1.	Nausea		
2.	Vomiting		
3.	Anorexia		
4.	Weight loss		
5.	Constipation not relieved by treatment		
6.	Abdominal pain		
7.	Dyspepsia		
8.	Renal stones		
9.	Polyuria		
10.	Nocturia		
11.	Bony pains		

Signature of Candidate **Signature of Supervisor/Cosupervisor**

12.	Fractures		
13.	Fatigue/lethargy		
14.	Impaired concentration		
15.	Confusion Stupor Coma		
16.	Depression		

Personal History

- Vegetarian/Non-vegetarian
- Smoker/Non-smoker
- Alcoholic/Non alcoholic: Duration Quantity
- Substance abuse
- Drug history:

Drug	Yes/no	Dose	Frequency	Duration
Lithium				
Thiazides				
Anti-estrogens				
Vitamin D supplements (Injectable/Oral)				
Calcium supplements				
Any other drug				

Menstrual history (female patients) - regular amount of flow

Obstetrical history (female patients):

Signature of Candidate **Signature of Supervisor/Cosupervisors**

Past history:

Diabetes mellitus		Bronchial asthma	
Hypertension		TB	
CKD		Arthritis	
CAD		Carcinoma	
CLD		Any other	

Surgery history:

Family history:

Diabetes mellitus		Bronchial asthma	
Hypertension		TB	
CKD		Arthritis	
CAD		Carcinoma	
CLD		Any other	

General physical examination:

Vitals-

Heart rate (beats/min)	Pulse rate (per min)	Temperature (Fahrenheit)	Blood pressure (mm of hg)	Respiratory rate (per minute)	Spo2 (%)

Signature of Candidate **Signature of Supervisor/Cosupervisors**

GCS:	
Pallor	
Icterus	
Clubbing	
Cyanosis	
Lymphadenopathy	
Edema	
JVP	
Trachea	
Thyroid	

Nutritional assessment- Body weight (kg) Height(m) BMI(kg/m^2)

Systemic examination -

1. CNS:

2. CVS:

3. Respiratory:

4. Abdomen:

Signature of Candidate **Signature of Supervisor/Cosupervisors**

Investigations

1.Hemogram	**At admission**	**At discharge**	**After 1 month of follow up (as advised by consultant)**	**After 3 months of follow up (as advised by consultant)**
Haemoglobin (g/dl)				
TLC (x 10^3/ul)				
N/L/M/E/B (%)				
Platelet Count (x 10^3/ul)				
MCV (fl)				
MCH (pg)				
MCHC (g/dl)				
ESR				
2. RFT's o Creatinine(mg/dl) o Urea(mg/dl) o Sodium(mmol/l) o Potassium(mmol/l) o Chloride(mmol/l)				
3. LFT's o Total bilirubin(mg/dl) o Direct bilirubin(mg/dl) o AST(u/l) o ALT(u/l) o Alkaline phosphatase(u/l) o Total protein(g/dl) o Serum albumin(g/dl)				
4. Serum Calcium (mg/dl)				
5. Serum Phosphorus (mg/dl)				
6. Urine Routine o Proteins				

Signature of Candidate **Signature of Supervisor/Cosupervisors**

○ Rbc's ○ Pus cells ○ Glucose				
7. ECG ○ Short QT interval				
8. Chest X-ray				

Other investigations (as required)	Report
Serum PTH(pg/ml)	
Vitamin D(ng/ml)	
CRP-quantitative(mg/l)	
X ray ○ Spine ○ Skull ○ Hands ○ Any other (as required)	
Abdominal Xray(erect/supine)	
USG abdomen	
USG neck	
MRI scan	
CT scan	
PET scan	
Sestamibi scan	
Bone scan	
Serum protein electrophoresis	
24 hour urine for light chain assay	
Bone marrow aspiration and/or biopsy	

Signature of Candidate **Signature of Supervisor/Cosupervisors**

Final Diagnosis:

Management :

- **Medical Treatment:**

- **Surgical Treatment:**

Outcome:

- Improved/ not improved with treatment
- Discharge / Death / Discharge against medical advice (DAMA) / Discharge on Request(DOR)

Follow up(either patient visits or telephonic):

	After 1month	**After 3 months**
Date		
Constitutional features		
Improvement in previous clinical signs and symptoms		
Appearance of new clinical symptoms/signs		
Investigations- ○ Serum calcium ○ Other as required		

Signature of Candidate **Signature of Supervisor/Cosupervisors**

INFORMED PATIENT CONSENT

Date: _____

I.....D/o, W/o, S/o.....

am willing to participate in the study **"CLINICAL PROFILE AND OUTCOME IN PATIENTS WITH HYPERCALCEMIA IN A TERTIARY CARE CENTRE"** The procedure with its complications has been explained to me in local vernacular language. I have fully understood that no special tests and extra expenditure in any form, merely for the purpose of thesis is being carried out. I am free to opt out the study any time without assigning any reason.

.....
Signature of the Witness

Name:

.....
Signature of the patient/legally authorized representative

Signature of Candidate

Signature of Supervisor

मरीज अनुमति फार्म

तिथि _____

मैं _____ पत्नी/पुत्र/पुत्री _____

निवासी _____

इस शोधकार्य "**CLINICAL PROFILE AND OUTCOME IN PATIENTS WITH HYPERCALCEMIA IN A TERTIARY CARE CENTRE**" में भाग लेने के लिए सहमत हूँ। मैं इस शोधकार्य में भाग लेने के लिए अपनी स्वेच्छा से तैयार हूँ। मैं पुष्टि करता/करती हूँ की यह स्वीकृति देने के लिए मुझे कोई आर्थिक प्रलोभन नहीं दिया गया और न ही दबाव डाला गया है। मुझे इस शोधकार्य का उद्देश्य स्पष्ट कर दिया गया है और मुझे यह विश्वास है की यह विज्ञान और मानवता के लाभ के लिए है। मुझे इस शोधकार्य में होने वाले जोखिम के बारे में समझा दिया गया है और मेरी समझ में यह जोखिम बहुत मामुली है।

मैं इस शोधकार्य में भाग लेने के सम्बन्ध में किसी भी समय अपनी अस्वीकृति व्यक्त कर सकता/सकती हूँ और मेरे अस्वीकृति व्यक्त करने का मेरे इलाज पर कोई प्रभाव नहीं पड़ेगा।

_____

गवाह के हस्ताक्षर

नाम:

_____

रोगी/ **कानूनी रूप से अधिकृत प्रतिनिधि** के हस्ताक्षर/अंगूठे का निशान

नाम:

_____

अन्वेषक के हस्ताक्षर

_____

विद्यार्थी के हस्ताक्षर

ਮਰੀਜ਼ ਰਜ਼ਾਮੰਦੀ ਫ਼ਾਰਮ

ਮਿਤੀ_____

ਮੈ_____ਪਤਨੀ/ਪੁੱਤਰ/ਪੁੱਤਰੀ_____

ਵਾਸੀ _____

"CLINICAL PROFILE AND OUTCOME IN PATIENTS WITH HYPERCALCEMIA IN A TERTIARY CARE CENTRE" ਤੇ ਚਲ ਰਹੀ ਖੋਜ ਵਿਚ ਹਿੱਸਾ ਲੈਣ ਲਈ ਰਜ਼ਾਮੰਦ ਹਾਂ। ਇਸ ਖੋਜ ਕੰਮ ਵਿਚ ਹਿੱਸਾ ਲੈਣ ਲਈ ਮੈ ਆਪਣੀ ਮਰਜ਼ੀ ਨਾਲ ਤਿਆਰ ਹਾਂ। ਮੈ ਇਹ ਦਸਣਾ ਚਾਹੁੰਦਾ ਹਾ/ ਚਾਹੁੰਦੀ ਹਾ ਕੇ ਇਹ ਰਜ਼ਾਮੰਦੀ ਦੇਣ ਵਾਸਤੇ ਮੈਨੂ ਕਿਸੇ ਵੀ ਤਰਾਂ ਦਾ ਲੋਭ-ਲਾਲਚ ਨਹੀ ਦਿੱਤਾ ਗਿਆ ਅਤੇ ਨਾ ਹੀ ਕੋਈ ਦਬਾ ਪਾਇਆ ਗਿਆ ਹੈ। ਮੈਨੂ ਇਸ ਖੋਜ ਦਾ ਮਨੋਰਥ ਸਮਝਾ ਦਿੱਤਾ ਗਿਆ ਹੈ ਅਤੇ ਮੈਨੂ ਇਹ ਭਰੋਸਾ ਦਵਾਇਆ ਗਿਆ ਹੈ ਕੇ ਇਹ ਖੋਜ ਵਿਗਿਆਨ ਅਤੇ ਮਾਨਵਤਾ ਦੀ ਭਲਾਈ ਲਈ ਹੈ। ਮੈਨੂ ਇਸ ਖੋਜ ਵਿਚ ਹੋਣ ਵਾਲੇ ਖਤਰੇ ਬਾਰੇ ਸਮਝਾ ਦਿੱਤਾ ਗਿਆ ਹੈ ਅਤੇ ਮੈਨੂ ਇਹ ਯਕੀਨ ਹੈ ਕੇ ਇਹ ਖਤਰਾ ਬਹੁਤ ਮਾਮੂਲੀ ਹੈ। ਮੈਨੂ ਇਸ ਖੋਜ ਕੰਮ ਵਿਚ ਹਿੱਸਾ ਲੈਣ ਦਾ ਢੰਗ – ਤਰੀਕਾ ਸਮਝਾ ਦਿੱਤਾ ਗਿਆ ਹੈ।

ਮੈ ਇਸ ਖੋਜ ਕੰਮ ਵਿਚ ਹਿੱਸਾ ਲੈਣ ਬਾਰੇ ਆਪਣੀ ਰਜ਼ਾਮੰਦੀ ਕਿਸੇ ਵੀ ਸਮੇ ਵਾਪਸ ਲੈ ਸਕਦਾ ਹਾਂ/ ਸਕਦੀ ਹਾ ਅਤੇ ਮੇਰੀ ਰਜ਼ਾਮੰਦੀ ਵਾਪਸ ਲੈਣ ਦਾ ਮੇਰੇ ਇਲਾਜ ਤੇ ਕੋਈ ਅਸਰ ਨਹੀ ਹੋਵੇਗਾ।

_____ _____

ਗਵਾਹ ਦੇ ਹਸਤਾਖਰ

ਮਰੀਜ਼/ ਕਾਨੂੰਨੀ ਤੌਰ ਤੇ

ਅਧਿਕਾਰਿਤ ਪ੍ਰਤਿਨਿਧੀ ਦੇ

ਹਸਤਾਖਰ

ਮਿਤੀ_____ ਮਿਤੀ_____

ਪਤਾ _____ ਪਤਾ _____

_____

ਨਿਰੀਖਕ ਦੇ ਹਸਤਾਖਰ

_____

ਸਿਖਿਆਰਥੀ ਦੇ ਹਸਤਾਖਰ